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CHAPTER 1
General Introduction and Aim of the Thesis
T.A. Trenning, A. Gharbharan, S. Levolger, J.L.A. van Vugt 
Adapted from: The Increasing Use of Computed Tomography to 
Assess Body Composition and its Clinical Relevance.
Erasmus Journal of Medicine 2015 Oct; 5 (1): 51-54
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INTRODUCTION
In recent years, body composition, i.e. the relative proportions of subcutaneous adipose 
tissue, visceral adipose tissue, and/or skeletal muscle tissue, has extensively been studied 
as a predictor for outcome following oncological treatment 1, transplant surgery 2, 3, 
emergency and trauma surgery 4, 5, intensive care unit (ICU) admission 6, and vascular 
surgery 7. Deviations in these components, which can also occur within a normal range 
of body weight or body mass index (BMI), are associated with individual risk and reduced 
survival in patients with various benign and malignant diseases 8.
The involuntary, age-dependent, depletion of skeletal muscle mass and reduction of 
skeletal muscle function is called sarcopenia, derived from the Greek sarx, meaning 
“flesh” and penia, meaning “lack of” 9. Sarcopenia was first described in geriatric patient 
populations 10. It is related to frailty, referred to as a status leading to an impaired reaction 
to stressors 11 and functional impairment in the elderly 12. Skeletal muscle depletion may 
represent an occult condition in individuals with normal or even high body weight, as in 
sarcopenic obesity 13. Moreover, skeletal muscle wasting is part of the cancer cachexia 
syndrome, a condition that leads to skeletal muscle wasting with or without the loss 
of adipose tissue. Up to 80% of patients with advanced cancer are affected by cancer-
induced cachexia, and an estimated 30% of cancer-related deaths result from cancer 
cachexia 14-20. Not only increasing age and cancer, but also other diseases such as liver 
failure, may significantly contribute to wasting of lean body and adipose tissue mass 20.
A brief history of body composition analysis using cross-sectional imaging
A reliable method that is applicable on a large scale and with high specificity, sensitivity, 
and reproducibility is recommended to perform skeletal muscle mass measurements. 
Computed tomography (CT) and magnetic resonance imaging (MRI) are known for 
their specificity and precision regarding body imaging and may reveal otherwise occult 
muscle depletion 21.
Between 1979 and 1981, Heymsfield et al. were the first to report the use of CT images 
to measure skeletal muscle and visceral adipose tissue mass 22. In 1986, Kvist et al. were 
the first to assess whole-body adipose tissue volumes with CT, using just several slices 23. 
Shen et al. showed a high correlation between two-dimensional abdominal skeletal 
muscle and adipose tissue areas measured on just a single slice and their respective 
three-dimensional total body volumes in a large sample of diverse subjects in 2004 24.
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In most studies that have later been performed, the third lumbar vertebra (L3) was 
chosen as the level to perform these measurements as a standardized landmark 1, 13. 
At this level, the rectus abdominis, obliquus internus abdominis, obliquus externus 
abdominis, transversus abdominis, psoas major, quadratus lumborum, and the erector 
spinae muscles are visible and can be manually selected using specialized software. Pre-
defined radio density ranges for muscle are used to discriminate between tissues. For 
muscle tissue the standard unit for radio density is used, being -30 to 150 Hounsfield 
units (HU) .Air is predefined as very radiolucent with a radio density of -1000 HU, pure 
water is 0 HU and metals +1000 HU. Since intra-abdominal organs may be within the 
same range of radio density as muscle, the approximate area of the muscles must be 
manually selected. These measurements are defined as the cross-sectional muscle area 
at lumbar level 3, adjusted for body height, resulting in the L3-muscle index (cm2/m2) 1.
In 2008, Prado et al. were the first to show that a low L3 muscle index was related to 
impaired outcome in patients suffering from malignancies of the upper respiratory and 
digestive tract 1. They introduced the term sarcopenia in oncology. Although strictly 
speaking, low skeletal muscle mass alone does not comply with the definition of 
sarcopenia of the European Working Group on Sarcopenia in Older People (EWGSOG), 
since it also includes low skeletal muscle function or strength 25. Nevertheless, this term 
is generally used in surgical and oncological literature to describe low skeletal muscle 
mass.
Advantages and limitations of CT images to measure skeletal muscle mass
The CT-based method provides more detail than the formerly used dual X-ray 
absorptiometry (DXA) and bioelectrical impedance analysis (BIA) 26. A great advantage 
of CT compared with these modalities is that CT is routinely performed in many 
oncological and surgical patients as part of the diagnostic work-up. As the total body is 
rarely depicted in this setting, the cross sectional area at the L3 level, which correlates 
well with the total muscle mass proves its use. Moreover, skeletal muscle radio density 
can be measured 24, 27. Low radio density represents a high amount of intramuscular 
adipose tissue 21.
Despite the fact that CT images are specific and precise and are considered the 
gold standard for body composition measurements by many authors 13, 28, 29, it is not 
recommended as a standard method to determine body composition in all populations. 
Besides extra expenses and logistics, patients are exposed to additional radiation. 
However, as CT is routinely used in practice for patients with abdominal cancers, this 
method does not add costs and does not entail additional patient radiation exposure. 
Thus, it is currently recommended as the method of choice for research purposes 20.
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AIM OF THIS THESIS
Although perioperative outcome has greatly improved during the last decades by the 
introduction of new surgical techniques and enhanced recovery after surgery (ERAS) 
programs 30, 31, preoperative risk assessment remains of utmost importance to further 
improve outcomes and adapt patient-tailored treatment strategies. Considering the 
increasing age of the population, the increasing incidence of cancer, and the increased 
surgical and medical treatment options, skeletal muscle mass could be an important 
addition used for risk assessment or as a therapeutic target to improve treatment 
outcomes. Therefore, the aim of this thesis was to investigate the applicability of skeletal 
muscle mass measurements and to define the relevance of decreased skeletal muscle 
mass in surgical oncology and liver transplant patients.
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A Comparative Study of Software Programs for 
Cross-Sectional Skeletal Muscle and Adipose 
Tissue Measurements on Abdominal Computed 
Tomography Scans of Rectal Cancer Patients
J.L.A. van Vugt, S. Levolger, A. Gharbharan, M. Koek, W.J. Niessen, 
J.W.A. Burger, S.P. Willemsen, R.W.F. de Bruin, J.N.M. IJzermans
Adapted from: Journal of Cachexia, Sarcopenia and Muscle 2017 Apr; 8 (2): 285-297
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ABSTRACT
Background: The association between body composition (e.g., sarcopenia or visceral 
obesity) and treatment outcomes, such as survival, using single-slice computed 
tomography (CT) based measurements has recently been studied in various patient 
groups. These studies have been conducted with different software programs, each 
with their specific characteristics, of which the inter-observer, intra-observer and inter-
software correlation are unknown. Therefore, a comparative study was performed.
Methods: Fifty abdominal CT scans were randomly selected from 50 different patients 
and independently assessed by two observers. Cross-sectional muscle area (CSMA, i.e. 
rectus abdominis, oblique and transverse abdominal muscles, paraspinal muscles and 
the psoas muscle), visceral adipose tissue area (VAT) and subcutaneous adipose tissue 
area (SAT) were segmented by using standard Hounsfield unit ranges and computed 
for regions of interest. The inter-software, intra-observer, and inter-observer agreement 
for CSMA, VAT, and SAT measurements using FatSeg, OsiriX, ImageJ, and SliceOmatic 
were calculated using intra-class correlation coefficients (ICC) and Bland-Altman 
analyses. Cohen’s κ was calculated for the agreement of sarcopenia and visceral obesity 
assessment. The Jaccard similarity coefficient was used to compare the similarity and 
diversity of measurements.
Results: Bland-Altman analyses and intra-class correlation coefficients indicated that 
the CSMA, VAT, and SAT measurements between the different software programs were 
highly comparable (ICC 0.979-1.000, p<0.001). All programs adequately distinguished 
between the presence or absence of sarcopenia (κ=0.88-0.96 for one observer and 
all k=1.00 for all comparisons of the other observer) and visceral obesity (all κ=1.00). 
Furthermore, excellent intra-observer (ICC 0.999-1.000, p<0.0001) and inter-observer 
agreement (ICC 0.988-0.999, p<0.0001) for all software programs were found. 
Accordingly, excellent Jaccard similarity coefficients were found for all comparisons 
(mean ≥0.964).
Conclusions: FatSeg, OsiriX, ImageJ, and SliceOmatic showed an excellent agreement 
for CSMA, VAT and SAT measurements on abdominal CT scans. Furthermore, excellent 
inter- and intra-observer agreement were achieved. Therefore, results of studies using 
these different software programs can reliably be compared.
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INTRODUCTION
Biological frailty and analytic morphomics (i.e. body composition) have increasingly 
gained interest in recent years in relation to treatment outcomes, such as complications 
and (disease-free) survival 1, 2. Frailty, a state of increased vulnerability towards 
stressors, leads to an increased risk of developing adverse health outcomes 3 and is an 
important predictor of complications after interventional procedures, such as surgery 
and chemotherapy 4-7. For example, frail patients undergoing colorectal surgery have 
a fourfold increased risk to develop major postoperative complications 5. One of the 
hallmark signs of frailty is sarcopenia, the involuntary depletion of skeletal muscle mass 8-11. 
It is estimated that up to 25% of persons under 70 years of age and over 50% of persons 
of 80 years and older experience sarcopenia 12. In addition, up to 80% of patients with 
advanced cancer are affected by cancer-induced cachexia, a clinical condition that also 
results in skeletal muscle wasting with or without the loss of body fat 13-15. Patients with 
cachexia are more prone to a reduced therapy effect 16 and patients with low skeletal 
muscle mass experience increased chemotherapy toxicity 17, 18. This ultimately results in 
death in nearly one third of all cancer patients 19-22.
Over the last years, numerous studies have used abdominal computed tomography 
(CT) scans to quantify skeletal muscle mass, for example in clinical 17, 18, 23-25 and surgical 
oncology 26, vascular surgery 27, and transplantation surgery 28, 29 patients. Furthermore, 
multiple studies measured visceral and/or subcutaneous adipose tissue on CT scans 30-33. 
However, different software programs have been used to perform these body 
composition analyses, such as FatSeg 33, OsiriX 7, ImageJ 24, and SliceOmatic 23. To be 
able to adequately compare study results, the comparability of these various software 
programs should be known. Therefore, the aim of this study was to investigate the 
agreement of these four different software packages for the assessment of cross-
sectional skeletal muscle and subcutaneous and visceral adipose tissue measurements 
on abdominal CT scans.
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METHODS
Patients
Fifty abdominal CT scans of patients who were scheduled for rectal cancer resection 
at Erasmus University Medical Center (Rotterdam, The Netherlands) between 2005 and 
2012 were randomly selected. All CT scans were routinely performed as part of the 
preoperative diagnostic work up or assessment of down staging after neo-adjuvant 
therapy. Only one CT scan was used per patient. None of the patients had an ostomy, 
abdominal wall deformity, abdominal wall tumor, or a CT scan with artefacts at the level 
of L3 that could potentially influence measurements. Self-reported weight and height 
in the preoperative work-up were retrospectively collected from electronic patient files.
Skeletal muscle and adipose tissue area measurements
The cross-sectional skeletal muscle area (CSMA), subcutaneous adipose tissue area 
(SAT) and visceral adipose tissue area (VAT) (cm²), including renal adipose tissue, were 
measured at the mid third lumbar vertebra (L3) level on a slice showing both transversal 
processes. CSMA measurements included the following muscles: psoas, paraspinal, 
transverse abdominal, external oblique, internal oblique and rectus abdominis. All 
abdominal CT scans were assessed on identical slices in a random order by two medically 
trained observers (AG [observer A] and JLAvV [observer B]), with great knowledge 
about radiological anatomy and extensive experience in skeletal muscle and adipose 
tissue area measurements using various software programs. Observer A performed 
measurements twice on identical a priori selected slices, whereas observer B performed 
a second reading without a priori selected slice numbers. The observers were blinded 
for each other’s measurements and for patient details. For each observer the time 
interval between two readings in the same patient with different software programs 
was at least one week. This resulted in an interval of at least four weeks between two 
readings within one patient with the same software program. Only the first reading of 
observer B was used for the inter-software and inter-observer comparisons.
The CSMA was corrected for height squared (m2), resulting in the L3 muscle index 
(SMI, cm2/m2). Patients were classified as having sarcopenia or not having sarcopenia 
according to previously described cut-off values (52.4 cm2/m2 for men and 38.5 cm2/m2 
for women) 23. Predefined cut-off values for visceral adipose tissue area to define visceral 
obesity of 163.8 cm² for men and 80.1 cm² for women were used 34. For subcutaneous 
adipose tissue no cut-off values have been reported in the literature.
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Four software programs were compared: FatSeg (developed by the Biomedical Imaging 
Group Rotterdam of Erasmus MC, Rotterdam, The Netherlands, using MeVisLab (Mevis 
Medical Solutions, Bremen, Germany)), OsiriX (Pixmeo SARL, Geneva, Switzerland), 
ImageJ (National Institutes of Health, Bethesda, Maryland, USA), and SliceOmatic 
(TomoVision, Magog, Canada). CSMA, VAT, and SAT were segmented using standard 
Hounsfield Unit (HU) thresholds in all four software programs. An intensity window 
between -30 HU and +150 HU was used for skeletal muscle tissue 35. For adipose tissue 
an intensity window between -190 HU and -30 HU was used 36. Since the tissue of 
interest is manually selected, competency in anatomic radiology is a prerequisite for 
these measurements.
FatSeg
FatSeg is an in-house developed software program to perform soft tissue measurements 
on CT scans and was developed using the MeVisLab development environment for 
medical image processing and visualization version 2.4 (available from http://www.
mevislab.de). Inner and outer contours of aforementioned skeletal muscle and adipose 
regions were manually traced. The skeletal muscle and adipose tissue areas were 
computed automatically using the preset HU intensity thresholds, and expressed in 
cm2. Intraluminal contents initially marked as adipose tissue were manually erased. 
Cutaneous tissue was included in the SAT measurement. Measurements were performed 
on a 3.2 GHz Intel® Core™ i5 Dell (Dell Inc., Round Rock, TX, USA) personal computer.
OsiriX
The open-source 32-bit edition of OsiriX version 5.8.5 (available from http://www.osirix-
viewer.com) was used. The ‘’Grow Region (2D/3D Segmentation)’’ tool was used to semi-
automatically select skeletal muscle and adipose tissue regions within our preset HU 
intensity thresholds. Non-skeletal muscle tissue regions adjacent to skeletal muscle were 
manually removed from the area selection using the brush option. The brush option 
was also used to manually erase intraluminal areas with contents having radiological 
density between -190 and -30 HU, resembling fatty content. Cutaneous tissue was not 
included in the SAT measurement. The skeletal muscle and adipose tissue areas were 
computed automatically and expressed in cm2 using a 1.3 GHz Intel® Core™ i5 MacBook 
Air (Apple Inc., Cupertino, CA, USA) and computer mouse.
ImageJ
ImageJ version 1.48 is a freely downloadable public domain software program developed 
by the National Institutes of Health for image processing and analyzing (available from 
http://rsbweb.nih.gov/ij/download.html). First, manual delineation of the outer contour 
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of the abdominal wall and paraspinal muscles was performed and the surface area of 
tissue with an attenuation between -30 and +150 HU was computed automatically 
(mm2) and manually divided by 100, resulting in cm2. Second, delineation of the inner 
contour of the abdominal wall, paraspinal and psoas muscles was performed in a similar 
fashion to allow for subsequent correction of intra-abdominal content with attenuation 
between the preset HU intensity thresholds. The inner contour was manually subtracted 
from the outer contour surface area, resulting in the cross-sectional skeletal muscle 
area (cm2) 37. The subcutaneous adipose tissue area measurements were performed 
in a similar manner as the muscle measurements, whereas visceral adipose tissue area 
measurements were performed by delineating a contour through the inner contour of 
the abdominal wall muscles, psoas muscles and vertebrae followed by manual erasing 
of intraluminal fatty content. Cutaneous tissue was included in the SAT measurement. 
A 3.2 GHz Intel® Core™ i5 Dell (Dell Inc., Round Rock, TX, USA) personal computer was 
used.
SliceOmatic
SliceOmatic (TomoVIsion, Magog, Canada) version 5.0 (64 bit; available from http://www.
tomovision.com/) was used. Tissue was semi-automatically selected with the ‘Region 
Growing’ mode using the ‘Grow 2D’ and ‘Paint’ tools. Non-skeletal muscle tissue regions 
adjacent to skeletal muscle having radiological density between the predefined HU 
thresholds were manually erased using the ‘Paint’ tool. Cutaneous tissue was included 
in the SAT measurement. A 3.2 GHz Intel® Core™ i5 Dell (Dell Inc., Round Rock, TX, USA) 
personal computer was used.
Cutaneous tissue disclosure
In OsiriX, cutaneous tissue is not included in the SAT measurement, because this is not 
automatically selected using the ‘’Grow Region (2D/3D Segmentation)’’ tool. SliceOmatic 
also allows to exclude encompassed skin. However, not all software programs allow to 
reliably exclude cutaneous tissue from SAT as a consequence of their measurement 
method: the delineation of tissue of interest using inner and outer contours. 
Consequently, to ensure highly comparable measurements in three rather than two 
software programs, cutaneous tissue was included in the SAT measurements with 
SliceOmatic. A comparison of SAT measurements using SliceOmatic with and without 
the inclusion of cutaneous tissue resulted in a median difference of 2.3% (interquartile 
range 0.8-3.8) and was considered acceptable.
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Statistical analysis
Continuous data are presented as mean with the standard error of the measurement 
(SEM). Normality was tested using the Shapiro-Wilk test. Differences between the 
different software packages and within and between observers were compared using 
the paired samples t-test for normally distributed data and the Wilcoxon signed rank 
test for data that was not normally distributed. The inter-software and inter- and intra-
observer agreement for the cross-sectional skeletal muscle, visceral adipose tissue 
and subcutaneous adipose tissue measurements were calculated using intra-class 
correlation coefficients (ICC) with 95% confidence intervals (CI) using a two-way mixed 
single measures model with absolute agreement. For the inter-observer correlation, the 
reading of observer B was compared with reading 1 of observer A. Ninety-five % limits 
of agreement were determined to investigate the agreement between the various 
software programs, according to the method described by Bland and Altman 38. The 
presence of proportional systematic bias was determined by linear regression analysis of 
the difference and mean of two measurements. The inter-software and inter- and intra-
observer agreement of the assessment of sarcopenia and visceral obesity were analyzed 
using Cohen’s κ coefficients. The ICC and Cohen’s κ coefficients were interpreted as poor 
(0.00-0.49), fair to good (0.50-0.74) and excellent (0.75-1.00), as proposed by Shrout and 
Fleiss 39. The Jaccard similarity coefficient, ranging from 0-1, was used to compare the 
similarity and diversity of measurements by dividing the area of the intersection by the 
size of the union of two measurements 40. An overlay of two measurements was created 
and the Jaccard similarity coefficient was calculated using MeVisLab version 2.7.1 (MeVis 
Medical Solutions AG, Bremen, Germany). A Jaccard similarity coefficient of 1 represents 
perfect overlap of two samples, whereas 0 represents no overlap. Two-tailed p-values 
<0.05 were considered statistically significant. All statistical analyses were performed 
using IBM SPSS Statistics for Windows version 21.0 (IBM Corp. Armonk, NY, USA).
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RESULTS
Patients
The study population consisted of 29 males (58%) and 21 females (42%) with a median 
age of 62 years (range 33 - 81) and a median body mass index (BMI) of 24.6 kg/m2 (range 
16.5 - 38.8). Ten patients had stage II (20.0%), 24 stage III (48.0%) and 15 stage IV (30.0%) 
rectal cancer. Tumor stage was unknown for one patient. The mean CSMA, VAT, and SAT 
for all measurements are provided in table 1 and table 2.
Inter-software agreement
The inter-software ICCs were excellent (≥0.999) for the CSMA, VAT, and SAT for all software 
programs with p-values <0.001 (table 3). Figure 1 and supplementary figures 1 and 2 
show the Bland-Altman 95% limits of agreement plots, with the mean difference and 
95% limits of agreement for the CSMA, VAT, and SAT for both observers. All plots show a 
good agreement between the various software programs. Small limits of agreement are 
observed in the CSMA measurements, whereas these limits of agreement are greater for 
the VAT and SAT measurements. Proportional systematic bias was observed between 
FatSeg and OsiriX for CSMA (p=0.049) for observer B (figure 1a) and between FatSeg and 
SliceOmatic for SAT (p=0.031) for observer A (supplementary figure 2c). Furthermore, 
proportional systematic bias was frequently observed between programs for VAT 
measurements (supplementary figure 1). Comparable results were achieved when non 
a priori selected slices of observer B were analyzed (data not shown). The mean Jaccard 
similarity coefficients for the inter-software comparisons are summarized in table 4 and 
depicted in figure 2.
Intra-observer and inter-observer agreement
The ICCs for the intra-observer agreement of observer A were all 0.979 or higher for 
the different software programs, approaching perfect correlation (table 1). The ICCs 
for the inter-observer agreement also approached perfect agreement (all ≥0.999, see 
table 2). The mean CSMA was significantly lower for observer A compared with observer 
B for all software programs. A significantly higher mean VAT of observer A was found 
using FatSeg (149.9 cm² versus 148.7 cm², p<0.001) and ImageJ (148.6 cm² versus 148.4 
cm², p=0.015) compared with observer B, whereas the mean VAT of both observers 
did not significantly differ for OsiriX (p=0.133) and SliceOmatic (p=0.412). The mean 
SAT did significantly differ for FatSeg (158.9 cm² versus 159.2 cm², p=0.005) between 
the observers. Comparable results were observed when non a priori selected slices of 
reading 2 of observer B were used for analyses (data not shown). The mean Jaccard 
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similarity coefficients for the inter- and intra-observer comparisons are summarized 
in table 5 and depicted in supplementary figures 3 and 4. All remaining worst Jaccard 
similarity coefficients are provided in supplementary figure 5.
Table 1. Mean cross-sectional skeletal muscle and visceral and subcutaneous adipose tissue 
area (cm2) measurements and intra-observer agreement indices (i.e. ICC) using FatSeg, OsiriX, 
ImageJ, and SliceOmatic of observer A. SEM, standard error of measurement; ICC, inter- and 
intra-class correlation coefficients; CI confidence intervals. 
Software
Observer A
Reading 1
(cm2) 
SEM
Reading 2
(cm2)
SEM
Mean difference
(95% CI)
p-value ICC (95% CI)
Skeletal muscle area
FatSeg 139.0 5.2 139.3 5.2 -0.3 (-0.6; 0.0) 0.072*
0.999 
(0.999-1.000)
OsiriX 139.4 5.2 138.7 5.1 0.7 (0.4; 1.0) <0.001*
0.999 
(0.999-1.000)
ImageJ 139.0 5.2 139.3 5.1 -0.3 (-0.6; -0.1) 0.013*
1.000 
(0.999-1.000)
SliceOmatic 138.7 5.2 138.6 5.2 0.1 (-0.2; 0.4) 0.441*
1.000 
(0.999-1.000)
Visceral adipose tissue area
FatSeg 149.9 13.1 149.2 13.1 0.7 (0.3; 1.0)
<0.001# 1.000 
(1.000-1.000)
OsiriX 147.6 13.0 147.3 13.0 0.3 (-0.3; 0.8)
0.220# 1.000 
(1.000-1.000)
ImageJ 148.6 13.0 150.8 12.8 -2.2 (-7.5; 3.1)
0.003# 0.979 
(0.964-0.988)
SliceOmatic 147.1 13.0 146.6 13.0 0.5 (0.2; 0.9)
0.004# 1.000 
(1.000-1.000)
Subcutaneous adipose tissue area
FatSeg 158.9 11.2 158.9 11.2 0.1 (-0.2; 0.3) 0.359#
1.000 
(1.000-1.000)
OsiriX 155.9 11.2 155.7 11.3 0.2 (-0.1; 0.4) 0.137#
1.000 
(1.000-1.000)
ImageJ 158.9 11.2 159.1 11.3 -0.2 (-0.5; 0.0) 0.201#
1.000 
(1.000-1.000)
SliceOmatic 158.8 11.3 158.8 11.3 0.0 (-0.3; 0.2) 0.448#
1.000 
(1.000-1.000)
Calculated with *paired-samples t-test and #Wilcoxon signed rank test
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Table 2. Mean cross-sectional skeletal muscle and visceral and subcutaneous adipose tissue 
area (cm2) measurements and inter-observer agreement indices (i.e. ICC) using FatSeg, OsiriX, 
ImageJ, and SliceOmatic of reading 1 of observer A and observer B. SEM, standard error of 
measurement; ICC, inter- and intra-class correlation coefficients; CI confidence intervals. 
Software
Observer A Observer B
Mean difference
(95% CI)
p-value
ICC (95% CI)
Reading 1
(cm2)
SEM
Reading 1
(cm2)
SEM
Skeletal muscle area (CSMA)
FatSeg 139.0 5.2 140.1 5.2 -1.1 (-1.4; -0.8) <0.001*
0.999 
(0.989-1.000)
OsiriX 139.4 5.2 139.7 5.1 -0.3 (-0.5; 0.0) 0.047*
1.000 
(0.999-1.000)
ImageJ 139.0 5.2 139.8 5.2 -0.8 (-1.0; -0.5) <0.001*
0.999 
(0.997-1.000)
SliceOmatic 138.7 5.2 139.3 5.2 -0.6 (-0.9; -0.2) 0.006*
0.999 
(0.998-1.000)
Visceral adipose tissue area (VAT)
FatSeg 149.9 13.1 148.7 13.1 1.2 (0.8; 1.5) <0.001#
1.000
(0.999-1.000)
OsiriX 147.6 13.0 147.3 13.0 0.3 (-0.3; 0.8) 0.133#
1.000
(1.000-1.000)
ImageJ 148.6 13.0 148.4 13.1 0.3 (-0.1; 0.6) 0.015#
1.000
(1.000-1.000)
SliceOmatic 147.1 13.0 146.9 13.0 0.2 (-0.1; 0.5) 0.412#
1.000
(1.000-1.000)
Subcutaneous adipose tissue area (SAT)
FatSeg 158.9 11.2 159.2 11.3 -0.3 (-0.5; -0.1) 0.005#
1.000
(1.000-1.000)
OsiriX 155.9 11.2 155.8 11.3 0.1 (-0.3; 0.5) 0.918#
1.000
(1.000-1.000)
ImageJ 158.9 11.2 158.7 11.2 0.2 (-0.2; 0.5) 0.306#
1.000
(1.000-1.000)
SliceOmatic 158.8 11.3 158.5 11.2 0.2 (0.0; 0.5) 0.183#
1.000
(1.000-1.000)
Calculated with *paired-samples t-test and #Wilcoxon signed rank test
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Table 3. Mean cross-sectional skeletal muscle and visceral and subcutaneous adipose tissue 
area (cm2) measurements and inter-software agreement indices (i.e. ICC) using FatSeg, OsiriX, 
ImageJ, and SliceOmatic of reading 1 of observer B. The results of observer A are comparable 
with those of observer B. SEM, standard error of measurement; ICC, inter- and intra-class 
correlation coefficients; CI confidence intervals.
Software program
Mean difference (cm²)
(95% CI)
SEM p-value
ICC
(95% CI)
Skeletal muscle area (CSMA)
FatSeg – OsiriX -0.4 (-0.8; 0.0) 0.184 0.047 0.999 (0.999-1.000)
FatSeg – ImageJ 0.0 (-0.3; 0.3) 0.151 0.992 1.000 (0.999-1.000)
FatSeg – SliceOmatic 0.3 (-0.2; 0.8) 0.230 0.207 0.999 (0.998-0.999)
OsiriX – ImageJ 0.4 (0.1; 0.7) 0.161 0.023 0.999 (0.999-1.000)
OsiriX – SliceOmatic 0.7 (0.3; 1.1) 0.189 0.001 0.999 (0.998-1.000)
ImageJ – SliceOmatic 0.3 (-0.1; 0.7) 0.208 0.165 0.999 (0.999-1.000)
Visceral adipose tissue area (VAT)
FatSeg – OsiriX 2.3 (1.6; 2.9) 0.326 <0.001 0.999 (0.995-1.000)
FatSeg – ImageJ 1.2 (0.8; 1.7) 0.203 <0.001 1.000 (0.999-1.000)
FatSeg – SliceOmatic 2.8 (2.3; 3.2) 0.238 <0.001 0.999 (0.971-1.000)
OsiriX – ImageJ -1.0 (-1.5; -0.6) 0.237 <0.001 1.000 (0.999-1.000)
OsiriX – SliceOmatic 0.5 (0.0; 0.9) 0.229 0.044 1.000 (1.000-1.000)
ImageJ – SliceOmatic 1.5 (1.2; 1.8) 0.158 <0.001 1.000 (0.995-1.000)
Subcutaneous adipose tissue area (SAT)
FatSeg – OsiriX 3.0 (2.5; 3.6) 0.256 <0.001 0.999 (0.948-1.000)
FatSeg – ImageJ 0.1 (-0.3; 0.4) 0.180 0.698 1.000 (1.000-1.000)
FatSeg – SliceOmatic 0.2 (-0.1; 0.5) 0.141 0.240 1.000 (1.000-1.000)
OsiriX – ImageJ -3.0 (-3.5; -2.5) 0.260 <0.001 0.999 (0.956-1.000)
OsiriX – SliceOmatic -2.9 (-3.3; -2.5) 0.211 <0.001 0.999 (0.932-1.000)
ImageJ – SliceOmatic 0.1 (-0.2; 0.4) 0.139 0.485 1.000 (1.000-1.000)
van_Vugt-layout.indd   33 22/11/2017   12:42
34
Chapter 2
Table 4. Mean Jaccard indices for inter-software comparisons of reading 1 of observer A and 
reading 1 of observer B. CSMA, cross-sectional muscle area; VAT, visceral adipose tissue area, 
SAT, subcutaneous adipose tissue area.
Mean Jaccard similarity coefficients
Observer A (reading 1) (range) Observer B (reading 1) (range)
CSMA VAT SAT CSMA VAT SAT
FatSeg – 
OsiriX 
0.978
(0.940-0.997)
0.964
(0.825-0.996)
0.965
(0.928-0.976)
0.983
(0.948-0.997)
0.973
(0.886-0.997)
0.965
(0.926-0.998)
FatSeg – 
ImageJ
0.982
(0.935-0.996)
0.981
(0.912-0.999)
0.988
(0.900-0.999)
0.987
(0.959-0.998)
0.981
(0.903-0.998)
0.990
(0.968-0.998)
FatSeg – 
SliceOmatic
0.978
(0.937-0.996)
0.970
(0.908-0.997)
0.989
(0.964-0.998)
0.981
(0.927-0.996)
0.972
(0.860-0.997)
0.987
(0.960-0.998)
OsiriX – 
ImageJ
0.982
(0.935-0.996)
0.968
(0.856-0.995)
0.964
(0.900-0.998)
0.983
(0.948-0.997)
0.976
(0.891-0.998)
0.966
(0.927-0.997)
OsiriX – 
SliceOmatic
0.979
(0.941-0.997)
0.974
(0.876-0.997)
0.988
(0.900-0.998)
0.985
(0.944-0.997)
0.973
(0.884-0.998)
0.967
(0.923-0.998)
ImageJ – 
SliceOmatic
0.979
(0.950-0.994)
0.967
(0.809-0.995)
0.966
(0.928-0.997)
0.983
(0.932-0.997)
0.975
(0.855-0.998)
0.988
(0.965-0.999)
Table 5. Mean Jaccard indices for inter-observer (reading 1 of observer A versus reading 1 of 
observer B) and intra-observer comparisons (reading 1 versus reading 2 of observer A). CSMA, 
cross-sectional muscle area; VAT, visceral adipose tissue area, SAT, subcutaneous adipose tissue 
area.
Mean Jaccard similarity coefficients
Inter-observer (range) Intra-observer (range)
CSMA VAT SAT CSMA VAT SAT
FatSeg
0.981
(0.949-0.997)
0.976
(0.908-0.998)
0.991
(0.969-0.999)
0.982
(0.961-1.000)
0.984
(0.916-0.999)
0.991
(0.956-1.000)
OsiriX
0.985
(0.960-0.997)
0.973
(0.835-0.997)
0.989
(0.960-1.000)
0.984
(0.953-0.997)
0.975
(0.838-0.998)
0.990
(0.967-1.000)
ImageJ
0.982
(0.931-0.993)
0.980
(0.905-0.997)
0.988
(0.899-0.999)
0.985
(0.948-1.000)
0.982
(0.891-0.998)
0.990
(0.900-1.000)
SliceOmatic
0.981
(0.939-0.997)
0.976 
(0.876-0.996)
0.989
(0.959-0.999)
0.986
(0.961-0.997)
0.980
(0.901-0.998)
0.993
(0.967-1.000)
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Figure 1. Bland-Altman 95% limits of agreement plots for the agreement between the various 
software programs (provided on the X-axes and Y-axes) for CSMA (cm2). The dotted lines are the 
mean of the difference and the 95% limits of agreement (± 2 SD) between the CSMA of reading 
1 of observer A and the solid lines of reading 1 of observer B.
Figure 1a. There was no proportional systematic bias for observer A (p=0.908), whereas there 
was significant bias for observer B (p=0.049).
Figure 1b. There was no proportional systematic bias for any observer (p=0.738 and p=0.359).
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Figure 1c. There was no proportional systematic bias for any observer (p=0.238 and p=0.704).
Figure 1d. There was no proportional systematic bias for any observer (p=0.857 and p=0.363).
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Figure 1e. There was no proportional systematic bias for any observer (p=0.185 and p=0.228).
Figure 1f. There was no proportional systematic bias for any observer (p=0.289 and p=0.843).
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Figure 2. Jaccard similarity coefficients (lowest and highest are shown) for inter-software 
comparisons of CSMA, VAT, and SAT (cm2) measurements (reading 1 of observer B). The green 
area represents similarity, whereas the red area represents discrepancy in measurements.
Figure 2a. The CSMA measured with FatSeg and ImageJ (1) and FatSeg and SliceOmatic (2), 
resulting in Jaccard similarity coefficients of 0.998 and 0.927, respectively.
Figure 2b. The VAT measured with ImageJ and SliceOmatic (1 and 2), resulting in Jaccard 
similarity coefficients of 0.998 and 0.855, respectively.
Figure 2c. The SAT measured with ImageJ and SliceOmatic (1) and OsiriX and SliceOmatic (2), 
resulting in Jaccard similarity coefficients of 0.999 and 0.923, respectively.
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The classification of sarcopenia and visceral obesity
The inter-software Cohen’s κ’s of the first reading of observer A for the classification 
of sarcopenia were 0.96 (between FatSeg and Osirix, OsiriX and ImageJ, and ImageJ 
and SliceOmatic), 0.92 (between FatSeg and ImageJ, and Osirix and SliceOmatic), and 
0.88 (between FatSeg and SliceOmatic). No inter-software differences were found in 
the classification of patients with and without sarcopenia for observer B. According to 
the cut-off values used, all software programs diagnosed sarcopenia in 16 men (55.2%) 
and 8 women (38.1%). This resulted in a Cohen’s κ of 1.00 for all comparisons between 
software programs (p<0.001).
The Cohen’s κ for the intra-observer agreement of sarcopenia assessment of observer 
A was 0.96 using FatSeg and ImageJ and 1.00 for OsiriX and SliceOmatic (all p<0.001).
The Cohen’s κ for the inter-observer agreement (reading 1 of observer A versus observer 
B) of sarcopenia assessment was 0.92 for SliceOmatic, 0.96 for FatSeg and ImageJ, and 
1.00 for Osirix (all p<0.001).
The classification of visceral obesity
In total, 17 men (58.6%) and 9 women (42.9%) were classified as visceral obese using 
FatSeg, OsiriX, ImageJ, and SliceOmatic in all readings. This resulted in a Cohen’s κ of 
1.00 for all comparisons (all p<0.001).
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DISCUSSION
This study shows that the inter-software agreement was excellent for all software 
programs. Furthermore, the inter-observer and intra-observer agreements were 
excellent for four distinct software programs to assess CSMA, VAT, and SAT on abdominal 
CT scans with high Jaccard similarity coefficients.
Body composition analyses using abdominal CT scans are increasingly being performed. 
In multiple surgical populations, such as vascular 27, gastrointestinal 7, 33, urological 41-43, 
gynecological 44 and transplantation surgery 29, the association between low skeletal 
muscle mass and an increased risk of postoperative complications, recurrent disease, or 
impaired survival has been shown. Low skeletal muscle mass is also related to discharge 
destination in elderly trauma patients 45, associated with an increased risk of dose-
limiting chemotherapy toxicity 17, 24, 25, 46 and with morbidity and mortality in various 
oncologic populations, such as lung cancer and melanoma patients 47, 48. Furthermore, 
CT-assessed visceral obesity is associated with worse short- and long-term outcome in 
distinct patient populations undergoing surgery 30. Various software programs have 
been used to measure body composition in these studies. The current study shows that 
the results of these studies can reliably be compared. Based on our findings it is likely 
that this is also true for other software programs which similarly compute skeletal muscle 
area by quantifying selected voxels within preset HU intensity thresholds (e.g., studies 
that used software programs designed in MATLAB [MathWorks, Natick, MA, USA] 49). 
Software programs for various body composition measurements on CT images, such 
as adipose tissue surface area, skeletal muscle tissue surface area and liver volumetric 
measurements, have been compared in multiple previous studies, demonstrating high 
levels of agreement 50-53. Excellent agreement levels between SliceOmatic and ImageJ 54, 
as well as between observers using SliceOmatic 55 for CSMA measurements have 
previously been reported. Furthermore, excellent agreement levels between OsiriX 
and ImageJ have been observed for paraspinal muscle measurements on magnetic 
resonance images 56. Nevertheless, this is the first study to compare multiple software 
programs for the measurement of CSMA, VAT, and SAT, showing that previous studies 
investigating the association between skeletal muscle mass on the one side and visceral 
or subcutaneous adipose tissue on the other side, and patient outcomes can reliably be 
compared.
The skeletal muscle area (cm2) measured at a single cross-sectional CT image at the 
level of the third lumbar vertebra (L3) is linearly related to total body skeletal muscle 
mass 57 and is therefore corrected for height squared (m2), as is conventional for 
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body composition measures. This results in the L3 muscle index (cm2/m2) 18. Another 
frequently used method is measuring the total psoas area (TPA) 27. The principle of 
TPA measurements is identical to L3 muscle area measurements, using single cross-
sectional CT images. Therefore, the findings of this study may be extrapolated to TPA 
measurements as well. Nevertheless, this should be confirmed in a future study.
Significant differences were observed between the mean skeletal muscle areas within 
and between observers. However, these mean differences are small and consequently 
not clinically relevant. Differences in individual measurements resulted, for instance, 
from the incorrect annotation of skeletal muscle tissue (see figure 2a2 for an example 
of an intra-observer difference). However, we decided not to correct measurements 
in retrospect to show inter- and intra-observer agreements. In our opinion, this study 
reflects daily practice, with observers who have excellent (radiological) anatomical 
knowledge performing body composition measurements. Regardless of these human 
errors and some inter- and intra-observer differences, high comparability between 
software programs was observed.
Significant differences between VAT measurements were also observed with greater 
mean differences between software. This could due to the greater complexity of the 
measurement technique, as intraluminal content (i.e. fat in stool) needs to be manually 
erased. The greatest significant mean differences in SAT could partly been explained 
by the fact that in OsiriX the cutaneous adipose tissue in not included in the SAT, in 
contrast to the other software programs. Furthermore, every tissue of interest needs to 
be manually selected in OsiriX, in contrast to the other programs in which methods of 
delineating or a painting brush can be used to select regions of interest.
Significant differences in the mean VAT (FatSeg and ImageJ) within observer A and in 
the mean VAT (FatSeg OsiriX, and SliceOmatic) and SAT (FatSeg, OsiriX, and ImageJ) 
between observers (reading 2 of observer A with non a priori selected slices; data not 
shown) were found, whereas the CSMA did not significantly differ. One explanation 
for the differences in VAT and SAT could be the random slice selection. After all, the 
distribution of the intra-abdominal content (e.g., bowel) can greatly differ between 
slices. Consequently, single slice measurement of visceral adipose tissue would not 
be clinical applicable and should be reserved for clinical research of patient cohorts 
rather than individual patients. For SAT, the variance of subcutaneous adipose tissue 
distribution could have led to the observed differences. Nevertheless, all differences are 
relatively small and could therefore be considered as not clinically relevant The inter-
observer agreement levels for OsiriX and SliceOmatic are in line with previous studies 
that showed a strong and significant correlation between CSMA measurements of 
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two observers 7, 55. The inter-observer agreements for FatSeg and ImageJ have never 
been reported before, whereas a high agreement for the classification of patients with 
sarcopenia, as expressed in Cohen’s κ, has previously been reported 7.
Several limitations apply to the current study and the used software programs. First, 
both observers in the current study were experienced in quantifying skeletal muscle 
mass using these software programs prior to conducting this study. Therefore, the 
agreement rates that were obtained may not apply to less experienced users. Second, 
OsiriX is only compatible with Macintosh, which is less commonly used in clinical 
practice. Furthermore, FatSeg is not freely downloadable as it is an in-house developed 
software program that has not been made publically available, in contrast to OsiriX and 
ImageJ. A license is required for the use of SliceOmatic. Third, this study could only assess 
the agreement of the measurement with different software programs on the same data. 
Intra- and inter-scanner reproducibility of the measurement could not be assessed with 
the current study design. Lastly, previous studies reported an approximate time of eight 
minutes to quantify skeletal muscle, visceral and subcutaneous adipose tissue in liver 
transplant patients using SliceOmatic 55. Although some differences in user-friendliness 
were observed while performing the measurements, these were not objectively 
observed and scored in the current study. Consequently, these are not described.
In conclusion, this study showed that four different software programs have an excellent 
agreement to measure VAT and SAT, and CSMA in particular on abdominal CT scans, 
which enables reliable comparison of results of studies that use these different software 
programs. Multiple slice analysis is preferred for VAT and SAT measurements.
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SUPPLEMENTARY MATERIAL
Supplementary figure 1. Bland-Altman 95% limits of agreement plots for the agreement 
between the various software programs (provided on the X-axes and Y-axes) for VAT (cm2). The 
dotted lines are the mean of the difference and the 95% limits of agreement (± 2 SD) between 
the VAT of reading 1 of observer A and the solid lines of reading 1 of observer B.
Supplementary figure 1a. There 
was proportional systematic bias for 
both observers (p=0.004 and p=0.043, 
respectively).
Supplementary figure 1b. There was 
proportional systematic bias for observer A 
(p=0.038), but not for observer B (p=0.154).
Supplementary figure 1c. There was 
proportional systematic bias for both 
observers (both p=0.002).
Supplementary figure 1d. There was 
proportional systematic bias for observer A 
(p=0.045), whereas there was no proportional 
systematic bias for observer B (p=0.202).
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Supplementary figure 1e. There was no 
proportional systematic bias for any observer 
(p=0.412 and p=0.114, respectively).
Supplementary figure 1f. There was no 
proportional systematic bias for observer A 
(p=0.068), whereas there was significant bias 
for observer B (p=0.014).
Supplementary figure 2. Bland-Altman 95% limits of agreement plots for the agreement 
between the various software programs (provided on the X-axes and Y-axes) for SAT (cm2). The 
dotted lines are the mean of the difference and the 95% limits of agreement (± 2 SD) between 
the SAT of reading 1 of observer A and the solid lines of reading 1 of observer B.
Supplementary figure 2a. There was no 
proportional systematic bias for any observer 
(p=0.534 and p=0.801, respectively).
Supplementary figure 2b. There was no 
proportional systematic bias for any observer 
(p=0.538 and p=0.112, respectively).
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Supplementary figure 2c. There was 
proportional systematic bias for observer A 
(p=0.031), whereas there was no proportional 
systematic bias for observer B (p=0.134).
Supplementary figure 2d. There was no 
proportional systematic bias for any observer 
(p=0.853 and p=0.344, respectively).
Supplementary figure 2e. There was no 
proportional systematic bias for any observer 
(p=0.511 and p=0.305, respectively).
Supplementary figure 2f. There was no 
proportional systematic bias for any observer 
(p=0.175 and p=0.939, respectively).
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Supplementary figure 3. Jaccard similarity coefficients (lowest and highest are shown) for 
inter-observer comparisons of CSMA, VAT, and SAT (cm2) measurements (reading 1 of observer 
A versus reading 1 of observer B). The green area represents similarity, whereas the red area 
represents discrepancy in measurements.
Supplementary figure 3a. 
The CSMA measured with 
FatSeg (1) and ImageJ (2), 
resulting in Jaccard similarity 
coefficients of 0.997 and 
0.931, respectively.
Supplementary figure 
3b. The VAT measured with 
FatSeg (1) and OsiriX (2), 
resulting in Jaccard similarity 
coefficients of 0.998 and 
0.835, respectively.
Supplementary figure 
3c. The SAT measured with 
OsiriX (1) and ImageJ (2), 
resulting in Jaccard similarity 
coefficients of 1.000 and 
0.899, respectively.
Supplementary figure 4. Jaccard similarity coefficients (lowest and highest are shown) for 
intra-observer comparisons of CSMA, VAT, and SAT (cm2) measurements (reading 1 versus 
reading 2 of observer A). The green area represents similarity, whereas the red area represents 
discrepancy in measurements.
Supplementary figure 4a. 
The CSMA measured with 
FatSeg (1) and OsiriX (2), 
resulting in Jaccard similarity 
coefficients of 1.000 and 
0.953, respectively.
Supplementary figure 
4b. The VAT measured with 
FatSeg (1) and OsiriX (2), 
resulting in Jaccard similarity 
coefficients of 0.999 and 
0.838, respectively.
Supplementary figure 
4c. The SAT measured with 
ImageJ (1 and 2), resulting in 
Jaccard similarity coefficients 
of 1.000 and 0.900, 
respectively. Furthermore, a 
Jaccard similarity coefficient 
of 1.000 was also observed in 
two other patients measured 
with FatSeg and OsiriX.
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Supplementary figure 5. All worst Jaccard similarity coefficients for the inter-software (5a), 
inter-observer (5b) and intra-observer (5c) agreement for the three body composition analyses 
except the ones that are shown in figure 2 and supplementary figures 2 and 3.
Supplementary figure 5a1a. 
CSMA measured with FatSeg 
and Image resulting in a 
Jaccard similarity coefficient 
of 0.959.
Supplementary figure 5a1b. 
CSMA measured with FatSeg 
and OsiriX resulting in a 
Jaccard similarity coefficient 
of 0.948.
Supplementary figure 5a1c. 
CSMA measured with ImageJ 
and OsiriX resulting in a 
Jaccard similarity coefficient 
of0.948.
Supplementary figure 5a1d. 
CSMA measured with ImageJ 
and SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.932.
Supplementary figure 5a1e. 
CSMA measured with OsiriX 
and SliceOmatic resulting in a 
Jaccard similarity coefficient 
of0.944.
Supplementary figure 5a2a. 
VAT measured with FatSeg 
and ImageJ resulting in a 
Jaccard similarity coefficient 
of0.903.
Supplementary figure 5a2b. 
VAT measured with FatSeg 
and OsiriX resulting in a 
Jaccard similarity coefficient 
of 0.886.
Supplementary figure 5a2c. 
VAT measured with FatSeg 
and SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.860.
Supplementary figure 5a2d. 
VAT measured with ImageJ 
and OsiriX resulting in a 
Jaccard similarity coefficient 
of 0.891.
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Supplementary figure 5a2e. 
VAT measured with OsiriX 
and SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.884.
Supplementary figure 5a3a. 
SAT measured with FatSeg 
and ImageJ resulting in a 
Jaccard similarity coefficient 
of0.968.
Supplementary figure 5a3b. 
SAT measured with FatSeg 
and OsiriX resulting in a 
Jaccard similarity coefficient 
of 0.926.
Supplementary figure 5a3c. 
SAT measured with FatSeg 
and SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.960.
Supplementary figure 5a3d. 
SAT measured with ImageJ 
and OsiriX resulting in a 
Jaccard similarity coefficient 
of 0.927.
Supplementary figure 5a3e. 
SAT measured with ImageJ 
and SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.965.
Supplementary figure 
5b1a. CSMA measured with 
FatSeg resulting in a Jaccard 
similarity coefficient of 0.949.
Supplementary figure 
5b1b. CSMA measured with 
OsiriX resulting in a Jaccard 
similarity coefficient of 0.931.
Supplementary figure 
5b1c. CSMA measured with 
SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.939.
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Supplementary figure 
5b2a. VAT measured with 
FatSeg resulting in a Jaccard 
similarity coefficient of 0.908.
Supplementary figure 
5b2b. VAT measured with 
ImageJ resulting in a Jaccard 
similarity coefficient of 0.905.
Supplementary figure 
5b2c. VAT measured with 
SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.876.
Supplementary figure 
5b3a. SAT measured with 
FatSeg resulting in a Jaccard 
similarity coefficient of 0.969.
Supplementary figure 
5b3b. SAT measured with 
OsiriX resulting in a Jaccard 
similarity coefficient of 0.961.
Supplementary figure 
5b3c. SAT measured with 
SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.959.
Supplementary figure 
5c1a. CSMA measured with 
FatSeg resulting in a Jaccard 
similarity coefficient of 0.961.
Supplementary figure 
5c1b. CSMA measured with 
ImageJ resulting in a Jaccard 
similarity coefficient of 0.948.
Supplementary figure 
5c1c. CSMA measured with 
SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.961.
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Supplementary figure 
5c2a. VAT measured with 
FatSeg resulting in a Jaccard 
similarity coefficient of 0.916.
Supplementary figure 
5c2b. VAT measured with 
ImageJ resulting in a Jaccard 
similarity coefficient of 0.891.
Supplementary figure 
5c2c. VAT measured with 
SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.901.
Supplementary figure 
5c3a. SAT measured with 
FatSeg resulting in a Jaccard 
similarity coefficient of 0.956.
Supplementary figure 
5c3b. SAT measured with 
OsiriX resulting in a Jaccard 
similarity coefficient of 0.967.
Supplementary figure 
5c3c. SAT measured with 
SliceOmatic resulting in a 
Jaccard similarity coefficient 
of 0.967.
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Contrast-Enhancement Influences Skeletal 
Muscle Density, but not Skeletal Muscle Mass, 
Measurements on Computed Tomography
J.L.A. van Vugt, R.R.J. Coebergh van den Braak, K.M. Veen, H.J. Schippers, S. Levolger, 
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ABSTRACT
Background: Low skeletal muscle mass and density have recently been discovered as 
prognostic and predictive parameters to guide interventions in various populations, 
including cancer patients. The gold standard for body composition analysis in cancer 
patients is computed tomography (CT). To date, the effect of contrast-enhancement on 
muscle composition measurements has not been established. The aim of this study was 
to determine the effect of contrast-enhancement on skeletal muscle mass and density 
measurements on four-phase CT studies.
Methods: In this observational study, two observers measured cross-sectional skeletal 
muscle area corrected for patients’ height (skeletal muscle index [SMI]) and density 
(SMD) at the level of the third lumbar vertebra on 50 randomly selected CT-examinations 
with unenhanced, arterial, and portal-venous phases. The levels of agreement between 
enhancement phases for SMI and SMD were calculated using intra-class correlation 
coefficients (ICCs).
Results: Mean SMI was 42.5 (±9.9) cm2/m2 on the unenhanced phase, compared with 
42.8 (±9.9) and 43.6 (±9.9) cm2/m2 for the arterial and portal-venous phase, respectively 
(both p<0.01). Mean SMD was lower for the unenhanced phase (30.9±8.0 Hounsfield 
Units [HU]) compared with the arterial (38.0±9.9 HU) and portal-venous (38.7±9.2 HU) 
phase (both p<0.001). No significant difference was found between SMD in the portal-
venous and arterial phase (p=0.161). The ICCs were excellent (≥0.992) for all SMIs and for 
SMD between the contrast-enhanced phases (0.949). The ICCs for the unenhanced phase 
compared with the arterial (0.676) and portal-venous (0.665) phase were considered fair 
to good.
Conclusions: Statistically significant differences in SMI were assessed between different 
enhancement phases. However, further work is needed to assess the clinical relevance 
of these small differences. Contrast-enhancement strongly influenced SMD values. 
Studies using this measure should therefore use the portal-venous phase of contrast-
enhanced CT-examinations.
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INTRODUCTION
The involuntary loss of skeletal muscle mass, quality and function is considered 
to be a result of aging (i.e. sarcopenia), or as part of muscle wasting syndromes (i.e. 
cancer cachexia, chronic diseases, bed rest) 1-3. Low skeletal muscle mass has recently 
been identified as a prognostic factor for treatment outcome and survival in various 
populations, such as in cancer and liver transplant patients 4, 5. Furthermore, it is 
associated with an increased risk of postoperative complications, chemotherapy 
toxicity and increased hospital expenditure 4, 6-8. Low skeletal muscle density, a measure 
for intramuscular adipose content and muscle quality, has recently been described as 
a risk factor for mortality in patients with lymphoma, melanoma, metastatic renal cell 
carcinoma, pancreatic carcinoma, and metastatic gastric cancer 9-13. Body composition 
measures may guide future interventions to manage skeletal muscle wasting and to 
increase patients’ resistance towards stressors, such as surgery and chemotherapy 14.
The gold standard and most used modality to assess body composition is computed 
tomography (CT) due to its wide availability, especially in cancer patients 15-17. Excellent 
inter-observer and intra-observer agreement, as well as excellent comparability of 
various commonly used software programs for skeletal muscle mass measurement have 
previously been described 18. However, the effect of contrast-enhancement on skeletal 
muscle mass and density measurements remains unclear. It is well-known that contrast-
enhancement may influence tissue attenuation 19 and may consequently influence 
skeletal muscle mass and density measurements. Nevertheless, various enhancement 
phases have been used in studies that investigated the association between CT-assessed 
skeletal muscle mass and density and outcome measures 9-12, 20. Therefore, the aim of this 
study was to compare skeletal muscle mass and density measurements on CT between 
different contrast-enhancement phases.
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METHODS
Patients
A total of 50 patients with cancer or evaluated for liver transplantation in Erasmus 
MC University Medical Center between 2009 and 2015 with available multiphase 
(unenhanced, arterial, portal-venous) abdominal CT-examinations were randomly 
selected retrospectively. Patients with CTs on which part of the cross-sectional 
skeletal muscle area was not depicted (e.g., due to obesity) or with artefacts (e.g., 
due to prostheses) were excluded. Date of birth, sex, body weight, and body height 
were collected from the electronic patient files within a month of the CT-examination. 
Body mass index (BMI) was calculated and patients were categorized as underweight 
(BMI <18.5), normal weight (BMI 20.0-24.9), overweight (BMI 25.0-29.9) or obese (BMI 
≥30.0) according to the World Health Organization (WHO) definitions 21. Approval from 
the local medical ethical committee was obtained and the study has been performed 
according to the 1964 Declaration of Helsinki and its later amendments.
CT scanning protocol
All CT examinations were performed according to a standardised protocol. First, an 
unenhanced phase was obtained. Afterwards, intravenous (IV) contrast administration 
in an antecubital vein followed by saline flush of 20ml was performed using a power 
injector. The contrast material used was Visipaque  320  mgI/ml (GE Healthcare, Cork, 
Ireland), adapted to a patient’s body weight. Patients with body weight <80 kg received 
120 ml contrast medium, whereas patients with body weight ≥80 kg received 150 ml 
contrast medium. Phases acquired were the arterial phase, determined using a bolus-
tracking technique, followed by the portal-venous phase acquired 70 seconds after 
contrast administration. For the arterial phase, a region of interest (ROI) is placed 
in the upper abdominal aorta; when the threshold of +100 HU is reached, scanning 
starts with a delay of 15 seconds. Estimated time after administration of the bolus is 
30-35 seconds for the arterial phase. The portal-venous phase is obtained with a fixed 
delay of 70 seconds after administration of the contrast material. Axial reconstructions 
were created with a slice thickness of 3mm in all phases. No adverse reactions were 
noted during contrast administration. All images were transferred to our local picture 
archiving and communication system (PACS).
An experienced abdominal radiologist (FEJAW) confirmed the different phases of 
contrast-enhancement per patient. Furthermore, the mean intraluminal attenuation (in 
HU) of the aorta was measured for every phase per patient.
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Skeletal muscle mass and density measurements
The cross sectional muscle area (CSMA) was measured at the level of the third lumbar 
vertebra for the various contrast-enhancement phases (i.e. unenhanced, arterial, portal-
venous). The selected slice was the one on which both transversal processes were 
visible. Two observers (HJWS and KMV) who were blinded for patient characteristics 
performed all measurements as previously described 22. An in-house developed software 
program (FatSeg, developed by the Biomedical Imaging Group Rotterdam of Erasmus 
MC, Rotterdam, The Netherlands, using MeVisLab [Mevis Medical Solutions, Bremen, 
Germany]) was used (figure 1). A previous study indicated excellent comparability 
between this and other frequently used software programs (i.e. SliceOmatic, OsiriX, and 
ImageJ) for body composition analyses 23. The inner and outer contours of the CSMA 
(including the psoas, rectus abdominis, transversus abdominis, internal and external 
abdominal oblique muscles) were manually outlined and the tissue within the threshold 
of -30 to +150 Hounsfield units (HU) was selected. CSMA was corrected for patients’ body 
height squared, as is common for body composition measures, resulting in the skeletal 
muscle index (SMI, cm²/m²). The mean HU value was recorded as a measure of skeletal 
muscle density. Low skeletal muscle mass was defined using previously described cut-
off values: skeletal muscle index <41 cm2/m2 for women regardless of BMI, and <43 and 
<53 cm2/m2 for men with BMI <25.0 and ≥ 25.0 kg/m2, respectively. The definition for low 
skeletal muscle density was identical for men and women: a skeletal muscle attenuation 
<41 for patients with BMI <25.0 kg/m2 and <33 for patients with BMI ≥ 25.0 kg/m2 24.
Statistical analysis
Normality of data was tested using the Shapiro-Wilk test. Continuous data are 
presented as median with interquartile range (IQR) or mean with standard deviation 
(±), depending on the normality of distribution. Categorical data are presented as 
counts with percentages. Differences between the different contrast-enhancement 
phases were tested using a paired t-test or Wilcoxon signed rank test, again depending 
on the normality of the distribution of the data. The agreement between observers 
(i.e. inter-observer agreement) and between contrast-enhancement phases (i.e. 
inter-enhancement phase agreement) were calculated using intra-class correlation 
coefficients (ICCs) with 95% confidence intervals (CIs) using a two-way mixed single 
measures model with absolute agreement. Bland and Altman plots with 95% CI were 
generated to investigate the agreement between contrast-enhancement phases 25. 
Linear regression was used to test for proportional systematic bias 26. Smallest detectable 
changes (SDC), expressing the smallest detectable difference considered a ‘’real’’ change 
in paired measures, were calculated for both skeletal muscle mass and density for the 
different contrast-enhancement phases using the following formula:
van_Vugt-layout.indd   61 22/11/2017   12:43
62
Chapter 3
53	
	
	
	
study	 indicated	 excellent	 comparability	 between	 this	 and	 other	 frequently	 used	 software	 programs	 (i.e.	
SliceOmatic,	OsiriX,	and	ImageJ)	for	body	composition	analyses	23.	The	inner	and	outer	contours	of	the	CSMA	
(including	 the	 psoas,	 rectus	 abdominis,	 transversus	 abdominis,	 internal	 and	 external	 abdominal	 oblique	
muscles)	were	manually	outlined	and	the	tissue	within	the	threshold	of	-30	to	+150	Hounsfield	units	(HU)	was	
selected.	 CSMA	 was	 corrected	 for	 patients’	 body	 height	 squared,	 as	 is	 common	 for	 body	 composition	
measures,	resulting	in	the	skeletal	muscle	index	(SMI,	cm²/m²).	The	mean	HU	value	was	recorded	as	a	measure	
of	 skeletal	muscle	density.	 Low	 skeletal	muscle	mass	was	defined	using	previously	 described	 cut-off	 values:	
skeletal	muscle	 index	<41	cm2/m2	for	women	regardless	of	BMI,	and	<43	and	<53	cm2/m2	for	men	with	BMI	
<25.0	and	≥	25.0	kg/m2,	respectively.	The	definition	for	low	skeletal	muscle	density	was	identical	for	men	and	
women:	a	skeletal	muscle	attenuation	<41	for	patients	with	BMI	<25.0	kg/m2	and	<33	for	patients	with	BMI	≥	
25.0	kg/m2	24.		
	
Statistical	analysis	
Normality	 of	 data	 was	 tested	 using	 the	 Shapiro-Wilk	 test.	 Continuous	 data	 are	 presented	 as	 median	 with	
interquartile	 range	 (IQR)	 or	 mean	 with	 standard	 deviation	 (±),	 depending	 on	 the	 normality	 of	 distribution.	
Categorical	 data	 are	 presented	 as	 counts	 with	 percentages.	 Differences	 between	 the	 different	 contrast-
enhancement	phases	were	tested	using	a	paired	t-test	or	Wilcoxon	signed	rank	test,	again	depending	on	the	
normality	of	 the	distribution	of	 the	data.	 The	agreement	between	observers	 (i.e.	 inter-observer	agreement)	
and	between	contrast-enhancement	phases	(i.e.	 inter-enhancement	phase	agreement)	were	calculated	using	
intra-class	 correlation	 coefficients	 (ICCs)	 with	 95%	 confidence	 intervals	 (CIs)	 using	 a	 two-way	 mixed	 single	
measures	model	with	absolute	agreement.	Bland	and	Altman	plots	with	95%	CI	were	generated	to	investigate	
the	agreement	between	contrast-enhancement	phases	25.	Linear	regression	was	used	to	test	for	proportional	
systematic	 bias	 26.	 Smallest	 detectable	 changes	 (SDC),	 expressing	 the	 smallest	 detectable	 difference	
considered	a	‘’real’’	change	in	paired	measures,	were	calculated	for	both	skeletal	muscle	mass	and	density	for	
the	different	contrast-enhancement	phases	using	the	following	formula:	
!ℎ#$%&	 ($	)*&+&,#+	-.)/+&	-#))	01	2&$)(,3 ± (1.96	:	 ;<=>?@ABC
D
),	
in	which	*	is	the	number	of	measurements	and	SEM	stands	for	standard	error	of	the	measurement	27.	The	SEM	
is	calculated	using	the	following	formula:	
E,#$2#12	F&G(#,(0$	[EF]	:	 1 − K!!.	
The	 agreement	 on	 sarcopenia	 assessment	 between	 observers	 and	 contrast-enhancement	 phases	 was	
calculated	using	Cohen’s	κ	coefficients.	 ICCs	and	Cohen’s	κ’s	ranging	from	0.00	to	0.49	were	interpreted	was	
poor,	whereas	 coefficients	 ranging	 from	0.50	 to	0.74	and	0.75	 to	1.00	were	 interpreted	as	 fair	 to	good	and	
excellent,	respectively	28.		
The	 average	 of	 the	 two	 measurements	 by	 the	 two	 observers	 was	 used.	 Two-sided	 p-values	 <0.05	 were	
considered	statistically	significant.	All	statistical	analyses	were	performed	using	SPSS	for	Windows	(IBM	Corp.,	
Armonk,	NY,	USA),	version	22.	 	
in which k is the number of measurements and SEM stands for standard error of the 
measurement 27. The SEM is calculated using the following formula:
53	
	
	
	
study	 indicated	 excellent	 comparability	 between	 this	 and	 other	 frequently	 used	 software	 programs	 (i.e.	
SliceOmatic,	OsiriX,	and	ImageJ)	for	body	composition	analyses	23.	The	inner	and	outer	contours	of	the	CSMA	
(including	 the	 psoas,	 rectus	 abdominis,	 transversus	 abdominis,	 internal	 and	 external	 abdominal	 oblique	
muscles)	were	manually	outlined	and	the	tissue	within	the	threshold	of	-30	to	+150	Hounsfield	units	(HU)	was	
selected.	 CSMA	 was	 corrected	 for	 patients’	 body	 height	 squared,	 as	 is	 common	 for	 body	 composition	
measures,	resulting	in	the	skeletal	muscle	index	(SMI,	cm²/m²).	The	mean	HU	value	was	recorded	as	a	measure	
of	 skeletal	muscle	density.	 Low	 skeletal	 uscle	mass	was	defined	using	previously	 described	 cut-off	 values:	
skeletal	muscle	 index	<41	cm2/m2	for	women	regardless	of	BMI,	and	<43	and	<53	cm2/m2	for	men	with	BMI	
<25.0	and	≥	25.0	kg/m2,	respectively.	The	definition	for	low	skeletal	muscle	density	was	identical	for	men	and	
women:	a	skeletal	muscle	attenuation	<41	for	patients	with	BMI	<25.0	kg/m2	and	<33	for	patients	with	BMI	≥	
25.0	kg/m2	24.		
	
Statistical	analysis	
Normality	 of	 data	 was	 tested	 using	 the	 Shapiro-Wilk	 test.	 Continuous	 data	 are	 presented	 as	 median	 with	
interquartile	 range	 (IQR)	 or	 mean	 with	 standard	 deviation	 (±),	 depending	 on	 the	 normality	 of	 distribution.	
Categorical	 data	 are	 presented	 as	 counts	 with	 percentages.	 Differences	 between	 the	 different	 contrast-
enhancement	phases	were	tested	using	a	paired	t-test	or	Wilcoxon	signed	rank	test,	again	depending	on	the	
normality	of	 the	distribution	of	 the	data.	 The	agreement	between	observers	 (i.e.	 inter-observer	agreement)	
and	between	contrast-enhancement	phases	(i.e.	 inter-enhancement	phase	agreement)	 ere	calculated	using	
intra-class	 correlation	 coefficients	 (ICCs)	 with	 95%	 confidence	 intervals	 (CIs)	 using	 a	 two-way	 mixed	 single	
measures	 odel	with	absolute	agreement.	Bland	and	Altman	plots	with	95%	CI	were	generated	to	investigate	
the	agreement	between	contrast-enhancement	phases	25.	Linear	regression	was	used	to	test	for	proportional	
systematic	 bias	 26.	 Smallest	 detectable	 changes	 (SDC),	 expressing	 the	 smallest	 detectable	 difference	
considered	a	‘’real’’	change	in	paired	measures,	were	calculated	for	both	skeletal	muscle	mass	and	density	for	
the	different	contrast-enhancement	phases	using the	following	formula:	
!ℎ#$%&	 ($	)*&+&,#+	-.)/+&	-#))	01	2&$)(,3 ± (1.96	:	 ;<=>?@ABC
D
),	
in	which	*	is	the	number	of	measurements	and	SEM	stands	for	standard	error	of	the	measurement	27.	The	SEM	
is	calculated	using	the	following	formula:	
E,#$2#12	F&G(#,(0$	[EF]	:	 1 − K!!.	
The	 agreement	 on	 sarcopenia	 assessment	 between	 observers	 and	 contrast-enhancement	 phases	 was	
calculated	using	Cohen’s	κ	coefficients.	 ICCs	and	Cohen’s	κ’s	ranging	from	0.00	to	0.49	were	interpreted	was	
poor,	whereas	 coefficients	 ranging	 from	0.50	 to	0.74	and	0.75	 to	1.00	were	 interpreted	as	 fair	 to	good	and	
excellent,	respectively	28.		
The	 average	 of	 the	 two	 measurements	 by	 the	 two	 observers	 was	 used.	 Two-sided	 p-values	 <0.05	 were	
considered	statistically	significant.	All	statistical	analyses	were	performed	using	SPSS	for	Windows	(IBM	Corp.,	
Armonk,	NY,	USA),	version	22.	 	
The agreement on sarcopenia assessment between observers and contrast-
enhancement phases was calculated using Cohen’s κ coefficients. ICCs and Cohen’s κ’s 
ranging from 0.00 to 0.49 were interpreted was poor, whereas coefficients ranging from 
0.50 to 0.74 and 0.75 to 1.00 were interpreted as fai  to good and excellent, respectively 
28.
The average of the two mea urements by the two bs rvers was used. Two-sided 
p-values <0.05 were considered statistically significant. All statistical analyses were 
performed using SPSS for Windows (IBM Corp., Armonk, NY, USA), version 22.
Figure 1. Example of skeletal muscle mass and density measurement on a contrast-enhanced 
CT slice in the portal-venous phase at the level of the third lumbar vertebra (L3). The cross-
sectional skeletal muscle area of this 71-year-old woman with a body mass index of 24.7 kg/
m² was 95.6 cm², resulting in a skeletal muscle index of 33.1 cm²/m². The mean skeletal muscle 
attenuation was 33 Hounsfield units. According to the cut-off values of Martin et al., this patient 
is considered to have both sarcopenia and low skeletal muscle density.
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RESULTS
Patient and CT characteristics
The study cohort consisted of 23 (46%) females and 27 (54%) males with a mean BMI of 
24.2 (± 4.0) kg/m². In total, 19 (38%) patients had a BMI ≥25 kg/m² and 4 (8%) patients 
were considered obese (i.e. BMI ≥30 kg/m²). All baseline characteristics are shown in 
supplementary table 1. The median intraluminal attenuation of the aorta was 41 (IQR 
37-45) HU in CT images without contrast-enhancement, 404 (IQR 320-514) HU in the 
arterial contrast-enhancement phase, and 158 (IQR 143-189) HU in the venous contrast-
enhancement phase (figure 2). The inter-observer ICCs were 0.999 for all contrast-
enhancement phases for the skeletal muscle area, and ≥0.980 for the skeletal muscle 
density.
Skeletal muscle mass measurements
An overall difference in SMI was found between the three contrast-enhancement 
phases (F(2, 98) = 56.174, p<0.001). The mean skeletal muscle index was 42.5 ± 9.9 cm²/
m² on the unenhanced phase, which was significantly lower compared with the arterial 
phase (42.8 ± 9.9 cm²/m², p=0.021) and the portal-venous phase (43.6 ± 9.9 cm²/m², 
p<0.001) (table 1, figure 3). A significant difference was also observed between the 
arterial and portal-venous phase (42.8 versus 43.6 cm²/m², p<0.001). Bland Altman 
plots with 95% limits of agreement for the SMI are shown in figure 4. There was no 
proportional systematic bias for any comparison. The ICCs were excellent (all >0.99) for 
all comparisons (table 1). Comparable results were found when using the cross-sectional 
muscle area (CSMA, supplementary figure 1). According to the cut-off values defined 
by Martin et al. 24, 22 (44%) patients were considered to have low skeletal muscle mass 
using unenhanced CT, compared with 21 (42%) patients using the arterial phase and 
24 (48%) patients using the portal-venous phase. This resulted in excellent Cohen’s κ’s 
of 0.959 (unenhanced versus arterial phase), 0.920 (unenhanced versus portal-venous 
phase), and 0.879 (arterial versus portal-venous phase) (table 2).
Skeletal muscle density measurements
An overall significant difference in skeletal muscle density between the three contrast-
enhancement phases was found (F(1.649, 80.813) = 150.167, p<0.001). The mean 
skeletal muscle density was lower for the unenhanced phase (30.9 ± 8.0 HU) compared 
with the arterial (38.0 ± 9.9 HU) and portal-venous (38.7 ± 9.2 HU) phase (both p<0.001), 
but not between the two latter (38.0 versus 38.7 HU, p=0.483) (table 1, figure 5).
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Figure 2. Median intraluminal aorta attenuation per contrast-enhancement phase. The 
whiskers represent the interquartile range.
Figure 3. Mean skeletal muscle index per contrast-enhancement phase. The whiskers represent 
the standard error of the mean. * indicates statistically significant difference
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Figure 4. Bland Altman plots with 95% limits of agreement for the comparison of the cross 
sectional muscle area (SMI in cm²/m²) of the unenhanced with arterial phase (A), unenhanced 
with the portal-venous phase (B) and arterial with the portal-venous phase (C). The solid black 
line represents the mean difference, the striped lines represent the mean ± 1.96 standard 
deviations, and the grey line represents the regression slope.
A C
B
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Figure 5. Mean skeletal muscle density per contrast-enhancement phase. The whiskers 
represent the standard error of the mean. * indicates statistically significant difference
Mean skeletal muscle density did not significantly differ between patients receiving 120 
or 150 ml of contrast medium in any contrast-enhancement phase. Bland Altman plots 
with 95% limits of agreement for the skeletal muscle density are shown in figure 6. There 
was a proportional systematic bias for the comparison of the unenhanced phase with 
the arterial (p=0.001) and portal-venous (p=0.007) phase, but not for the comparison of 
the arterial with the portal-venous phase (p=0.113). The ICCs for the unenhanced phase 
compared with the arterial (0.676) and portal-venous (0.665) phase were considered fair 
to good, whereas the ICC between the arterial and portal-venous phase was considered 
excellent (0.949). The SDCs for skeletal muscle density measurements were considerably 
higher than for skeletal muscle mass measurements. The mean difference in skeletal 
muscle density between the arterial and venous contrast-enhancement phases (-0.6 
HU) was within the SDC (1.90 HU) (table 1). According to the cut-off values defined by 
Martin et al. 24, 40 (80%) patients were considered to have low skeletal muscle density 
using unenhanced CT, compared with 25 (50%) patients using the arterial phase and 
19 (38%) patients using the portal-venous phase. This resulted in Cohen’s κ’s of 0.400 
(unenhanced versus arterial phase), 0.266 (unenhanced versus portal-venous phase), 
and 0.680 (arterial versus porta-venous phase) (table 2).
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Figure 6. Bland Altman plots with 95% limits of agreement for the comparison of the mean 
skeletal muscle density (SMD in Hounsfield Units [HU]) of the unenhanced with arterial phase 
(A), unenhanced with the portal-venous phase (B) and arterial with the portal-venous phase (C). 
The solid black line represents the mean difference, the striped lines represent the mean ± 1.96 
standard deviations, and the grey line represents the regression slope.
C
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DISCUSSION
This is the first study to demonstrate differences in CT-based skeletal muscle mass and 
skeletal muscle density measurements due to different stages of contrast-enhancement 
in multiphase CT. Importantly, although statistically significant differences in skeletal 
muscle mass were found between contrast-enhancement phases, these could be 
considered as not clinically relevant in contrast with the differences found for skeletal 
muscle density measurements.
The influence of CT-assessed sarcopenia on treatment outcome has increasingly gained 
interest last years. Sarcopenia is associated with increased vulnerability, postoperative 
complications and mortality, chemotherapy toxicity, and overall survival 4, 5. Recently, 
skeletal muscle density has been identified as a prognostic factor in various populations, 
whereas skeletal muscle mass was not 9-12, 20. Skeletal muscle density, expressed as the 
mean Hounsfield unit value of the selected skeletal muscle area, is correlated with 
skeletal muscle lipid content 29. Furthermore, low skeletal muscle mass is associated with 
increased (dose-limiting) chemotherapy toxicity 8, 30-32, and may be a superior measure 
to dose chemotherapy rather than body surface area which is currently being used 33.
Particularly in cancer patients, CT is considered the gold standard to measure skeletal 
muscle mass and density because it is routinely being performed (i.e. for diagnosis, 
treatment planning, and treatment evaluation) and consequently widely available 1, 15, 34. 
CT-based assessment of skeletal muscle mass is an easy and reliable method correlated 
with total body skeletal muscle mass and known for its excellent inter- and intra-
observer agreement 18, 35. However, previous studies on the association between 
skeletal muscle density and treatment outcome, did not report whether unenhanced 
or contrast-enhanced CT images were used to measure skeletal muscle density 9-12, 20. 
Results should therefore be interpreted with caution. To increase comparability within 
and between studies, based on our results, we recommend performing measurements 
in portal-venous contrast-enhanced phase CT examinations, as this phase is routinely 
being performed in cancer patients. Moreover, identification of various tissues is easier 
on contrast-enhanced CT examinations due to increased attenuation differences. When 
previously established cut-off values (e.g., those defined by Martin et al. 24) are used, 
measuring skeletal muscle density on unenhanced or contrast-enhanced CT may lead 
to over- or underestimating the number of patients with low skeletal muscle density, 
respectively. This explains the poor Cohen’s κ’s for the classification of patients’ skeletal 
muscle density in the current study. Therefore, we recommend to at least report the 
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contrast-enhancement phase used to measure skeletal muscle mass and density. 
Ultimately, one should seek for consensus which contrast-enhancement phase should 
preferably be used.
Recently, promising results to reverse cancer-induces skeletal muscle wasting have been 
described in animal studies 36. Currently, multiple trials are being performed in humans 
to investigate drugs for the treatment of cachexia 37. However, the general opinion is 
that treatment of cachexia should be multimodal, of which nutritional intervention is 
one modality 14, 38, 39. Treatment strategies may be adapted as well, depending on the 
cancer-induced muscle loss. Body composition measures assessed on CT may guide the 
indication and effectiveness of these therapies.
Although all CTs used for this study have been performed within a relatively short 
time frame (2009-2015) in one center only, the possible use of different type of CT 
scanners may have led to differences in observations between patients. Indeed, there 
is a difference in density measurements between different vendors. However, all 
examinations included in this study were performed on Siemens (Erlangen, Germany) 
CT scanners. All scanners were calibrated daily and calibrated using a phantom monthly. 
Furthermore, we used identical scanning protocols for all patients, reducing differences 
in measurements resulting from technique variation. Nevertheless, variations on these 
protocols may have occurred.
Furthermore, contrast distribution depends on various factors, such as cardiac output, 
vascular status 40, which were unknown for the current study population, and body 
weight and body lean mass. However, one may expect that the influence of these 
factors on the uptake of contrast medium by skeletal muscles of the core are minimal 
in rest. Also, scanning protocols using thresholds to start scanning correct for this. 
Consequently, these influences may be considered negligible. After all, we did not find 
significant differences in mean skeletal muscle density between patients receiving 120 
ml or 150 ml of contrast medium. Furthermore, each patient forms its reference in this 
study as paired t-tests have been used. Furthermore, the variation in aortic intraluminal 
attenuation measurements in each contrast phase was relatively small. Contrary to a 
previous study 18, consecutive measures in the various contrast-enhancement phases 
were not performed on identical slices, since patients’ movements and differences 
in breath-hold may have led to variations in the level on which measurements were 
performed. These factors could, however, better be controlled for in a future prospective 
study. Moreover, although single-slice cross-sectional areas are strongly correlated with 
whole body skeletal muscle mass, this remains an estimation only, which may introduce 
a potential error of several kilograms. Finally, inter-observer variation may have led to 
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measurement differences, although the inter-observer agreement for skeletal muscle 
mass measurements is excellent 18 and the mean of the two observers was used for 
analyses to further minimize inter-observer differences.
In conclusion, significant and clinically relevant differences in skeletal muscle density 
were observed between contrast-enhancement phases, whereas significant but not 
clinically relevant differences were found in skeletal muscle mass measurements. We 
recommend using the portal-venous phase of contrast-enhanced CT for studies that 
describe the association between skeletal muscle density and outcome measures to 
improve comparability of studies.
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SUPPLEMENTARY MATERIAL
Supplementary table 1. Baseline characteristics of the included patients.
Characteristic N = 50
Age, years 62 (50-69)
Indication CT
 Pancreatic cancer
 Perihilar cholangiocarcinoma
 Hepatocecullar carcinoma
 Liver transplantation evaluation
16 (32.0)
5 (10.0)
21 (42.0)
8 (16.0)
BMI, kg/m²
 < 20
 20-24.9
 25-29.9
 ≥ 30
23.9 (21.0-26.5)
5 (10.0)
26 (52.0)
15 (30.0)
4 (8.0)
Continuous parameters are shown as median with interquartile range, dichotomous parameters as count with percentages. 
Abbreviations: CT, computed tomography; BMI, body mass index.
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Supplementary figure 1. Bland Altman plots with 95% limits of agreement for the comparison 
of skeletal muscle index (CSMA in cm²/m²) of the unenhanced with arterial phase (A), 
unenhanced with the portal-venous phase (B) and arterial with the portal-venous phase (C). 
The solid black line represents the mean difference, the striped lines represent the mean ± 1.96 
standard deviations, and the grey line represents the regression slope.
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Estimated Skeletal Muscle Mass and Density Values 
Measured on Computed Tomography Examinations 
Established in over One Thousand Healthy Subjects
J.L.A. van Vugt, Y. van Putten, I.M. van der Kall, S. Buettner, R.W.F. de Bruin, 
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ABSTRACT
Background: There is still debate regarding adequate cut-off points to categorize 
patients as having sarcopenia (low skeletal muscle mass) based on computed 
tomography (CT) measurements. No international consensus has been reached yet. 
Moreover, there is insufficient knowledge on skeletal muscle mass in healthy persons, 
particularly in a Western-European population.
Methods: Skeletal muscle mass at the level of the third lumbar vertebra (skeletal 
muscle index, cm²/m²) and density (Hounsfield units, HU) were measured on contrast-
enhanced CT images in live kidney donors, which may be considered as healthy subjects. 
Differences between sex, body mass index (BMI), age groups, and ASA classification 
were assessed. Groups were compared using the Mann-Whitney-U and Kruskal-Wallis 
tests.
Results: Of the 1073 included patients, 499 (46.5%) were male. Median age was 51 
years and median BMI 25.4 kg/m². Male gender, increased age, and increased BMI were 
significantly associated with both an incremental skeletal muscle mass and density. 
Nomograms including these parameters were developed to calculate the estimated 
skeletal muscle mass and density of a healthy subject.
Conclusions: Skeletal muscle density and mass were significantly associated with 
sex, age, and BMI in a large cohort of Western-European healthy subjects. The newly 
developed nomograms may be used to calculate the estimated healthy skeletal muscle 
mass for individuals in patient populations.
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INTRODUCTION
To perform body composition analyses, a precise method which is applicable with high 
specificity on a large scale is a precondition. In 1979, Heymsfield et al. reported the use 
of computed tomography (CT) to measure skeletal muscle and visceral adipose tissue 
mass 1. Kvist et al. were the first to assess whole-body adipose tissue volumes with 
computed tomography studies using just several slices in 1986 2. A standardized part of 
the body with images at specific skeletal landmarks were chosen 3. Shen et al. showed 
high correlations between two-dimensional abdominal skeletal muscle and adipose 
tissue areas measured on just a single slice and their respective three-dimensional total 
body volumes, after examination in a large sample of diverse subjects in 2004 4.
In most later studies the third lumbar vertebra (L3) was usually chosen as the level 
to perform these measurements. Prado et al. were first to show that measurements 
performed at the level of L3 were related to impaired outcomes in malignancies of the 
upper respiratory and digestive tract in 2008 5. Many publications followed in various 
populations 6, 7. This CT-based method was also shown to provide more detail than the 
formerly used dual X-ray absorptiometry (DXA) and bioelectrical impedance analysis 
(BIA) 8.
There is still debate regarding adequate cut-off points to categorize patients as having 
sarcopenia. Prado et al. used cut-off values based on risk stratification 5. These have 
been used commonly, yet some studies use different cut-off values 9-11. No international 
consensus has been reached yet, and different cut-off values for skeletal muscle 
mass lead to variations in the reported prevalence of sarcopenia 12. Moreover, there 
is insufficient knowledge on skeletal muscle mass in healthy persons, particularly 
in Western-European populations. Therefore, the aim of this study was to define 
references values for skeletal muscle mass and density measurements on abdominal CT 
examinations established in healthy subjects.
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METHODS
Subjects
All subjects ≥18 years of age participating in a live kidney donation program between 
May 2010 and August 2015 in Erasmus MC University Medical Center (Rotterdam, the 
Netherlands) and between January 2003 and January 2012 in Radboud University 
Medical Center (Nijmegen, the Netherlands) were identified. Sex, age at the moment 
of the abdominal CT examination, and self-reported body height and body length were 
recorded. The body mass index (BMI, kg/m²) was calculated. Furthermore, the American 
Society of Anesthesiologists (ASA) classification was used to categorize physical status. 
This study was approved by the Institutional Review Boards (IRB) of both centers and a 
waiver for informed consent was granted.
Skeletal muscle mass and density measurements
Routinely performed contrast-enhanced abdominal CT examinations to evaluate 
vascular anatomy of the kidney donors were collected. The skeletal muscle mass and 
density measurements were performed as previously described 13. In short, the cross-
sectional skeletal muscle area (cm²) was quantified at the level of the third lumbar 
vertebra (L3) using Hounsfield Units (HU) thresholds (i.e. -30 HU to +150 HU) by 
manually outlining the following muscle groups: the psoas, paraspinal, and abdominal 
wall muscles. The cross-sectional skeletal muscle area (CSMA) was adjusted for subjects’ 
body height, resulting in the skeletal muscle index (SMI, cm²/m²). The mean muscle 
density (in HU), a measure for intramuscular adipose tissue infiltration, of the selected 
skeletal muscle tissue was also recorded. Subjects with low skeletal muscle mass and 
density were classified according to cut-off values that are currently most used 11. Only 
patients with contrast-enhanced CT examinations were included, since significant 
differences have been reported in outcome measure between contrast-enhanced and 
unenhanced CT images 14.
Statistical analyses
Categorical data are presented as counts with percentages, whereas continuous data 
are presented as mean (± standard deviation [SD]) or median (interquartile range [IQR]) 
depending on the normality of data distribution. Groups were compared using Student’s 
t-tests or one-way ANOVA analysis in the case of normal distribution and the Mann-
Whitney U or Kruskal-Wallis H test in the case of not normally distributed data. After 
linearity was assessed, a multivariable linear regression analysis was used to investigate 
the association between skeletal muscle density and mass and various patient 
characteristics. The linear regression coefficients were used to create nomograms. Two-
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sided p-values <0.05 were considered statistically significant. Analyses were performed 
using SPSS for Windows version 22 (IBM Corp., Armonk, NY, USA) and the RMS package 
in R version 3.03 (http://www.r-project.org).
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RESULTS
Subjects
In total, 1163 subjects were identified, of whom a CT examination was available in 1145 
patients. In 56 subjects not all skeletal muscle mass of interested was depicted on CT, 
10 subjects only had an unenhanced CT, 3 had a CT without the level of L3 depicted, 
2 had CTs with artefacts that significantly influenced measurements, and in 1 subject 
we experienced technical difficulties that did not allow measurements. The remaining 
1073 subjects (92.3%) formed the study cohort. Of these patients, the median age was 
51 (IQR 41-59) years and 499 (46.5%) were male. All baseline characteristics are shown 
in table 1.
Table 1. Baseline characteristics.
Characteristic N = 1073
Sex
 Men
 Women
499 (46.5)
574 (53.5)
Age, years 51 (41-59)
Body height, m
 Men
 Women
1.72 (1.66-1.79)
1.79 (1.74-1.84)
1.67 (1.62-1.71)
Body weight, kg
Men
 Women
76 (67-86)
83 (75-91)
70 (63-78)
BMI, kg/m²
 Men
 Women
25.4 (23.4-28.4)
25.7 (23.9-28.5)
24.9 (23.0-28.1)
ASA classification
 1
 2
 3
 Missing
686 (63.9)
374 (34.9)
4 (0.4)
9 (0.8)
Abbreviations: ASA, American Society of Anesthesiologists.
The median CSMA for all patients was 137.6 (IQR 117.7-172.5) cm², corresponding to a 
median SMI of 47.4 (IQR 41.9-54.6) cm/m². CSMA was significantly higher in men (174.2 
[IQR 159.0-193.0) cm²) than in women (119.2 [IQR 109.6-130.3]), p<0.001. The median 
muscle attenuation for all patients was 44 (IQR 38-49) HU.
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Influence of sex, age, BMI, and ASA classification on skeletal muscle mass 
and density
The association between sex, age, BMI, and ASA classification with skeletal muscle 
index and skeletal muscle attenuation is shown in table 2. Both skeletal muscle mass 
and density were significantly higher in males compared with females (figure 1) and 
significantly decreased with and incremental increase in age (figure 2). Skeletal muscle 
mass significantly increased with an incremental increase in BMI, whereas skeletal muscle 
attenuation showed a significant decrease (figure 3). No significant differences were 
found between patients with ASA classification 1 versus patients with ASA classification 
2-3 with regards to skeletal muscle mass, whereas patients with ASA classification 1 
had a significantly higher skeletal muscle density compared with patients with ASA 
classification 2-3 (figure 4).
Classification of subjects using established cut-off values
According to the cut-off values by Martin et al. 11, a total of 113 (10.5%) patients 
were considered to have low skeletal muscle mass and 309 (28.8%) patients to have 
low skeletal muscle density. The prevalence of low skeletal muscle mass significantly 
differed between age groups (13.3% in patients aged 18-39, 54.4% in patients aged 
40-59, and 32.4% in patients aged ≥60, p<0.001). Also, the prevalence of low skeletal 
muscle density significantly differed between age groups (5.3% in patients aged 18-39, 
47.8% in patients aged 40-59, and 46.9% in patients aged ≥60, p<0.001). Differences 
between patients with low and high skeletal muscle mass, and low and high skeletal 
muscle density, are summarized in table 3.
Multivariable linear regression analysis for factors associated with skeletal 
muscle mass and density and the development of nomograms
A multivariable linear regression analysis showed that sex, age, and BMI were 
independently associated with both skeletal muscle mass and density, whereas ASA 
classification was not (table 4).
Using these parameters, nomograms were created for skeletal muscle index (figure 5) 
and skeletal muscle density (figure 6) stratified for sex. For example, a 40-year-old man 
(22 points) with a BMI of 28 (42 points) has a total of 64 points, corresponding to a SMI 
of 56 cm2/m2 (figure 5a). Another example: a 65-year-old woman (25 points) with a BMI 
of 20 (18 points) has a total of 43 points, corresponding with a muscle density of 30 HU 
(figure 6b). Finally, an online calculator was developed (Supplementary material).
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Table 2. The association between sex, age, body mass index (BMI), and American Society for 
Anesthesiologists (ASA) classification and skeletal muscle mass and density measures.
Characteristic N (%)
Skeletal muscle
index, cm²/m²
p-value
Skeletal muscle
attenuation, HU
p-value
Sex
 Men
 Women
499 (46.5)
574 (53.5)
54.4 (49.7-60.2)
42.8 (39.4-46.9)
<0.001
45 (40-50)
43 (36-49)
<0.001
Age, years
Men
 18-39
 40-59
 ≥60
Women
 18-39
 40-59
 ≥60
119 (23.8)
268 (53.7)
112 (22.4)
112 (19.5)
324 (56.4)
138 (24.0)
58.5 (52.9-63.5)
54.3 (49.6-59.7)
52.4 (47.6-56.0)
44.0 (40.2-48.0)
43.1 (39.5-46.9)
41.3 (38.5-46.1)
<0.001
0.005
50 (45-55)
44 (40-48)
41 (36-45)
49 (44-54)
43 (37-48)
37 (32-42)
<0.001
<0.001
BMI, kg/m²
Men
 <20
 20.0-24.9
 25.0-29.9
 ≥30
Women
 <20
 20.0-24.9
 25.0-29.9
 ≥30
19 (3.8)
185 (37.1)
226 (45.3)
69 (13.8)
33 (5.7)
256 (44.6)
211 (36.8)
74 (12.9)
46.4 (44.3-49.7)
51.2 (46.7-55.3)
57.2 (52.4-61.2)
60.3 (55.0-65.2)
37.7 (36.4-41.9)
41.5 (38.5-45.1)
44.1 (40.0-47.6)
47.2 (43.3-51.2)
<0.001
<0.001
48 (44-54)
46 (42-52)
43 (38-48)
42 (34-47)
51 (45-55)
44 (40-50)
40 (36-46)
39 (31-44)
<0.001
<0.001
ASA classification*
Men 
 1
 2-3
Women
 1
 2-3
318 (64.4)
176 (35.6)
368 (64.6)
202 (35.4)
55.3 (49.8-60.4)
53.1 (49.3-59.2)
42.6 (39.3-46.5)
43.4 (39.4-47.3)
0.172
0.133
45 (41-51)
42 (37-47)
44 (39-50)
40 (34-46)
<0.001
<0.001
* 9 missing values.
Table 3. Differences between patients who have been classified as having low/high skeletal 
muscle mass and low/high skeletal muscle density according to Martin et al..
Low skeletal 
muscle mass
High skeletal 
muscle mass
p-value
Low skeletal 
muscle 
density
High skeletal 
muscle 
density
p-value
Sex
 Men 100 (32.4) 399 (52.2) <0.001 34 (30.1) 465 (48.4) <0.001
Age, years 55 (46-62) 50 (40-58) <0.001 58 (53-65) 50 (40-58) <0.001
BMI, kg/m² 24.8 (22.3-27.3) 25.6 (23.7-28.7) <0.001 28.4 (25.7-30.7) 25.0 (23.1-28.0) <0.001
ASA classifi-
cation*
 1
 2-3
189 (61.6)
118 (38.4)
497 (65.7)
260 (34.3) 0.207
50 (44.2)
63 (55.8)
636 (66.9)
315 (33.1)
<0.001
* 9 missing values.
van_Vugt-layout.indd   88 22/11/2017   12:43
89
Estimated normal values
4
Table 4. Multivariable linear regression analysis to identify parameters that are independently 
associated with skeletal muscle mass (upper analysis) and density (lower analysis).
B SE 98% CI p-value
Skeletal muscle mass Sex (female) -11.07 0.38 -11.83; -10.32 <0.001
Age (years) -0.11 0.02 -0.14; -0.08 <0.001
BMI (categories) 3.77 0.25 3.28; 4.27 <0.001
ASA (3 vs 1-2) -0.25 0.42 -1.08; 0.58 0.549
Skeletal muscle density Sex (female) -1.70 0.49 -2.65; -0.75 <0.001
Age (years) -0.32 0.02 -0.36; -0.28 <0.001
BMI (categories) -3.28 0.32 -3.90; -2.65 <0.001
ASA (3 vs 1-2) -0.99 0.54 -2.04; 0.07 0.066
Figure 1. Skeletal muscle index (SMI) and skeletal muscle density (SMD) stratified by sex.
** indicates p<0.001.
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Figure 2. Skeletal muscle index (SMI) and skeletal muscle density (SMD) stratified by age groups 
(i.e. 18-39, 40-59, ≥60 years) for men (A) and women (B).
** indicates p<0.001.
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Figure 3. Skeletal muscle index (SMI) and skeletal muscle density (SMD) stratified by body mass 
index (BMI) groups (i.e. <20, 20-24.9, 25.0-29.0, ≥30 kg/m²) for men (A) and women (B).
** indicates p<0.001.
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Figure 4. Skeletal muscle index (SMI) and skeletal muscle density (SMD) stratified by American 
Society of Anesthesiologists (ASA) classification for men (A) and women (B).
** indicates p<0.001.
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Figure 5. Nomogram showing reference values for skeletal muscle index for men (A) and 
women (B), adjusted for age and body mass index (BMI).
A
B
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Figure 6. Nomogram showing reference values for skeletal muscle density for men (A) and 
women (B), adjusted for age and body mass index (BMI).
A
B
van_Vugt-layout.indd   94 22/11/2017   12:43
95
Estimated normal values
4
DISCUSSION
This is the first study that described skeletal muscle mass and density measurements 
on CT in a large population of healthy subjects. Currently, most studies classify patients 
as having low skeletal muscle mass or density based on cut-off values that have been 
established in patient specific populations, such as cancer 5, 9, 11 or liver transplantation 
patients 15, 16, to predict overall survival. Consequently, the reported prevalence of low 
CT-assessed skeletal muscle mass and density may greatly differ between studies 6, 7. We 
proposed reference values, stratified for sex and adjusted for age and BMI, which may 
be used to classify patients as having low skeletal muscle mass. Use of these reference 
values may increase comparability of studies with varying populations.
Live kidney donors form a unique cohort, as they may be considered as healthy subjects 
rather than patients, with an equal distribution of men and women and a relatively broad 
range in age. A previous study among 45 healthy Japanese adults willing to donate a 
part of their liver also defined normal values for skeletal muscle mass measured on CT 17. 
In this study, median CSMA was 155.0 cm² in men and 111.7 cm² women, which is 
considerably lower compared with our study. Furthermore, the incidence of overweight 
and obesity is lower in Asia compared with Europe and North-America 18. This underlines 
the need for reference values which are specific per geographical region (i.e. European, 
Asian, and North-American) or ethnicity, as genetics are an important determinant of 
muscularity 19, 20. Another Japanese study proposed reference values for low skeletal 
muscle mass based on CT in 541 adult donors for living donor liver transplantation 21. 
However, skeletal muscle mass was assessed on psoas muscle measurements only 
rather than CSMA and skeletal muscle density was not assessed 21. Although comparable 
findings were reported 21, the psoas muscle alone may not be a valid representation of 
total body skeletal muscle mass 22. Lower skeletal muscle mass in younger and female 
patients was also observed among the general population in the United Kingdom using 
bioelectrical impedance analysis (BIA) 23 and among Mexican elderly using dual-energy 
X-ray absorptiometry (DXA) 24.
Besides sex, age, and BMI, another significant predictor for skeletal muscle mass and 
density is comorbidity. However, our study cohort consisted of live kidney donors, 
which may be considered healthy subjects. Consequently, 99.6% of our cohort had a 
low ASA classification (i.e. ASA 1 or 2). Therefore, we did not find an association between 
ASA classification and skeletal muscle mass or density. The healthy status of our subjects 
may also explain the relatively low prevalence of low skeletal muscle mass and density, 
particularly in the older patients (i.e. ≥60 years), because all patients were considered fit 
enough to donate one kidney.
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Interestingly, a recent study showed that grip strength depends on socioeconomic 
status (measured using household income) 25. Another study described the association 
between household income and frailty in middle-aged and older adults in Switzerland 26. 
We, however, did decide not to include socioeconomic status as a parameter to defined 
reference values for skeletal muscle mass and density, because it would reduce its 
clinical applicability. Nevertheless, it would be interesting to investigate the association 
between body composition and socioeconomic status in a future study. Previous 
studies also described differences in grip strength 25 and muscle mass 24 between races. 
Unfortunately, we were not able to include race as a parameter, since the number of 
non-Caucasian patients would be too small.
Inherent to the study’s retrospective character, we were not able to investigate 
normal values of muscle strength and gait speed, which are considered essential to 
diagnose sarcopenia (i.e. the involuntary age-related loss of skeletal muscle mass and 
function) 27. Future prospective studies may therefore combine our reference values 
with measures of muscle strength and function (e.g., gait speed). Nevertheless, the 
association between CT-assessed skeletal muscle mass and density has frequently been 
described and seems a strong predictive factor in various patient populations, such as 
cancer patients 6 and liver transplant candidates 7. Particularly automatic segmentation, 
which is currently being developed 28, may greatly increase implementation in daily 
practice. Another limitation of the current study is that most body weight and height 
measures were self-reported. This may have led to discrepancies between the true BMI 
and self-reported BMI. In particular, overweight individuals tend to under-report and 
underweight individuals to over-report 29, 30. Although our results enable calculating the 
estimated normal value for skeletal muscle mass and density in patients, our findings 
should externally being validated in patients cohorts.
Computed tomography is routinely made as part of the diagnostic tract, preoperative 
work-up or to assess down staging in most oncological and surgical populations. The 
total body is rarely depicted in this setting. Therefore, the CSMA at the level of L3, 
which accurately estimated total body skeletal muscle mass 4, 31 proved its use. CT is 
currently the golden standard for body composition measurements 32 with excellent 
inter- en intra-observer agreement 13. Some studies advocate that CSMA is superior to 
psoas muscle measurements alone 33, whereas other studies state otherwise 16. Besides 
skeletal muscle mass, visceral and subcutaneous adipose tissue may also be measured 
on CT 34, 35. However, these measurements are greatly influenced by some factors, such 
as the position of the visceral organs 13. Therefore, we decided not to measure adipose 
tissue in the current study.
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In conclusion, sex, age, and BMI were independently associated with skeletal muscle 
mass and density measured on CT in over a thousand healthy subjects in a Western-
European cohort. Our reference values, which are easily available using the online 
calculator (supplementary material), may be used to calculate the estimated healthy 
skeletal muscle mass for individuals in patient populations.
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ABSTRACT
Background: Preoperative risk assessment in cancer surgery is of importance to 
improve treatment and outcome. The aim of this study was to assess the impact of CT-
assessed sarcopenia on short- and long-term outcomes in patients undergoing surgical 
resection of gastrointestinal and hepatopancreatobiliary malignancies.
Methods: A systematic search of Embase, PubMed and Web of Science was performed 
to identify relevant studies published before 30 September 2014. PRISMA guidelines 
for systematic reviews were followed. Screening for inclusion, checking the validity 
of included studies and data extraction were carried out independently by two 
investigators.
Results: After screening 692 records, 13 observational studies with a total of 2884 
patients were included in the analysis. There was wide variation in the reported 
prevalence of sarcopenia (17.0–79 %). Sarcopenia was independently associated with 
reduced overall survival in seven of ten studies, irrespective of tumor site. Hazard ratios 
(HRs) of up to 3.19 (hepatic cancer), 1.63 (pancreatic cancer), 1.85 (colorectal cancer) 
and 2.69 (colorectal liver metastases, CLM) were reported. For esophageal cancer, the 
HR was 0.31 for increasing muscle mass. In patients with colorectal cancer and CLM, 
sarcopenia was independently associated with postoperative mortality (colorectal 
cancer: odds ratio (OR) 43.3), complications (colorectal cancer: OR 0.96 for increasing 
muscle mass; CLM: OR 2.22) and severe complications (CLM: OR 3.12).
Conclusions: Sarcopenia identified before surgery by single-slice CT is associated with 
impaired overall survival in gastrointestinal and hepatopancreatobiliary malignancies, 
and increased postoperative morbidity in patients with colorectal cancer with or 
without hepatic metastases.
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INTRODUCTION
Advanced surgical techniques, developments in perioperative care and the introduction 
of enhanced recovery programs have improved surgical outcomes 1–5. Nevertheless, 
risk assessment before major abdominal surgery remains of paramount importance 
to further improve outcomes after cancer surgery. Known factors that are predictive 
of short-term outcome include albumin levels, American Society of Anesthesiologists 
(ASA) classification and emergency surgery, whereas advanced age and disseminated 
disease determine long-term outcome 6–8. Outcomes of patients with similar age, tumor 
stage and ASA classification may be very different in clinical practice. Therefore, the risk 
factors commonly used to predict outcome after cancer surgery may reflect the patient’s 
general health status and physiological reserves insufficiently. An important risk factor 
for worse outcome is frailty, which is poorly reflected by the traditional determinants 
of outcome 9–13. Frailty is defined as a biological syndrome characterized by decreased 
reserve and resilience to stress factors across multiple physiological systems, and has 
been shown to be associated with adverse health outcomes 14,15. A hallmark sign of 
frailty is sarcopenia, the involuntary loss of skeletal muscle mass 16–18. The prevalence of 
sarcopenia in healthy individuals increases with advanced age, ranging from 9 % at 45 
years and up to 64 % in individuals aged over 85 years 19.
Sarcopenia is characterized by a loss of skeletal muscle mass, skeletal muscle strength 
and physical performance 20. It has been shown to impair physical performance and 
survival in geriatric, non-cancer populations 21,22, and to impair survival in a variety of 
clinical conditions, such as cancer 23. Up to 80 % of patients with advanced cancer are 
affected by cancer-induced cachexia, a clinical condition that also results in skeletal 
muscle wasting with or without loss of body fat 24–26. Cachectic patients are more prone 
to a reduced effect of therapy and increased chemotherapy toxicity 27–29. It has been 
estimated that as many as 30 % of cancer-related deaths result from cachexia 30–33. 
One study 23 showed that sarcopenia was associated with decreased survival in obese 
patients with cancer by using CT to assess reduced skeletal muscle mass 34 (figure 1).
A systematic review was undertaken to investigate the influence of low skeletal muscle 
mass or skeletal muscle density assessed by CT on short- and long-term outcomes 
in patients undergoing surgery for gastrointestinal and hepatopancreatobiliary 
malignancies.
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Figure 1. Transverse CT image at the level of L3 showing a cross-sectional area of skeletal 
muscle mass highlighted in red, including the psoas, paraspinal, transverse abdominal, external 
oblique, internal oblique and rectus abdominis muscles.
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METHODS
Eligibility criteria were established a priori. A systematic search was performed to 
identify all original articles on patients undergoing surgical resection of malignancies 
of the gastrointestinal tract or hepatopancreatobiliary system, in which preoperative 
abdominal CT was used to assess skeletal muscle mass. The Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed 35.
Included in the analysis were studies that reported on the prevalence of sarcopenia, 
and at least one of the following outcomes: postoperative mortality, postoperative 
complications, length of intensive care (ICU) stay, length of hospital stay, disease-free 
survival and overall survival.
The search was limited to papers in English with a publication date from January 
2000 to September 2014. Three search strings with corresponding search terms were 
constructed (table S1, supporting information). The same search strings were used to 
develop queries in the EMBASE, PubMed and Web of Science databases.
The EMBASE database search was performed using the following query: 
(‘sarcopenia’:de,ab,ti OR ‘analytic morphomics’:de,ab,ti OR ‘body composition’:de,ab,ti 
OR ‘muscle depletion’:de,ab,ti OR ‘muscle mass’:de,ab,ti OR ‘psoas area’:de,ab,ti OR 
‘myopenia’:de,ab,ti OR ‘core muscle’:de,ab,ti OR ‘lean body mass’:de,ab,ti OR ‘muscular 
atrophy’:de,ab,ti) AND (‘cancer’:de,ab,ti OR ‘neoplasms’:de,ab,ti OR ‘malignancy’:de,ab,ti) 
AND (‘surgery’:de,ab,ti OR ‘resection’:de,ab,ti OR ‘esophagectomy’:de,ab,ti OR 
‘gastrectomy’:de,ab,ti OR ‘hepatectomy’:de,ab,ti OR ‘colectomy’:de,ab,ti OR 
‘pancreatectomy’:de,ab,ti or ‘cholecystectomy’:de,ab,ti). Similar queries were 
constructed for PubMed and Web of Science.
Duplicate records were removed and abstracts screened independently by two 
investigators to determine which records were eligible for further analysis. Abstracts 
were included for initial analysis if sarcopenia in patients undergoing surgical treatment 
with gastrointestinal or hepatopancreatobiliary malignancies was described. Abstracts 
that described sarcopenia determined by means other than abdominal CT or patients 
undergoing non-surgical treatment were excluded from further analysis. Records 
without abstracts, case reports, review articles, opinion articles and experimental 
studies were excluded.
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Eligibility of studies and assessment of methodological quality
Full-text articles of the remaining records were subsequently retrieved and screened 
independently by two investigators. All original articles that met the inclusion criteria 
were included. Additional relevant references were sought in the included full-text 
articles. Two investigators independently assessed the methodological quality of the 
included studies using the Newcastle–Ottawa quality assessment scale for cohort 
studies 36 for each a priori defined outcome measure.
Data extraction
Data regarding study design and results were extracted independently by two 
investigators for each eligible study. Extracted data included age, sex distribution, 
patient selection, prevalence of sarcopenia, postoperative mortality, postoperative 
complications, length of ICU stay, length of hospital stay, disease-free survival and 
overall survival. If univariable and multivariable analyses had been performed to adjust 
for known risk factors, the latter was used for interpretation of the results.
Statistical analysis
Outcomes are reported as originally shown. The prevalence of sarcopenia described 
in this review applies to the total population of each study. Therefore, rates could not 
be provided for subgroups (such as by cancer stage) separately. No meta-analysis was 
performed because there was great heterogeneity between studies.
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RESULTS
The literature search was performed on 30 September 2014 and identified an initial 
692 records, of which 27 were found to be potentially relevant (figure 2). From these 
27 records, seven full-text articles were excluded as sarcopenia was assessed by means 
other than abdominal CT, four articles did not report relevant outcome data, and three 
articles reported on a population that received non-surgical treatment for the studied 
tumors. The remaining 13 studies matched the inclusion criteria 37–49. Cross-referencing 
yielded no additional results. The included studies provided data on patients with 
esophageal, gastric, pancreatic, primary liver and colorectal cancer, and resectable 
hepatic colorectal metastases (table 1). No studies reported on patients with bile duct 
or gallbladder cancer.
Prevalence of sarcopenia in different malignancies
The prevalence of sarcopenia as assessed by CT-based skeletal muscle mass measurement 
in patients undergoing surgery for gastrointestinal and hepatopancreatobiliary 
malignancies was reported in nine studies 37–45,47. None of the studies 39,41,42,44,45,49 
that compared characteristics in patients with and without sarcopenia reported on 
significant differences regarding cancer stage, differentiation grade or biomarkers. 
Despite comparable age and sex distribution between studies, there was a wide 
variation in the prevalence of sarcopenia, ranging from 17.0% in a cohort of patients 
with hepatic colorectal metastases 45 to 79 % in a cohort with esophageal and gastric 
cancer 37. In agreement, cohorts of patients with esophageal and gastric cancer reported 
a widespread prevalence of sarcopenia before surgery, ranging from 43 to 79% 37,38. Less 
variation in the prevalence of sarcopenia was observed among patients undergoing 
surgical resection of hepatocellular carcinoma (40.3–54.1%) 39–41, colorectal cancer 
(38.9–47.7%) 42,43 and hepatic colorectal metastases (17.0–19.4%) 44,45. One study 47 
reported a prevalence of sarcopenia of 25.0% in patients with pancreatic cancer. Two 
studies 37,38 reported an increase in the prevalence of sarcopenia among patients with 
esophageal and gastric cancer following neoadjuvant chemotherapy. The impact of 
neoadjuvant therapy on the prevalence of sarcopenia was not assessed in the colorectal 
cancer studies included in the present analysis. A possible impact of age or sex on the 
prevalence of sarcopenia could not be discerned. Detailed information regarding the 
prevalence of sarcopenia is shown in table 2.
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Table 2. Studies reporting the prevalence of sarcopenia in gastrointestinal malignancies.
Reference Malignancy Prevalence (%)
Awad et al.37 Esophageal and gastric cancer Before NACRT: 57 | Before resection: 79
Yip et al.38 Esophageal cancer Before NACRT: 26 | Before resection: 43
Voron et al.39 Hepatocellular carcinoma 54.1
Itoh et al.40 Hepatocellular carcinoma 40.5
Harimoto et al.41 Hepatocellular carcinoma 40.3
Peng et al.47 Pancreatic cancer 25.0
Lieffers et al.42 Colorectal cancer 38.9
Reisinger et al.43 Colorectal cancer 47.7
van Vledder et al.44 Colorectal liver metastases 19.4
Peng et al.45 Colorectal liver metastases 17.0
NACRT, neoadjuvant chemotherapy.
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Short-term postoperative morbidity and mortality
Data regarding complication rate, length of ICU stay, length of hospital stay, 
postoperative morbidity and postoperative mortality were reported in ten 37–39,41–43,45–48 
of the 13 studies included in the analysis (table 3).
An increased postoperative morbidity rate was found in patients with sarcopenia in 
all studies where this was reported among patients undergoing surgical resection of 
colorectal cancer 42,43,48 and hepatic colorectal metastases 45. One study 48 reported that an 
increase in psoas density protected against overall (odds ratio (OR) 0.96, 95% c.i. 0.94 to 
0.99; p=0.004) and infectious (OR 0.95, 0.93 to 0.98; p=0.001) complications in a cohort of 
302 patients 48. Another investigation 42 observed an increase in infectious complications 
in patients with versus those without sarcopenia (23.1 versus 12.6%; p=0.036) in a cohort 
of 234 patients. Subgroup analysis revealed that the risk was especially pronounced 
in elderly patients (65 years or older) with sarcopenia (29.6 versus 8.8%; p=0.005). This 
difference remained significant in multivariable analysis (adjusted OR 4.6, 1.5 to 13.9; 
p=0.007). The overall complication rate was not described. An increased risk of major 
postoperative complications (Clavien–Dindo grade IIIa or higher) among patients with 
sarcopenia compared with those without was reported among patients undergoing 
hepatic resection for colorectal metastases (22 versus 8% respectively; OR 3.12; p=0.020) 45. 
However, the study did not specify the type of complications. Another investigation 43 
showed a strong association between sarcopenia and 30-day mortality combined with 
in-hospital mortality after elective colorectal cancer surgery (8.8 versus 0.6% in patients 
with and without sarcopenia respectively; OR 43.3, 2.74 to 685.2, p=0.007).
No association between sarcopenia and postoperative morbidity and mortality was 
found in patients undergoing resection for esophageal or hepatocellular cancer 37,39,41,46. 
Specifically, in a cohort of 557 patients undergoing pancreatic cancer resection 47, there 
was no difference in the rate of any postoperative complication (44.6 versus 51.8% in 
men with and without sarcopenia respectively, p=0.28, 41.5 versus 43.4% respectively 
among women, p=0.80), major postoperative complications (20.6 versus 24.8% for 
men, p=0.49; 12.1 versus 20.5% for women, p=0.15) or 30-day postoperative mortality 
(1.4 versus 0.5% for men, p=0.44; 0 versus 0.5% for women, p=1.00). However, the 90-
day mortality rate differed between men with and without sarcopenia (9.5 versus 2.7% 
respectively; p=0.02).
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Two studies 43,46 that reported on anastomotic leakage following surgical resection of 
colorectal and esophageal cancer did not demonstrate an association with sarcopenia.
Two studies adjusted for body mass index (BMI) in the multivariable analyses. One 43 
reported that sarcopenia was a risk factor for 30-day mortality, whereas BMI was not. 
Similarly, in another investigation 45 sarcopenia, but not BMI, was a risk factor for 
postoperative complications.
Length of intensive care unit and hospital stay
Peng and colleagues reported a prolonged ICU admission (more than 2 days) for patients 
with sarcopenia undergoing resection with curative intent for hepatic colorectal 
metastases compared with those without sarcopenia (15 versus 4% respectively; 
p=0.004) 45, but did not demonstrate a difference in the mean length of ICU stay in patients 
undergoing surgical resection of pancreatic cancer (mean (s.d.) 0.5(2.0) versus 0.5(1.7) 
days respectively for men, p=1.00; 0.2(0.6) versus 0.2(0.6) days among women, p=0.74) 47. 
In two 42,45 of five studies 37,38,42,45,47 reporting length of hospital stay, patients with 
sarcopenia had a delayed discharge from hospital. Hospital stay was slightly prolonged 
in patients with sarcopenia undergoing resection with curative intent for hepatic 
colorectal metastases (6.6 versus 5.4 days; p=0.03) 45. The impact of sarcopenia on length 
of hospital stay may be greater in conjunction with other patient characteristics. For 
instance, hospital stay was significantly longer in patients with sarcopenia than in those 
without for all patients undergoing surgery for colorectal cancer (15.9 versus 12.3 days; 
p=0.038). The corresponding rates for patients aged 65 years or older were 20.2 versus 
13.1 days (p=0.008). In addition, sarcopenia was an independent factor for the need for 
rehabilitation in patients aged 65 years and older (OR 3.1, 95% c.i. 1.4 to 9.4; p<0.040) 42. 
The two studies 42,45 that reported an increased length of hospital stay in patients with 
sarcopenia also observed an increased number of postoperative complications. Length 
of hospital stay did not significantly differ between patients with and without sarcopenia 
in studies of pancreatic cancer 47 and esophageal and gastric cancer 37,38,
Disease-free survival
Nine studies 38–41,44–46,48,49 described the association between sarcopenia and disease-free 
survival. Data regarding disease-free survival rates and times in the individual studies 
are shown in table 4 and figure 3.
van_Vugt-layout.indd   117 22/11/2017   12:43
118
Chapter 5
Ta
bl
e 
4.
 S
tu
di
es
 re
po
rt
in
g 
th
e 
im
pa
ct
 o
f s
ar
co
pe
ni
a 
on
 lo
ng
-t
er
m
 o
ut
co
m
es
 in
 g
as
tr
oi
nt
es
tin
al
 m
al
ig
na
nc
ie
s.
Re
fe
re
nc
e
M
al
ig
na
nc
y
D
is
ea
se
-f
re
e 
su
rv
iv
al
O
ve
ra
ll 
su
rv
iv
al
Aw
ad
 e
t a
l.3
7
Es
op
ha
ge
al
 a
nd
 g
as
tr
ic
 c
an
ce
r
n.
r.
12
-m
on
th
 m
or
ta
lit
y 
eq
ua
l i
n 
pa
tie
nt
s 
w
ith
 lo
w
 F
FM
 
an
d 
th
os
e 
w
ith
 n
or
m
al
 F
FM
 a
ft
er
 N
AC
RT
 (p
=0
.5
7)
Sh
ee
tz
 e
t a
l.4
6  
Es
op
ha
ge
al
 c
an
ce
r
N
AC
RT
: H
R 
0.
83
 (0
.5
2,
1.
33
) f
or
 in
cr
ea
si
ng
 L
PA
 
(p
=0
.4
33
)*
N
o 
N
AC
RT
: H
R 
0.
33
 (0
.1
4,
 0
.8
0)
 fo
r i
nc
re
as
in
g 
LP
A
 
(p
=0
.0
14
)*
N
AC
RT
: H
R 
0.
77
 (0
.4
6,
 1
.2
8)
 fo
r i
nc
re
as
in
g 
LP
A
 
(p
=0
.3
11
)*
N
o 
N
AC
RT
: H
R 
0.
31
 (0
.1
2,
 0
.8
2)
 fo
r i
nc
re
as
in
g 
LP
A
 
(p
=0
.0
18
)*
 
Yi
p 
et
 a
l.3
8  
Es
op
ha
ge
al
 c
an
ce
r
n.
s.
A
ft
er
 c
he
m
ot
he
ra
py
: M
ed
ia
n 
25
.6
 m
on
th
s 
ve
rs
us
 
m
ed
ia
n 
no
t r
ea
ch
ed
 (p
=0
.0
63
)
Ito
h 
et
 a
l.4
0
H
ep
at
oc
el
lu
la
r c
ar
ci
no
m
a
H
R 
1.
30
 (0
.8
5,
 2
.0
0)
 (p
=0
.2
15
)*
H
R 
1.
96
 (1
.0
6,
 2
.8
3)
 (p
=0
.0
31
)*
H
ar
im
ot
o 
et
 a
l.4
1  
H
ep
at
oc
el
lu
la
r c
ar
ci
no
m
a
5-
ye
ar
: 1
3.
0 
ve
rs
us
 3
3.
2 
(p
=0
.0
13
)
H
R 
0.
97
 (0
.9
5,
 1
.0
0)
 fo
r i
nc
re
as
in
g 
m
us
cl
e 
m
as
s 
(p
=0
.0
16
)*
5-
ye
ar
: 7
1 
ve
rs
us
 8
3.
7%
 (p
=0
.0
01
)
H
R 
0.
90
 (0
.8
4,
 0
.9
6)
 fo
r i
nc
re
as
in
g 
m
us
cl
e 
m
as
s 
(p
=0
.0
02
)*
Vo
ro
n 
et
 a
l.3
9
H
ep
at
oc
el
lu
la
r c
ar
ci
no
m
a
H
R 
3.
03
 (1
.6
7,
 5
.4
9)
 (p
<0
.0
01
)*
H
R 
3.
19
 (1
.2
8,
 7
.9
6)
 (p
=0
.0
13
)*
Pe
ng
 e
t a
l.4
7
Pa
nc
re
at
ic
 c
an
ce
r
n.
a.
M
, 3
-y
ea
r: 
20
.3
 v
er
su
s 3
9.
2%
 (p
<0
.0
50
)
F, 
3-
ye
ar
: 2
6.
1%
 v
er
su
s 4
0.
8 
(p
<0
.0
50
)
3-
ye
ar
: H
R 
1.
63
 (1
.2
8,
 2
.0
7)
 (p
<0
.0
01
)*
Ju
ng
 e
t a
l.4
9  
Co
lo
re
ct
al
 c
an
ce
r
p=
0.
94
6*
H
R 
1.
85
 (1
.1
0,
 3
.1
3)
 (p
=0
.0
22
)*
Sa
be
l e
t a
l.4
8  
Co
lo
re
ct
al
 c
an
ce
r
H
R 
0.
97
 (0
.9
5,
 1
.0
0)
 (p
=0
.0
3)
 fo
r i
nc
re
as
in
g 
PD
n.
s.*
 
H
R 
0.
97
 (0
.9
5,
 1
.0
0)
 fo
r i
nc
re
as
in
g 
PD
 (p
=0
.0
4)
n.
s.*
Pe
ng
 e
t a
l.4
5
Co
lo
re
ct
al
 li
ve
r m
et
as
ta
se
s
H
R 
1.
07
 (p
=0
.7
8)
H
R 
1.
05
 (p
=0
.8
0)
va
n 
Vl
ed
de
r e
t a
l.4
4
Co
lo
re
ct
al
 li
ve
r m
et
as
ta
se
s
H
R 
1.
96
 (1
.2
9,
 2
.9
7)
 (p
=0
.0
02
)*
H
R 
2.
69
 (1
.6
7,
 4
.3
2)
 (p
<0
.0
01
)*
D
at
a 
ar
e 
sh
ow
n 
fo
r 
gr
ou
ps
 w
ith
 v
er
su
s 
w
ith
ou
t 
sa
rc
op
en
ia
 u
nl
es
s 
in
di
ca
te
d 
ot
he
rw
is
e.
 H
az
ar
d 
ra
tio
s 
(H
Rs
) 
ar
e 
sh
ow
n 
w
ith
 9
5 
%
 c
.i.
 *
M
ul
tiv
ar
ia
bl
e 
an
al
ys
is
. N
AC
RT
, n
eo
ad
ju
va
nt
 
ch
em
or
ad
io
th
er
ap
y;
 L
PA
, l
ea
n 
ps
oa
s 
ar
ea
; n
.s.
, n
ot
 s
ig
ni
fic
an
t; 
n.
a.
, n
ot
 a
va
ila
bl
e;
 P
D
, p
so
as
 d
en
si
ty
.
van_Vugt-layout.indd   118 22/11/2017   12:43
119
Systematic review surgical oncology
5
125	
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Study	 HR	 95	per	cent	CI	 HR	Plot	(log	scale)	
Dichotomous	variable	(sarcopenia	yes/no)	
Itoh	(2014)40	 1.30	 [0.85;	2.00]	
	
Voron	(2014)39	 3.03	 [1.67;	5.49]	
	
Van	Vledder	(2012)44	 1.96	 [1.29;	2.97]	
	
	 	 	 	
Continuous	variable	(muscle	area	or	index)	
Harimoto	(2014)41	 0.97	 [0.95;	1.00]	
	
Sheetz	(2014)	NACRT46	 0.83	 [0.52;	1.33]	
	
Sheetz	(2014)	non-NACRT46	 0.33	 [0.14;	0.80]	
	
	 	 	 	
Figure 3. Forest plots showing studies that reported disease-free survival. Only studies 
reporting hazard ratios with 95 % c.i. are shown. NACRT, neoadjuvant chemoradiotherapy.
In patients with esophageal cancer, sarcopenia was associated with impaired disease-
free survival in those who underwent surgical resection without receiving neoadjuvant 
chemoradiotherapy independently of age, sex and tumor stage (hazard ratio (HR) 
0.33, 95% c.i. 0.14 to 0.80; p=0.014) 46. However, no association between sarcopenia 
and disease-free survival was observed in patients who underwent surgical resection 
following neoadjuvant chemoradiotherapy 38,46.
Patients with hepatocellular cancer who had sarcopenia had an increased risk of disease 
recurrence in two 39,41 of three 39–41 studies. One study 39 reported a median disease-free 
survival of 10.1 months in patients with sarcopenia and 34.2 months in those without 
sarcopenia (p<0.001), and an independent association between sarcopenia and 
disease-free survival (HR 3.03, 95% c.i. 1.67 to 5.49; p<0.001). Another study 41 reported 
5-year disease-free survival rates in patients with and without sarcopenia of 13.0 and 
33.2% respectively (p=0.013). In multivariable analysis, a high skeletal muscle mass 
was independently associated with a lower risk of disease recurrence (HR 0.97, 0.95 to 
1.00; p=0.016). Yet another study 40 reported reduced disease-free survival in patients 
undergoing hepatocellular cancer resection in univariable analysis (HR 1.62, 1.11 to 2.36; 
p=0.012), but this association did not remain significant in the multivariable analysis (HR 
1.30, 0.85 to 2.00; p=0.215).
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In patients with primary colorectal cancer, sarcopenia impaired disease-free survival in 
one 48 of the two studies 48,49 reporting on disease recurrence. One study 48 described a 
protective effect of high psoas muscle density (HR 0.97, 0.95 to1.00; p=0.03). However, 
there was no significant difference in disease-free survival between patients with 
normal and low skeletal muscle mass in another study 49. No median survival times, or 
1-, 3- or 5-year survival rates were reported.
In patients with hepatic colorectal metastases, one study 44 reported a median disease-
free survival time of 8.7 months in patients with sarcopenia compared with 15.1 months 
in patients without sarcopenia (HR 1.96, 1.29 to 2.97; p=0.002). However, another 
investigation 45 found no association between sarcopenia and disease-free survival in 
patients with hepatic colorectal metastases; the 5-year recurrence-free survival rate was 
23 and 27% in patients with and without sarcopenia respectively (p=0.78).
Five studies 39–41,44,49 made an adjustment for BMI in the analysis of the prognostic 
value of sarcopenia for disease-free survival. Whereas sarcopenia was associated with 
disease-free survival in four of nine studies, no association between BMI and disease-
free survival was reported in patients with hepatocellular cancer, colorectal cancer or 
hepatic colorectal metastases.
Overall survival
Most authors reported a significant decrease in overall survival in patients with 
sarcopenia compared with those without sarcopenia. This effect was observed 
irrespective of cancer site or tumor origin 39–41,44,46-49. Data regarding survival rates and 
median survival times in the individual studies are shown in table 4 and figure 4.
Among patients with esophageal cancer, a trend towards decreased survival among 
those with sarcopenia was reported in one study (median overall survival 25.6 months 
versus median not reached for patients without sarcopenia; p=0.063) 38. In another 
study 46, overall survival was impaired in patients who had esophageal cancer with 
sarcopenia and did not receive neoadjuvant chemotherapy (HR 0.31, 95% c.i. 0.12 to 
0.82; p=0.018), whereas no significant association was found among patients who did 
receive neoadjuvant chemotherapy (HR 0.77, 0.46 to 1.28; p=0.311).
A study 39 among patients with hepatocellular carcinoma reported a median survival 
time of 52.3 and 70.3 months in patients with and without sarcopenia respectively 
(p=0.015), with a remarkably impaired 1-year survival rate (69.8 versus 95.5%; p=0.015). 
Another investigation 41 described a less severe impact of sarcopenia on survival in 
patients with hepatocellular carcinoma, with a reduction in 5-year survival rate from 
van_Vugt-layout.indd   120 22/11/2017   12:43
121
Systematic review surgical oncology
5
83.7 to 71% (p=0.001). In a study47 of patients who had surgery for pancreatic cancer, the 
3-year survival rate was lower in patients with sarcopenia than in those without (20.3 
versus 39.2% in men, p=0.003; 26.1 versus 40.8% in women, p=0.03). In the multivariable 
analysis, sarcopenia remained independently associated with an increased risk of death 
at 3 years (HR 1.63, 1.28 to 2.07; p<0.001).
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Figure	4.	Forest	plots	showing	studies	that	reported	the	overall	survival.	Only	studies	reporting	hazard	ratios	
with	95	per	cent	c.i.	are	shown.	NACRT,	neoadjuvant	chemoradiotherapy	
	
	
	
	
	 	
Study	 HR	 95	per	cent	CI	 HR	Plot	(log	scale)	
Dichotomous	variable	(sarcopenia	yes/no)	
Itoh	(2014)40	 1.96	 [1.06;	2.83]	
	
Jung	(2014)49	 1.85	 [1.10;	3.13]	
	
Peng	(2012)47	 1.63	 [1.28;	2.07]	
	
Voron	(2014)39	 3.19	 [1.28;	7.96]	
	
Van	Vledder	(2012)44	 2.69	 [1.67;	4.32]	
	
	 	 	 	
Continuous	variable	(muscle	area	or	index)	
Harimoto	(2014)41	 0.9	 [0.84;	0.96]	
	
Sheetz	(2014)	NACRT46	 0.77	 [0.46;	1.28]	
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Figure 4. Forest plots showing studies that reported the overall survival. Only studies reporting 
hazard ratios with 95 % c.i. are shown. NACRT, neoadjuvant chemoradiotherapy.
Median overall survival times, or 1-, 3- or 5-year survival rates were not reported for 
patients with colorectal cancer in any of the included studies. In patients with hepatic 
colorectal metastases, one study 44 reported a median survival time of 23.8 versus 59.8 
months for patients with and without sarcopenia (HR 2.69, 1.67 to 4.32; p<0.001). Two 
studies 38,45 found a decreased overall survival in patients with sarcopenia in univariable 
but not in multivariable analyses.
Five studies undertook multivariable analysis in which the predictive effect of sarcopenia 
on overall survival was adjusted for BMI. Sarcopenia was independently associated with 
overall survival in seven of ten studies, whereas no association between BMI and overall 
survival was reported in patients with hepatocellular cancer and hepatic colorectal 
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metastases 39–41,44. However, one study 49 found that a BMI of 25 kg/m2 or higher was a 
risk factor for impaired overall survival independent of sarcopenia in patients with stage 
III colorectal cancer who received adjuvant chemotherapy.
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DISCUSSION
Several conclusions can be drawn from this systematic review of the impact of CT-
assessed sarcopenia on short- and long-term outcomes in resectable gastrointestinal 
and hepatopancreatobiliary malignancies. Sarcopenia decreased overall survival, 
and increased recurrence rates following surgical resection in patients with hepatic 
colorectal metastases and hepatocellular cancer. Patients with sarcopenia undergoing 
surgery for colorectal cancer and hepatic colorectal metastases also had a prolonged 
length of stay after surgery. Because of the heterogeneity of the included studies, the 
possible influence of age and sex on the prevalence of sarcopenia could not be assessed.
A previous review 52 described the relationship between CT-assessed core muscle 
size and mortality, postoperative morbidity and length of stay after major abdominal 
surgery. This systematic review included eight retrospective cohort studies, of which 
five investigated outcomes in oncological populations. As in the present investigation, 
sarcopenia was associated with increased morbidity, length of hospital stay and 
mortality. The relationship between sarcopenia and recurrence was not described.
Preoperative risk stratification is of utmost importance in patient selection for surgery, 
as it may help physicians to identify patients with a high risk of worse outcome after 
surgery. A tool suitable for risk evaluation should be inexpensive, easily obtainable 
and reliable. Bioelectrical impedance analysis, dual-energy X-ray absorptiometry 
and skinfold measurement are often not performed routinely during the oncological 
evaluation, whereas the majority of patients undergo abdominal CT as part of 
preoperative investigations. Cross-sectional muscle area can be measured rapidly 
by single-slice analysis of abdominal CT images, and is linearly related to total body 
skeletal muscle mass 53; this measurement has a low level of interobserver variability 43,53. 
CT-based skeletal muscle mass measurement in patients with cancer may identify those 
at an early stage of frailty, which would otherwise have been undetected clinically 54.
It is still unknown whether treatment of sarcopenia may improve outcomes. 
Understanding of muscle wasting in cancer has greatly increased over the past decade 55,56 
and has led to new treatment options, such as myostatin inhibitors 57,58. A phase II clinical 
trial on the efficacy of myostatin inhibitors in patients with advanced or metastatic 
pancreatic cancer receiving chemotherapy is ongoing, with overall survival as the 
primary endpoint. There are, however, several other ongoing clinical trials investigating 
stabilization or reversal of muscle loss in patients with cancer 59.
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The present study has some limitations. The included studies were heterogeneous in 
design, and were predominantly retrospective, observational studies which precluded 
meta-analysis of the results. Consequently, no causative relationship between sarcopenia 
and outcome could be demonstrated. Furthermore, the present investigation is likely 
to have been influenced by submission or publication bias. As there is no standard 
definition of CT-based assessment of muscle mass, different methods were used, which 
also hampered evaluation of the results. Investigations that measured total cross-
sectional area of muscle mass used distinct sex-specific cut-off values 23,44. These cut-off 
values were obtained using the same method of stratification in two different patient 
populations, yielding two distinct sets of cut-off values. As such, these values may not be 
interchangeable and applicable to all populations. Another recent study 60 developed a 
third set of cut-off values, which were both sex- and BMI-specific; these included muscle 
attenuation, based on Hounsfield units, as a marker for fat infiltration of muscle. These 
cut-off values remain to be validated.
Sarcopenia impairs overall survival, and may increase postoperative morbidity. Muscle 
mass assessment by CT may assist in preoperative decision-making, particularly for 
patients who are thought to be unfit for surgery or who have a high risk of complications.
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APPENDICES
Appendix S1 Modified Newcastle–Ottawa Scale for cohort studies (short-term 
outcome). A study can be awarded a maximum of one star for each numbered item 
within the selection and outcome categories. A maximum of two stars can be given for 
comparability
Selection
1)  Representativeness of the exposed cohort
a)  truly representative of the average _______________ (describe) in the community 
¯
b)  somewhat representative of the average ______________ in the community ¯
c)  selected group of users, e.g., nurses, volunteers
d)  no description of the derivation of the cohort
• Star if demographics (age and gender) and indication of surgical resection are both 
clearly explained and reasonably representative; may be subjective
2)  Selection of the non-exposed cohort
a)  drawn from the same community as the exposed cohort ¯
b)  drawn from a different source
c)  no description of the derivation of the non-exposed cohort 
• Star if sarcopenic patients were identified within the same cohort as non-sarcopenic 
patients
3) Ascertainment of exposure
a) secure record (e.g., surgical records) ¯
b) structured interview ¯
c)  written self report
d)  no description
• Star if computed tomography was used in the assessment of sarcopenia and 
presence of sarcopenia is clearly defined
4)  Demonstration that outcome of interest was not present at start of study
a)  yes ¯
b)  no
• Star if any statement is given regarding absence of prior history associated with 
muscle wasting; may be subjective
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Comparability
1)  Comparability of cohorts on the basis of the design or analysis
a)  study controls for _____________ (select the most important factor) ¯
• Star if study controls patient gender
b)  study controls for any additional factor ¯   (This criteria could be modified to indicate 
specific control for a second important factor)
• Star if study controls for patient age
Outcome
1)  Assessment of outcome
a)  independent blind assessment ¯
b) record linkage ¯
c)  self report 
d) no description
• Star if post-operative complications are clearly defined or scored on basis of a 
validated classification of surgical complications
2)  Was follow-up long enough for outcomes to occur
a)  yes (select an adequate follow-up period for outcome of interest) ¯
 b) no
• Star if study reports a median follow-up exceeding 30 days
• Star if data regarding 30-day mortality is obtained through record linkage
3)  Adequacy of follow-up of cohorts
a) complete follow up – all subjects accounted for ¯
b) subjects lost to follow-up unlikely to introduce bias – small number lost – over  80 
% follow-up, or description provided of those lost) ¯
c) follow-up rate less than  80 % and no description of those lost
d) no statement
• Star if all subjects are accounted for.
• Star if more than 80 % described or if those lost to follow-up have been described.
van_Vugt-layout.indd   130 22/11/2017   12:43
131
Systematic review surgical oncology
5
Appendix S2 Modified Newcastle–Ottawa Scale for cohort studies (disease-free 
survival). A study can be awarded a maximum of one star for each numbered item 
within the selection and outcome categories. A maximum of two stars can be given for 
comparability
Selection
1) Representativeness of the exposed cohort
a) truly representative of the average _______________ (describe) in the community 
¯
b) somewhat representative of the average ______________ in the community ¯
c) selected group of users, e.g., nurses, volunteers
d) no description of the derivation of the cohort
• Star if demographics (age and gender) and indication of surgical resection are both 
clearly explained and reasonably representative; may be subjective
2) Selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort ¯
b) drawn from a different source
c) no description of the derivation of the non-exposed cohort 
• Star if sarcopenic patients were identified within the same cohort as non-sarcopenic 
patients
3) Ascertainment of exposure
a) secure record (e.g., surgical records) ¯
b) structured interview ¯
c) written self report
d) no description
• Star if computed tomography was used in the assessment of sarcopenia and 
presence of sarcopenia is clearly defined
4) Demonstration that outcome of interest was not present at start of study
a) yes ¯
b) no
• Star if any statement is given regarding absence of prior history associated with 
muscle wasting; may be subjective
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) study controls for _____________ (select the most important factor) ¯
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• Star if study controls patient gender
b) study controls for any additional factor ¯   (This criteria could be modified to indicate 
specific control for a second important factor)
• Star if study controls for patient age
Outcome
1) Assessment of outcome
a) independent blind assessment ¯
b) record linkage ¯
c) self report 
d) no description
• Star if disease-free survival is obtained through patient records
• Star if disease-free survival is obtained through record linkage
2) Was follow-up long enough for outcomes to occur
a) yes (select an adequate follow-up period for outcome of interest) ¯
 b) no
• Star if study reports a median follow-up exceeding 24 months 
3) Adequacy of follow-up of cohorts
e) complete follow up – all subjects accounted for ¯
f ) subjects lost to follow-up unlikely to introduce bias – small number lost – over  80 
% follow-up, or description provided of those lost) ¯
g) follow-up rate less than  80 % and no description of those lost
h) no statement
• Star if all subjects are accounted for.
• Star if more than 80 % described or if those lost to follow-up have been described.
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Appendix S3 Modified Newcastle–Ottawa Scale for cohort studies (overall survival). 
A study can be awarded a maximum of one star for each numbered item within 
the selection and outcome categories. A maximum of two stars can be given for 
comparability
Selection
1) Representativeness of the exposed cohort
a) truly representative of the average _______________ (describe) in the community 
¯
b) somewhat representative of the average ______________ in the community ¯
c) selected group of users, e.g., nurses, volunteers
d) no description of the derivation of the cohort
• Star if demographics (age and gender) and indication of surgical resection are both 
clearly explained and reasonably representative; may be subjective
2) Selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort ¯
b) drawn from a different source
c) no description of the derivation of the non-exposed cohort 
• Star if sarcopenic patients were identified within the same cohort as non-sarcopenic 
patients
3) Ascertainment of exposure
a) secure record (e.g., surgical records) ¯
b) structured interview ¯
c) written self report
d) no description
• Star if computed tomography was used in the assessment of sarcopenia and 
presence of sarcopenia is clearly defined
4) Demonstration that outcome of interest was not present at start of study
a) yes ¯
b) no
• Star if any statement is given regarding absence of prior history associated with 
muscle wasting; may be subjective
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) study controls for _____________ (select the most important factor) ¯
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• Star if study controls patient gender
b) study controls for any additional factor ¯   (This criteria could be modified to indicate 
specific control for a second important factor)
• Star if study controls for patient age
Outcome
1) Assessment of outcome
a) independent blind assessment ¯
b) record linkage ¯
c) self report 
d) no description
• Star if overall survival is obtained through patient records
• Star if overall survival is obtained through record linkage
2) Was follow-up long enough for outcomes to occur
a) yes (select an adequate follow-up period for outcome of interest) ¯
 b) no
• Star if study reports a median follow-up exceeding 24 months
• Star if study reports collection of survival data by record linkage using e.g., civil 
registrars at a time point exceeding at least 24 months 
3) Adequacy of follow-up of cohorts
i) complete follow up – all subjects accounted for ¯
j) subjects lost to follow-up unlikely to introduce bias – small number lost – over  80 
% follow-up, or description provided of those lost) ¯
k) follow-up rate less than  80 % and no description of those lost
l) no statement
• Star if all subjects are accounted for.
• Star if more than 80 % described or if those lost to follow-up have been described.
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Functional Compromise Reflected by Sarcopenia, 
Frailty, and Nutritional Depletion Predicts Adverse 
Postoperative Outcome after Colorectal Cancer Surgery
K.W. Reisinger, J.L.A. van Vugt, J.J.W. Tegels, C. Snijders, K.W.E. Hulsewé, 
A.G.M. Hoofwijk, J.H.M.B. Stoot, M.F. von Meyenfeldt, G.L. Beets, J.P.M. Derikx, M. Poeze
Adapted from: Annals of Surgery 2015 Feb; 261 (2): 345-352
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ABSTRACT
Background: Functional compromise in elderly colorectal surgical patients is 
considered as a significant factor of impaired postoperative recovery. Therefore, the 
predictive value of pre-operative functional compromise assessment was investigated. 
Sarcopenia is a hallmark of functional compromise.
Methods: 310 consecutive patients who underwent oncologic colorectal surgery were 
enrolled in a prospective digital database. Sarcopenia was assessed using the L3 muscle 
index using Osirix® on pre-operative computed tomography (CT). Groningen Frailty 
Indicator (GFI) and Short Nutritional Assessment Questionnaire (SNAQ) scores were 
used to assess frailty and nutritional compromise. Predictors for anastomotic leakage, 
sepsis and mortality were analyzed by logistic regression analysis.
Results: Age was an independent predictor of mortality (p=0.04; odds ratio (OR), 1.17; 
95% confidence interval (CI), 1.01 – 1.37). 30-day/in-hospital mortality rate in sarcopenic 
patients was 8.8% versus 0.7% in non-sarcopenic patients (p=0.001; OR 15.5; 95% CI, 2.00 
– 120). Sarcopenia was not predictive for anastomotic leakage or sepsis. Combination 
of high SNAQ score, high GFI score and sarcopenia strongly predicted sepsis (p=0.001; 
OR, 25.1; 95% CI, 5.11 – 123), sensitivity, 46%; specificity, 97%; positive likelihood ratio, 
13 (95% CI, 4.4 – 38); negative likelihood ratio, 0.57 (95% CI, 0.33 – 0.97). 
Conclusions: Functional compromise in colorectal cancer surgery is associated with 
adverse postoperative outcome. Assessment of functional compromise by means 
of a nutritional questionnaire (SNAQ), a frailty questionnaire (GFI), and sarcopenia 
measurement (L3 muscle index) can accurately predict postoperative sepsis.
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INTRODUCTION
With an increasingly aging population, the number of older cancer patients is 
concomitantly rising. Currently 50 percent of patients with colorectal cancer is aged 
70 years or older 1. Older patients are at increased risk for developing peri-operative 
complications and suffer from higher mortality rates 2. Postoperative recovery plays a 
crucial role in cancer treatment with respect to survival, morbidity, and quality of life 3-5. 
Hence, pre-operative assessment is important to identify patients at risk for developing 
postoperative complications. Widely accepted risk assessments are however considered 
to be subjective and imprecise and not focused on patients with cancer 6.
It is hypothesized that functional compromise in the older surgical patient is a significant 
predictor of postoperative complications 7, 8. A widely investigated aspect of functional 
compromise is frailty. Frailty is a state of increased vulnerability towards stressors in 
older individuals, leading to an increased risk of developing adverse health outcomes 9. 
However, the definition of frailty remains controversial and there is no consensus about 
the clinical use of frailty as a preoperative predictor for postoperative outcome in elderly 
patients 7. Weight loss, low muscle strength, reduced physical activity, exhaustion, and 
decreased walking speed are elements of a physical definition of frailty 6, 8, whereas 
comorbidity, polypharmacy, physical functioning, nutritional and cognitive status, 
depression and social support are a more multidimensional tool to assess frailty 10-12. In 
addition, sarcopenia is an important factor in functional compromise and depletion of 
skeletal muscle can occur in normal-weight, overweight and obese patients and does 
therefore not equal ordinary weight loss or cachexia 13, 14. Malnutrition is another key 
element of functional compromise that is associated with poor clinical outcome 15. In 
elderly patients, preoperative malnutrition is common, and worsens the condition of 
this already vulnerable population 16.
In this study we investigated whether functional compromise is associated with 
postoperative morbidity and mortality after colorectal surgery. The following parameters 
of functional compromise were evaluated: CT-based measurement of muscle mass, 
Groningen Frailty Index (GFI) 17 and Short Nutritional Assessment Questionnaire (SNAQ) 18. 
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METHODS
Patients
All consecutive patients who underwent oncologic colorectal surgery in a single non-
academic center with a dedicated team of colorectal surgeons from January 2010 until 
May 2012 were enrolled in a prospective digital cohort and analyzed retrospectively. The 
only exclusion criterion was unavailability of a preoperative CT scan. Data in the database 
included characteristics of the primary tumor and oncologic staging, specifications of 
surgical treatment, chemotherapy, radiotherapy, and postoperative complications and 
included a preoperative CT-scan of the abdomen which was performed routinely for 
tumor staging.
Complications
The following complications were analyzed prospectively in detail: anastomotic leakage 
(surgically and/or radiologically) and/or intra-abdominal abscess diagnosed by CT 
examination or treated by percutaneous drainage or surgery, sepsis and septic shock 
(defined as two or more of the following criteria positive: (1) temperature >38°C or 
<36°C; (2) heart rate >90 bpm; (3) respiratory rate >20 breaths/min or PaCO2 <32 mmHg; 
(4) white blood cell count >12x109/L, <4x109/L, or >10% immature (band) forms plus 
documented infection and hypotension despite adequate fluid resuscitation (in case of 
septic shock) 19), and postoperative mortality (within 30 days postoperatively or within 
same period of hospital admission). The 30-day mortality for patients discharged within 
this period was verified by checking the municipal personal records database.
Pre-operative CT-based muscle measurements
All patients underwent a CT-scan of the abdomen as part of routine pre-operative 
assessment, which was delivered on CD-ROM or DVD. Measurements were performed 
using Osirix® Version 3.3 (32-bit; http://www.osirix-viewer.com). The cross-sectional 
skeletal muscle surface (cm²) assessment of sarcopenia was performed at the level 
of the third lumbar vertebra (L3) on two consecutive transversal coupes on which 
both vertebral spines were visible 20. The ‘Grow Region (2D/3D Segmentation)’ tool in 
the menu of the program facilitated to automatically select all skeletal muscle mass 
in one coupe. The distinction between different tissues is based on Hounsfield Units 
(HU). A threshold range of -30 HU to +110 HU was used for skeletal muscle. Muscles 
measured were: psoas, paraspinal, transverse abdominal, external oblique, internal 
oblique and rectus abdominis muscles (figure 1). Hand-adjustment of the selected 
areas was performed if necessary and the muscle area was calculated automatically 20. 
The averages of the two measurements were used for calculations. Two investigators 
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independently measured all L3-muscle area surface parameters (J.v.V. and J.T.). A third 
investigator (K.R.) performed a random control measurement on 10% of the CT-scans. 
All investigators did not have specific skills in radiology.
Figure 1. Computed tomography image at the third lumbar vertebral level. The following 
skeletal muscles are outlined in red: psoas, paraspinal, transverse abdominal, external oblique, 
internal oblique and rectus abdominis muscles. This female sarcopenic patient had an L3 
muscle index of 34.3 cm²/m².
Sarcopenia
The L3-muscle area surfaces were normalized for patient height to calculate the L3-
muscle index and expressed in cm²/m². The cut-off values used for sarcopenia were 52.4 
cm²/m² for men and 38.5 cm²/m² for women, based on the method of Prado et al. 14.
Groningen Frailty Indicator (GFI)
The GFI has been developed as a simple screening instrument for frailty 17. The GFI screens 
on physical, cognitive, social and emotional items (Appendix 1). The maximum score is 
15 points. Patients scoring 5 or more points were considered frail 17. A trained nurse 
routinely performed GFI-scores at pre-operative consultation or hospital admission in 
patients aged 70 or older.
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Short Nutritional Assessment Questionnaire (SNAQ)
The SNAQ is a valid and reproducible tool to detect malnourished hospitalized patients 
without the need to calculate percentage weight loss or BMI 18. The maximum score is 5 
points (Appendix 2). Patients with a score of 3 points or more on the SNAQ were classified 
as malnourished (requiring nutritional support and supervision by a dietician) 18. 
A trained nurse routinely performed SNAQ-scores at pre-operative consultation or 
hospital admission.
Statistical analysis
Frequencies are presented as absolute numbers and percentages. Continuous data 
are presented as mean (standard error of the mean [SEM]). Normality was tested using 
Kolmogorov-Smirnov. Differences between groups were analyzed with the Pearson chi-
square test for dichotomous parameters. Odds ratios and 95% confidence intervals were 
calculated by logistic regression analysis. For the calculation of significant predictors 
of mortality and complications, univariate analyses with clinically relevant parameters 
were performed. Significant predictors (p<0.05) or predictors showing a trend towards 
significance (0.05≤p<0.20) based on univariate analysis were entered into multivariable 
logistic regression analysis. Interactions between sarcopenia, GFI scores and SNAQ 
scores were tested. Functional compromise was defined as sarcopenia, high GFI score 
and high SNAQ score. Diagnostic accuracy of functional compromise assessment to 
predict postoperative complications was evaluated by calculating sensitivity, specificity, 
positive likelihood ratio (LR+), and negative likelihood ratio (LR-) using crosstabs. 
The interobserver agreement (J.v.V., J.T., K.R.) of the L3 muscle index assessment of 
sarcopenia was analyzed by Pearson’s correlation and Cohen’s kappa coefficient. Two-
tailed p-values <0.05 were considered significant. All statistical analyses were performed 
using SPSS® 20.0 (SPSS Inc, Chicago, IL, USA).
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RESULTS
Patients
340 patients were enrolled in the prospective database. In 30 patients, no staging CT 
scan was available, for which the main reason was emergency surgery. Therefore 310 
patients undergoing both elective and acute colorectal resection were included in the 
analyses of the current study. The patient characteristics are listed in table 1. Of these 
310 patients, 148 (47.7%) were identified as sarcopenic as defined by muscle index at 
L3 level; 90/155 (58.1%) males and 58/155 (37.4%) females. Mean L3 muscle indexes 
for males and females were 51.5 (0.65) cm²/m² and 40.7 (0.53) cm²/m², respectively. Of 
patients aged 70 or older, 41 (24.6%) were frail as defined by a GFI score of 5 or more. 
SNAQ scores were 3 points or higher in 36 (11%) of all patients.
Interobserver agreement of CT-based muscle measurement by Osirix®
Two independent investigators measured the L3 muscle areas of all patients, showing a 
strong and significant correlation (R²=0.98; p<0.0001). Bland-Altman analysis produced 
95% limits of agreement, -5.9% – 8.7%. The kappa (κ) of sarcopenia assessment by CT 
image analysis using Osirix® was 0.87 (95% confidence interval (CI), 0.82 – 0.93). The 
random control measurement on 10% of the CT-scans by a third investigator yielded 
excellent correlation (R²=0.98; p<0.0001) and a kappa of 0.74 (95% CI, 0.46 – 1.00).
Mortality
Fourteen patients died within 30 days or during hospital admission (4.5%). Causes of 
mortality are listed in table 2. In univariate analyses sarcopenia (p=0.009), male gender 
(p=0.02), age (p=0.002), epidural analgesia (p=0.14), medical history of abdominal 
surgery (p=0.02), ASA classification (p=0.02), and stage 3-4 disease (p=0.14) were 
significant predictors of postoperative mortality or showed a trend towards significance. 
Multivariable logistic regression revealed male gender (OR, 49.29 (95% CI, 2.48 – 978.4); 
p=0.01), sarcopenia (OR, 43.30 (95% CI, 2.74 – 685.2); p=0.007), age (OR, 1.17; 95% CI, 
1.01 – 1.37; p=0.04), and medical history of abdominal surgery (OR, 31.16 (3.09 – 313.9); 
p=0.004) being independent predictors of mortality. Logistic regression results are 
summarized in table 3a.
To evaluate the effect of functional compromise on mortality in more detail, interactions 
between SNAQ ≥3, GFI ≥5, and sarcopenia were studied. None of the interactions 
increased the predictive value of sarcopenia.
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Table 1. patient characteristics
Number of patients (%) Mean (SEM)
Sex Male 155 (50.0)
Female 155 (50.0)
Age (years) 69 (0.6)b
> 70 159 (51.3)
BMI (kg/m²) 26.3 (0.26)b
> 25 182 (58.7)
Length of hospital stay 
(days)
11 (0.6)b
ASA I 17 (5.5)
II 219 (70.6)
III 62 (20.0)
IV 12 (3.9)
Laparoscopy 33 (10.6)
Primary anastomosis 249 (80.3)
Tumor location Colon 205 (66.1)
Rectum 105 (33.9)
Complications
Anastomotic leakage and /or 
abscess
37 (14.9)
Sepsis 14 (4.5)
Death 14 (4.5)
Cause-related death 8 (2.6)
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Table 2. causes of mortality 
Cause Postoperative day of mortality 
Sarcopenic patients (n=13)
1 Pneumonia, sepsis, cardiorespiratory failure 47
2 Sepsis of surgical site origin 5
3 Sepsis of surgical site origin 2
4 Sepsis of surgical site origin 2
5 Cardiorespiratory failure after anastomotic leakage 25
6 Pneumonia 30
7 Sepsis of surgical site origin 7
8 Pneumonia 3
9 Cardiorespiratory failure 8
10 Pneumonia 7
11 Unknown cause, probably pneumonia 35
12 Intraoperative presacral bleeding 0
13 Gastric hemorrhage 10
Non-sarcopenic patients (n=1)
14 Anastomotic leakage 25
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Table 3a. Logistic regression analysis for risk factors of mortality.
Mortality rate
Univariate analysis Multivariable analysis
Odds ratio p-value Odds ratio p-value
Sarcopenia
No 1/162 1 1
Yes 13/148 15.50 (2.00-120.0) 0.009 43.30 (2.74-685.2) 0.007
GFI ≥5
No 8/114 1
Yes 3/39 0.68 (0.09-5.45) 0.72
SNAQ ≥3
No 8/185 1
Yes 4/112 0.82 (0.24-2.79) 0.75
Gender
Female 2/155 1 1
Male 12/155 6.42 (1.41-29.18) 0.02 49.29 (2.48-978.4) 0.01
Age 1.12 (1.04-1.20) 0.002 1.17 (1.01-1.37) 0.04
Epidural
No 8/117 1
Yes 6/193 0.44 (0.15-1.29) 0.14
Previous abdominal surgery
No 5/208 1 1
Yes 9/102 3.93 (1.28-12.05) 0.02 31.16 (3.09-313.9) 0.004
ASA
I 0/17 1 0.02
II 5/219 ∞ (0.00-∞) 1.00
III 8/62 ∞ (0.00-∞) 1.00
IV 1/12 ∞ (0.00-∞) 1.00
Disease stage
1-2 3/107 1
3-4 9/122 2.76 (0.73-10.48) 0.14
BMI >25 kg/m²
No 8/128 1
Yes 6/182 0.51 (0.17-1.51) 0.23
Smoking
No 4/170 1
Yes 8/140 2.12 (0.62-7.21) 0.23
Diabetes
No 11/252 1
Yes 3/58 1.20 (0.32-4.43) 0.79
Definition of mortality: 30-day mortality and/or in-hospital mortality
Values in parentheses are 95% confidence intervals 
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Anastomotic leakage
The incidence of anastomotic leakage and/or intra-abdominal abscess was 37 
(14.9%) in patients with a primary anastomosis. Mortality within this group was 9.3%. 
Significant predictors or predictors showing a trend for anastomotic leakage and/
or intra-abdominal abscess were sarcopenia (p=0.13), SNAQ ≥3 (p=0.08), medical 
history of abdominal surgery (p=0.06), surgery of the rectum (p=0.02), open surgery 
(p=0.10), stapled anastomosis (p=0.06), stage 3-4 disease (p=0.04), and need for blood 
transfusion (p<0.001). In multivariable analysis, stage 3-4 disease (OR, 3.68; 95% CI, 1.18 
– 11.4; p=0.02) and need for blood transfusion (OR, 7.81; 95% CI, 2.81 – 21.8; p=0001) 
were independent predictors of anastomotic leakage and/or intra-abdominal abscess. 
Logistic regression results are summarized in table 3b.
To evaluate the effect of functional compromise on anastomotic leakage in more detail, 
interactions between SNAQ ≥3, GFI ≥5, and sarcopenia were studied. None of the 
interactions were significantly predictive of anastomotic leakage.
Sepsis
Fourteen patients (4.5%) developed sepsis. Mortality within this group was 36%. 
Univariate analysis demonstrated that GFI ≥5 (p=0.03), SNAQ ≥3 (p=0.003), age (p=0.03), 
epidural analgesia (p=0.14), and medical history of abdominal surgery (p=0.17) were 
significant predictors of sepsis or showed a trend towards significance. In multivariable 
logistic regression analysis, SNAQ ≥3 was independently predictive of postoperative 
sepsis (OR, 4.37; 95% CI, 1.07 – 17.9; p=0.04). Logistic regression results are summarized 
in table 3c.
To evaluate the effect of functional compromise on sepsis in more detail, interactions 
between SNAQ ≥3, GFI ≥5, and sarcopenia were studied. The interaction between 
SNAQ ≥3 and GFI ≥5 compared to SNAQ ≥3 alone increased the capability of predicting 
postoperative sepsis (OR, 13.1; 95% CI, 3.02 – 57.2; p=0.001). The interaction between 
SNAQ ≥3, GFI ≥5, and sarcopenia further increased the risk of sepsis (OR, 25.1; 95% CI, 
5.11 – 123; p=0.001).
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Table 3b. Logistic regression analysis for risk factors of anastomotic leakage.
Anastomotic 
leakage rate
Univariate analysis Multivariable analysis
Odds ratio p-value Odds ratio p-value
Sarcopenia
No 24/133 1
Yes 13/116 0.57 (0.28-1.19) 0.13
GFI ≥5
No 12/92 1
Yes 5/30 1.33 (0.42-4.15) 0.62
SNAQ ≥3
No 21/147 1
Yes 14/91 2.33 (0.90-6.00) 0.08
Gender
Female 16/126 1
Male 21/123 1.42 (0.70-2.86) 0.33
Age 0.99 (0.96-1.02) 0.57
Previous abdominal surgery
No 20/168 1
Yes 17/81 1.97 (0.97-4.00) 0.06
Disease stage
1-2 6/97 1 1
3-4 17/109 2.80 (1.06-7.43) 0.04 3.68 (1.18-11.4) 0.02
Tumor location
Colon 22/188 1
Rectum 15/61 2.46 (1.18-5.12) 0.02
Type of surgery
Laparoscopy 1/29 1
Laparotomy 36/220 5.48 (0.72-41.56) 0.10
Anastomosis
Manual 15/137 1
Stapled 21/106 2.01 (0.98-4.12) 0.06
Blood transfusion
No 19/207 1 1
Yes 18/42 7.42 (3.43-16.06) <0.001 7.81 (2.81-21.8) <0.001
Smoking
No 17/133 1
Yes 20/116 1.47 (0.70-3.08) 0.30
Diabetes
No 31/203 1
Yes 6/46 0.83 (0.33-2.13) 0.70
Anastomotic leakage and/or intra-abdominal abscess in 249 patients with primary anastomosis
Values in parentheses are 95% confidence intervals 
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Table 3c. Logistic regression analysis for risk factors of sepsis.
Sepsis rate
Univariate analysis Multivariable analysis
Odds ratio p-value Odds ratio p-value
Sarcopenia
No 6/162 1
Yes 8/148 1.49 (0.50-4.39) 0.47
GFI ≥5
No 5/114 1
Yes 6/39 3.96 (1.14-13.83) 0.03
SNAQ ≥3
No 6/185 1 1
Yes 6/112 6.17 (1.84-20.64) 0.003 4.37 (1.07-17.9) 0.04
Gender
Female 8/155 1
Male 6/155 0.74 (0.25-2.19) 0.59
Age 1.07 (1.01-1.14) 0.03
Epidural
No 8/117 1
Yes 6/193 0.44 (0.15-1.29) 0.14
Previous abdominal surgery
No 7/208 1
Yes 7/102 2.12 (0.72-6.20) 0.17
Disease stage
1-2 4/107 1
3-4 4/122 0.87 (0.21-3.58) 0.85
ASA
I 0/17 1 0.95
II 10/219 ∞ (0.00-∞) 1.00
III 4/62 ∞ (0.00-∞) 1.00
IV 0/12 1.00 (0.00-∞) 1.00
Smoking
No 7/170 1
Yes 7/140 1.21 (0.40-3.70) 0.74
Diabetes
No 11/252 1
Yes 3/58 1.62 (0.50-5.29) 0.42
Values in parentheses are 95% confidence intervals 
van_Vugt-layout.indd   149 22/11/2017   12:43
150
Chapter 6
Diagnostic accuracy of SNAQ/GFI/sarcopenia score to predict sepsis
As a strong association of functional compromise (the combination of high SNAQ, high 
GFI, and sarcopenia) with sepsis was shown by the previous data, the clinical applicability 
of this functional compromise assessment needed further exploration. Therefore, the 
diagnostic accuracy of (pre-operative) functional compromise assessment to predict 
postoperative sepsis was investigated. A positive functional compromise test was 
defined as SNAQ ≥3, GFI ≥5, and sarcopenia (L3 muscle index <52.4 cm²/m² for men, and 
<38.5 cm²/m² for women). This resulted in sensitivity, 46%; specificity, 97%; LR+, 13 (95% 
CI, 4.4 – 38); LR-, 0.57 (95% CI, 0.33 – 0.97). Subgroup analysis of patients undergoing 
rectal surgery revealed a higher diagnostic accuracy; sensitivity, 67%; specificity, 98%; 
LR+, 29 (95% CI, 3.61 – 239); LR-, 0.34 (95% CI, 0.07 – 1.69).
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DISCUSSION
The association of functional compromise and unfavorable postoperative outcome in 
colorectal surgery has been described before 8, 10.  Robinson and co-workers investigated 
frailty, an important aspect of functional compromise, using a scoring system based 
on 7 items of different domains and showed that frailty increased healthcare costs and 
30-day readmission rates. However, postoperative complications were not specified 10. 
Another study involving elderly colorectal surgery patients demonstrated a 4-fold 
increased risk for major postoperative complications when frailty was present 8. The 
frailty assessment used was based on the criteria of Fried et al. 21, i.e. 3 or more items of 
the following: unintentional weight loss (10 lbs in past year), self-reported exhaustion, 
weakness (grip strength), slow walking speed, and low physical activity. The current 
study underlines and extends the abovementioned findings for several reasons. First, 
this is the largest cohort thus far addressing the influence of functional compromise 
including frailty on postoperative outcome in colorectal surgery. Second, the proposed 
functional compromise assessment is easy to perform as staging CT scans are routinely 
performed and SNAQ and GFI questionnaires can be completed in only few minutes 
time. In most Dutch hospitals, nutritional assessment and GFI assessments are part of 
standard care at hospital admission. Third, this study highlights metabolic and functional 
compromise to be associated with postoperative mortality in colorectal surgery.
As in the present study, elderly patients showed higher rates of short-term postoperative 
mortality and sepsis, pointing at a the role of sepsis causing postoperative death in 
these patients. Moreover, 9 out of 13 mortality cases in sarcopenic patients were caused 
by sepsis or pneumonia. In the context of major abdominal surgery, it could be assumed 
that sepsis may be the consequence of inadequate gut barrier function, especially in the 
cancer bearing host. Loss of intestinal barrier function is indeed correlated with sepsis 22-24. 
In addition, it has been demonstrated that gut barrier dysfunction and endotoxemia 
develop concurrently with cachexia in a mouse model of colorectal neoplasia 25. In the 
current study, low muscle mass strongly correlated with mortality, however the link 
with sepsis could not be made statistically. It could be hypothesized that sarcopenia 
reflects a state of prolonged catabolism impairing host immune function and leading 
to an inadequate response to inflammatory stimuli. A strong association with sepsis 
was found when muscle mass assessment was combined with SNAQ and GFI scores, 
indicating that muscle wasting as a reflection of the more comprehensive syndrome 
of functional compromise predicts postoperative morbidity. Although an elevated 
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inflammatory response has been observed in sarcopenic colorectal cancer patients 26, 
future studies should address the unraveled link between frailty, gut barrier function 
and development of sepsis.
A correlation between elevated serum markers of preoperative systemic inflammatory 
response and postoperative infectious complications and mortality has been established 
extensively 27, 28. Specifically, the Glasgow Prognostic Score (GPS) comprising C-reactive 
protein (CRP) and albumin levels is an easily obtainable and accurate scoring system 
to predict postoperative morbidity and mortality in patients undergoing colorectal 
surgery 29. The current study presents another point of view of potentially the same 
phenomenon, namely physical impairment of the cancer bearing host reflected as 
functional compromise and systemic inflammation. Cause and effect remain to be 
determined and in future studies, both SNAQ/GFI/sarcopenia score and GPS should be 
acquired, for combination of both scores may increase predictive accuracy.
Remarkably, anastomotic leakage and/or intra-abdominal abscess could not be 
predicted by sarcopenia, SNAQ or GFI scores, nor by their interactions. The predictive 
factors found in this study were stage 3-4 cancer, i.e. advanced disease and need for 
blood transfusion. This observation was in line with the results of the large prospective 
study of Boccola and colleagues 30. The effect underlying the association between stage 
3-4 disease and anastomotic leakage has not been investigated in our study, however a 
nutritional cause seems unlikely as a high SNAQ score was not independently predictive 
in multivariable analysis. An increased inflammatory state could be hypothesized in 
advanced cancer stage, but markers for inflammation were not included in our analyses.
Identifying surgical patients at risk for developing complications remains challenging. 
Therefore, an important clinical implication can be drawn from this study. The easy-
to-perform functional compromise assessment presented here (SNAQ, GFI and 
sarcopenia) may be used to detect high-risk patients and to adapt treatment regimens 
accordingly, i.e. primary diverting ileostomy or colostomy. The preoperative period can 
be considered to improve functional parameters by nutritional support and physical 
exercise 31. Exercise may increase physical functioning and overall quality of life in 
cancer patients 32, 33. The best anabolic response is obtained when exercise is combined 
with nutritional support, such as essential amino acid ingestion 34, 35. Physical exercise 
must be performed 2-3 days a week to increase muscle strength 36, therefore this 
should be supervised. Furthermore, many patients undergo neoadjuvant treatment 
which generates a timeframe for prehabilitation strategies. Finally, as the SNAQ/GFI/
van_Vugt-layout.indd   152 22/11/2017   12:43
153
Functional compromise in colorectal cancer
6
sarcopenia score specifically predicts sepsis, intensive monitoring can be opted for in 
patients at risk. Future studies may elucidate whether these high-risk patients could 
benefit from selective decontamination of the digestive tract (SDD) 37.
The L3 muscle index measure is a widely available, objective and precise measurement 
for peri-operative assessment of lean body mass. In the current study, a very good 
interobserver variability was demonstrated by two investigators who had not received 
any specific radiological training. As mentioned before, an important remark should 
be made regarding the cut-off values of the L3 index to diagnose sarcopenia. As 
these values are based on obese cancer patients, they might not be applicable to all 
populations. Sarcopenia incidence by the definition in the present study was 48%, which 
is a rather high number in colorectal cancer patients who have not been reported to 
suffer from severe muscle wasting, potentially indicating an underestimated proportion 
of functional loss in this group. It is therefore highly desirable to define cut-off values 
based on healthy subjects and different cancer type populations. Nonetheless, the 
cut-off values described by Prado et al. are based on mortality prediction, which was 
supported in the current study. Another limitation is the retrospective nature of the 
study. However, all patients in the study cohort were included in a prospective database 
(Dutch Surgical Colorectal Audit) and only patients without an available staging CT scan 
were excluded. As a consequence, the probability of selection bias was negligible. Due 
to the retrospective nature of the study, DXA scans and other tests for sarcopenia were 
not available. However, CT-based muscle area measurement is a well-documented and 
readily obtainable alternative to detect sarcopenia 14. The findings of the present study 
should nonetheless be confirmed in a second, prospective cohort including other tests 
for sarcopenia.
This study shows that functional compromise in colorectal cancer surgery is associated 
with adverse postoperative outcome. Moreover, assessment of functional compromise 
by means of a nutritional questionnaire (SNAQ), a frailty questionnaire (GFI), and CT-
based sarcopenia measurement (L3 muscle index), i.e. the SNAQ/GFI/sarcopenia score 
can accurately predict postoperative sepsis.
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APPENDICES
Appendix 1: items of Groningen Frailty Indicator (GFI) score 1
Mobility
Is the patient able to carry out these tasks single handed without any help? (The 
use of help resources such as walking stick, walking frame, wheelchair, is considered 
independent)
1. Shopping
2. Walking around outside (around the house or to the neighbors)
3. Dressing and undressing
4. Going to the toilet
Physical Fitness
5. What mark does the patient give himself/herself for physical fitness? (scale 0 to 10)
Vision
6. Does the patient experience problems in daily life due to poor vision?
Hearing
7. Does the patient experience problems in daily life due to being hard of hearing?
Nourishment
8. During the last 6 months has the patient lost a lot of weight unwillingly? (3 kg in 1 
month or 6 kg in 2 months)
Morbidity
9. Does the patient take 4 or more different types of medicine?
Cognition (Perception)
10. Does the patient have any complaints about his/her memory or is the patient known 
to have a dementia syndrome?
Psychosocial
11. Does the patient sometimes experience emptiness around him/her?
12. Does the patient sometimes miss people around him/her?
13. Does the patient sometimes feel abandoned?
14. Has the patient recently felt downhearted or sad?
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15. Has the patient recently felt nervous or anxious?
Sum
Scoring:
Questions 1–4: Independent = 0; dependent = 1
Question 5: 0–6 = 1; 7–10 = 0
Questions 6–9: No = 0; yes = 1
Question 10: No and sometimes = 0; yes = 1
Questions 11–15: No = 0; sometimes and yes = 1
Appendix 2: items of Short Nutritional Assessment Questionnaire (SNAQ) score 2
Item Score
Did you lose weight unintentionally?
More than 6 kg in the last 6 months 3
More than 3 kg in the last month 2
Did you experience a decreased appetite over the last month? 1
Did you use supplemental drinks or tube feeding over the last month? 1
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Skeletal Muscle Depletion is Associated with 
Severe Postoperative Complications in Patients 
Undergoing Cytoreductive Surgery with 
Hyperthermic Intraperitoneal Chemotherapy for 
Peritoneal Carcinomatosis of Colorectal Cancer
J.L.A. van Vugt, H.J.W. Braam, T.R. van Oudheusden, A. Vestering,
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ABSTRACT
Background: In patients undergoing colorectal cancer surgery, skeletal muscle 
depletion (sarcopenia) is associated with impaired postoperative recovery and 
decreased survival. The aim of this study was to determine whether skeletal muscle 
depletion could predict postoperative complications in patients undergoing CRS-HIPEC 
for peritoneal carcinomatosis of colorectal cancer.
Methods: All consecutive patients with an available preoperative CT scan who 
underwent CRS-HIPEC for peritoneal carcinomatosis of colorectal cancer in two centers 
were analyzed. Skeletal muscle mass was determined using the L3 muscle index on the 
preoperative CT scan. The cut-off values defined by Prado et al. were used to classify 
patients as sarcopenic or non-sarcopenic.
Results: In total, 90 out of 206 included patients (43.7%) were classified as sarcopenic. 
Sarcopenic patients underwent significantly more reoperations compared with non-
sarcopenic patients (25.6% versus 12.1%, p=0.012). The mean L3 muscle index was 
significantly lower in patients who developed severe postoperative complications 
compared with patients without severe postoperative complications (43.3 cm2/m2 
versus 47.0 cm2/m2, p=0.005). In a multivariable logistic regression model, L3 muscle 
index was the only parameter that was independently associated with the risk of severe 
postoperative complications (OR 0.93 [95% CI 0.87-0.99], p=0.018).
Conclusions: Skeletal muscle mass depletion, assessed using CT-based muscle mass 
measurements, is associated with an increased risk of severe postoperative complications 
in patients undergoing CRS-HIPEC for colorectal peritoneal carcinomatosis and could 
therefore be used in preoperative risk assessment.
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INTRODUCTION
Peritoneal seeding of colorectal cancer (peritoneal carcinomatosis [PC]) occurs 
in approximately 7% of patients at primary surgery and in up to 19% of patients 
during follow-up 1. CytoReductive Surgery (CRS) with Hyperthermic IntraPEritoneal 
Chemotherapy (HIPEC) improves outcome in patients with peritoneal carcinomatosis 
with 5-year survival rates up to 40% 2. Nevertheless, this treatment option is associated 
with considerable rates of postoperative complications and mortality 3. A recent 
study showed that the occurrence of severe postoperative complications in patients 
undergoing CRS-HIPEC for colorectal peritonitis carcinomatosis is associated with 
impaired overall and disease-free survival 4, 5.
Therefore, the development of preoperative risk assessment tools is of utmost 
importance, particularly in oncologic populations undergoing major surgery. Skeletal 
muscle depletion (sarcopenia), a key determinant of frailty and cancer cachexia, 
is associated with a complicated postoperative course and decreased survival in 
patients undergoing surgery for colorectal cancer 6-9. However, the predictive value of 
skeletal muscle mass assessment in patients undergoing CRS-HIPEC has never been 
investigated. We hypothesized that preoperative skeletal muscle mass measurement 
could be an adequate method to predict severe postoperative complications in patients 
undergoing CRS-HIPEC for colorectal peritoneal carcinomatosis.
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METHODS
Patients and data collection
All consecutive patients who underwent CRS-HIPEC for peritoneal carcinomatosis of 
colorectal cancer in the St Antonius Hospital, Nieuwegein, the Netherlands and the 
Catharina Hospital, Eindhoven, the Netherlands between April 2005 and December 2013 
were enrolled into a prospectively maintained database and analyzed retrospectively. 
Only patients who underwent a complete CRS-HIPEC procedure were included in the 
current study. Patients without a computed tomography (CT)-scan suitable for skeletal 
muscle mass analysis or with unrecorded height were excluded. Data regarding patient 
characteristics (e.g., age, sex, medical history), disease status (number of regions 
affected with PC, primary tumor location, diagnosis of PC), treatment (operative time, 
estimated blood loss, number of bowel anastomosis, completeness of cytoreduction 
score [CCR]) and postoperative recovery (postoperative complications, mortality, length 
of hospital stay) were retrieved from the database. Tumor characteristics were obtained 
from postoperative pathology reports. Postoperative complications were classified 
according to the Clavien-Dindo Classification of Surgical Complications 10. Severe 
postoperative complications were defined as Clavien-Dindo Classification ≥ 3 (i.e. the 
need for re-intervention, ICU-admission or death).
Surgical procedure
CRS-HIPEC was performed by two dedicated surgical teams as previously described 11. 
In summary, tumor load was estimated after laparotomy using the simplified peritoneal 
cancer index 12 and all macroscopically suspected lesions were surgically removed 
(cytoreductive surgery). After cytoreductive surgery, the abdominal cavity was perfused 
with isotonic dialysis fluid with an inflow temperature of 42 °C. Mytomycin-C at a dose 
of 35 mg/m2 was added to the perfusate using 28 French catheters when a stable 
temperature of 41 °C was reached. Intraperitoneal perfusion was continued for 90 
minutes. Hereafter, the perfusion fluid was drained from the abdominal cavity, bowel 
continuity was restored and intra-abdominal drains were placed when appropriate. 
All patients were treated according to the Enhanced Recovery After Surgery (ERAS) 
principles 13.
Skeletal muscle mass measurements
Abdominal CT scans were routinely performed as part of the preoperative work-up. 
Measurements of the muscle surface were performed using OsiriX version 3.3 (32-bit; 
http://www.osirix-viewer.com) by a medically trained member of the research group 
(AV) according to previously conducted studies 9. In summary, the cross-sectional 
van_Vugt-layout.indd   164 22/11/2017   12:43
165
Low skeletal muscle mass in HIPEC
7
muscle surface (cm2) was assessed at the level of the third lumbar vertebra (L3) on 
two consecutive transversal coupes on which both transverse processes were visible. 
Measurements included the psoas, paraspinal, transverse abdominal, external oblique, 
internal oblique and rectus abdominis muscles. The average of these two L3 muscle 
surface area measurements was normalized for patient height, resulting in the L3 
muscle index (cm2/m2). Only preoperative abdominal CT scans were used. The cut-off 
values of 52.4 cm2/m2 for men and 38.5 cm2/m2 for women defined by Prado et al. were 
used to classify patients as sarcopenic (muscle depletion) or non-sarcopenic (no muscle 
depletion) 14.
Statistical analysis
Frequencies are presented as absolute numbers and percentages. Continuous data are 
presented as median with interquartile ranges (IQR). Normality of data was tested using 
the Kolmogorov-Smirnov test. Differences between groups were analyzed using the 
Pearson Chi-square test for dichotomous variables and Student t-test or Mann-Whitney 
U test for continuous variables, depending on normality. Two-tailed p-values <0.05 
were considered statistically significant. Odds ratios (OR) with 95% confidence intervals 
(CI) were calculated using logistic regression analysis, which was performed to identify 
risk factors for the occurrence of severe postoperative complications. All significant 
variables resulting from the univariable logistic regression analysis were entered into 
a multivariable logistic regression analysis. Since the L3 muscle index greatly depends 
on sex, gender was also included in the multivariable logistic regression analysis. All 
statistical analyses were performed using IBM® SPSS® Statistics Version 21 (SPSS Inc., 
Chicago, IL, USA).
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RESULTS
A total of 299 patients were enrolled in the two databases. An assessable abdominal 
CT scan was available in 206 (68.9%) patients. Since both hospitals are tertiary referral 
centers for HIPEC procedures, unavailability of a preoperative abdominal CT scan that 
was performed in the referring hospital was the most common reason for exclusion 
(n = 79). Other reasons for exclusion were the presence of an ostomy (n = 3) or tumor 
growth through the abdominal wall at L3-level (n = 1) leading to difficulties to accurately 
identify skeletal muscle tissue, artifacts (n = 2), missing of imaging at L3-level (n =1) or 
incomplete imaging of the abdominal wall muscles at the level of L3, for example due 
to obesity or deformities (n = 7).
In total, 90 (43.7%) patients were classified as sarcopenic. The time interval between 
abdominal CT and surgery did not significantly differ between the sarcopenic and non-
sarcopenic groups (median 36 versus 28 days, p=0.281). Apart from BMI (median 23.5 
kg/m2 versus 26.4 kg/m2, p<0.001) and regions affected with PC (mean 2.9 versus 3.4, 
p=0.034), baseline characteristics (table 1) and intra-operative outcomes (table 2) did 
not significantly differ between sarcopenic and non-sarcopenic patients. Sarcopenic 
patients underwent significantly more reoperations compared with non-sarcopenic 
patients (25.6% versus 12.1%, p=0.012) (table 2). Trends towards a significant difference 
in the occurrence of any postoperative complication (54.4% versus 41.4%, p=0.062), 
severe postoperative complications (33.3% versus 21.6%, p=0.058) and abdominal 
fistula (5.6% versus 0.9%, p=0.088) were observed.
The mean L3 muscle index was significantly lower in patients who developed severe 
postoperative complications (i.e. Clavien-Dindo Classification ≥ 3) compared with 
patients without severe postoperative complications (43.3 cm2/m2 versus 47.0 cm2/m2, 
p=0.005).
In univariable logistic regression analysis, an incremental L3 muscle index (OR 0.95 [95% 
CI 0.92-0.99], p=0.01), more affected regions with PC (OR 1.34 [95% CI 1.11-1.73], p=0.005), 
longer operative time (OR 1.31 [95% CI 1.07-1.59], p=0.008) and more estimated intra-
operative blood loss (OR 1.49 [95% CI 1.06-2.08], p=0.021) were associated with the 
occurrence of severe postoperative complications (table 3). Together with gender, these 
factors were entered into the multivariable logistic regression model. An incremental L3 
muscle index was the only parameter that remained independently associated with the 
risk of severe postoperative complications (OR 0.93 [95% CI 0.87-0.99], p=0.018).
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Table 1. Patient and tumor characteristics.
Muscle depletion
n = 90 (43.7 %)
No muscle depletion
n = 116 (56.3 %)
p-value
Gender
Male
Female
46 (51.1)
44 (48.9)
54 (46.6)
62 (53.4)
0.516
Age 62.1 (10.0) 60.3 (10.1) 0.206
ASA
I
II
III
28 (32.6)
56 (65.1)
2 (2.3)
31 (29.2)
71 (67.0)
4 (3.8)
0.774
BMI 23.5 (21.3-25.3) 26.4 (24.1-30.0) <0.001
Regions affected with PC 2.9 (1.5) 3.4 (1.4) 0.034
Diagnosis of initial PC
Synchronous
Metachronous
53 (58.9)
37 (41.1)
64 (55.2)
52 (44.8)
0.593
Tumor location
Colon
Rectum
76 (87.4)
11 (12.6)
100 (90.1)
11 (9.9)
0.544
Tumor stage
1
2
3
4
0 (0.0)
4 (4.5)
48 (53.9)
37 (41.6)
1 (0.9)
3 (2.7)
42 (37.5)
66 (58.9)
0.067
Lymph node stage
0
1
2
24 (27.6)
30 (34.5)
33 (37.9)
34 (30.1)
31 (27.4)
48 (42.5)
0.560
Tumor differentiation
Good
Moderate
Poor
5 (6.3)
58 (73.4)
16 (20.3)
4 (4.6)
58 (66.7)
25 (28.7)
0.426
Tumor histology
Adenocarcinoma
Mucinous carcinoma
Signet cell carcinoma
66 (73.3)
21 (23.3)
3 (3.3)
79 (68.1)
32 (27.6)
5 (4.3)
0.713
Time interval CT - surgery (days) 36 (17-56) 28 (15-49) 0.281
Continuous parameters are presented as mean (SD) or median (IQR); categorical parameters are presented as number 
(%). ASA, American Society of Anesthesiologists classification; BMI, body mass index; PC, peritoneal carcinomatosis; CT, 
computed tomography of the abdomen
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Table 2. Intra-operative and postoperative outcomes.
Muscle depletion
n = 90 (43.7 %)
No muscle depletion
n = 116 (56.3 %)
p-value
Intra-operative outcomes
 Operative time (min) 400 (339.75-451.75) 398.5 (331.25-471) 0.991
 Estimated blood loss (ml) 600 (300-1200) 700 (300-1500) 0.768
 Cytoreduction
 CCR 0-1
 CCR 2
87 (96.7)
3 (3.3)
113 (97.4)
3 (2.6)
0.752
 Anastomosis (yes) 66 (74.2) 84 (72.4) 0.780
 Stomy (yes) 41 (45.6) 47 (40.5) 0.468
Postoperative outcomes
Any complication 49 (54.4) 48 (41.4) 0.062
 Anastomotic leakage* 15 (22.7) 11 (13.1) 0.122
 Intra-abdominal abscess 10 (11.1) 15 (12.9) 0.692
 Ileus/gastroparesis 18 (20.0) 15 (12.9) 0.170
 Abdominal fistula 5 (5.6) 1 (0.9) 0.088
 Pneumonia 6 (6.7) 10 (8.6) 0.602
 Pulmonary embolism 1 (1.1) 0 (0.0) 0.437
 Urinary tract infection 6 (6.7) 9 (7.8) 0.765
Severe complication# 30 (33.3) 25 (21.6) 0.058
Reoperation 23 (25.6) 14 (12.1) 0.012
30-day/in hospital mortality 2 (2.2) 3 (2.6) 0.866
Length of stay (days) 11.0 (8-19.5) 11.5 (8-16) 0.646
Continuous parameters are presented as median (IQR); categorical parameters are presented as number (%). CCR, 
completeness of cytoreduction. * Data available from 150 patients with an anastomosis; # Clavien-Dindo Classification ≥ 3 
(i.e. the need for re-intervention, ICU-admission or death)
van_Vugt-layout.indd   168 22/11/2017   12:43
169
Low skeletal muscle mass in HIPEC
7
Table 3. Logistic regression analysis for risk factors associated with severe postoperative 
complications (i.e. Clavien-Dindo Classification ≥ 3).
Univariable
OR (95% CI)
p-value Multivariable
OR (95% CI)
p-value
L3 muscle index (cm2/m2) 0.95 (0.91-0.99) 0.008 0.93 (0.87-0.99) 0.018
Gender
 Male
 Female
1
1.45 (0.78-2.70)
0.245 1
0.66 (0.25-1.78)
0.412
Age 1.01 (0.98-1.05) 0.439
ASA
 I
 II
 III
1
1.40 (0.68-2.90)
1.77 (0.29-10.76)
0.364
0.536
BMI 0.93 (0.86-1.01) 0.076
Diagnosis of initial PC
 Synchronous
 Metachronous
1
1.13 (0.61-2.11)
0.694
Tumor location
 Colon
 Rectum
1
0.74 (0.26-2.12)
0.576
Tumor stage 0.83 (0.49-1.39) 0.467
Lymph node stage 1.15 (0.79-1.69) 0.465
Regions affected with PC 1.36 (1.08-1.70) 0.008 1.26 (0.96-1.66) 0.102
Operative time (hours) 1.32 (1.08-1.62) 0.006 1.19 (0.91-1.57) 0.210
Estimated blood loss (liters) 1.47 (1.05-2.05) 0.024 1.23 (0.84-1.80) 0.287
Anastomosis
 No
 Yes
1
1.93 (0.89-4.16)
0.094
OR, Odds ratio; 95% CI, 95% confidence interval; ASA; American Society of Anesthesiologists classification; BMI, body mass 
index; PC, peritoneal carcinomatosis.
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DISCUSSION
Our study supports the hypothesis that preoperative skeletal muscle mass measurements 
can be used to predict a complicated postoperative recovery in patients undergoing 
CRS-HIPEC for colorectal peritoneal carcinomatosis. Sarcopenic patients undergo 
significantly more reoperations compared with non-sarcopenic patients. Moreover, 
an incremental L3 muscle index is an independent predictor for a lower rate of severe 
postoperative complications.
The association between skeletal muscle depletion and the risk of severe postoperative 
complications has been established in various surgical oncology populations, among 
which patients undergoing hepatectomy for colorectal liver metastases 15. Patients 
undergoing CRS-HIPEC may sustain severe postoperative complications and mortality 
rates up to 30% and 3% respectively 3. Hence, preoperative risk assessment is of utmost 
importance to identify patients (un)fit for surgery and to assist patient and physician in 
the shared decision-making process. Moreover, the occurrence of severe postoperative 
complications is associated with impaired overall and disease-free survival 4, 5. Currently 
available assessments are considered imprecise and not focused on oncologic patients 16. 
For example, the widely used ASA (American Society of Anesthesiologists) classification 
is subjective with great inconsistency between anaesthesiologists 16, 17. While an 
incremental L3 muscle index was protective for the occurrence of severe postoperative 
complications in our study, no association with ASA classification was found. Skeletal 
muscle mass assessment may more objectively reflect a patient’s physiological reserves, 
which are essential to tolerate and rehabilitate from major interventions such as 
cytoreductive surgery. Therefore, it seems a valuable element in the development of 
preoperative risk assessment scores.
CT-based L3 muscle index measurement is an easily obtainable, objective, and precise 
method to assess skeletal muscle mass with a limited inter-observer variability 9. 
Since all patients scheduled for CRS-HIPEC routinely undergo CT-imaging as part of 
the preoperative work-up, abdominal CT scans are widely available. The time interval 
between CT scan and surgery could potentially be used to optimize patients for 
surgery without causing a treatment delay. Optimizing treatment options could include 
nutritional support, physical exercise therapy and treatment of secondary anorexia 
causes (e.g., pain and nausea) and inflammation-related metabolic changes (e.g., by 
anti-inflammatory drugs) 18. Considering surgical prehabilitation a fast effect of the 
anti-catabolic treatment would be desirable. Therefore, the development of drugs 
targeting pathways involved in skeletal muscle synthesis and breakdown is wanted. For 
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example, myostatin, inducing muscle depletion, and insulin-like growth factor (IGF)-1, 
stimulating protein synthesis, are potential therapeutic targets with promising results 
in animal models 19, 20.
Although the current study shows an association between an incremental L3 muscle 
index and decrease in the occurrence of severe postoperative complications, the clinical 
practicability would increase when cut-off values to define skeletal muscle depletion 
could be used instead of the continuous L3 muscle index. The currently used cut-off 
values, defined by Prado et al. and acknowledged in an international consensus meeting, 
are based on mortality prediction in obese patients with pulmonary and gastrointestinal 
cancer 14, 21. These cut-off values were frequently used in previous surgical series 6, 9, 22, 
enabling comparison of outcome in various populations and studies. However, it 
remains questionable whether these cut-off values are generalizable for every patient 
population, particularly for a non-obese surgical population. In our study, the use of 
these cut-off values may have led to an overestimation of patients with low skeletal 
muscle mass, since the mean BMI was 25.6 kg/m2 and only 15.5% of patients were 
classified as obese (BMI ≥ 30 kg/m2). Nevertheless, the prevalence of skeletal muscle 
mass depletion in our study (43.7%) is comparable to two previous studies on skeletal 
muscle depletion in colorectal cancer surgery patients, reporting a prevalence of 38.9% 
and 47.7%, respectively 6, 9.
Interestingly, in patients with skeletal muscle depletion significantly fewer regions 
affected with peritoneal carcinomatosis and a trend towards a significantly lower tumor 
stage was observed than in those without. These findings suggest that skeletal muscle 
depletion is not solely determined by tumor load and that other factors may play a role. 
In a mouse model, interactions between tumor and its environing tissue, i.e. activation 
of cytokines and white blood cells, seemed to induce cancer cachexia 23. Tumor and 
patient specific factors influencing skeletal muscle mass should be further investigated.
This study is limited by its retrospective nature, which may have led to selection bias. 
First, selection may have occurred in the referral of patients from other centers to our 
two HIPEC centers. Second, there is a selection of patients considered fit for surgery 
during preoperative consultation in our and the referring centers. This might have 
resulted in additional exclusion of sarcopenic patients, as they are likely to be unfit for 
surgery. Finally, during laparotomy it is decided to continue the procedure based on 
several criteria: significant tumor load in the mesenteries and extensive adhesions may 
be contraindication to precede the procedure. The current study cohort only consisted 
of patients who underwent a complete CRS-HIPEC procedure.
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In conclusion, skeletal muscle mass depletion, assessed using CT-based muscle mass 
measurements, is associated with an increased rate of severe postoperative complications 
in patients undergoing CRS-HIPEC for colorectal peritoneal carcinomatosis and could be 
used in preoperative risk assessment. Future research should elucidate the etiology of 
skeletal muscle mass depletion and focus on developing effective treatment strategies 
to counteract its deleterious effects in patients undergoing surgery.
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Impact of Low Skeletal Muscle Mass and 
Density on Short and Long-Term Outcome after 
Resection of Stage I-III Colorectal Cancer:
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ABSTRACT
Background: Preoperative low skeletal muscle mass and density are associated with 
increased postoperative morbidity in patients undergoing curative colorectal cancer 
surgery. However, the long-term effects of low skeletal muscle mass and density remain 
uncertain.
Methods: Patients with stage I-III colorectal cancer undergoing surgery, enrolled in 
a prospective observational cohort study, were included. Skeletal muscle mass and 
density were measured on computed tomography examinations. Patients with high and 
low skeletal muscle mass and high and low skeletal muscle density, defined according 
to pre-established cut-offs, were compared regarding postoperative complications and 
mortality, disease-free survival (DFS), overall survival (OS), and cancer-specific survival 
(CSS).
Results: In total, 816 patients (53.9% males) with a median age of 70 (IQR 62-77) were 
included. About half of the patients had low skeletal muscle mass (50.4%) and density 
(64.1%). The rate of severe postoperative complications (Clavien-Dindo grade ≥3a) was 
significantly higher in patients with low versus high skeletal muscle and density (20.9% 
versus 13.6%, p=0.006; 20.0% versus 11.8%, p=0.003). Low skeletal muscle density was 
independently associated with severe postoperative complications (OR 1.89, 95% CI 
1.11-3.23, p=0.020). The postoperative (i.e. 90-day) mortality rate was higher in patients 
with low skeletal muscle mass and density compared with patients with high skeletal 
muscle mass and density (3.6% versus 1.7%, p=0.091; and 3.4% versus 1.0%, p=0.038). 
No differences in DFS were observed. After adjustment for covariates such as age and 
Charlson Comorbidity Index, univariate differences in OS and CSS between patients 
with high and low skeletal muscle mass and density disappeared.
Conclusions: Low skeletal muscle mass and density are associated with short-term, but 
not long-term, outcome in patients undergoing curative colorectal cancer surgery. The 
preoperative period may be used to optimize patients.
van_Vugt-layout.indd   178 22/11/2017   12:43
179
Low skeletal muscle mass in CRC
8
INTRODUCTION
Colorectal cancer is one of the leading causes of cancer-related death with an estimated 
total cancer burden of 7% and a great impact on disability-adjusted life years worldwide 1, 2. 
Recently, there has been a rising interest in the impact of low skeletal muscle mass 
and density on short and long term outcome in cancer patients 3. Skeletal muscle 
depletion may result from cancer, as part of the cancer-cachexia syndrome, and aging 
(i.e. sarcopenia, the involuntary age-related loss of skeletal muscle mass and strength) 4.
The impact of low skeletal muscle mass and density on postoperative outcome (i.e. 
postoperative complications and mortality) 2, 5-8 and chemotherapy toxicity 9-11 has 
frequently been described in colorectal cancer patients. Furthermore, low skeletal 
muscle mass and density are prognostic factors in patients undergoing surgery for 
colorectal metastases 12, 13 or chemotherapy for metastatic colorectal cancer 9, 14. 
However, its effect on long -term outcome in patients with stage I-III colorectal cancer 
has been reported in only a few studies 15-17.
Therefore, the aim of the present study was to investigate the association between low 
skeletal muscle mass and density on both short and long-term outcome in patients 
undergoing colorectal cancer surgery with curative intent in a multi-center prospective 
study.
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METHODS
Study design and patient selection
Patients were selected from the MATCH study, an ongoing prospective observational 
cohort study enrolling patients undergoing curative resection for primary colorectal 
cancer in seven centers in the region of Rotterdam, the Netherlands 18, 19. The study was 
approved by the Institutional Review Board and all patients provided written informed 
consent (MEC-2007-088). All aspects listed in the STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) guidelines were followed, and the 
paper was written accordingly 20.
All patients with stage I-III colorectal cancer, according to the 5th edition of the American 
Joint Cancer Committee staging manual, included in the first six years of the MATCH 
study (July 1st 2007 – July 1st 2013) were included in the current study. Exclusion criteria 
were unavailability of a preoperative computed tomography (CT) scan or unknown 
body mass index (BMI). Baseline characteristics (e.g., sex, age), tumor characteristics (e.g., 
tumor location and grade), surgical characteristics (e.g., type of resection, blood loss), 
and additional treatment (e.g., radio- or chemotherapy) were collected. Comorbidity 
was graded according to the American Society of Anesthesiologists (ASA) classification 
and the Charlson Comorbidity Index 21. BMI was categorized in groups <20, 20-24.9, and 
≥25 kg/m².
Outcome parameters
All postoperative complications occurring within 30 days after surgery, during hospital 
admission or during readmission within 30 days after discharge, were recorded. Severity 
was graded according to the Clavien-Dindo (CD) classification 22. Severe complications 
were defined as CD grade ≥3a. The comprehensive complications index, integrating 
all complications including their severity in a scale from 0 (no complication) to 100 
(death) 23, was calculated for each patient. Postoperative mortality was defined as 
mortality within 90 days postoperatively. Length of hospital stay (LOS) was calculated 
from the date of surgery to the date of discharge. Discharge status, i.e. home or other 
(rehabilitation, nursing home) was recorded.
Disease-free (DFS) and overall (OS) and survival were calculated from the date of 
surgery until recurrence or death, respectively. Survival status and cause of death 
were obtained from the Dutch Central Bureau of Statistics (CBS), which were used to 
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investigate differences in colorectal cancer-specific survival. Patients who were still alive 
on December 31, 2016 were censored. Patients who underwent a non-radical resection 
were excluded from the disease-free survival analysis.
Skeletal muscle mass and density measurements
Skeletal muscle mass and density were measured on contrast-enhanced CT scans, 
which were routinely performed as part of preoperative diagnosis and work-up. 
Only preoperative CT examinations were included. In rectal cancer patients, only CT 
examinations performed after neoadjuvant therapy were included.
As previously described 13, the total cross-sectional muscle area (cm²) at the level of 
the third lumbar vertebra (L3) was selected and adjusted for patients’ height using a 
validated software package 24. This resulted in the skeletal muscle index (SMI; cm²/m²). 
The mean muscle attenuation (in Hounsfield Units [HU]) of the cross-sectional muscle 
area was noted as a measure of skeletal muscle density.
The cutoff values used to define low skeletal muscle mass were 41 cm2/m2 for women, 
43 cm2/m2 for men with a BMI <25 kg/m2 and 53 cm²/m² for men with a BMI ≥25 kg/m2 
as described by Martin et al 25. Low skeletal muscle density was defined as HU <41 for 
patients with a BMI <25 kg/m² and HU <33 for patients with a BMI ≥25 kg/m2 25.
Statistical analysis
Frequencies are presented in absolute numbers and percentages. Continuous data are 
presented as median with the interquartile range (IQR). Differences between groups 
were tested using the Chi-squared and Mann-Whitney U tests where appropriate. 
Kaplan Meier estimates and Cox regression analysis were used for the survival analysis. 
Factors with a significance level of p<0.1 in the univariate analysis were selected for 
a multivariable analysis with the factor of interest (low skeletal muscle mass and/
or density). Univariate and multivariable logistic regression analysis was performed 
to investigate the association between low skeletal muscle mass and density and 
the occurrence of severe complications. All analyses were performed using SPSS for 
Windows version 22 (IBM Corp., Armonk, NY, USA). Two-sided p-values <0.05 were 
considered to be statistically significant.
van_Vugt-layout.indd   181 22/11/2017   12:43
182
Chapter 8
RESULTS
Patient characteristics
A total of 981 patients with stage I-III colorectal cancer were included in the MATCH-
study in the period July 1, 2007 to July 1, 2013. No preoperative CT examination was 
available in 157 patient records and BMI could not be retrieved from 8 patient charts, 
leaving a total sample size of 816 patients. The median time between CT and surgery 
was 33 (IQR 22-47) days. Baseline characteristics of included and excluded patients did 
not differ significantly, besides type of surgery (open surgery 41.9% in included patients 
versus 52.1% in excluded patients, p=0.032), number of patients with a stoma (72.2% 
versus 59.4%, p=0.001), and number of colon tumors (71.1% versus 61.2%, p=0.012).
All patient characteristics are listed in table 1 and 2. Just over half of the patients (50.4%) 
were considered to have low skeletal muscle mass before surgery, which was more often 
observed in colon cancer rather than rectal cancer patients (52.9% vs 44.5%, p=0.029). 
In the low skeletal muscle mass group, 44.9% of the patients were male compared to 
63.1% in the group with high skeletal muscle mass (p<0.001). Furthermore, median age 
was significantly higher in patients with low skeletal muscle mass, whereas BMI was 
significantly lower (both p<0.001). Although the median Charlson Comorbidity Index 
was not significantly different for the two groups, ASA classification was significantly 
higher in patients with low skeletal muscle mass (p=0.044).
Similar differences were observed between the low and high skeletal muscle density 
group for sex, age, BMI, ASA classification, tumor location, and adjuvant therapy. 
Interestingly, the CCI was significantly higher in the low skeletal muscle density group 
compared with the high skeletal muscle density group (p<0.001). Patients in the low 
skeletal muscle density group had a lower tumor stage compared with the high density 
group (p=0.002). However, the median age of stage III patients was significantly lower 
compared with stage I and II (66.5 versus 70 and 72, respectively, p<0.001). Patients in 
the low skeletal muscle density group less often received neoadjuvant chemo- and/or 
radiotherapy (p=0.002).
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Table 1. Baseline characteristics stratified for high and low skeletal muscle mass.
High skeletal muscle 
mass
n = 404 (49.5%)
Low skeletal muscle 
mass
n = 412 (50.5%)
p-value
Sex (male) 255 (63.1) 185 (44.9) <0.001
Age 66 (59-74) 73 (65-79) <0.001
BMI
 <20
 20-24.9
 ≥25.0
2 (0.5)
171 (42.3)
231 (57.2)
25 (6.1)
152 (36.9)
235 (57.0)
<0.001
Charlson comorbidity index 0 (0-2) 0 (0-1) 0.831
ASA classification
 I
 II
 III
 IV
 V
80 (19.8)
250 (61.9)
65 (16.1)
6 (1.5)
0 (0.0)
50 (12.1)
278 (67.5)
72 (17.5)
7 (1.7)
1 (0.2)
0.044
CEA 3.4 (1.9-7.1) 3.3 (2.0-8.3) 0.251
Type of surgery
 Open
 Laparoscopic
 Conversion
161 (39.9)
197 (48.8)
44 (10.9)
180 (43.7)
198 (48.1)
33 (8.0)
0.282
Stoma 122 (30.2) 104 (25.2) 0.104
Blood loss (ml) 150 (30-350) 100 (30-300) 0.570
Duration of surgery (minutes) 150 (114-195) 150 (110-194) 0.837
Surgical margins
 Positive
 Negative
8 (2.0)
393 (97.3)
15 (3.6)
396 (96.1)
0.155
Tumor stage
 I
 II
 III
131 (32.4)
130 (32.2)
143 (35.4)
124 (30.1)
163 (39.6)
125 (30.3)
0.080
Tumor location
 Colon
 Rectum
273 (67.6)
131 (32.4)
307 (74.5)
105 (25.5)
0.029
Tumor grade
 Good
 Moderate
 Poor
 Other
106 (26.2)
239 (59.2)
43 (10.6)
8 (2.0)
113 (27.4)
239 (58.0)
43 (10.4)
17 (4.1)
0.979
Angioinvasive growth 35 (8.7) 35 (8.5) 0.910
Neoadjuvant therapy 111 (27.5) 97 (23.5) 0.205
Adjuvant therapy
 Systemic
 Radiotherapy
91 (22.5)
1 (0.2)
67 (16.3)
0 (0.0)
0.043
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Table 2. Baseline characteristics stratified for high and low skeletal muscle density.
High skeletal muscle 
density
n = 288 (35.3%)
Low skeletal muscle 
density
n = 524 (64.1%)
p-value
Sex (male) 189 (65.6) 249 (47.5) <0.001
Age 63 (56-69) 74 (66-80) <0.001
BMI
 <20
 20-24.9
 ≥25.0
9 (3.1)
97 (33.7)
182 (63.2)
18 (3.4)
224 (42.7)
282 (53.8)
0.034
Charlson comorbidity index 0 (0-1) 1 (0-2) <0.001
ASA classification
 I
 II
 III
 IV
 V
76 (26.4)
183 (63.5)
25 (8.7)
1 (0.3)
0 (0.0)
54 (10.3)
341 (65.1)
112 (21.4)
12 (2.3)
1 (0.2)
<0.001
CEA 3.1 (2.0-7.9) 3.5 (2.0-7.4) 0.433
Type of surgery
 Open
 Laparoscopic
 Conversion
107 (37.2)
153 (53.1)
26 (9.0)
232 (44.3)
241 (46.0)
50 (9.5)
0.119
Stoma 88 (30.6) 137 (26.1) 0.170
Blood loss (ml) 150 (20-400) 150 (40-300) 0.488
Duration of surgery (minutes) 158 (120-196) 150 (110-194) 0.130
Surgical margins
 Positive
 Negative
8 (2.8)
276 (95.8)
15 (2.9)
509 (97.1)
0.970
Tumor stage
 I
 II
 III
89 (30.9)
84 (29.2)
115 (39.9)
164 (31.3)
207 (39.5)
153 (29.2)
0.002
Tumor location
 Colon
 Rectum
190 (66.0)
98 (34.0)
387 (73.9)
137 (26.1)
0.018
Tumor grade
 Good
 Moderate
 Poor
 Other
86 (29.9)
161 (55.9)
28 (9.7)
8 (2.8)
133 (25.4)
313 (59.7)
59 (11.3)
9 (1.7)
0.354
Angioinvasive growth 23 (8.0) 47 (9.0) 0.727
Neoadjuvant therapy 92 (31.9) 115 (21.9) 0.002
Adjuvant therapy
 Systemic
 Radiotherapy
76 (26.4)
0 (0.0)
82 (15.6)
1 (0.2)
0.001
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Postoperative complications and mortality
The prevalence of (severe) postoperative complications, postoperative mortality and 
differences in length of stay and discharge status are shown in table 3. A significantly 
higher proportion of patients with low skeletal muscle mass (20.9% versus 13.6%, 
p=0.006) and density (20.0% versus 11.8%, p=0.003) experienced at least one severe 
postoperative complication (CD grade ≥3a). The Comprehensive Complication Index was 
significantly higher in patients with low skeletal muscle density compared with patients 
with high skeletal muscle density (p<0.001), whereas a non-significant difference 
was found between patients with low and high skeletal muscle mass (p=0.121). In 
multivariable analysis, low skeletal muscle mass was independently associated with the 
occurrence of severe postoperative complications (OR 1.89, 95% CI 1.11-3.23, p=0.020), 
whereas a non-significant association was found for low skeletal muscle density (OR 
1.84, 95% CI 0.99-3.41, p=0.053) (table 4).
LOS was significantly longer in patients with low compared with high skeletal muscle 
mass (8 [IQR 6-13] versus 7 [IQR 5-10] days, p=0.035) and in patients with low compared 
with high skeletal muscle density (8 [IQR 6-14] versus 7 [IQR 5-10] days, p<0.001). Patients 
with low skeletal muscle mass and density were significantly more often discharged to a 
place other than home (p=0.035 and p<0.001, respectively).
The postoperative (i.e. 90-day) mortality rate was higher in patients with low skeletal 
muscle mass and density compared with patients with high skeletal muscle mass and 
density (3.6% versus 1.7%, p=0.091; and 3.4% versus 1.0%, p=0.038, respectively). Due 
to the small number of events, a multivariable analysis was not performed for 90-day 
mortality.
Disease-free survival
Neither low skeletal muscle mass (HR 1.17, 95% CI 0.84-1.62, p=0.356) nor low skeletal 
muscle density (HR 1.17, 95% CI 0.83-1.64, p=0.386) were associated with disease-
free survival (table 5). The 1-year, 3-year, and 5-year DFS rates did not significantly 
differ between patients with low and high skeletal muscle mass (89.8%, 81.1%, and 
77.1% versus 92.4%, 84.4%, and 81.1%; p=0.233, p=0.239, and p=0.207, respectively), 
nor between patients with low and high skeletal muscle density (91.0%, 82.7%, and 
78.1% versus 91.4%, 83.2%, and 80.9%; p=0.859, p=0.855, and p=0.557, respectively). 
Therefore, no multivariable analysis was performed.
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Table 4. Multivariable logistic regression model for severe postoperative complications (i.e. CD 
≥ 3).
Adjusted OR (95% CI) p-value
Skeletal muscle mass
 High
 Low
1
1.91 (1.12-3.25)
0.018
Low skeletal muscle density
 High
 Low
1
1.87 (1.01-3.46)
0.045
Age, years 1.01 (0.98-1.03) 0.731
Charlson comorbidity index 1.15 (0.99-1.33) 0.063
Type of surgery
 Open
 Laparoscopic
 Conversion
1
0.66 (0.38-1.13)
1.13 (0.53-2.42)
0.131
0.756
Stoma
 No
 Yes
1
1.30 (0.64-2.63)
0.465
Blood loss (100 ml) 1.06 (1.02-1.10) 0.002
Tumor location
 Colon
 Rectum
1
0.89 (0.23-3.42)
0.859
Neoadjuvant therapy
 No
 Yes
1
1.54 (0.38-6.29)
0.544
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Table 5. Cox proportional hazards analysis for disease-free survival.
HR (95% CI) p-value
Skeletal muscle mass
 High
 Low
1
1.17 (0.84-1.62)
0.356
Low skeletal muscle density
 High
 Low
1
1.17 (0.83-1.64)
0.386
Sex
 Female
 Male
1
1.07 (0.77-1.48)
0.694
Age 1.02 (1.00-1.04) 0.027
BMI
 <20
 20-24.9
 ≥25.0
1
0.87 (0.31-2.40)
1.17 (0.43-3.17)
0.780
0.765
Charlson comorbidity index 1.09 (0.98-1.21) 0.103
ASA classification
 I
 II
 III
 IV
 V
1
1.28 (0.80-2.03)
1.04 (0.56-1.93)
0.98 (0.23-4.16)
-
0.302
0.900
0.975
CEA 1.00 (1.00-1.01) 0.154
Type of surgery
 Open
 Laparoscopic
 Conversion
1
0.80 (0.57-1.13)
1.11 (0.64-1.92)
0.212
0.710
Stoma
 No
 Yes
1
1.94 (1.39-2.70)
<0.001
Blood loss (100 ml) 1.02 (1.00-1.05) 0.114
Duration of surgery (hours) 1.02 (0.87-1.20) 0.802
Tumor stage
 I
 II
 III
1
1.13 (0.70-1.84)
2.88 (1.88-4.41)
0.619
<0.001
Tumor location
 Colon
 Rectum
1
1.72 (1.24-2.40)
0.001
Tumor grade
 Good
 Moderate
 Poor
 Other
1
0.87 (0.59-1.29)
1.50 (0.87-2.56)
1.98 (0.78-5.04)
0.484
0.141
0.152
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HR (95% CI) p-value
Angioinvasive growth
 No
 Yes
1
1.85 (1.14-3.00)
0.013
Neoadjuvant therapy
 No
 Yes
1
1.77 (1.27-2.48)
0.001
Adjuvant therapy
 No
 Yes
1
0.91 (0.60-1.37)
0.643
Comprehensive complication index 1.01 (1.00-1.02) 0.058
Patients with positive surgical margins were excluded.
Overall-survival and cancer-specific survival
After a median follow-up of 76.5 months, 236 of the 816 (28.9%) patients had died. Eight 
patients (1.0%) were lost to follow-up. The median 1-year, 3-year, and 5-year OS estimates 
were 93.1%, 82.3%, and 73.3% in patients with low skeletal muscle mass compared with 
95.3%, 87.8%, and 78.8% in patients with high skeletal muscle mass (p=0.193, p=0.029, 
and p=0.414, respectively), and 92.6%, 82.2%, and 72.3% in patients with low skeletal 
muscle density compared with 97.2%, 90.3%, and 82.9% in patients with high skeletal 
muscle density (p=0.007, p=0.002, and p=0.089, respectively) (figure 1).
In univariate analysis, both low skeletal muscle mass (HR 1.35, 95% CI 1.10-1.74, p=0.024) 
and low skeletal muscle density (HR 1.86, 95% CI 1.38-2.50, p<0.001) were associated 
with decreased OS. However, no significant association was found in multivariable 
analysis after adjustment for covariates such as age, Charlson Comorbidity Index, tumor 
stage, and the Comprehensive Complication Index (table 6).
A significant difference in cancer-specific survival was observed between patients with 
low and high skeletal muscle density (p=0.046), whereas no significant difference was 
observed between patients with low and highs skeletal muscle mass (p=0.235) (figure 
2). However, in multivariable analysis no significant associations were found.
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Figure 1. A. Kaplan-Meier curve for overall survival for patients with low skeletal muscle mass 
and high skeletal muscle mass (p=0.023). B. Kaplan-Meier curve for overall survival for patients 
with low skeletal muscle density and high skeletal muscle density (p<0.001).
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Figure 2. A. Kaplan-Meier curve for cancer-specific survival for patients with low skeletal muscle 
mass and high skeletal muscle mass (p=0.235). B. Kaplan-Meier curve for cancer-specific survival 
for patients with low skeletal muscle density and high skeletal muscle density (p=0.046).
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Table 6. Cox proportional hazards analysis for overall survival, excluding those patients who 
died postoperatively (i.e. Comprehensive complication index 100) (n=797).
HR
(95% CI)
p-value Adjusted HR
(95% CI)
p-value
Skeletal muscle mass
 High
 Low
1
1.35 (1.03-1.76)
0.029 1
1.06 (0.80-1.42)
0.680
Low skeletal muscle density
 High
 Low
1
1.75 (1.29-2.36)
<0.001 1
0.91 (0.65-1.29)
0.600
Sex
 Female
 Male
1
0.89 (0.68-1.16)
0.399
Age 1.07 (1.05-1.09) <0.001 1.06 (1.05-1.08) <0.001
BMI
 <20
 20-24.9
 ≥25.0
1
0.63 (0.32-1.25)
0.63 (0.32-1.24)
0.186
0.184
Charlson comorbidity index 1.26 (1.18-1.35) <0.001 1.17 (1.09-1.27) <0.001
ASA classification
 I
 II
 III
 IV
 V
1
2.83 (1.66-4.82)
4.22 (2.37-7.51)
3.19 (1.06-9.62)
55.32 (7.15-427.98)
<0.001
<0.001
0.040
<0.001
CEA 1.00 (1.00-1.01) 0.308
Type of surgery
 Open
 Laparoscopic
 Conversion
1
0.67 (0.51-0.89)
1.05 (0.69-1.62)
0.006
0.811
1
1.07 (0.77-1.50)
1.77 (1.11-2.82)
0.678
0.017
Stoma
 No
 Yes
1
1.64 (1.24-2.16)
<0.001 1
2.02 (1.47-2.77)
<0.001
Blood loss (100 ml) 0.98 (0.95-1.02) 0.368
Duration of surgery (hours) 0.86 (0.75-0.99) 0.033 0.83 (0.71-0.97) 0.021
Tumor stage
 I
 II
 III
1
1.31 (0.92-1.85)
1.81 (1.29-2.55)
0.135
0.001
1
1.48 (1.03-2.15)
3.14 (2.11-4.68)
0.036
<0.001
Tumor location
 Colon
 Rectum
1
1.12 (0.84-1.50)
0.450
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HR
(95% CI)
p-value Adjusted HR
(95% CI)
p-value
Tumor grade
 Good
 Moderate
 Poor
 Other
1
0.86 (0.61-1.20)
1.79 (1.15-2.77)
1.21 (0.48-3.04)
0.374
0.010
0.685
1
0.82 (0.58-1.17)
1.59 (1.00-2.54)
0.86 (0.34-2.18)
0.265
0.051
0.747
Angioinvasive growth
 No
 Yes
1
1.00 (0.86-1.17)
0.994
Neoadjuvant therapy
 No
 Yes
1
0.97 (0.71-1.32)
0.824
Adjuvant therapy
 No
 Yes
1
0.68 (0.47-0.97)
0.036 1 
0.69 (0.43-1.11)
0.124
Comprehensive complication index 1.02 (1.01-1.02) <0.001 1.01 (1.00-1.02) 0.003
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DISCUSSION
In this study, we found that low skeletal muscle mass and density were predictors for 
short-term outcome (i.e. postoperative complications, mortality, LOS, and discharge 
status) in patients undergoing curative intent resection of colorectal cancer, but not for 
long-term outcome (i.e. overall, cancer-specific, and disease-free survival).
Our results are in line with the study of Sabel et al., which also found an association 
between psoas density and short-term, but not long-term outcome 17. As in our study, 
an association was observed in univariate analysis, which did not hold after adjustment 
for age and Charlson Comorbidity Index, which are known to be two strong prognostic 
factors. A recent study also observed a univariable association between reduced 
skeletal muscle mass and overall survival, but not in multivariable analysis 26, whereas 
another study among 805 patients undergoing colorectal cancer surgery did find 
independent associations between myopenia (i.e. low skeletal muscle mass) and overall 
and disease-free survival 16. However, the latter also included stage IV cancer patients. 
Another Japanese study among 220 patients also found an independent association 
between low skeletal muscle mass and overall and recurrence-free survival 15. However, 
in these studies patients were classified as having myopenia using cut-off values which 
have been derived in a North-American cohort and the sex-specific lowest quartile for 
skeletal muscle mass, respectively. These cut-off values are not stratified for BMI 27. We 
choose to use the more recently proposed cut-off values by Martin et al., stratified for 
both sex and BMI 25. Furthermore, we excluded stage IV patients, since their diagnosis 
and treatment greatly differ from patients with stage I-III (i.e. non metastasized) disease. 
Furthermore, the effect of proinflammatory cytokine levels and muscle wasting is 
probably more severe in stage IV patients compared with stage I-III patients.
The fact that low skeletal muscle mass and density are associated with short-term, 
but not long-term, outcome suggests an increased vulnerability of colorectal cancer 
patients towards stressors, such as surgery (i.e. frailty) 28. Once patients have survived 
the postoperative period, the effects of low skeletal muscle mass and density disappear. 
Other risk factors, such as age and comorbidity, become more important for the clinical 
course of a given patient. We hypothesize that most cancer populations, such as stage 
I-III colorectal cancer patients, generally reach a functional status after treatment (i.e. 
surgery) that is close to pre-disease levels 29. In contrast, other cancer populations 
undergoing cancer surgery including sicker patients, such as pancreatic or liver cancer 
patients, have an increased risk of spiraling down a vicious circle, which progressively 
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enhances physical impairment. Furthermore, the more dismal prognosis of these 
cancers may at least be one cause that could explain the prognostic value of low skeletal 
muscle mass and/or density in these patients 3.
The absence of a preoperatively elevated inflammatory response (i.e. elevated neutrophil 
to lymphocyte ratio), as well as laparoscopy, are associated with preservation of skeletal 
muscle mass after colorectal cancer surgery, whereas higher age, female gender, higher 
ASA classification are associated with a further decrease of skeletal muscle mass 30. 
Particularly in the last three months of life in advanced colorectal cancer patients, a 
significant increase in high metabolic rate tissues (e.g., liver, tumor) and a concurrent 
increase in resting energy expenditure and decrease in peripheral tissue (i.e. skeletal 
muscle mass and adipose tissue) has been shown 31. Future research should elucidate 
the value of skeletal muscle preservation or decrease over time to early predict survival 
or disease recurrence.
The association between low skeletal muscle mass and density, and complications after 
colorectal cancer surgery has been described before 2, 3, 5-8, 26, 32. This association may 
explained in part by an increased inflammatory state in patients with low skeletal muscle 
mass and increased age and frailty 33-36. As previously suggested 8, the preoperative 
period allows for prehabilitation of colorectal cancer patients that could reduce 
postoperative complications and mortality. Particularly in rectal cancer patients, the 
period of neoadjuvant chemo- and/or radiotherapy, may form a perfect time window, as 
such programs are proven to be safe in patients undergoing chemotherapy 37, 38. Such an 
intervention should be multidimensional, including at least exercise therapy, nutritional 
support, and therapeutics (e.g., anti-inflammatory drugs or myostatin antagonists). 
Currently, multiple studies are being conducted investigating medication to reduce or 
reverse cancer-induced skeletal muscle depletion 39-41.
Counterintuitively, patients in the low skeletal muscle density group had a lower tumor 
stage compared with the high density group. However, a similar association was observed 
in a previous by Miyamoto et al. 14, whereas other studies did not find any significant 
differences in cancer stage within non-metastasized patients 7. In our study population, 
these differences are explained by the significant differences in age. Furthermore, tumor 
burden in patients without distant metastases may be less important than other factors, 
such as tumor biology, as previously described 36. A significantly lower proportion of 
patients with low skeletal muscle density or mass underwent adjuvant chemotherapy, 
which may be explained by the fact that these patients were considered less fit.
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Although this is currently the largest, and the only multicenter, study investigating the 
effect of low skeletal muscle mass and density on postoperative outcome in colorectal 
cancer patients undergoing surgery, non-significant differences may still be the result 
of an underpowered study. Furthermore, some patients could not be included because 
of unavailability of eligible CT examinations or body height that was not recorded in 
patient charts. Especially in rectal cancer patients CT examinations were often lacking. 
This may have led to some selection bias. However since most important baseline 
characteristics (such as sex, age, comorbidity, and tumor stage) of excluded patients did 
not significantly differ from included patients, this bias is probably limited.
In conclusion, low skeletal muscle mass and density are associated with an impaired 
postoperative recovery and increased postoperative complication rate. No association 
was found with overall, cancer-specific, and disease-free survival. The preoperative 
period may be used to optimize patients preoperatively.
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Low Skeletal Muscle Density is Associated with Early 
Death in Patients with Perihilar Cholangiocarcinoma 
Regardless of Subsequent Treatment
J.L.A. van Vugt, M.P. Gaspersz, J. Vugts, S. Buettner, S. Levolger, R.W.F. de Bruin, 
W.G. Polak, J. de Jonge, F.E.J.A. Willemssen, B. Groot Koerkamp, J.N.M. IJzermans
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ABSTRACT
Background: Low skeletal muscle mass is associated with increased postoperative 
morbidity and worse survival following liver resection for perihilar cholangiocarcinoma 
(PHC). The objective of this study was to investigate skeletal muscle mass and density to 
predict survival of all patients with suspected PHC, regardless of treatment.
Methods: Baseline characteristics and parameters regarding disease and treatment 
were collected of all patients with PHC from 2002-2014. Skeletal muscle mass and 
density were measured at the level of the third lumbar vertebra on CT-scans. The 
association between skeletal muscle mass and density with overall survival (OS) was 
investigated using the Kaplan-Meier method en Cox survival.
Results: Median OS did not differ between patients with and without low skeletal 
muscle mass (p=0.203), whereas a significantly lower median survival was observed in 
patients with low (7.0 months, 95%CI 4.7-9.3) compared with patients with high (12.1, 
95%CI 8.1-16.1) skeletal muscle density (p=0.004). Low skeletal muscle density was 
independently associated with decreased survival (HR 1.78, 95%CI 1.03-3.07, p=0.04) 
within the first six months, but not after six months (HR 0.68, 95%CI 0.44-1.07, p=0.093), 
after adjusting for age, tumor size, and suspected peritoneal or other distant metastases 
on imaging.
Conclusions: A time-dependent effect of skeletal muscle density on mortality was 
found in patients with PHC, regardless of subsequent treatment. Low skeletal muscle 
density may identify patients at risk for early death.
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INTRODUCTION
The prognosis of patients with perihilar cholangiocarcinoma (PHC) is poor. After 
curative-intent resection the median survival is 19-39 months with a 5-year survival rate 
of 10-40% 1-3. However, only about one in four patients with suspected PHC undergoes 
surgical resection. The majority of patients receives palliative treatment or best 
supportive care and have a median survival of only 6 months 4-6.
Multiple staging systems are available to predict prognosis in patients with (suspected) 
PHC 4, 7-9. However, the majority of staging systems, such as the frequently used American 
Joint Committee on Cancer (AJCC) staging system, are applicable only to the minority 
of patients that undergo surgical resection 7. Prognostic factors and models for all PHC 
patients regardless of treatment are rare 9.
Recently, low skeletal muscle mass (i.e. sarcopenia), as part of the cancer cachexia 
syndrome 10, 11, has been introduced as a biomarker to predict treatment complications and 
worsened survival in gastrointestinal and hepato-pancreato-biliary cancer patients 12, 13. 
It may detect malnutrition that is not visible otherwise 14. Three studies found that 
preoperative low skeletal muscle mass was also associated with worse outcome in 
patients undergoing surgical resection of extrahepatic biliary cancer 15 and PHC 16, 17. 
However, the association between sarcopenia and outcome in all PHC patients, 
regardless of treatment, and the prognostic value of skeletal muscle density remain 
unknown. Therefore, the aim of this study was to investigate the prognostic value of 
skeletal muscle mass and density at initial presentation in all patients with suspected 
PHC.
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METHODS
Patients and data collection
All patients aged 18 years and older with suspected PHC who presented in Erasmus 
University Medical Center between 2002 and 2014 were identified, regardless of 
subsequent treatment. Demographics (e.g., age, sex) and clinical (e.g., presence 
of cholangitis or icterus at presentation), drainage, laboratory (e.g., bilirubin and 
carbohydrate antigen (CA) 19.9 levels), and treatment (e.g., chemotherapy, surgery) 
parameters were collected from digital medical records. Body mass index (BMI) was 
categorized according to the World Health Organization (WHO) classification 18. PHC 
was defined as a mass at or near the biliary confluence, arising between the origin of the 
cystic duct and the segmental bile ducts 19. In the absence of histopathological evidence, 
the diagnosis of suspected PHC was based on the opinion of the multidisciplinary 
hepatopancreatobiliary team based on clinical, radiological, endoscopic, and laboratory 
observations. Patients were excluded if benign disease was considered more likely 
during follow up. Patients who visited our center for drainage only once, or who already 
underwent treatment (i.e. surgery, chemotherapy) in the referral center, were also 
excluded.
Radiological examinations (i.e. contrast-enhanced computed tomography (CT) and/or 
magnetic resonance imaging (MRI) with or without cholangiopancreatography) were 
re-assessed by an experienced abdominal radiologist. Parameters assessed on imaging 
were tumor visibility, tumor size, Bismuth-Corlette classification 20, vascular involvement 8, 
lobar atrophy, lymph node status, and the presence of distant metastases. Based on 
these findings, the AJCC stage (7th edition) was assessed 19. Stage I and II were analyzed 
together for the clinical AJCC stage, because T1 (stage I) and T2 (stage 2) cannot be 
distinguished on imaging alone. Vascular involvement was defined as tumor contact of 
at least 180 degrees around the portal vein and/or hepatic artery and its side branches. 
Involvement of lymph nodes along the cystic duct, common bile duct, hepatic artery 
and portal vein was classified as N1 and lymph node involvement around the aorta, 
caval vein, superior mesenteric artery, and celiac artery as N2 19.
The municipal records database was checked for patients’ survival status on May 
9th 2016. A waiver was granted for this study from the Medical Ethical Committee of 
Erasmus University Medical Center.
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Diagnostic work-up and treatment algorithm
The diagnostic work-up included, but was not limited to, imaging with contrast-
enhanced CT, MRI, and/or MRI with cholangiopancreatography (MRCP). Typically, 
patients were only considered for exploratory laparotomy in the absence of metastatic 
disease and with involvement of less than 180 degrees of the hepatic artery. A resection 
was performed only when a complete resection (R0) was anticipated with an adequate 
functional liver remnant. Patients with metastatic or locally advanced (i.e. unresectable) 
disease were offered palliative chemotherapy. All other patients received best supportive 
care and palliative drainage.
Skeletal muscle mass and density
Skeletal muscle mass was measured on abdominal CT, using an in-house developed 
software package as previously described 21, 22. In short, the cross-sectional skeletal 
muscle area (CSMA, in cm²) was measured at the level of the third lumbar vertebra (L3) 
using a Hounsfield unit (HU) range of -30 to +150. The CSMA was adjusted for patients’ 
height squared, as is conventional for body composition measurements, resulting in 
the skeletal muscle index (SMI, cm²/m²). The SMI is strongly correlated with total body 
skeletal muscle mass 23, 24. Patients were classified as having low or normal/high SMI 
according to previously defined cut-off values in patients with PHC undergoing surgery 16. 
The mean HU value of the CSMA, as a measure of skeletal muscle density that is closely 
related to muscle function 25, 26, was also recorded. Patients were divided in groups of low 
skeletal muscle density (below the median sex-specific value) and high skeletal muscle 
density (above the median sex-specific value) 27. Sarcopenic obesity was defined as 
low skeletal muscle mass and BMI ≥30 kg²/m² and myosteatotic obesity as low skeletal 
muscle density and BMI ≥30kg²/m².
The first abdominal CT during the diagnostic work-up of PHC was used. Patients without 
available contrast-enhanced CT imaging during diagnostic work-up (i.e. before any 
treatment) were excluded, because treatment may influence skeletal muscle density 
measurements. Furthermore, patients of whom not all skeletal muscles at the level of L3 
were depicted on CT were excluded from further analysis.
Statistical analyses
Continuous data are reported as median with interquartile range (IQR) or mean with 
standard deviation (SD), depending on the normality of the distribution. Normality 
of the distribution was tested using the Shapiro-Wilk test. Categorical variables are 
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reported as counts with percentages. Fischer’s exact or chi-squared tests were used for 
the comparison of proportions, while continuous parameters were compared using 
Student’s t-tests.
Overall survival (OS) was measured from the date of first presentation in the tertiary 
referral center. Survival estimates were compared using the Kaplan-Meier method 
and the log-rank test. Logistic regression analysis was used to compare the 3-months, 
6-months, 1-year, 3-year, and 5-year survival rates. The association between skeletal 
muscle mass and density and survival was investigated using a multivariable Cox 
proportional hazard regression model, adjusting for known risk factors 9 and additional 
factors that were associated with impaired survival in univariable analysis. Hazard 
ratios (HRs) with 95% confidence interval (CI) were reported. Due to the large number 
of missing values, CA19-9 was not included in the final model. A subgroup analysis 
was performed in unresectable patients only. The effect of skeletal muscle density 
on the hazard was allowed to vary before and after 6 months of follow-up. Therefore, 
an interaction term between time and skeletal muscle density was included in the 
Cox regression model 28. Two-tailed p-values below 0.05 were considered statistically 
significant. All statistical analyses were performed using SPSS for Windows (IBM Corp., 
Armonk, NY, USA), version 22.
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RESULTS
Patient and tumor characteristics
In total, 285 patients who presented with suspected PHC in our center were identified. 
Of these 285 patients, a contrast-enhanced abdominal CT was available for 233 (81.8%) 
patients, who formed the study cohort. The median age was 66 (IQR 57-74) years, 
and 140 (60.1%) patients were male. The median BMI was 24.7 (IQR 22.4-26.8) kg²/m² 
and 17 (7.3%) patients were obese. Body height was missing for 23 (9.9%) patients. 
Consequently, these patients were excluded from analyses requiring body height (i.e. 
skeletal muscle mass), but included in analyses using skeletal muscle density. Due to 
missing body height and/or weight, BMI was unknown for 50 (21.5%) patients. Twenty-
eight (12.7%) patients had AJCC stage I/II, 50 (22.6%) stage III, and 143 (64.7%) stage IV 
(table 1). The median time between the first available contrast-enhanced CT performed 
for the suspicion on PHC and the first presentation in the tertiary referral center was 11 
(IQR -3-25) days.
Treatment characteristics
Forty-one (17.6%) patients underwent surgical resection including two liver 
transplantation, and 72 (30.9%) patients underwent a laparotomy without resection. In 
these 72 patients, the intraoperative finding of metastases and locally advanced disease 
were the most common reasons for renouncing resection. The remaining 120 (51.5%) 
patients were considered unresectable at initial presentation, of whom 13 (11.3%) 
received palliative chemotherapy.
Low skeletal muscle mass
In total, 103 of the 210 (49.0%) of patients were considered to have low skeletal muscle 
mass (table 1). The median SMI was significantly higher in males (47.6 [IQR 43.6-51.9] 
cm²/m²) compared with females (38.3 [IQR 35.0-43.5] cm²/m²), p<0.001. Patients 
with low skeletal muscle mass were significantly older compared with patients with 
high skeletal muscle mass (69 versus 64 years, p=0.040) and had significantly higher 
C-reactive protein levels (19 versus 9, p=0.002) and CA19.9 levels (254 versus 162, 
p=0.039). Median BMI was significantly lower in patients with low versus high skeletal 
muscle mass (23.7 versus 25.7, p<0.001). Few patients had a BMI ≥30 kg²/m² and low 
skeletal muscle mass (n=3) or low skeletal muscle density (n=11). Finally, the rate of 
metastatic disease at initial presentation was significantly higher in patients with low 
skeletal muscle mass (15.5% versus 4.7%, p=0.009) and non-significant differences were 
observed in treatment groups.
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Low skeletal muscle density
Low skeletal muscle density was observed in 131 (56.2%) patients. Males had a 
significantly higher skeletal muscle density compared with females (38 [IQR 31-43] versus 
31 [IQR 25-39] HU, p<0.001). While median BMI was higher in patients with high skeletal 
muscle mass, it was significantly higher in patients with low skeletal muscle density 
compared with high skeletal muscle density (25.2 versus 24.4, p=0.032). Furthermore, 
patients with low skeletal muscle density were older (70 versus 58 years, p<0.001), had 
a higher CRP level (17 versus 9, p=0.023), presented more with unresectable disease 
(87.0% versus 78.0%, p<0.001) and were less frequently treated with chemotherapy 
(8.8% versus 21.7%, p=0.007), table 1.
Survival
In total, 221 (94.8%) patients died during the study period. Median follow-up of the 
included patients who were alive at last follow-up was 25.3 (IQR 18.3-85.5) months. The 
3-month, 6-month, 1-year, 3-year, and 5-year survival rates in the entire cohort were 
79.0%, 60.9%, 42.1%, 7.7%, and 3.0%, respectively. Median OS for the entire cohort was 
9.6 (4.1-20.5) months. Median OS for patients who underwent resection was 29.1 months 
compared with 7.9 months in patients who did not undergo resection (p<0.001).
Skeletal muscle mass and density and overall survival
The median OS did not differ between patients with low skeletal muscle mass and high 
skeletal muscle mass (10.8 months [95% CI 7.7-13.8] versus 10.3 months [95% CI 8.2-
12.3], p=0.203), figure 1, whereas a significantly lower median survival was observed in 
patients with low compared with patients with high skeletal muscle density (7.0 months 
[95% CI 4.7-9.3] versus 12.1 months [95% CI 8.1-16.1], p=0.004), figure 2.
Lower survival rates were observed in patients with low skeletal muscle density 
compared with patients with high skeletal muscle density at 3 months (71.0% versus 
89.2%, p=0.001; odds ratio [OR] 3.38, 95% CI 1.63-7.02, p=0.001), 6 months (51.9% 
versus 72.5%, p=0.003; OR 2.45 95% CI 1.11-4.26, p=0.002) and 1 year (35.1% versus 
51.0%, p=0.015; OR 1.92, 95% CI 1.13-3.26, p=0.015), but not at 3 and 5 years (6.1% 
versus 9.8%, p=0.294, and 2.3% versus 3.9%, p=0.086, respectively). After adjusting 
for age, tumor size, and suspected peritoneal or other distant metastases on imaging, 
low skeletal muscle density was independently associated with decreased survival (HR 
1.78, 95% CI 1.03-3.07, p=0.004) within the first six months, but not after six months (HR 
0.68, 95% CI 0.44-1.07, p=0.093) (table 2). Similar results were observed when sex was 
added to the analyses and in a subgroup analysis in unresectable patients only (data not 
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shown). An incremental skeletal muscle density (entered as a continuous measure) was 
also independently associated with decreased survival within six months (HR 0.96, 95% 
CI 0.93-0.99, p=0.002), but not after six months.
Table 2. Cox proportional hazard regression analysis for factors associated with impaired 
survival.
Univariable Multivariable
HR (95% CI) p-value HR (95% CI) p-value
Age (years) 1.02 (1.01-1.03) 0.001 1.02 (1.01-1.04) 0.003
Sex
 Female
 Male
1 (ref )
1.01 (0.77-1.32)
0.945
BMI ≥25 (kg/m²) 1.04 (0.77-1.40) 0.803
ECOG (WHO) performance status
 1-2
 3-4
1 (ref )
1.31 (0.69-2.48)
0.403 1 (ref )
1.63 (0.72-3.69)
0.243
Bilirubin >200 (µmol/L) 1.48 (1.00-2.19) 0.051 1.04 (0.67-1.60) 0.866
CA19.9 >1000 (kU/L) 1.87 (1.29-2.70) 0.001
Albumin (g/dL) 0.99 (0.96-1.02) 0.429
C-reactive protein (mg/L) ≥100 2.10 (1.05-4.18) 0.036
Cholangitis before or at presentation 1.48 (0.84-2.60) 0.180
Tumor size >3cm 2.31 (1.72-3.09) <0.001 2.24 (1.60-3.15) <0.001
Suspicious lymph nodes on imaging*
 N0
 N1
 N2
1 (ref )
1.37 (1.01-1.87)
1.48 (1.03-2.13)
0.046
0.033
1 (ref )
1.57 (1.08-2.28)
1.37 (0.91-2.06)
0.018
0.134
Suspected distant metastases on imaging 1.46 (0.97-2.20) 0.072 3.74 (1.93-7.26) <0.001
Lobar atrophy on imaging 1.04 (0.77-1.41) 0.793
Vascular involvement on imaging§ 1.44 (1.09-1.91) 0.011 1.30 (0.91-1.85) 0.150
Low skeletal muscle mass 1.99 (0.91-1.59) 0.204
Low skeletal muscle density (<6 months)# 2.09 (1.34-3.27) 0.001 1.78 (1.03-3.07) 0.040
Low skeletal muscle density (≥6 months)# 1.20 (0.85-1.69) 0.306 0.68 (0.44-1.07) 0.093
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; BMI, Body Mass Index; ECOG, Eastern Cooperative Oncology 
Group; WHO, World Health Organization.
* Involvement of lymph nodes was assessed according to the AJCC (7th edition) 1.
# The effect of skeletal muscle density on the hazard varied with time. Hence, an interaction term between skeletal muscle 
density and time was used to calculate the time-dependent effect of skeletal muscle density on the hazard.
§ Vascular involvement on imaging was defined as tumor contact of at least 180 degrees around the portal vein and/or 
hepatic artery and its side branches.
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Figure 1. Kaplan-Meier survival curves for patients with high and low skeletal muscle mass 
(SMI).
Figure 2. Kaplan-Meier survival curves for patients with high and low skeletal muscle density 
(SMD).
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DISCUSSION
This study showed that low skeletal muscle density is an independent prognostic factor 
for overall survival within the first six months after initial presentation in patients with 
PHC. Skeletal muscle mass was not an independent prognostic factor.
This is the first study that investigated the association between skeletal muscle mass, 
skeletal muscle density and outcome in all patients with PHC in a unique Western series 
of patients with both resectable and unresectable PHC. In other tumors, such as follicular 
lymphoma, melanoma, and metastatic renal cell and gastric carcinoma no association 
between skeletal muscle mass and survival was shown, whereas skeletal muscle density 
was an independent prognostic factor 27, 29-32. The similarity between these studies and 
the current study is the aggressive course of the disease, which may have led to the 
inability to accurately predict outcome.
An intriguing hypothesis described by Hayashi et al. is that a decrease in skeletal muscle 
density is detected earlier on CT than a decrease in skeletal muscle mass 31. Recent 
studies show that skeletal muscle density is mainly correlated with intramuscular 
adipose tissue content 26, while low skeletal muscle mass results from limited muscle 
growth and increased muscle wasting 33. The mechanisms leading to and effects of these 
two processes are probably different and further research on their pathophysiology 
is warranted. Tumor biology may play an important role, since the effects of skeletal 
muscle mass and density on outcome vary per tumor sort and within tumor sorts and 
altered body composition is associated with an elevated inflammatory response 34, 35.
The independent association between skeletal muscle mass and density has frequently 
been found in survival analyses of previous studies 12, 36. Nevertheless, this is the first 
study to describe a time-dependent effect, independently of previously described risk 
factors for impaired survival in patients with PHC 9. Although it should be assessed, time-
dependency of covariates is often not assessed, leading to bias in survival analyses in 
a great part of literature 28. Low skeletal muscle density influenced survival in the three 
to six months after initial diagnosis. However, this effect faded hereafter. This suggests 
that patients with the poorest survival are those with the lowest skeletal muscle density. 
Another reason why no effect was found after three and five years could have been the 
low median survival time (i.e. 7.9 months in unresectable and 29.1 months in resected 
patients), resulting in low patient numbers. Although we did not correct for treatment 
in multivariable analysis, we strongly believe that the model accurately reflects daily 
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practice. After all, the parameters assessed at first presentation greatly determine 
treatment and consequently (indirectly) correlate with survival. Our results should 
therefore be interpreted as valid in an “all-comers” patient population.
Notably, the rate of patients that underwent resection or received chemotherapy was 
lower in the low skeletal muscle density group. Furthermore, patients undergoing 
resection were significantly younger. These findings suggest a preoperative selection 
process of patients considered fit for surgery and chemotherapy. After all, none of 
the parameters representing tumor load (i.e. bilirubin level, CA19-9 level, vascular 
involvement, tumor size) that possibly may have influenced resectability, were 
significantly higher in patients with low skeletal muscle density. However, it should 
be noted that the median time interval between first presentation in the tertiary 
hospital and resection was 79 days. This time window may have led to further clinical 
deterioration and these findings should therefore be interpreted with caution. The 
significantly lower BMI and higher age in patients with low skeletal muscle density are in 
line with previous findings, as increasing age and adiposity are known for its association 
with intramuscular adipose tissue content 25, 37.
The majority of all prognostic models for PHC have been developed in patients 
undergoing surgical resection 9, 19. However, the latter group forms the greatest number 
of patients with PHC, since only around a quarter of all patients undergo resection 4-6. 
The value of skeletal muscle mass and density measurements to identify patients at 
risk for impaired outcome seems promising, particularly in hepaticopancreatobiliary 
cancer patients 12, 16, 17, 38. Unfortunately, the number of patients who underwent surgical 
resection was too small to validate previously described findings regarding CT-assessed 
skeletal muscle mass and impaired outcome in patients with PHC undergoing surgery 16, 17. 
Future studies should include low skeletal muscle density as a poor prognostic factor.
No international consensus has been reached on the definition of uniform cut-off points 
for CT-assessed skeletal muscle mass and density measurements yet 39, and various cut-
off points are being used 16, 21, 23, 25. Optimum stratification by means of the log-rank test 
is a method to identify optimal cut-off points for survival in a study cohort that has 
frequently been used 16, 21, 23, 25. However, with a relatively small study cohort, it is highly 
questionable as to whether cut-off points can be reproduced in another sample of 
patients. Therefore, we choose to use the sex-specific median to group patients into low 
and high skeletal muscle density. Skeletal muscle density and survival was entered into 
the survival analysis as a continuous variable, since previous reports with large cohorts 
did not report sex differences in skeletal muscle attenuation 25. Ideally, definitive cut-off 
points should be developed that are derived from healthy persons.
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Although surgical resection is the main determinant of survival in perihilar 
cholangiocarcinoma, we opted to focus on the effects of pre-treatment parameters, 
in particular the impact of sarcopenia on patient survival. At the time of diagnosis, 
sarcopenia is easily measured using a spiral CT of the abdomen 21, 23-26. Previous 
studies as well as the results of this study show that sarcopenia is heavily correlated 
with cancer stage and treatment, yet across all strata of treatment and cancer stage 
patients with sarcopenia perform worse 40, 41. This indicates that, regardless of further 
choices sarcopenia is an independent predictor of outcome. By only taking into account 
the preoperative sarcopenia and radiological imaging, we therefore believe we have 
described the predictive ability of patient predisposition regardless of any treatment 
decisions. This predictive information could be valuable to improve informed clinical 
decision-making.
Some limitations of the current study should be acknowledged. A drawback is the 
retrospective character of the study design. Although a systematic search was performed 
in the electronic patient record, this may have led to selection bias. Furthermore, some 
variables had a high number of missing values. In 77 patients, for example, CA 19.9 was 
unknown, because this tumor marker assessment has not routinely been performed 
before 2010. Although only contrast-enhanced CTs were used for skeletal muscle mass 
and density measurements, possible differences as a consequence of the use of different 
CT scanners and scanning protocols in various hospitals, could not be precluded. The 
effect of contrast-enhancement on skeletal muscle mass and density measurements 
has not been evaluated. Skeletal muscle mass and density were measured at one time 
only (i.e. at initial presentation). Future studies could evaluate consecutive CT scans over 
time to allow the analysis of skeletal muscle mass and density changes over time and 
their association with treatment and mortality.
In conclusion, a time-dependent association between skeletal muscle density and 
mortality was found in patients with PHC, regardless of subsequent treatment. Low 
skeletal muscle density may identify patients with PHC at risk for early death. This 
finding should be validated in a larger, external cohort and future studies are needed to 
investigate the additional value of skeletal muscle density measurements in prognostic 
models.
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ABSTRACT
Liver transplant outcome has improved considerably as a direct result of optimized 
surgical and anesthesiological techniques and organ allocation programs. As there is 
still a shortage of human organs, strict selection of transplant candidates remains of 
paramount importance. Recently, CT-assessed low skeletal muscle mass (i.e. sarcopenia) 
was identified as a novel prognostic parameter to predict outcome in liver transplant 
candidates. A systematic review and meta-analysis on the impact of CT-assessed skeletal 
muscle mass on outcome in liver transplant candidates were performed according to 
the PRISMA-guidelines. Nineteen studies, including 3803 patients in partly overlapping 
cohorts, fulfilled the inclusion criteria. The prevalence of sarcopenia ranged from 22.2-
70%. An independent association between low muscle mass and post-transplantation 
and waiting list mortality was described in four of the six and six of the eleven studies, 
respectively. The pooled hazard ratios of sarcopenia were 1.84 (95% CI 1.11-3.05, p=0.02) 
and 1.75 (95% CI 0.99-3.00, p=0.05), for post-transplantation and waiting list mortality, 
respectively, independent of Model for End-stage Liver Disease (MELD) score. Less 
consistent evidence suggested a higher complication rate, particularly infections, in 
sarcopenic patients. In conclusion, sarcopenia is an independent predictor for outcome 
in liver transplantation patients and could be used for risk assessment.
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INTRODUCTION
As human organ shortage remains prevalent, strict selection of transplant candidates 
is of paramount importance. The combination of waiting list mortality and post-
transplantation survival are key deciding factors in waiting list placement. Currently, 
the Model for End-stage Liver Disease (MELD) score, a validated risk-based system that 
predicts waiting list mortality, is used to allocate donor livers 2. Although the introduction 
of the MELD-score has led to a decreased number of patients on the waiting list, 
shortened waiting time and decreased waiting list mortality despite increasing disease 
severity 3, objective parameters reflecting a patient’s nutritional and functional status 
in particular are lacking and attempts have been made to modify and improve the 
MELD-score 4, 5. Frailty, the inability to adequately respond to stressors (i.e. surgery), for 
instance, has been identified as a prevalent syndrome in liver transplant candidates that 
strongly predicts waiting list mortality 6.
Skeletal muscle wasting (i.e. sarcopenia), which is a common syndrome in chronic 
diseases such as liver failure, is a key feature of frailty. The association between 
sarcopenia and treatment outcomes, such as complications and survival, using single-
slice computed tomography (CT) based measurements has recently been described 
in various patient groups 7. Sarcopenia is frequently found to be an independent 
predictor for treatment outcome, and is considered to be a stronger predictive marker 
than conventional risk factors, such as age and American Society of Anesthesiologists 
(ASA) classification 8, 9. However, study results remain inconclusive. Therefore, the aim 
of this study was to systematically review the impact of CT-based skeletal muscle 
measurements on outcome in patients awaiting or undergoing liver transplantation.
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METHODS
The study was registered in the PROSPERO International prospective register of 
systematic reviews (CRD42015019086) 8. A priori defined eligibility criteria were 
established. All original studies that investigated the influence of skeletal muscle mass 
by means of abdominal CT in patients who underwent liver transplantation or were 
registered on the waiting list were identified by a systematic search performed in 
EMBASE, PubMed, and Web of Science, which was limited to English papers published 
between January 2000 and February 2015. The following search terms were used: 
(‘sarcopenia’:de,ab,ti OR ‘analytic morphomics’:de,ab,ti OR ‘body composition’:de,ab,ti 
OR ‘muscle depletion’:de,ab,ti OR ‘muscle mass’:de,ab,ti OR ‘psoas area’:de,ab,ti OR 
‘myopenia’:de,ab,ti OR ‘core muscle’:de,ab,ti OR ‘lean body mass’:de,ab,ti OR ‘muscular 
atrophy’:de,ab,ti) AND (‘liver transplantation’:de,ab,ti). Similar queries were used 
for PubMed and Web of Science. The systematic review was performed according to 
the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines 10.
Eligibility of studies and assessment of methodological quality
Duplicate records were removed and all abstracts were independently screened by 
two investigators to determine eligibility for further analysis. All abstracts describing 
the prevalence or predictive value for complications and survival of sarcopenia in 
patients awaiting or undergoing liver transplantation were further assessed. Studies 
that measured muscle mass with other means than CT were excluded. Only original 
studies were included. Case reports, review articles, opinion articles and experimental 
studies were excluded. The remaining full-text articles were subsequently retrieved and 
independently screened by two investigators. All articles within the inclusion criteria 
were included in the systematic review. The included full-text articles were screened 
for additional relevant references. The methodological quality of the included studies 
was independently assessed by two investigators using the Newcastle-Ottawa Quality 
Assessment Scale for Cohort Studies for each a priori defined outcome measure 11. This 
is a ten-point scale, with 0 being poorest quality and 9 being highest quality. Quality 
assessment was performed separately for short and long term outcomes.
Data extraction
Two investigators independently extracted data regarding study design and results, 
including: age, gender distribution, patient selection, indication for liver transplantation 
or disease etiology, Body Mass Index (BMI), albumin level, MELD-score, presence 
of cirrhosis, details on skeletal muscle mass measurement methods, prevalence of 
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sarcopenia, waiting list mortality, post-transplantation mortality and complications, 
length of intensive care unit (ICU) and hospital stay, graft survival, and overall survival. 
Relevant information for the meta-analyses that could not be extracted from the articles 
was requested from the corresponding authors and when provided, included in the 
review. If not stated otherwise, results from multivariable analyses were used for the 
interpretation of the data.
Statistical analysis
All outcomes are reported as in the original articles. A meta-analysis was performed 
using Review Manager 5.3 (The Nordic Cochrane Center, Copenhagen, Denmark). Data 
are presented as hazard ratios (HR) with 95% confidence intervals (CI). If not stated 
otherwise, results of adjusted analyses were used. Random effects models were used 
to calculate summary estimates and to adjust for potential heterogeneity. Studies were 
weighted according to the inverse of the variance of the log hazard ratio. Overall effects 
were assessed using the Z-test and heterogeneity was tested using Cochran’s chi-
square test. The I2 statistic was used to assess heterogeneity, which was defined as low, 
moderate, or high with I2 values above 25%, 50%, and 75%, respectively 12. If a research 
group contributed multiple studies with (partly) overlapping cohorts or relevant data 
was missing in the articles, the research group was contacted to provide additional 
data. If this data could not be provided, only the most relevant study was entered into 
the meta-analysis. Two-sided p-values <0.05 were considered statistically significant.
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RESULTS
Of the 470 records that were found on February 3rd, 2015, 28 full text articles were 
considered potentially relevant (figure 1). From these 28 records, eight studies assessed 
muscle mass with means other than CT and one study was performed in another 
population than patients awaiting or undergoing liver transplantation. The remaining 
nineteen studies, including 3803 patients, were included in this systematic review 13-30. 
Cross-referencing yielded no additional records.
table 1 shows the population characteristics and the quality of the enrolled studies. The 
main indications for liver transplantation were viral liver infections (i.e. hepatitis B and 
C), followed by alcoholic liver cirrhosis. Around 65% was male and the mean age was 52 
to 62 years. The median MELD-score ranged from 9-21, the median albumin level from 
2.8 to 3.4 g/dl, and median BMI from 24.0 to 29.4 kg/m². Eight studies included cirrhosis 
patients only 13, 16, 18, 23-25, 27, 28, of which one study Child Pugh A patients only 28. 
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Figure 1. PRISMA Flow Chart of included studies.
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Table 1. Study population characteristics.
Author, 
Year
Patient selection
n 
(%♀)
Age
BMI 
(kg/
m²)
MELD-
score
Albu-
min 
(g/dl)
LT indication
Quality 
points*
C S
Bergerson,
2014 1
All patients 
undergoing 
LT because of 
alcohol, NASH or 
PSC cirrhosis 
(2000 – 2012)
40 
(35)
57† 29† 15† 3.0†
NASH 53%
PSC 25%
Alcoholic 23%
HCC 35%
n/a n/a
Cruz,
2013 2
Adults evaluated 
for LT
(Jan 2005 – Dec 
2008)
234 
(33)
55† 28† 21† 3.0†
HBV/HCV 25% 
Alcoholic 24%
Alcoholic + HBV/HCV 12%
NASH 12%
Autoimmune/PSC/PBC 11%
Fulminant liver failure 5%
Other 11%
HCC n/a
n/a 6/9
DiMartini,
2013 3
First time 
LT without 
transplantation of 
other organs 
(Jan 2005 – Dec 
2008)
338 
(34)
55† 28† 20† 3.0†
HBV/HCV 27%
Alcoholic 23%
NASH 14%
Autoimmune/PSC/PBC 12%
Alcohol + HBV/HCV 9%
Fulminant liver failure 4%
Other 11%
HCC n/a
7/9 7/9
Durand,
2014 4
All consecutive 
patients with 
cirrhosis listed 
for deceased 
donor LT 
(2002 – 2011)
562 
(19)
53† 26† 16† N/a
Alcoholic 42%
HCV 30%
HBV 15%
Biliary disease 5%
Other 8%
HCC 46%
n/a 3/9
Englesbe,
2010 5
Adult patients 
undergoing LT 
(2002 – 2008)
163 
(37)
52† 28† 19† 2.8†
HCV 35%
Alcoholic 12%
PSC 10%
PBC 6%
Other 25%
HCC 13%
n/a 7/9
Giusto,
2015 6
Adult patients 
with liver 
cirrhosis under 
evaluation for LT 
without acute 
liver failure and 
HCC beyond 
Milan criteria 
(2011 – 2013)
59 
(22)
59‡ 25‡
HCC: 
11‡
No 
HCC: 
16‡
N/a
HBV/HCV 56%
Alcoholic 22%
Other 22%
HCC 41%
n/a 7/9
Hamaguchi,
2014 7
Adult patients 
undergoing LDLT 
(Jan 2008 – Oct 
2013)
200 
(53)
54‡ N/a 18‡ N/a
HBV/HCV 19%
PSC/PBC 17%
Other 31%
HCC 34%
n/a 5/9
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Author, 
Year
Patient selection
n 
(%♀)
Age
BMI 
(kg/
m²)
MELD-
score
Albu-
min 
(g/dl)
LT indication
Quality 
points*
C S
Krell,
2013 8
Adult patients 
undergoing LT 
(June 2002 – Aug 
2008)
207 
(38)
52†
T1#: 27†
T2#: 28†
T3#: 29†
T1#: 
23†
T2#: 
19†
T3#: 
18†
N/a
HBV/HCV 30%
Autoimmune/PBC/PSC 23%
Alcoholic 15%
NASH 4%
Fulminant liver failure 2%
Other 12%
HCC 25%
5/9 n/a
Lee,
2014 9
Adult patients 
undergoing LT 
(2000 – 2011)
325 
(39)
52†
T1#: 27†
T2#: 28†
T3#: 30†
18†
T1#: 
2.9†
T2#: 
2.8†
T3#: 
2.9†
Cirrhosis 40%
HCV 29%
HCC 39%
6/9 6/9
Masuda,
2014 10
Patients 
undergoing LDLT  
(Nov 2003 – Dec 
2011)
204 
(50)
54† 24†
≥20:
S: 24%
NS: 
10%
N/a
HBV/HCV 63%
PBC 13%
Alcoholic 5%
Other 19%
HCC n/a
6/9 5/9
Meza-
Junco, 
2013 11
Consecutive 
patients with 
HCC and cirrhosis 
evaluated for LT
116 
(16)
58† 29† 9† 3.4†
HBV/HCV 60%
Alcoholic + HCV 20%
Alcoholic 11%
NASH 7%
Other 3%
HCC 100%
n/a 6/9
Montano-
Loza,
2012 12
Consecutive 
patients with 
cirrhosis 
evaluated for LT 
(10% underwent 
LT)
112 
(30)
54† 28† 13† 3.1†
HBVHCV 30%
Alcoholic 22%
Autoimmune/PBC/PSC 19%
Alcoholic and HCV 16%
Other 13%
HCC n/a
n/a 7/9
Montano-
Loza,
2014 13
Cirrhosis patients 
undergoing LT 
(2000 – 2012)
248 
(32)
55†
S: 25†
NS: 29†
20†
S: 3.3† 
NS: 
3.4†
HBV/HCV 60%
Alcoholic 19%
Autoimmune/PBC/PSC 15%
NASH 6%
Other 1%
HCC 39%
5/9 7/9
Tandon,
2012 12
Adult patients 
on the LT waiting 
list without 
HCC, acute liver 
failure, prior LT, 
multivisceral LT, 
LRLT 
(Feb 2005 – Nov 
2009)
142 
(40)
53‡ 27‡ 15‡ 3.0‡
HCV + alcoholic 38%
Autoimmune/PBC/PSC 25%
Alcoholic 20%
Cryptogenic/NAFLD 11%
Other 7%
HCC 0%
n/a 6/9
Toshima,
2015 14
LDLT recipients 
(Nov 2003 – Dec 
2011)
143 
(48)
S: 
55†
NS: 
55†
24†
S: 17†
NS: 13†
N/a N/a 6/9 n/a
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Author, 
Year
Patient selection
n 
(%♀)
Age
BMI 
(kg/
m²)
MELD-
score
Albu-
min 
(g/dl)
LT indication
Quality 
points*
C S
Tsien,
2014 15
Adult cirrhosis 
patients 
undergoing LT 
(Jul 2009 – Jul 
2011)
53 
(23)
57† 29† 13† 3.3†
Viral 42%
Alcoholic + viral 23%
NASH 8%
Other 28%
HCC 64%
4/9 4/9
Valero,
2015 16
Child Pugh 
A patients 
undergoing 
hepatic resection 
or OLT for HCC 
or ICC
(2000 – 2013)
96 
(39)
62† 27† 10† 3.7†
29% underwent LT
(100% HCC)
ICC 30%
HCC 70%
6/9 6/9
Waits,
2014 17
Adult patients 
who received 
liver transplants 
from deceased 
donors
(2000 – 2011)
348 
(38)
51†
T1¶: 27†
T2¶: 28†
T3¶: 29†
T1¶: 
20†
T2¶: 
17†
T3¶: 
18†
T1¶: 
2.9†
T2¶: 
2.8†
T3¶: 
2.8†
HCV 38%
HCC 27%
n/a 6/9
Yadav,
2015 18
All patients listed 
for LT 
(Jul 2008 – Jul 
2011)
213 
(39)
55†
29†
S: 24†
NS: 29†
16† 3.3†
HCV 44%
Alcoholic 16%
NASH 14%
PBC/PSC 8%
Cryptogenic 6%
Other 12%
HCC n/a
n/a 7/9
† mean. ‡ median. * Scored with the Newcastle-Ottawa quality assessment scale for cohort studies, on a scale of 0 to 9, with 
0 being poorest quality and 9 being highest quality. Quality assessment was performed separately for short and long term 
outcomes. # Tertiles based on skeletal muscle mass. ¶ Tertiles (young, middle, oldest) based on chronological age (psoas 
area, psoas density and abdominal aneurysmal calcifications). Abbreviations: LT; Liver Transplantation, C; complications, S; 
survival, LDLT; Living Donor Liver Transplantation, OLT; Orthotropic Liver Transplantation, HCC; Hepatocellular Carcinoma 
(either primary etiology or concomitant); BMI; Body Mass Index (kg2/m2), MELD; Model For End-Stage Liver Disease Score, 
S; patients with sarcopenia, NS; patients without sarcopenia, N/a; Not available. NASH; Nonalcoholic Steatohepatitis, PSC; 
Primary Sclerosing Cholangitis, HBV; Hepatitis B Virus, HCV; Hepatitis C Virus, PBC; Primary Biliary Cirrhosis, LRLT; living 
related liver transplantation.
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Definitions and prevalence of sarcopenia
A great variety in skeletal muscle measurement methods and definitions used to 
classify patients as sarcopenic or non-sarcopenic was observed. The methods of muscle 
measurement and sarcopenia definitions that were used are summarized in table 2. 
Nine studies reported the cross-sectional muscle area with corresponding skeletal 
muscle index 13-15, 18, 23-25, 30, whereas the psoas area was reported in eight studies 16, 17, 
19, 20, 22, 26-28 and the dorsal muscle group area in one study 21. One study calculated the 
morphometric age (calculated with total psoas area, psoas density and abdominal 
aortic calcifications) 29. The mean skeletal muscle index ranged from 43.0 cm²/m² to 54.3 
cm²/m² 14, 30. The prevalence of sarcopenia was reported in seventeen studies 13-15, 17-28, 
30 and ranged from 22.2% 30 to nearly 70% 14. The prevalence greatly depended on the 
definition used. All studies that reported the prevalence of sarcopenia separately for 
males and females, reported a higher prevalence among males 13, 15, 18, 22-26, 30.
Waiting list mortality
Four 16, 23, 24 of the six 16, 18, 23, 24, 30 studies investigating the association between skeletal 
muscle mass and mortality among patients being evaluated for or awaiting liver 
transplantation found an independent association. All details about survival rates and 
times can be found in table 3. The forest plot in figure 2a shows the meta-analysis of the 
association between sarcopenia and waiting list mortality with a pooled hazard ratio 
(HR) of 1.75 (95% CI 0.99-3.00, p=0.05) and low heterogeneity between studies (I²=33%). 
Nevertheless, the evidence is limited, because three of the four studies with positive 
outcome were performed in one center 23, 24.
In the study of Durand et al., an increasing transversal psoas muscle thickness corrected 
for height was associated with reduced mortality in both a pre-MELD cohort (HR 0.92 
[95% CI 0.86-0.98], p=0.02) and MELD-era cohort (HR 0.86 [95% CI 0.78-0.94], p=0.001). 
Furthermore, the discrimination for waiting list mortality of the MELD-psoas area score 
was superior over the MELD-score and MELDNa-score (i.e. MELD-score with the addition 
of serum sodium), particularly in patients with a MELD-score ≤25 or refractory ascites 16. 
Waiting list mortality was also greater among sarcopenic patients compared with non-
sarcopenic patients in the study of Tandon et al. (log-rank p=0.04), and sarcopenia was 
an independent predictor of overall mortality in multivariable analysis (HR 2.36 [95% CI 
1.23-4.53], p=0.009) 24. Remarkably, outcome in sarcopenic patients with a low MELD-
score (<15) was similar as for patients with a high MELD-score (≥ 15) with or without 
sarcopenia. In subgroup analyses, sarcopenia remained associated with mortality in 
patients with a low MELD-score (log rank p=0.02), whereas it was not in patients with 
a high MELD-score (log rank p=0.59). None of the other included studies performed 
comparable subgroup analyses.
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Table 2. Methods used to measure skeletal muscle mass, definitions used to classify patients as 
sarcopenic and the prevalence of sarcopenia within studies.
Author, 
Year
Muscles
measured
Software Level
Cut off values / 
definition
Muscle area / 
density
Sarcopenia 
prevalence
Bergerson,
2014 
CSA (SMI)
MITK 
software 
package
L3
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
♀ 41.9 cm2/m2†
♂ 52.2 cm2/m2†
♀ 43%
♂ 62%
Cruz,
2013 
CSA (SMI) SliceOmatic
Closest to 
L3-L4
disc space
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
43.0 cm2/m2†
Nearly 70%
♂ 76%
DiMartini,
2013 
CSA (SMI) SliceOmatic
Closest to 
L3-L4
disc space
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
43.8 cm2/m2†
♀ 38.5 cm2/m2†
♂ 46.5 cm2/m2†
68%
Durand,
2014 
APMT, TPMT 
(right psoas 
muscle)
N/a N/a
N/a (continuous 
parameter 
used)
N/a N/a
Englesbe,
2010 
TPA, PD MATLAB L4
Sex specific 
tertiles
TPA: 19.6 cm²†
PD: 101.0HU†
33%
(lowest tertile)
Giusto,
2015 
CSA (SMI)
Leonardo 
Syngo
Closest to 
L3-L4
disc space
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
♀ 36.0 cm2/m2‡
♂ 49.9 cm2/m2‡
76%
♀ 69%
♂ 78%
Hamaguchi,
2014 
TPA (PMI), 
IMAC
Aquarius NET 
server
At level of 
subfascial 
muscular 
tissue in 
multifidus 
muscle
PMI:
♀ 4.1 cm2/m2
♂ 6.7 cm2/m2
IMAC:
♀ -0.2 HU
♂ -0.4 HU
N/a
Low TPI: 44%
High IMAC: 45%
Krell,
2013 
TPA MATLAB L4
Sex specific 
tertiles
High TPA:
♀ 19.8 cm²†
♂ 29.2 cm²†
Low TPA:
♀ 9.5 cm²†
♂ 19.8 cm²† 
33%
(lowest tertile)
Lee,
2014 
DMG*, PA MATLAB T12, L4
Sex specific 
tertiles
DMG:
♀ 25.3 cm²†
♂ 33.9 cm²†
TPA:
Low: 12.8 cm²†
High: 27.9 cm²†
33%
(lowest tertile)
Masuda,
2014 
TPA N/a
L3 (caudal 
end)
TPA: <5th 
percentile 
per gender 
according to 
healthy donors;
♀ 380 mm2
♂ 800 mm2
531 mm²‡
♀ 423 mm²‡
♂ 761 mm²‡
47%;
♀ 36%
♂ 58%
Meza-
Junco, 2013 
CSA (SMI) SliceOmatic L3
BMI ≥ 25:
♀ 41.0 cm2/m2
♂ 53.0 cm2/m2
BMI < 25:
43.0 cm2/m2
54.0 cm²/m²†
30%;
♀ 28%
♂ 31%
Montano-
Loza,
2012 
CSA (SMI) SliceOmatic L3
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
51.0 cm²/m²†
40%;
♀ 18%
♂ 50%
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Author, 
Year
Muscles
measured
Software Level
Cut off values / 
definition
Muscle area / 
density
Sarcopenia 
prevalence
Montano-
Loza,
2014 
CSA (SMI) SliceOmatic L3
BMI ≥ 25:
♀ 41.0 cm2/m2
♂ 53.0 cm2/m2
BMI < 25:
43.0 cm2/m2
50.0 cm²/m²†
45%
♀ 30%
♂ 52%
Tandon,
2012 
CSA (SMI) SliceOmatic L3
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
♀ 44.9 cm²/m²‡
♂ 50.8 cm²/m²‡
41%;
♀ 21%
♂ 54%
Toshima,
2015 
TPA N/a
L3 (caudal 
end)
TPA: <5th 
percentile 
per gender 
according to 
healthy donors;
♀ 380 mm2¥
♂ 800 mm2¥
S: 484.2 mm²†¥
NS: 689.6 mm²†¥
46%
♀ 30%
♂ 52%
Tsien,
2014 
TPA (PMI)
Leonardo 
Workstation
using 
Oncocare
L4
PMI < 50 years:
♀ 10.5 cm2/m2
♂ 12.3 cm2/m2
PMI > 50 years:
♀ 10.3 cm2/m2
♂ 10.1 cm2/m2
PMI: 9.2 cm²/m²†
(33.0 HU†) 62%
Valero,
2015 
TPA, TPV
ImageJ, AW 
Workstation 
Volume
L3
PMI:
♀ 64.2 cm2/m2
♂ 78.4 cm2/m2
TPV:
♀ 23.0 cm3/m
♂ 34.1 cm3/m
TPA¶: 784.4 
mm²/m²†
TPV: 30.4 cm³/m†
49%
Waits,
2014 
Morphometric 
age (including 
TPA, PD)
MATLAB L4
Morphometric 
age (TPA, 
PD and AA 
calcification) 
as continuous 
variable
TPA:
♀ 14.6 cm²†
♂ 23.1 cm²†
PD:
♀ 49.1 HU†
♂ 48.8 HU†
n/a
Yadav,
2015 
CSA (SMI) SliceOmatic L3
♀ 38.5 cm2/m2
♂ 52.4 cm2/m2
54.3 cm²/m²†
SMI survivors 
(alive/LT) 54.6 
vs non-survivors 
53.1 (deceased 
on waiting list), 
p=0.40
22%
♀ 13.1%
♂ 28.1%
Sarcopenia 
survivors (alive/
LT) 22% vs 
non-survivors 
(deceased on 
waiting list) 24%, 
p=0.77
† mean. ‡ median. * Any muscle contained within the region posterior to the spine and ribs, and no more lateral than 
the lateral-most edges of the erector spinae muscles. ¶ 743.1 mm²/m² for liver transplant patients. ¥ Reported as cm² in 
the original article. Abbreviations: CSA; Cross Sectional Area, APMT; Axial Psoas Muscle Thickness; TPMT; Transversal Psoas 
Muscle Thickness, TPA; Total Psoas Area, IMAC; Intramuscular Adipose Content (defined as region of interest of multifidus 
muscle (Hounsfield units) divided by region of interest of subcutaneous fat (Hounsfield units)), TPV; Total Psoas Volume, 
PD; Psoas Density, N/a; Not available, L3; third lumbar vertebra; L4; fourth lumbar vertebra, T12; twelfth thoracic vertebra, 
HU; Hounsfield units, SMI; Skeletal Muscle Index (cm2/m2); PMI; Psoas Muscle Index (cm2/m2), BMI; Body Mass Index; AA; 
abdominal aneurysm, PSMA; Paraspinal Muscle Area, PSMI; Paraspinal Muscle Index, AWMA; Abdominal Wall Muscle Area, 
AWMI, Abdominal Wall Muscle Index.
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Table 3. Studies reporting the impact of sarcopenia on waiting list mortality in patients 
evaluated for liver transplantation or registered on the waiting list.
Author, Year Survival
Durand,
2014 
Pre-MELD: HR 0.92 (0.86-0.98), p=0.02
MELD-era: HR 0.86 (0.78-0.94), p=0.001
(for increasing TPMI)
Giusto,
2015 
HR 0.89 (0.79-1.00)*
Meza-Junco, 
2013 
Median survival: S 16 (95% CI 4-28) vs NS 28 (21-34) months, log rank p=0.003
6-month survival S vs NS: 67% vs 90%
1-year survival S vs NS: 52% vs 82%
Sarcopenia (with MELD/CP): HR 2.20 (1.21-4.02), p=0.01
Sarcopenia (individual components MELD/CP): 2.53 (1.35-4.73), p=0.004
Montano-Loza,
2012 
Median survival: S 19 (7-30) vs NS 34 (14-55), log rank p=0.005
6-month survival S vs NS: 71% vs 90%
1-year survival S vs NS: 53% vs 83%
Sepsis related death S vs NS: 22% vs 8%, p=0.02
Sarcopenia (with MELD/CP): HR 2.21 (1.23-3.95), p=0.008#
Sarcopenia (individual components MELD/CP): 2.11 (1.13-3.94), p=0.02
Tandon,
2012 
1-, 2-, and 5-year survival rates S vs NS: (63%, 51%, 51% vs 79%, 74%, 70% respectively),
log-rank p=0.04; Low MELD (<15): log rank p=0.02; High MELD (≥15): log rank p=0.59
Sarcopenia: HR 2.36 (1.23-4.53), p=0.009
Yadav,
2015 
Sarcopenia: HR 1.25 (0.62-2.55), p=0.54#
# Unadjusted data. * Provided by the authors after personal communication. Abbreviations: HR; Hazard ratio, S; sarcopenic 
patients, NS; non-sarcopenic patients, SMI; Skeletal Muscle Index, TPMI; Transversal Psoas Muscle Index, TPA; Total Psoas 
Area, IMAC; Intramuscular Adipose Content, PMI; Psoas Muscle Index, DMG; Dorsal Muscle Group, MELD; Model for End-
stage Liver Disease, CP; Child Pugh score, CI; confidence interval, MA; Muscle Attenuation, LT; Liver Transplantation.
Sarcopenia was also an independent predictor of mortality in patients evaluated for liver 
transplantation in the studies of Meza-Junco et al. and Montano-Loza et al. 23. In both 
studies multivariable analyses were performed with MELD and Child Pugh scores on the 
one hand and with their individual components on the other hand, which all showed 
sarcopenia to be an independent predictor for mortality. Furthermore, Montano-Loza et 
al. reported a significantly higher sepsis related death in sarcopenic patients compared 
with non-sarcopenic patients (22% versus 8%, p=0.02), whereas no difference was 
found in liver failure related death 24. Meza-Junco et al. reported a trend for higher liver 
failure related death in sarcopenic patients compared with non-sarcopenic patients 
(33% versus 15%, p=0.08 23.
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Figure 2. Forest plots of the association between sarcopenia and survival.
2a. Forest plot showing studies that reported the association between sarcopenia and waiting 
list mortality. Due to data provided by authors that was more precise than the data published 
in the article or rounding off upwards of downwards by Review Manager, the confidence 
intervals can somewhat differ from the original confidence intervals. For the study of Yadav 
et al. , unadjusted results were used because the multivariable analysis in the manuscript 
suggested a level of precision that did not correspond with the number of observed events. 
Because the studies of Meza-Junco et al. , Montano-Loza et al. , and Tandon et al.  were 
performed in overlapping cohorts and the first was performed in patients with HCC, only the 
most representative study was included in the meta-analysis (i.e. all consecutive patients with 
cirrhosis being evaluated for liver transplantation) . The authors of these studies stated that at 
most fifteen patients were included in the study of Tandon et al.  that were also included in the 
other studies. Including the study of Tandon et al.  in the meta-analysis, resulted in a pooled HR 
of 1.93 (95% CI 1.33-2.80, p=0.0005), Z of 3.48 and I² of 1%.
2b. Forest plot showing studies that reported the association between sarcopenia and post-
transplantation survival. Due to data provided by authors that was more precise than the 
data published in the article or rounding off upwards of downwards by Review Manager, the 
confidence intervals can somewhat differ from the original confidence intervals. Hamaguchi et 
al. , Masuda et al. , and Valero et al.  performed measurements of the psoas muscle area, whereas 
Montano-Loza et al.  performed measurements of the cross-sectional muscle area. A meta-
analysis of studies that assessed skeletal muscle mass by measuring the psoas muscle area only 
resulted in a pooled HR of 2.21 (95% CI 1.25-3.90, p=0.007), Z of 2.72, and I² of 49%. A meta-
analysis excluding the study of Valero et al. , that included only few patients that underwent 
liver transplantation for hepatocellular- or cholangiocarcinoma, resulted in a pooled HR of 2.04 
(95% CI 1.05-3.92, p=0.03), Z of 2.11, and I² of 71% and a meta-analysis of Hamaguchi et al.  and 
Masuda et al.  resulted in a pooled HR of 2.78 (95% CI 1.59-4.85, p=0.0003), Z of 3.60 and I² of 
24%.
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2c. Forest plot showing studies that reported the association between skeletal muscle mass 
and post-transplantation survival. Only studies that reported the skeletal muscle index (cm²/
m²) were included, as the other studies used different units of measurement. Due to data 
provided by authors that was more precise than the data published in the article or rounding 
off upwards of downwards by Review Manager, the confidence intervals can somewhat differ 
from the original confidence intervals. The hazard ratios shown represent an incremental 
increase in skeletal muscle index. Since DiMartini et al.  and Cruz et al.  performed studies 
in overlapping cohorts, only the latter was included in the meta-analysis. Additional results 
without stratification by gender that were provided by the authors of DiMartini et al.  and these 
results were used in the meta-analysis. The authors also provided the results used for the study 
of Giusto et al. after personal communication .
Yadav et al. investigated the relationship between sarcopenia, six-minute walk distance 
and health-related quality of life in liver transplant candidates and found no association 
between sarcopenia and overall mortality. The unadjusted HR was 1.25 (95% CI 0.62-
2.55, p=0.54) and was used for the meta-analysis rather than the adjusted HR, as the 
multivariable analysis suggested a level of precision that did not correspond with the 
number of observed events 30. Although the mean MELD-scores were comparable 
between these studies, the MELD-score of the study cohort of Yadav et al. varied from 
9 to 40 30. In the study of Giusto et al., CT-assessed muscle mass was compared with 
Dual-Energy X-Ray Absorptiometry (DEXA) and anthropometry. The skeletal muscle 
index was not predictive for mortality on the waiting list (HR 0.89 [95% CI 0.79-1.00], 
kindly provided by the authors after personal communication), whereas mid-arm 
muscle circumference and fat-free mass index were, also after adjusting for sex, MELD-
score, age, and interaction between sex and mid-arm muscle circumference and fat-free 
mass index, respectively 18. However, the aim of this study was not to investigate the 
association between skeletal muscle mass and patient outcome and only 59 patients 
were included.
Post-transplantation survival
In the eleven studies that investigated the association between skeletal muscle mass 
and post-transplantation survival, seven described an association 14, 15, 17, 19, 21, 22, 29, and 
three no association 18, 25, 27, 28. All details about median survival times, yearly survival 
rates and the association between skeletal muscle mass and overall survival are 
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summarized in table 4. The forest plot in figure 2b shows the association between 
sarcopenia and post-transplantation survival (pooled HR 1.84 [95% CI 1.11-3.05], p=0.02) 
with moderate heterogeneity between studies (I²=60%). When studies that measured 
psoas muscle area were included only, this resulted in low heterogeneity (I²=49%) and 
a pooled HR of 2.21 (95% CI 1.25-3.90, p=0.007). When the study of Valero et al. 28, that 
included only few patients that underwent liver transplantation for hepatocellular- or 
cholangiocarcinoma, was excluded, the pooled HR was 2.03 (95% CI 1.05-3.92, p=0.03, 
Z=2.11, I²=71%). Finally, a meta-analysis of the studies of Hamaguchi et al. 19 and Masuda 
et al. 22 resulted in a pooled HR of 2.78 (95% CI 1.59-4.85, p=0.0003), Z of 3.60 and I² of 
24%.
Meta-analyzing studies that reported the association between skeletal muscle index, 
as a continuous measure, and post-transplantation survival showed a pooled HR of 
0.98 (95% CI 0.95-1.00, p=0.03) per incremental skeletal muscle index (figure 2c). Since 
DiMartini et al. 15 and Cruz et al. 14 performed studies in overlapping cohorts, only the 
latter was included in the meta-analysis. Additional results without stratification by 
gender were kindly provided by the authors of DiMartini et al. 15, and these results were 
used in the meta-analysis. The results used for the study of Giusto et al. were also kindly 
provided by the authors after personal communication 18.
Cruz et al. reported a protective effect of increasing skeletal muscle index on mortality 
(HR 0.97 [95% CI 0.94-0.99], p=0.04) 14, whereas the protective effect of the psoas muscle 
index was only found significant for males (HR 0.95, p=0.01) and not for females (HR 
0.98, p=0.55) in the study of DiMartini et al. 15. Every standard deviation increase in 
dorsal muscle group area, as assessed by Lee et al., was also independently associated 
with increased overall (odds ratio [OR] 0.62 [95% 0.49-0.77], p<0.001), one-year (OR 0.53 
[95% CI 0.36-0.78], p=0.001), and five-year (OR 0.53 [95% CI 0.38-0.70], p<0.001) survival, 
as well as total psoas area for one-year survival (OR 0.43 [95% CI 0.30-0.62], p<0.001) 21. 
In line with this, Englesbe et al. also found an independent association between total 
psoas area and survival (HR 0.27 [0.14-0.53], p<0.001 per increasing 1000 mm²) 17. The 
variously defined parameter sarcopenia was an independent predictor for mortality in 
the study of Masuda et al. (HR 2.06 [95% CI 1.01-4.20], p=0.047) 22, high intramuscular 
adipose content (OR 3.90 [95% CI 2.03-7.76], p<0.001) and low PMI (OR 3.64 [1.90-7.17], 
p<0.001) have also been identified as independent predictors for impaired survival 19. 
Waits et al. showed that morphometric age (including total psoas area, psoas density 
and abdominal aortic calcifications) was a risk factor for mortality per year increase (HR 
1.03 [95% CI 1.02-1.04], p<0.001) 29.
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Table 4. Studies reporting the impact of sarcopenia on overall survival in patients undergoing 
liver transplantation.
Author, Year Survival
Cruz,
2013 
SMI: HR 0.97 (0.94 – 0.99), p=0.04
DiMartini,
2013 
♂ PMI: HR 0.95 (p=0.01)
♀ PMI: HR 0.98 (p=0.55)
Englesbe,
2010 
1-year survival S vs NS: 49.7% vs 87%
3-year survival S vs NS: 26.4% vs 77.2%
(lowest vs highest tertile)
TPA: HR 0.27 (0.14-0.53), p<0.0001
(per increasing 1000 mm2)
Giusto,
2015 
HR 0.99 (0.90-1.11)*
Hamaguchi,
2014 
Median survival low vs normal TPA: 17.6 vs 33.9 months
Median survival high vs normal IMAC: 21.9 vs 32.4 months
High IMAC: OR 3.90 (2.03-7.76), p<0.001
Low PMI: OR 3.64 (1.90-7.17), p<0.001
Lee,
2014 
Overall survival:
DMG: OR 0.62 (0.49-0.77), p<0.001 (per SD increase)
1-year survival:
DMG: OR 0.53 (0.36-0.78), p=0.001 (per SD increase)
TPA: OR 0.43 (0.30-0.62), p<0.001 (per SD increase)
5-year survival:
DMG: OR 0.53 (0.38-0.70) p<0.001 (per SD increase) 
Masuda,
2014 
Sarcopenia: HR 2.06 (1.01-4.20), p=0.047
3-year survival S vs NS: 74.5% vs 88.9% (p=0.02)
5-year survival S vs NS: 69.7% vs 85.4% (p=0.02)
Montano-
Loza,
2014 
Median survival S vs NS: 117 (95% CI 84-151) vs 146 (95% CI 110-182) months,
log rank p=0.4
1-year survival rate S vs NS: 89% vs 91%
5-year survival rate S vs NS: 74% vs 76%
Sarcopenia: HR 1.23 (0.77-1.98), p=0.4#
SMI: HR 0.99 (0.96-1.01), p=0.3#
MA: HR 0.99 (0.96-1.02), p=0.5#
Tsien,
2014 
Pre-OLT sarcopenia associated with mortality (p=0.06)#
Non-significant association of continued reduction in muscle area with higher mortality 
(p=0.08)#
Valero,
2015 
Median survival S vs NS: 38.5 vs 69.1 months (p=0.32)
1-year survival rate S vs NS: 76.6% vs 87.8% (p=0.15) 
3-year survival rate S vs NS: 61.7% vs 71.4% (p=0.31) 
5-year survival rate S vs NS: 55.3% vs 69.4% (p=0.32)
Sarcopenia: HR 1.34 (0.61-2.76), p=0.43
Waits,
2014 
Morphometric age: HR 1.03 (1.02-1.04), p<0.001 (per year)
1-year mortality morphometric age: OR 1.04 (1.03-1.06), p<0.001 (per year)
5-year mortality morphometric age: OR 1.03 (1.02-1.06), p<0.001 (per year)
# Unadjusted data. * Provided by the authors after personal communication. Abbreviations: HR; Hazard ratio, S; sarcopenic 
patients, NS; non-sarcopenic patients, SMI; Skeletal Muscle Index, TPMI; Transversal Psoas Muscle Index, TPA; Total Psoas 
Area, IMAC; Intramuscular Adipose Content, PMI; Psoas Muscle Index, DMG; Dorsal Muscle Group, MELD; Model for End-
stage Liver Disease, CP; Child Pugh score, CI; confidence interval, MA; Muscle Attenuation, LT; Liver Transplantation.
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Tsien et al. described a nonsignificant association between pretransplant sarcopenia 
and mortality (p=0.06) and higher mortality in patients with continued reduction in 
muscle area (p=0.08) in a relatively small cohort of 53 patients 27. The median survival 
in the studies of Montano-Loza et al. 25 among cirrhosis patients undergoing liver 
transplantation and Valero et al. 28, among a relatively heterogeneous population of 
hepatocellular- and intrahepatic cholangiocarcinoma patients undergoing curative 
intent hepatic resection (70.9%) or liver transplantation (29.1%), did not significantly 
differ between sarcopenic and non-sarcopenic patients (117 versus 146 months, log 
rank p=0.4; and 38.5 versus 69.1 months, p=0.32, respectively). Neither sarcopenia 25, 28 
nor skeletal muscle index or muscle attenuation 25 were predictive for mortality in 
regression models. Although Montano-Loza et al. found no association overall in a 
population with a relatively high MELD-score and hepatocellular carcinoma prevalence, 
male patients undergoing liver transplantation in the lowest skeletal muscle mass sextile 
showed significantly impaired survival compared with patients in the other sextiles 25. 
Finally, Giusto et al. found no significant association between skeletal muscle index and 
post-transplant mortality after adjustment for age, gender and MELD-score (adjusted HR 
1.0 [95% CI 0.90-1.11], data provided by the authors after personal communication) 18. 
Post-transplantation complications and transplantation related mortality
In both studies reporting overall post-transplantation complications, low skeletal 
muscle mass was associated with increased risk of postoperative complications 
(table 5) 21, 28. The study of Lee et al. showed that an increase in both the total psoas 
area and the dorsal muscle group with one standard deviation was associated with an 
increased risk for complications within one year after transplantation (OR 0.48 [95% CI 
0.32-0.72], p<0.001, and OR 0.67 [95% CI 0.50-0.90], p=0.007, per standard deviation 
increase in dorsal muscle group area) 21. In the study of Valero et al. post-transplantation 
complications occurred in 40.4% of sarcopenic patients compared with 18.4% in non-
sarcopenic patients (p=0.01). Sarcopenia was an independent predictor for postoperative 
complications in multivariable analysis (OR 3.06 [95% CI 1.07-8.72], p=0.03) 28. All severe 
postoperative (23.4%) complications (i.e. Clavien-Dindo classification ≥ IIIa) occurred in 
patients with sarcopenia. No differences were observed in 30- and 90-day mortality rates 
in sarcopenic and non-sarcopenic patients respectively (4.3% versus 0%, p=0.24 and 
8.5% versus 2.0%, p=0.20) 28. The three-month mortality rate in the study of Montano-
Loza et al. was 5% in sarcopenic patients compared with 2% in non-sarcopenic patients 
(p=0.20) 25. In the study of DiMartini et al., the relative risk for in-hospital mortality was 
0.97 (p>0.05) 15.
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Krell et al. reported that patients with a total psoas area in the lowest tertile had a 4.6-
fold increased risk (95% CI 2.25-9.53) to develop any post-transplantation infection 
compared with patients in the highest tertile. In a multivariable model, pretransplant 
total psoas area was an independent predictor for the occurrence of severe infections 
(HR 0.38 [95% CI 0.23-0.65], p<0.01) together with age and pretransplant bilirubin level. 
These factors remained significant when infections were stratified by pathogen type 
(i.e. bacterial, viral or fungal) 20. In line with this, Masuda et al. found that sarcopenia 
was an independent predictor for sepsis (HR 5.31 [95% CI 1.53-18.40], p=0.009) in a 
cohort of 228 patients, which occurred in 17.7% of sarcopenic patients and 7.4% of 
non-sarcopenic patients 22. On the other hand, no independent association was found 
between sarcopenia and sepsis in a sub study in the same patient cohort (n=143) of 
Toshima et al. (OR 1.72 [95% CI 0.67-5.03], p=0.263) 26. However, both studies performed 
a multivariable analysis of risk factors for postoperative sepsis including ten and thirteen 
parameters respectively on only 25 (49%) and twelve events respectively. Therefore, 
the methodology of these studies could be questioned. Although the overall 90-day 
infection rate did not significantly differ between sarcopenic and non-sarcopenic 
patients (29% versus 20%, p=0.1) in a study of Montano-Loza et al., bacterial infections in 
particular within 90 days after transplantation occurred significantly more in sarcopenic 
patients compared with non-sarcopenic patients (26% versus 15%, p=0.04) 25. However, 
no multivariable analysis has been performed for bacterial infections.
Only one study reported that five patients had confirmed acute graft rejection without 
specifying them as (non-)sarcopenic 27.
Post-transplantation length of hospital stay
Four studies reported on length of stay outcomes (table 5) 15, 25, 27, 28. DiMartini et al. 
performed a Poisson regression analysis and found skeletal muscle mass to be predictive 
for length of both hospital and ICU stay, as well as intubation days (all p<0.001) 15. 
Furthermore, sarcopenic patients were more likely to be discharged to another hospital 
or nursing home rather than home (p=0.04) 15. A significantly increased length of ICU (12 
days versus 6 days, p=0.001) and hospital stay (40 days versus 25 days, p=0.005) was also 
found in cirrhosis patients undergoing liver transplantation by Montano-Loza et al. 25, 
whereas Valero et al. found non-significant differences regarding hospital stay between 
sarcopenic and non-sarcopenic patients who underwent hepatic resection with curative 
intent or transplantation for hepatocellular- or intrahepatic cholangiocarcinoma (12.1 
days versus 9.7 days, p=0.50) 28. Obviously, these patients have a distinct postoperative 
recovery compared with transplant patients. Furthermore, Tsien et al. 27, who measured 
the psoas area in only 53 patients, found no association with length of hospital stay in 
contrast to Montano-Loza et al. 25 and DiMartini et al. 15, who performed cross-sectional 
skeletal muscle measurements in larger cohorts.
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DISCUSSION
In recent years, multiple narrative reviews regarding sarcopenia among transplantation 
patients have been published 31-33. This is the first systematic review of studies that 
investigated the influence of skeletal muscle mass by means of abdominal CT in 
patients who were evaluated for or underwent liver transplantation or were registered 
on the waiting list. According to the current findings, there is consistent evidence 
that sarcopenia is associated with impaired survival, independent of other risk factors 
such as age and MELD-score or its individual components. This association was found 
both before and after the introduction of the MELD-score (i.e. in the United States in 
2002) 34. Due to a substantial heterogeneity between reported outcome measures, less 
consistent evidence suggests that sarcopenia is associated with post-transplantation 
complications, which may be infectious complications in particular.
Some findings of this systematic review are conflicting and multiple reasons could be 
postulated. Definitions of sarcopenia greatly varied, as there currently is no consensus 
regarding adequate cut-off values. Although liver transplant patients greatly differ 
from cancer patients, most studies used cut-off values based on oncological studies, 
such as those defined by Prado and colleagues 35. This could have led to inadequate 
classification of patients as (non-)sarcopenic. Therefore, one could wonder whether one 
set of cut-off values would be applicable for various populations and gender-, age-, 
ethnicity-, and disease-specific cut-off values may be needed. One study described the 
association between morphometric age, but the association between the individual 
skeletal muscle mass components (i.e. psoas area and psoas density) was not described 29. 
Besides multiple definitions for sarcopenia, multiple methods to perform skeletal 
muscle mass measurements (e.g., psoas area, cross-sectional area) have been used 
throughout studies.
Sarcopenia was associated with waiting list mortality in four studies 16, 23, 24, whereas 
two other studies reported no significant association 18, 30. Besides different cut-off 
values and methods used, an explanation of this difference could be a varying range 
of MELD-score within these studies. After all, the association between sarcopenia and 
waiting list mortality was found in patients with lower MELD-scores in particular 16, 24. No 
association between sarcopenia and overall post-transplantation survival was reported 
in three studies 18, 25, 28. The varying study populations could be an explanation for these 
conflicting results, as well as the use of BMI- and sex-specific cut-off values that are 
used to predict survival in cancer patients, in transplant populations 36. Meza-Junco et 
al. included hepatocellular cancer patients who underwent liver transplantation only 
and used the same cut-off values. They indeed found an independent association 
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with survival 23. In all but one study with questionable methodology 26, describing the 
association between pre-transplantation sarcopenia and post-transplantation short-
term outcome, sarcopenia was independently associated with complications and 
mortality.
This systematic review postulates that skeletal muscle mass is a prognostic factor, 
independent of MELD-score. Although it remains to be investigated whether skeletal 
muscle mass assessment is superior to the ‘eyeball test’, i.e. the subjective clinician’s 
assessment of a patient’s physical status or frailty, it could objectively underscore 
subjective assessments 17. The study of Tandon et al. showed that sarcopenic patients 
with a low MELD-score had a similar outcome compared with patients with a high 
MELD-score with or without sarcopenia 24. Therefore, skeletal muscle mass assessment 
may be used to more accurately select liver transplant patients and allocate organs in 
the future. After all, a selection of patients that is at risk for early mortality is probably 
not adequately identified by the MELD-score, since 71% of the patients who died on 
the waiting list had a MELD-score ≤25 at registration in the study of Durand et al. 16. 
Although this would be a challenge due to the current organ shortage, patients with 
a low MELD-score and low skeletal muscle mass could, for example, be prioritized on 
the waiting list or be selected for targeted treatment of muscle wasting. Currently, such 
trials are being performed 37 and potential drugs are being investigated 38 in cancer 
populations.
Despite the strong prognostic value of the MELD-score, the survival of 15-20% of the 
patients cannot accurately be predicted 34. The most frequently reported limitation of 
the MELD-score is the lack of parameters reflecting patients’ nutritional and functional 
status. Therefore, modifications of the MELD-score, such as the MELDNa-score and the 
5-variable MELD-score, including serum sodium and albumin levels respectively, have 
been developed 4, 5, 39. Both scores improved mortality prediction. The outcome of this 
systematic review supports that sarcopenic liver transplant candidates face a worsened 
outcome. Besides the superiority of the MELD-psoas area score of Durand et al. over the 
MELD-score and MELDNa-score to predict waiting list mortality 16, the predictive value 
of the MELD-Sarcopenia score was found superior compared with the MELD-score in a 
recent study 40. However, validation of these scores is recommended. If validated, clinical 
trials are warranted to investigate whether transplantation in sarcopenic patients with 
lower MELD-scores may be preferential. Prospective trials are also needed to investigate 
the natural course of sarcopenia following liver transplantation. Little is known on 
whether skeletal muscle mass fully normalizes, and how post-transplantation change 
in muscle mass impacts outcome, such as the development of post-transplantation 
diabetes mellitus 27.
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Preoperative risk assessment remains of paramount importance in patients who have 
been allocated a donor liver. Some studies suggest that a poor nutritional status, for 
instance reflected by the subjective global assessment, impairs post-transplantation 
outcomes 41-43. However, these measures are frequently considered as subjective 44. 
Furthermore, limiting factors, such as fluid retention, could hamper nutritional 
assessment 16. Single-slice CT-assessed skeletal muscle measurements are considered an 
objective and easy-to-perform method with high inter-observer agreement that could 
be performed on routinely available CT scans 8. Up to now, no gold standard has been 
established to perform body composition measurements. However, CT imaging was the 
method of preference in an expert consensus meeting on cachexia 45, particularly in 
cirrhotic patients who frequently have ascites 18.
Some limitations of the current review and included studies should be mentioned. First, 
all included studies were retrospective, observational cohort studies. Although this may 
have resulted in selection bias, the study cohorts consisted of non-selected, consecutive 
patients listed for or undergoing liver transplantation. Second, selective publication 
of data could have led to an underestimation of negative results. Third, four research 
groups from Canada, 23-25, Ann Arbor 17, 20, 21, 29 and Pittsburg 13-15, USA, and Japan 22, 26 
published multiple original articles including patient populations from their center that 
were all included in the current review. These four centers contributed to thirteen of the 
nineteen studies. Therefore, the number of patient cohorts studied is likely to be smaller 
than the number of original articles included in this systematic review.
In conclusion, sarcopenia impairs outcome in patients awaiting or undergoing liver 
transplantation. Skeletal muscle mass assessment may contribute to pre-transplantation 
risk assessment.
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A Nomogram with Sarcopenia Surpasses the 
MELD Score in Predicting Waiting List Mortality 
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A Competing Risk Analysis in a National Cohort
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ABSTRACT
Background: Frail patients with low MELD scores may be under prioritised. Low 
skeletal muscle mass (i.e. sarcopenia) has been identified as risk factor for waiting 
list mortality and a recent study proposed to incorporate sarcopenia in the MELD 
score (i.e. MELD-Sarcopenia score). We aimed to investigate the association between 
sarcopenia and waiting list mortality, and to validate the MELD-Sarcopenia score (i.e. 
MELD+10.35*Sarcopenia).
Methods: We identified consecutive patients with cirrhosis listed for liver transplantation 
in the Eurotransplant registry between 2007-2014 and mesures skeletal muscle mass on 
computed tomography (CT). A competing risk analysis was used to compare survival of 
patients with and without sarcopenia,  and concordance (c) indices were used to assess 
performance of the MELD and MELD-Sarcopenia score. We created a nomogram of the 
best predictive model.
Results: We included 585 patients with a median MELD of 14 (IQR 9-19), of which 254 
(43.4%) were identified as having sarcopenia. Median waiting list survival was shorter 
in patients with sarcopenia than those without (p<0.001). This effect was even more 
pronounced in patients with MELD ≤15. The discriminative performance of the MELD-
Sarcopenia score (c-index 0.820) for 3-month mortality was lower than MELD score 
alone (c-index 0.839). Apart from sarcopenia and MELD score, other predictive variables 
were occurrence of hepatic encephalopathy before listing, and recipient age. A model 
including all these variables yielded a c-index of 0.851.
Conclusions: Sarcopenia was associated with waiting list mortality in liver transplant 
candidates with cirrhosis, particularly in patients with lower MELD scores. The MELD-
Sarcopenia score was successfully validated in this cohort. However, incorporating 
sarcopenia in the MELD score had limited added value in predicting waiting list mortality.
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INTRODUCTION
Model for end-stage liver disease (MELD) score is the most frequently used method to 
prioritise patients with end-stage livers disease for liver transplantation and it is calculated 
using serum levels of bilirubin and creatinine and the international normalized ratio 
(INR) 1. Despite its strong predictive value, disease severity is underestimated in about 
15-20% pf cirrhotic patients by the MELD score, resulting in an inaccurate prediction 
of survival 2. Amongst others, conditions such as hyponatremia and hypoalbuminemia 
have been identified as additional risk factors for impaired waiting list survival. This 
knowledge resulted in modifications of the original MELD score; i.e. the MELDNa and 
five-variable MELD score, respectively 3-5. Moreover, a frequently reported drawback of 
the MELD score is the lack of an objective parameter reflecting patients’ physical and 
nutritional status, as was albumin in the old Child-Turcotte-Pugh score. Consequently, 
patients with a biochemically low MELD score, but with malnutrition or low skeletal 
muscle mass (sarcopenia), may be under prioritised in the current system 6. Indeed, 
sarcopenia, a hallmark sign of frailty and functional decline 7, 8, has recently been found 
to predict waiting list mortality 9, 10. Montano-Loza et al. found a significantly shorter 
waiting list survival in patients with sarcopenia, and therefore included sarcopenia in 
the MELD score (i.e. MELD-Sarcopenia score). This score showed a higher predictive 
accuracy for waiting list mortality than the MELD score alone 10.
This particular MELD-Sarcopenia score is of great interest for the generally catabolic 
cirrhotic population. However, the MELD-Sarcopenia score has not been externally 
validated. And, in addition, most studies investigating the association between 
sarcopenia and waiting list mortality were performed in North-American populations 9-15, 
which differ from Western-European populations (e.g., regarding body mass index (BMI), 
race, and healthcare accessibility). Furthermore, they were hampered by limited sample 
size and methodology, while not taking into account competing risks on the waiting 
list 11-14, 16. Particularly in transplant patients, competing risk analyses are considered 
superior to proportional hazard models 17, 18. Therefore, our aims were 1) to investigate 
the association between sarcopenia and waiting list mortality in a Western-European 
cohort using competing risk analysis, 2) to validate the MELD-Sarcopenia score, and 3) 
to identify the best performing predictive model in patients with cirrhosis listed for liver 
transplantation.
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MATERIALS AND METHODS
Patients and data acquisition
We identified all consecutive adult (≥18 years) patients with cirrhosis who have been 
placed on the waiting list for liver transplantation in one of the liver transplantation 
centers in the Netherlands (i.e. Erasmus MC University Medical Center, Rotterdam; 
Leiden University Medical Center, Leiden; and Groningen University Medical Center, 
Groningen) between 2007-2014, using the prospective Eurotransplant registry 19. 
Patients listed for retransplantation, multivisceral transplantation, candidates on 
the high urgency list, or patients below 18 years old were excluded. All registry data 
was collected prospectively, except for the occurrence of liver-related complications 
before listing (i.e. ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, 
esophageal variceal bleeding), which was collected retrospectively. Patients with 
hepatocellular carcinoma (HCC) were transplanted only if they fulfilled the Milan criteria 20. 
The MELD score and recipient age were calculated at the time of listing. The study 
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and 
was approved by the Institutional Review Boards of all involved centers. A waiver for 
informed consent was granted.
Skeletal muscle mass measurements
Computed tomography (CT) scanning is the gold standard to measure skeletal muscle 
mass, particularly in end-stage liver disease patients, since these measurements are 
not influenced by the presence of ascites or edema 16. For the purpose of this study we 
used CT examinations which were performed routinely as part of the liver transplant 
evaluation. Since liver transplant candidates are prone to skeletal muscle wasting over 
time, we included only those CT examinations that were performed within 90 days from 
waiting list placement. We calculated the cross-sectional skeletal muscle area (CSMA; 
figure 1) and the skeletal muscle index (SMI), as previously described in more detail 21. 
In short, the CSMA was calculated using the transversal slice at the level of the third 
lumbar vertebra (L3 in cm2) and divided by patients’ squared height resulting in the 
skeletal muscle index (SMI, cm²/m²). We chose L3 as it has been shown that the SMI at 
the level of L3-L4 gives an accurate estimation of total body skeletal muscle mass 22. 
A previously validated non-commercial software tool developed at the Erasmus MC 
University Medical Center was used for the calculation of the CSMA 23.
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Figure 1. Cross-sectional skeletal muscle area (CSMA, in cm²) at the level of the third lumbar 
vertebra (L3).
The MELD-Sarcopenia score
The MELD-Sarcopenia score, as established by Montano-Loza et al. 10, is based on pre-
established cut-off values for the SMI (i.e. males with BMI <25: <43 cm²/m², males with 
BMI ≥25: <53 cm²/m², females: <41 cm²/m²) 24. Therefore, we classified patients as having 
sarcopenia using the same cut-off values. As the MELD-Sarcopenia score was calculated 
as follows: MELD + (10.35 * Sarcopenia) 10, this corresponds with a 10.35-point increase 
in the MELD score in patients with sarcopenia. In addition, to test the robustness of 
our data, patients were also classified as having sarcopenia using another recently 
developed cut-off values in a cohort of end-stage liver disease patients by Carey et al.; 
50 cm²/m² for men and 39 cm²/m² for women 25.
Statistical analyses
Categorical data are reported as counts with percentages. Continuous data are reported 
as the median with interquartile range (IQR). The Chi-square test was used to compare 
categorical data. Depending on the normality of the distribution (non)parametrical tests 
were used to compare continuous data. Multiple imputations were performed, using 5 
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imputed datasets to correct for bias due to missing values (i.e. serum albumin (n=73, 
12.5%) and sodium levels (n=74, 12.6%) as they had not been routinely performed in 
one center). We used MICE package for R version 3..3.3 for this multiple imputation. 
Because these parameters were not associated with waiting list mortality after backward 
stepwise selection, we performed a complete-case analysis.
The primary endpoint of this study was waiting list mortality. To account for immortal 
time bias, waiting list time (i.e. survival) was defined from the date of CT onwards 
until transplantation, removal from the waiting list, or death occured. Patients who 
were removed from the waiting list because of clinical deterioration or progression of 
HCC outside of the Milan criteria were considered deceased at time of removal if they 
indeed died within 3 months after waiting list removal. We censored patients who were 
removed for reasons other than abovementioned, as well as patients who were still on 
the waiting list on 31 December 2016. Survival status was checked using the municipal 
record database.
We regarded the chance of occurrence of our primary endpoint and the chance of 
transplantation as competing risks. Therefore, we plotted the cumulative incidence 
functions for patients with and without sarcopenia according to the definition of Martin 
et al. (SarcopeniaM) 
24 and Carey et al. (SarcopeniaC) 
25 with transplantation as competing 
risk. Secondly, we assessed the performance of the MELD and MELDNa scores with 
or without adjustment for SarcopeniaM and SarcopeniaC, and the MELD-Sarcopenia 
score by calculating the concordance index (c-index) using Wolbers’ method and the 
subdistribution hazard as proposed by Fine and Gray.. The method by Wolbers et al. is an 
adaptation of Harrell’s concordance index for competing risk analyses 26, 27. The c-indices 
were calculated for 3-month waiting list survival, as the MELD score was designed to 
predict 3-month mortality, 2 and internal validation was performed using bootstrapping 
with 100 samples. The subdistribution hazard ratio (sHR) is the instantaneous risk of 
dying from a particular cause κ given that the subject has not died from cause κ. Finally, 
a multivariable competing risk analysis was performed, using a subdistribution hazards 
approach as proposed by Fine and Gray 17, 28, to identify risk factors for waiting list 
mortality. Using a backward stepwise selection based on the Akaike Information Criterion 
(AIC), factors were selected for the final model The highest performance (based on the 
c-index), age, serum albumin level, serum sodium level, and complications before listing 
were included in the full model before selection. As patients with a low MELD score 
and low skeletal muscle mass may benefit from a higher priority on the waiting list, a 
subgroup analysis was performed in patients with a MELD score ≤15. Each independent 
parameter associated with impaired survival was assigned a specific weighted score 
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using the regression coefficient from the multivariable analysis 29. Subsequently, these 
parameters were used to create a nomogram of the best model which was developed 
according to the TRIPOD statement 30.
In order to put our findings in perspective with previous studies that did not use 
competing risk analysis, we also performed univariate analysis using the Kaplan-Meier 
method with log-rank test and multivariable Cox proportional hazards analysis.
Two-sided p-values <0.05 were considered statistically significant. A c-statistic of 
<0.50 is equal to chance, a c-statistic of >0.7 is considered a useful test. Analyses were 
performed using SPSS for Windows version 22 (IBM Corp., Armonk, NY, USA) and the 
RMS package in R version 3.03 (http://www.r-project.org).
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RESULTS
Patients
In total, 841 adult patients with cirrhosis were listed during the study period. A CT 
examination within 90 days of the listing date was available for 585 of the 841 (69.6%) 
patients; all others were excluded. Hence, the study cohort comprised 585 patients. 
The majority was male (n=404, 69.1%) and the median MELD score was 14 (IQR 9-19). 
A malignancy (i.e. HCC or perihilar cholangiocarcinoma (PHC)) was diagnosed in 193 
(33.0%) patients. All baseline characteristics are shown in table 1. Baseline characteristics 
did not significantly differ between the included and excluded patients, except for 
median serum sodium (138 mmol/l versus 140 mmol/l, p=0.001), median age (56 [IQR 
48-62] versus 54 [IQR 47-60] years, p=0.049), and the distribution of etiology (p=0.024), 
which was caused by a higher proportion of HCC/PHC among included patients (33.0% 
versus 20.9%, p=0.001). In total, 425 patients (72.6%) underwent liver transplantation, 
15 (2.6%) were still on the waiting list at the end of the study period, and 145 (24.8%) 
were removed for reasons indicated in table 2. Of the latter group, 90 (15.4%) died on 
the waiting list or were removed and consequently died within 30 months from removal. 
The median time between waiting list placement and CT was 31 (IQR 15-51) days. After 
a median follow-up of 54 months, median overall survival in transplanted patients was 
117 months (95% CI 73-160 months). The 3-month, 1-year, 3-year, and 5-year post-
transplant overall survival rates were: 95.7%, 90.3%, 83.0%, 79.7%, respectively.
SarcopeniaM was observed in 254 patients (43.4%) (table 1). Patients with SarcopeniaM 
had a significantly lower BMI (p=0.001), a higher MELD score (p<0.001), and a higher 
MELDNa score (p=0.001). Furthermore, patients with SarcopeniaM experienced more 
liver-related complications before waiting list placement compared with patients 
without sarcopenia (73.2% versus 62.8%, p=0.008). SarcopeniaC was observed in 266 
patients (45.5%). The median MELD-Sarcopenia score was 18 [IQR 12-26].
The association between sarcopenia and waiting list mortality
The median time on the waiting list was 7 months (IQR 3-12) and this was significantly 
shorter in patients with SarcopeniaM than patients without SarcopeniaM (6 [IQR 
2-10] versus 8 [IQR 4-14], p<0.001). The proportion of patients who underwent liver 
transplantation did not differ between patients with and without SarcopeniaM (71.7% 
versus 73.4%, p=0.636), whereas the proportion of patients who were removed from 
the waiting list or died was significantly higher in patients with sarcopenia (20.5% 
versus 11.5%, p=0.003).
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Using cumulative function incidence analysis, a significant difference in waiting list 
survival was found between patients with and without SarcopeniaM (p=0.003; table 3, 
figure 2), but not between patients with and without SarcopeniaC (p=0.350; figure 3). 
The Kaplan-Meier survival curves showed comparable findings (Supplementary figures 
1 and 2).
Table 2. Reasons for removal from the waiting list. Other indications included patient 
preference, substance abuse, no indication after hemihepatectomy, and the development of 
Alzheimer’s disease or other malignancies. 
Removal Reason n (%)
Liver transplantation 425 (72.6)
Clinical deterioration / mortality 80 (13.7)
Progression of HCC beyond Milan criteria 42 (7.2)
Improved liver function / stable situation 15 (2.6)
Other 8 (1.4)
Not removed, still on waiting list (31 December 2016) 15 (2.6)
Abbreviations: HCC, Hepatocellular Carcinoma.
Table 3. Performance of the various scores and sarcopenia classifications using competing risk 
analysis. The presented c-indices show the discriminative value to predict 3-month waiting list 
mortality.
Score sHR 95% CI p-value C-index
MELD 1.09 1.06-1.11 <0.001 0.839
MELDNa 1.05 1.03-1.08 <0.001 0.824
SarcopeniaM 1.88 1.24-2.86 0.003 0.598
SarcopeniaC 1.22 0.81-1.83 0.350 0.515
MELD
SarcopeniaM
1.09
1.69
1.06-1.11
1.09-2.61
<0.001
0.018
0.834
MELDNa
SarcopeniaM
1.05
1.49
1.03-1.08
0.94-2.36
<0.001
0.092
0.798
MELD
SarcopeniaC
1.09
1.12
1.06-1.11
0.73-1.72
<0.001
0.610
0.835
MELDNa
SarcopeniaC
1.06
0.93
1.03-1.08
0.59-1.47
<0.001
0.750
0.792
MELD-Sarcopenia 1 1.08 1.05-1.10 <0.001 0.820
Abbreviations: sHR, subdistribution Hazard Ratio; CI, Confidence Interval; MELD, Model for End-stage Liver Disease; 
C-index, Concordance index; SE, Standard Error.
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Figure 2. Cumulative incidence functions for patients with and without SarcopeniaM. The 
median waiting list survival was significantly shorter in patients with sarcopenia (HR 1.88 [95% 
CI 1.24-2.86], p=0.003).
Mortality was significantly higher in patients with SarcopeniaM than in patients without 
SarcopeniaM after 1 month (35.0% versus 20.8%, p<0.001), 3 months (48.4% versus 
32.3%, p<0.001), 1 year (84.3% versus 75.5%, p=0.010), and 3 years (96.9% versus 
93.7%, p=0.078), whereas no differences were observed for patients with and without 
SarcopeniaC.
Performance of the various scores
table 3 shows the performance of the various scores, with the corresponding c-indices 
for 3-month waiting list mortality. SarcopeniaM adjusted for the MELD score showed 
an excellent discriminative performance to predict 3-month mortality (c-index 0.834). 
However, it did not exceed the discriminative performance of the MELD score alone 
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(c-index 0.839). The discriminative performance of SarcopeniaC was poor (c-index 
0.515), but increased to 0.835 when adjusted for MELD score. The c-index for the MELD-
Sarcopenia score was 0.820. Supplementary table 1 shows comparable data based on 
Cox regression analysis. An overestimation of the discriminative value was observed 
compared with competing risk analysis.
Figure 3. Cumulative incidence functions for patients with and without SarcopeniaC. No 
survival differences were found between patients with and without sarcopenia (HR 1.22 [95% 
CI 0.81-1.83, p=0.350]).
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A multivariable competing risk analysis and the development of a 
nomogram
After backward selection using the AIC, the model with the highest discriminative 
performance to predict waiting list mortality included MELD score (sHR 1.09 [95% CI 
1.06-1.12], p<0.001), hepatic encephalopathy before listing (sHR 1.80 [95% CI 1.12-2.87], 
p=0.014), age (sHR 1.02 [95% CI 0.99-1.05], p=0.085) and SarcopeniaM (sHR 1.51 [95% CI 
0.97-2.34], p=0.067), with a c-index of 0.851 (table 4). The nomogram of this model, is 
depicted in figure 4.
We performed stratified analyses based on low and high MELD-scores (cut-off MELD 
score 15). The independent additive effect of sarcopenia was strongly present in the 
group with low MELD-scores (n=342, sHR 2.10 [95% CI 1.05-4.2], p=0.035) but not in 
the group with high MELD-scores (n=243, sHR 1.30 [95% CI 0.75-2.26], p=0.349). The 
calibration of the nomogram was assessed and showed fair calibration, particularly for 
patients at low risk for waiting list mortality (figures 5a and 5b).
Table 4. Multivariable competing risk analysis according to Fine and Gray for waiting list 
survival. Variables were selected using a backwards stepwise selection based on the Akaika 
Information Criterion (AIC). The model was based on 578 patients due to missing data on the 
occurrence of hepatic encephalopathy before listing in 7 patients. The discriminative value of 
the model was excellent with a c-index of 0.851 for 3-month waiting list mortality.
sHR 95% CI p-value
MELD 1.09 1.06-1.12 <0.001
SarcopeniaM 1.51 0.97-2.34 0.067
Age, years 1.80 1.12-2.87 0.014
Hepatic encephalopathy before listing 1.02 1.00-1.05 0.085
Abbreviations: sHR, subdistribution Hazard Ratio; CI, Confidence Interval; MELD, Model for End-stage Liver Disease.
Figure 4. Nomogram to predict waiting list survival. The sum of the specific weighted scores 
was associated with decreased survival.
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Figure 5a. Calibration plot (A) and calibration bar plot (B) for the nomogram. Particularly 
patients with a low risk on waiting list mortality are accurately predicted using the nomogram.
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DISCUSSION
In this study we found that sarcopenia was a risk factor for waiting list mortality in a 
cohort of Western-European liver transplant candidates with cirrhosis. The MELD-
Sarcopenia score had a discriminative performance (c-index 0.82 for 3-month mortality), 
which was comparable with the discriminative performance in the training cohort of 
the original study (c-index 0.85) 10, but lower than the original MELD score (c-index 
0.84) in our cohort. A final competing risk model included SarcopeniaM, MELD score, 
age, and presence of hepatic encephalopathy before listing as predictors for waiting list 
mortality. This may be attributed to the fact that prioritization and allocation of donor 
organs and transplant candidates as well as waiting list mortality are all strongly related 
to the MELD score, resulting in a self-fulfilling prophecy.
The association between sarcopenia and mortality in patients evaluated or listed for liver 
transplantation has been previously described 6, 11-15, 25. However, most studies have been 
performed in predominantly (and partly overlapping) North-American populations 11-15, 25. 
Furthermore, most studies included a relatively small number of patients varying from 
n=59 to n=213 11-14, 16, and moreover none of the studies took competing risks on the 
waiting list into account. Which is important while we show that the prognostic value 
of the results obtained by ‘normal’ cox-proportional hazard analyses as opposed to 
competing risk analyses, overestimated rather than underestimated survival. The current 
study is the first multicenter Western-European study with a large number of patients. 
In our cohort median waiting list period was 7 (IQR 3-12) months, after which 72.6% 
of patients underwent transplantation and 15.4% were removed from or died on the 
waiting list or within 3 months after removal. In the cohort of Carey et al., including 396 
listed patients, only 50% underwent transplantation and 28% were delisted or died 25. 
Similarly, in the cohort of Montano-Loza et al., which included cirrhotic patients with 
a comparable MELD score, only 34% underwent transplantation and 39% died with a 
median follow-up of 11 months 10. The difference in outcomes as compared to our study 
could be explained by the fact that the cohort of Montano-Loza consists of cirrhotic 
patients who were evaluated for liver transplantation, but not necessarily listed yet. The 
greater homogeneity of our cohort may also explain some of the differences, amongst 
others the higher discriminative performance of the MELD-Sarcopenia score using both 
Cox regression and competing risk analysis.
Apart from the MELD-Sarcopenia score, others proposed a score for waiting list mortality 
with muscle mass included in the MELD score: the MELD-psoas score. In this score, only 
the psoas muscle area was measured rather than the cross-sectional muscle area 6. The 
cross-sectional measurements have previously been validated whereas results regarding 
van_Vugt-layout.indd   269 22/11/2017   12:43
270
Chapter 11
accuracy of psoas muscle measurements are conflicting. Two? recent studies suggested 
that psoas muscle measurements are inferior to total skeletal muscle measurements 31, 32. 
But, in contrast, the psoas muscle is successfully used in liver transplantation patients 
according to a French study 33. In addition, a Japanese study also included measures 
of skeletal muscle in the MELD score (Muscle-MELD score) to predict mortality after 
living-donor liver transplantation (LDLT) 34. However, today, it remains unknown which 
of the two measurements most accurately reflects total body skeletal muscle mass, and 
subsequently predicts mortality.
To date, there are no generally accepted cut-off values to classify patients with sarcopenia. 
The most frequently used definition is that of Martin et al. (SarcopeniaM 
24), who created 
cut-off values for sarcopenia to predict survival in cancer patients. These are based on 
sex and BMI (for men). Validity of the use of BMI is argued; as a high proportion of liver 
transplant candidates suffers from ascites (59.9% in our cohort), subsequently BMI 
will be overestimated and hence sarcopenia could be overestimated in male patients. 
Nevertheless, the discriminative performance using these cut-off values was excellent in 
our cohort, whereas no survival differences were found with the cut-off values of Carey 
et al. (SarcopeniaC 
25). This is of interest, while the cut-off values in the latter study were 
defined to predict waiting list mortality in liver transplant candidates, particularly. After 
adjusting sarcopeniac 
25 for the MELD score, the discriminative performance drastically 
increased, which underlines the strong predictive power of the MELD score.
As reflected by a higher proportion of liver-related complications, sarcopenia is strongly 
correlated with severity of liver disease. It may therefore contribute to better prioritising 
liver transplant candidates, as these patients are at risk to die or to deteriorate 
prematurely and this risk is currently not reflected in their MELD-score. In line with 
previous results 6, we found that sarcopenia is a stronger prognostic factor in patients 
with a low compared with patients with a high MELD score (based on a cut-off for MELD 
score of 15). Therefore, patients with sarcopenia and a low MELD score may be under 
prioritised in the current allocation system.
Possible explanations as to why liver disease leads to skeletal muscle depletion and 
sarcopenia are altered food intake, hypermetabolism from chronic disease, altered 
amino acid profiles, endotoxemia, accelerated starvation and decreased mobility 35. 
Moreover, hyperammonia was recently described as an additional mediator in the liver-
muscle axis 35. Skeletal muscle mass serves as storage for ammonia and depletion of 
muscle mass could therefore explain the increased rate of hepatic encephalopathy in 
patients with sarcopenia.
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Both functional impairment at the moment of listing 8 and a significant functional 
decline over time during the waiting period (both measured with the Short Physical 
Performance Battery) have been previously associated with an increased risk of death, 
independent of the severity of liver disease 7. Therefore, the waiting list period, or 
even the liver transplant evaluation period, offer a window of opportunity to improve 
functional status. Suggested regimens may consist of the use of proteins with low 
ammoniagenic potential, leucine enriched amino acid supplementation, long-term 
ammonia lowering strategies and a combination of resistance and endurance exercise 
to increase muscle mass and function 35.
This study has some limitations we would like to address. Although we used the 
prospective Eurotransplant registry data with all consecutive patients who have been 
listed for liver transplantation, some data was collected retrospectively (e.g. serum 
albumin and sodium levels) which led to missing data in a few cases. However, we tried 
to overcome bias due to missing data using multiple imputations for these laboratory 
values. Moreover, CT examinations performed within 90 days from listing were not 
available in all patients, as the time interval between screening and the eventual listing 
data greatly varied. Although we internally validated our findings in a prospective, 
national cohort, external validation may be warranted. Finally, we only have data on 
CT examinations at the moment of listing instead of follow-up data on skeletal muscle 
wasting along the waiting list period. One of the major advantages of the MELD score 
is the ability to easily calculate the MELD score at bedside. Nevertheless, evaluation 
of skeletal muscle mass will only take a couple of extra minutes extra per patient but 
could be of additional value for patients’ quality of life and survival 36. For this purpose, 
automated software is currently under development 36, 37.
In conclusion, sarcopenia is strongly associated with waiting list survival in liver 
transplant candidates with cirrhosis. Our model may be used to identify patients at risk 
for waiting list mortality, particularly those with otherwise lower MELD scores. These 
patients may benefit from more intensive follow-up, monitoring, and training programs 
or prioritising on the waiting list.
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Low Skeletal Muscle Mass is Associated with 
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ABSTRACT
Background: Low skeletal muscle mass is associated with poor postoperative outcomes 
in cancer patients. Furthermore, it is associated with increased healthcare costs in the 
United States. We investigated its effect on hospital expenditure in a Western-European 
healthcare system, with universal access.
Methods: Skeletal muscle mass (assessed on CT) and costs were obtained for patients 
who underwent curative-intent abdominal cancer surgery. Low skeletal muscle mass 
was defined based on pre-established cut-offs. The relationship between low skeletal 
muscle mass and hospital costs was assessed using linear regression analysis and Mann-
Whitney U-tests.
Results: 452 patients were included (median age 65, 61.5% males). Patients underwent 
surgery for colorectal cancer (38.9%), colorectal liver metastases (27.4%), primary 
liver tumours (23.2%), and pancreatic/periampullary cancer (10.4%). In total, 45.6% 
had sarcopenia. Median costs were €2,183 higher in patients with low compared with 
patients with high skeletal muscle mass (€17,144 versus €14,961; p<0.001). Hospital 
costs incrementally increased with lower sex-specific skeletal muscle mass quartiles 
(p=0.029). After adjustment for confounders, low skeletal muscle mass was associated 
with a cost increase of €4,061 (p=0.015).
Conclusions: Low skeletal muscle mass was independently associated with increased 
hospital costs of about €4,000 per patient. Strategies to reduce skeletal muscle wasting 
could reduce hospital costs in an era of incremental healthcare costs and an increasingly 
aging population.
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INTRODUCTION
Low skeletal muscle mass is a strong predictor of complications, reduced therapy 
effect, impaired survival in gastrointestinal and hepatopancreatobiliary cancer patients 
undergoing surgery 1-3, and dose-limiting chemotherapy toxicity 4-6.  In addition to 
clinical outcome, recent studies from the United States showed that low skeletal muscle 
mass is associated with increased healthcare costs 7-9.
However, the lower accessibility and higher uninsured rate of the American healthcare 
system, which is known to be greatly affected by income 10, may impair extrapolation to 
other healthcare systems with universal access 11-13. Because European healthcare costs 
are increasingly rising, we aimed to assess the effect of low skeletal muscle mass on 
hospital costs of patients undergoing curative-intent surgery for abdominal cancer in a 
Western-European healthcare system.
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MATERIALS AND METHODS
Patients and data acquisition
In this retrospective study, patients aged 18 years or older who underwent curative surgery 
for gastrointestinal or hepatopancreatobiliary cancers in our center were identified from 
various databases (including colorectal carcinoma 14-16, hepatocellular carcinoma 17, 
colorectal liver metastases 18, perihilar 19 or intrahepatic 19 cholangiocarcinoma, 
and pancreatic or periampullary cancer 20). Patients underwent surgery between 
2005 and 2015. Only patients with a CT imaging within 90 days preoperatively were 
included. Demographics and patient characteristics were collected from electronic 
patient files. Preoperative physical status was assessed using the American Society 
of Anesthesiologists (ASA) score 21. Overweight was defined as a body mass index 
(BMI) ≥ 25 kg/m2, according to the definition of the World Health Organization 22. 
Postoperative complications were identified in the medical patient files and recorded. 
Severity of postoperative complications was scored according to the Clavien-Dindo 
classification 23. Severe complications were defined as complications with grade 3a or 
higher. Postoperative mortality was defined as mortality during hospital stay or within 
30 days after surgery. Length of hospital stay was calculated by counting admission 
days from the day of surgery. An hospital stay exceeding 7 days was considered a 
prolonged hospital stay. Patients were divided in two groups according to the extent 
of surgery: 1. Major surgery (i.e. the resection of at least two hepatic segments and a 
wedge resection or the resection of at least three hepatic segments, pancreatic surgery, 
and pelvic exenteration for locally advanced rectal cancer); 2. Minor surgery (i.e. one- or 
two hepatic segment resections, and colorectal resections). The study was approved by 
the Medical Ethical Committee of Erasmus MC University Medical Center and a waiver 
for informed consent was granted.
Skeletal muscle mass measurements
Skeletal muscle mass was measured on computed tomography (CT) examinations that 
were routinely performed as part of diagnostic or preoperative work-up, as previously 
described 18. In short, the cross-sectional skeletal muscle area was measured at the level 
of the third lumbar vertebra on a slice on which both transversal processes were visible 
using a Hounsfield unit threshold of -30 to +150. The cross-sectional muscle area was 
then corrected for patients’ height squared, as is conventional for body composition 
measurements, resulting in the skeletal muscle index (SMI, cm2/m2). Patients were 
classified as having low skeletal muscle mass according to predefined cut-off values 
established by Martin and colleagues: males with body mass index (BMI) <25: <43 cm²/
m², males with BMI ≥25: <53 cm²/m², females: <41 cm²/m² 24. Furthermore, patients were 
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divided in sex-specific quartiles based on their skeletal muscle index. In patients who 
underwent induction or neoadjuvant chemo(radio)therapy, the CT after chemotherapy 
was used.
Cost analyses
Costs were abstracted from the hospital’s electronic accounting system, which is 
based on activity based costing. All costs that were made during the index admission 
for surgery, including surgical costs and all costs in the postoperative period and 
independent of (medical) discipline, were included. Total costs were calculated by the 
sum of all unit cost-prices. These cost prices are covering the full cost prices. Financial 
data was limited to expenses within the index admission and did not include costs after 
discharge from the index admission or costs made outside our center. Adjustment for 
inflation was performed by indexing all cost-prices to the year 2015 according to data of 
the Dutch Healthcare Authority. All financial data are reported in Euros (€).
Statistical analyses
Categorical data are reported as counts with percentages, whereas continuous data are 
reported as median with interquartile range (IQR) or mean with standard deviation (SD), 
depending on their normality of distribution. Categorical data was compared using the 
chi-squared test. The Mann-Whitney-U and Kruskall-Wallis H tests was used to compare 
hospital costs between groups. A multivariable linear regression analysis was performed 
to investigate the independent association of the presence of low skeletal muscle mass 
with increased costs after correction for possible confounding and clinically relevant 
factors. Sex-specific skeletal muscle mass quartiles were compared using one-way 
ANOVA analysis. Continuous baseline and outcome characteristics were dichotomized, 
according to clinically relevant cut-off points, and subgroup analyses were performed 
to investigate the effect of low skeletal muscle mass on total hospital costs in various 
subgroups. Patients who died during hospital admission or within 30 days postoperative 
were excluded from the subgroup analyses based on length of hospital stay. Two-sided 
p-values <0.05 were considered statistically significant. All analyses were performed 
using SPSS for Windows (IBM Corp., Armonk, NY, USA), version 22.
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RESULTS
Patients
In total, 602 patients were identified. Of these patients, no preoperative CT was available 
in 83 patients (13.8%) and no costs were available for 18 (3.0%) patients. In 49 patients 
(8.1%) the CT was not performed within 90 days preoperatively. This resulted in 452 
patients (75.1%) who formed the study cohort, of whom 278 (61.5%) were male and 
174 (38.5%) female with a median age of 65 (IQR 58-71) years. Most patients underwent 
surgery for colorectal carcinoma (n=176, 38.9%), followed by colorectal liver metastases 
(n=124, 27.4%), hepatocellular carcinoma (n=53, 11.7%), pancreatic or periampullary 
cancer (n=47, 10.4%), intrahepatic cholangiocarcinoma (n=32, 7.1%), and perihilar 
cholangiocarcinoma (n=20, 4.4%). Baseline characteristics are summarized in table 1.
The association between low skeletal muscle mass and treatment outcomes
Almost half of our cohort (45.6%, n=206) had low skeletal muscle mass. Patients with 
low skeletal muscle mass experienced more postoperative complications compared 
with patients with normal skeletal muscle mass (55.1% versus 44.9%, p=0.031), and 
showed an increased length of hospital stay (median 9 [IQR 7-14] versus 8 [IQR 6-12] 
days, p=0.005). Non-significant differences were observed for severe postoperative 
complications and postoperative mortality (table 2).
Total hospital costs in patients with low and normal skeletal muscle mass
The median total hospital costs per patient were €16,021 (IQR 11,714-23,381). Total 
hospital costs significantly differed between cancer types, and were highest in patients 
operated on for perihilar cholangiocarcinoma and lowest in patients who underwent 
surgery for colorectal liver metastases (table 3). Patients undergoing major surgery had 
significantly higher costs compared with patients undergoing minor surgery (€21,124 
[IQR 14,618-29,884] versus €12,989 [IQR 10,029-16,736], p<0.001).
Total costs were higher for patients with low skeletal muscle mass compared with 
patients with normal skeletal muscle mass (€17,144 [IQR 12,694-25,102] versus €14,961 
[IQR 10,744-21,200]; p<0.001), resulting in a median difference of €2,183 (12.7%). 
In univariable linear regression analysis, presence of low skeletal muscle mass was 
associated with a cost increase of €4,979 (p=0.002). After classifying patients in sex-
specific quartiles based on skeletal muscle mass, a decreasing trend in median total 
hospital costs per patient was observed per incremental quartile (1st quartile €18,320; 
2nd quartile €16,172; 3rd quartile €15,501; 4th quartile €14,655; p=0.029, figure 1).
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Table 1. Baseline characteristics.
All patients
n=452
Low skeletal 
muscle mass
n=206
Normal skeletal 
muscle mass
n=246
p-value
Sex
 Males
 Females
278 (61.5)
174 (38.5)
111 (53.9)
95 (46.1)
167 (67.9)
79 (32.1)
0.002
Age (years) 64.7 (57.8-71.4) 65.1 (58.3-73.0) 64.5 (57.2-70.3) 0.069
BMI (kg/m²)* 25.2 (22.7-27.9) 25.1 (21.8-27.2) 25.2 (23.4-28.6) 0.008
ASA classification#
 1-2
 3-4
334 (79.3)
87 (20.7)
154 (78.6)
42 (21.4)
180 (80.0)
45 (20.0)
0.718
Cancer diagnosis
 Colorectal
 CRLM
 HCC
 Pancreatic/periampullary
 ICC
 PHC
176 (38.9)
124 (27.4)
53 (11.7)
47 (10.4)
32 (7.1)
20 (4.4)
75 (36.4)
38 (18.4)
27 (13.1)
34 (16.5)
19 (9.2)
13 (6.3)
101 (41.1)
86 (35.0)
26 (10.6)
13 (5.3)
13 (5.3)
7 (2.8)
<0.001
Abbreviations: BMI, Body Mass Index (* missing for 2 patients); ASA, American Society for Anesthesiologists (# missing for 
34 patients); CRLM, Colorectal Liver Metastases; HCC, Hepatocellular Carcinoma; ICC, Intrahepatic Cholangiocarcinoma; 
PHC, Perihilar Cholangiocarcinoma.
Table 2. Treatment outcomes.
Low skeletal muscle 
mass
n=206
Normal skeletal 
muscle mass
n=246
p-value
Any postoperative complication 113 (55.1) 110 (44.9) 0.031
Any severe postoperative complication* 48 (23.4) 47 (19.2) 0.273
Postoperative mortality# 15 (7.3) 9 (3.7) 0.087
Length of hospital stay (days)‡ 9 (7-14) 8 (6-12) 0.005
* Defined as Clavien-Dindo classification ≥ 3a
# Defined as in-hospital or 30-day mortality
‡ Without patients who died in-hospital or within 30 days postoperatively
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Table 3. Total hospital costs per cancer type.
Cancer type Total hospital costs, € (IQR) p-value
Colorectal 15,121 (11,718-19,945) <0.001
CRLM 12,431 (8,721-14,679)
HCC 22,396 (16,368-32,474)
Pancreatic/periampullary 22,057 (18,509-25,445)
ICC 30,130 (18,710-40,827)
PHC 36,542 (28,122-53,126)
Abbreviations: IQR, Interquartile Range; CRLM, Colorectal Liver Metastases, HCC, Hepatocellular Carcinoma; ICC, 
Intrahepatic Cholangiocarcinoma; PHC, Perihilar Cholangiocarcinoma.
Figure 1. Total hospital costs by skeletal muscle mass in sex-specific quartiles. The total hospital 
costs significantly decreased per skeletal muscle index sex-specific quartile (p=0.003).
Median hospital costs were also higher for patients with low skeletal muscle mass 
compared to patients without low skeletal muscle mass within the subgroup of males 
(€17,823 [IQR 12,816-24,973] versus €15,444 [IQR 10,363-22,396], p=0.006) and females 
(€16,755 [IQR 12,081-25,257] versus €14,606 [IQR 11,152-20,898], p=0.121) (figure 2a), 
patients <65 years (€17,184 [IQR 12,619-25,073] versus €14,572 [IQR 10,151-21,250], 
p=0.025) and ≥65 years (€18,256 [IQR 12,808-25,131] versus €15,490 [IQR 11,060-
21,098], p=0.041) (figure 2b) and with overweight (€17,392 [IQR 12,808-23,851] versus 
€14,667 [IQR 10,277-21,263], p=0.018) and under- or normal weight (€17,410 [IQR 
12,457-25,351] versus €15,444 [IQR 10,905-21,179], p=0.048) (figure 2c).
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Figure 2. Total hospital costs stratified by the presence of low skeletal muscle mass per patient 
characteristic. * p<0.05, ** p<0.001
The influence of low skeletal muscle mass and postoperative complications 
on total hospital costs
Within the group of patients who did not experience any postoperative complication, 
the median hospitals costs for patients with low skeletal muscle mass were higher 
compared with the median costs for patients without low skeletal muscle mass 
(€13,141 [IQR 9,933-18,046] versus €11,715 [IQR 9,161-16,027], p=0.055), figure 3a. 
The same association was observed in patients who did not experience any severe 
postoperative complications (€15,448 [IQR 12,079-21,789] in patients with low skeletal 
muscle mass versus €13,658 [IQR 9,938-18,270] in patients without low skeletal muscle 
mass, p=0.006), figure 3b. The same effect was observed in patients who did (p=0.084) 
or did not (p=0.019) die in-hospital or within 30 days postoperatively, and in patients 
with normal (p=0.041) and prolonged (p=0.434) hospital stay (figure 3d) (figure 3c). Low 
skeletal muscle mass was associated with increased total hospital costs in the subgroup 
of patients undergoing major resections (p=0.099), but not within the subgroups of 
minor resections (p=0.238), figure 4.
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Figure 3. Total hospital costs stratified by the presence of low skeletal muscle mass per 
treatment outcome. * p<0.05, ** p<0.001
Figure 4. Total hospital costs stratified by the presence of low skeletal muscle mass per surgical 
treatment group. Major surgery included hepatic resections of at least two segments and a 
wedge resection or the resection of at least three hepatic segments, pancreatic surgery, and 
pelvic exenteration for locally advanced rectal cancer. Minor surgery included less than two 
hepatic segment resections and colorectal resections. * p<0.05
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Multivariable linear regression analysis
In linear regression analysis, the presence of low skeletal muscle mass was independently 
associated with higher total hospital costs, after adjusting for the extent of surgery, sex, 
age, overweight, and ASA classification (table 4). Presence of low skeletal muscle mass 
resulted in a cost increase of €4,061 (95% confidence interval [CI] 809-7,312; p=0.015). 
When skeletal muscle index was used as a continuous parameter, an incremental 
increase in skeletal muscle index (cm²/m²) was associated with €278 (95% CI 32-524, 
p=0.027).
Table 4. Multivariable linear regression analysis for the total costs per patient.
B,
Euros
Standard Error,
Euros
p-value
Low skeletal muscle mass 4,061 1,654 0.015
Age (≥65 years) 484 1,648 0.769
Sex (male) 2,126 1,693 0.210
Overweight (BMI ≥25 kg/m²) -587 1,650 0.722
ASA classification (3 or 4) 7,205 2,044 <0.001
Extent of surgery (major surgery) 11,127 1,650 <0.001
Abbreviations: BMI, Body Mass Index; ASA, American Society of Anesthesiologists
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DISCUSSION
In this study in a Western-European healthcare system among patients undergoing 
gastro-intestinal cancer surgery we found that the costs were €2,183 higher in patients 
with low skeletal muscle mass. Furthermore, total costs increased gradually across four 
levels of the skeletal muscle index for both men and women, which is in line with a 
previous study 7. Finally, significant differences in costs in patients with low skeletal 
muscle mass compared with patients without low skeletal muscle mass were observed 
in patients undergoing major surgery, while this difference was not significant in 
patients undergoing minor surgery.
Advanced age is associated with both an increased risk of cancer and an increased 
risk of postoperative complications 25. With increasing longevity and an increasingly 
aging population, the number of older cancer patients is steadily growing. About 58% 
of all cancers and 69% of cancer deaths occur in patients aged 65 years and older 26. 
The number of elderly patients undergoing cancer surgery is also rapidly growing. For 
example, 50% of patients with colorectal cancer are 70 years or older 27. Therefore, low 
skeletal muscle mass, resulting from both age-related sarcopenia and disease-related 
cachexia, may be a highly interesting parameter in an era of an increasingly aging 
population.
Besides increased costs, we found significantly more complications and a significantly 
longer hospital stay in patients with low skeletal muscle mass, which is in line with 
current literature 1. Significant differences in hospital costs between patients with and 
without low skeletal muscle mass were particularly observed in patients who did not 
experience any (severe) postoperative complications, did not die during admission or 
within 30 days postoperatively, or did not have a prolonged hospital stay. This finding 
suggests that increased costs may be directly related to the occurrence of (severe) 
complications requiring an increased use of resources (e.g., prolonged (ICU) stay, 
laboratory tests, radiological examinations and radiological or surgical re-interventions), 
as previously described 28, 29. This is underlined by the fact that we found a significant 
difference in patients undergoing major surgery, known for more complex care and 
relatively high postoperative complication rates, but not in patients undergoing minor 
surgery. However, based on our results these costs may preoperatively be predicted by 
CT-based skeletal muscle mass measurements. Skeletal muscle mass measurements are 
known for their great inter- and intra-observer agreement 30, while ASA classification, 
for example, is often considered a parameter that is not eligible for cancer patients 
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and subjective with great inter-rater inconsistency 31, 32. Low skeletal muscle mass may 
thus be used as a parameter for case-mix corrections to compare treatment outcomes 
between centers.
To date, all studies performed to assess the association between low skeletal muscle 
mass and healthcare costs showed a positive association, favoring patients with normal 
skeletal muscle mass 7-9, 33, 34. To our knowledge, this study is the first to show that low 
skeletal muscle mass may be a highly reliable measure to predict impaired outcome 
and increased hospital costs in surgical cancer patients in Western-European healthcare 
systems. Since European healthcare costs are increasingly rising and low skeletal muscle 
mass  suggested to be a remediable condition, antagonizing skeletal muscle mass 
loss in cancer patients may be a powerful target to reduce hospital resource use and 
costs. Besides prehabilitation programs (i.e. physical exercise therapy combined with 
nutritional supplementation), promising results have been shown in animal studies 35. 
Multiple phase II trials are currently being performed 36. On the other hand, low skeletal 
muscle mass may be a measure of advanced disease, or even a final common pathway 
from cancer to death. Low skeletal muscle mass, as a measure of frailty and physical 
status of patients, may therefore also be added to case-mix correction models.
Some limitations of this study should be acknowledged. A number of costs during 
hospital admission (i.e. medication and feeding) may not have been recorded and 
consequently missed in the analyses. In addition, no data was available after discharge 
from our hospital. It has previously been shown that patients with low skeletal muscle 
mass experience a delayed recovery and are more likely not to rehabilitate at home 8, 37. 
This may have led to an underestimation of the true total costs in patients with 
low skeletal muscle mass and thus an underestimation of the difference in costs 
between patients with and without low skeletal muscle mass. However, the total 
hospital costs are in line with a previous Dutch study investigating costs after major 
abdominal surgery in an academic center 28 and the study of Kirk et al. which showed 
that the greatest difference in costs occurs in the first 30 days after surgery 8. Due to 
the retrospective design of this study, CT examinations have not been performed in 
identical scanners. A previous study, however, showed that fat area measurements 
(based on the same principle) on CT examinations performed with various scanners in 
individuals had excellent agreements, independent of the scanner used 38. Some of the 
non-significant differences found may be explained by a limited sample size. Finally, we 
only investigated the association between skeletal muscle mass and healthcare costs, 
rather than sarcopenia, characterized by both skeletal muscle mass and function loss 
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39, or cachexia, characterized by both skeletal muscle mass and body weight loss 40. 
Although low skeletal muscle mass a hallmark parameter of both syndromes, future 
studies should confirm our results in patients with sarcopenia or cachexia.
In conclusion, total hospital costs are €4,061 higher in patients with low skeletal muscle 
mass compared with patients with normal skeletal muscle mass after correction for 
extent of surgery and ASA classification. The search for a treatment of low skeletal 
muscle mass might therefore lead to a reduction of complications and hospital costs 
in an era of incremental healthcare costs and an increasingly aging population. Future 
prospective studies regarding skeletal muscle mass should consider including total 
costs as outcome measure.
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ABSTRACT
Low skeletal muscle mass (sarcopenia) is associated with increased morbidity and 
mortality in liver transplant candidates. We investigated the association between 
sarcopenia and hospital costs in patients listed for liver transplantation. Consecutive 
patients with cirrhosis listed for liver transplantation between 2007-2014 in a 
Eurotransplant center were identified. The skeletal muscle index ([SMI], cm2/m2) was 
measured on CT performed within 90 days from waiting list placement. The lowest 
sex-specific quartile represented patients with sarcopenia. In total, 224 patients were 
included. Median time on the waiting list was 170 (IQR 47-306) days and median MELD-
score was 16 (IQR 11-20). The median total hospital costs in patients with sarcopenia 
were €11,294 (IQR 3,570-46,469) compared with €6,878 (IQR 1,305-20,683) in patients 
without sarcopenia (p=0.008). In multivariable regression analysis, an incremental 
increase in SMI was significantly associated with a decrease in total costs (€455 per 
incremental SMI, 95%CI 11-900, p=0.045), independent of the total time on the waiting 
list. In conclusion, sarcopenia is independently associated with increased health-related 
costs for patients on the waiting list for liver transplantation. Optimizing skeletal muscle 
mass may therefore lead to a decrease in hospital expenditure, in addition to greater 
health benefit for the transplant candidate.
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INTRODUCTION
Liver transplantation is the only curative treatment for patients with end-stage liver 
disease 1. The 1-year and 3-year survival rates of patients who undergo orthotopic liver 
transplantation in Europe and the United States are around 85% and 80%, respectively 1. 
While allocation of donor organs is based on the Model for End-stage Liver Disease 
(MELD) score 2, 3, which measures liver function, patients on the waiting list are at 
increased risk for major morbidity and mortality, particularly due to infections 1, 4-6. 
Indeed, hospital admissions in patients with end-stage liver disease occur frequently 
and are costly 7-9.
One of the factors related to hospital admissions is frailty, which is defined as the increased 
vulnerability to stressors due to reduced physiological reserves. Frailty is a known risk 
factor for adverse outcome in cirrhosis and liver transplant patients 10-13. Sarcopenia, 
defined as the involuntary loss of skeletal muscle mass and function, is part of the 
frailty syndrome and highly prevalent among patients with end-stage liver disease 14. In 
patients with cirrhosis, low skeletal muscle mass is associated with increased mortality 
on the liver transplantation waiting list and post-transplant morbidity and mortality, 
independently of well-established predictors such as the MELD score 14, 15. Sarcopenia 
has also been associated with higher healthcare costs in abdominal cancer patients 
undergoing surgery 16-18. To date, only one study from the United States described the 
association between gait speed, as a measure of frailty, and increased hospital costs in 
patients with cirrhosis 11. However, generalizability of these data is limited because, as 
a consequence of income inequality, great differences exist between the United States 
and Western Europe regarding healthcare accessibility 19-21.
The primary objective of this study, therefore, was to investigate the association 
between skeletal muscle mass and hospital costs in patients with cirrhosis listed for liver 
transplantation in a European transplant center. A secondary objective was to assess 
the association between skeletal muscle mass and total hospital costs during admission 
for liver transplantation in the subgroup of patients who eventually underwent liver 
transplantation.
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METHODS
Patients and data acquisition
All consecutive patients who were listed for liver transplantation from January 2007 
to December 2014 at Erasmus MC University Medical Center were identified using 
the Eurotransplant registry 22. Patients listed for reasons other than cirrhosis (n=30), 
patients with acute liver failure/listed with high urgency (n=58), patients undergoing 
re-transplantation (n=58), and those removed because of clinical improvement (n=9) or 
other reasons such as patient preferences or substance abuse (n=5) were excluded. The 
following parameters were collected at the moment of liver transplantation screening: 
sex, age, body height and weight, etiology of liver disease, blood group, MELD score, 
and the occurrence of complications (i.e. ascites, spontaneous bacterial peritonitis, 
hepatic encephalopathy, or variceal bleeding) before listing. All hospital admissions 
(including one-day admissions) with corresponding indication were recorded and the 
cumulative days of hospital stay were calculated. The indication for hospital admission 
was scored as follows: decompensated cirrhosis, infection, scheduled intervention (e.g., 
transarterial chemoembolization (TACE), radiofrequency ablation (RFA), endoscopic 
retrograde cholangio-pancreatography (ERCP), coloscopy, biopsy), other, or unknown.
The endpoint of the study was reached when patients underwent liver transplantation, 
were removed from the waiting list (due to clinical deterioration), or died on the waiting 
list. Patients who were removed from the waiting list because of clinical improvement 
or who were still on the waiting list at December 31, 2016, were excluded. All patients 
with hepatocellular carcinoma (HCC) were transplanted within the Milan criteria 23. 
Patients with HCC with disease progression beyond the Milan criteria were removed 
from the waiting list and considered as clinically deteriorated. In the study period, no 
prehabilitation program was conducted.
In patients who underwent liver transplantation, the cumulative length of hospital stay 
(LOS) was calculated as the sum of the index admission and all readmissions within 30 
days of discharge. The Institutional Review Board approved the study and a waiver for 
informed consent was granted.
Skeletal muscle mass measurements
The cross-sectional skeletal muscle area (cm2) was measured on contrast-enhanced 
(portal-venous phase) abdominal computed tomography (CT) at the level of the third 
lumbar vertebra (L3) and adjusted for patients’ height squared, as previously described 
(figure 1) 24. This resulted in the skeletal muscle index (cm²/m²), a measure strongly 
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correlated with total body skeletal muscle mass 25. Established cut-off values take body 
mass index (BMI) into account 26, which is known to be inaccurate in patients with liver 
failure due to ascites and peripheral edema. Consequently, sex-specific skeletal muscle 
mass quartiles were created. Patients in the lowest sex-specific quartile were considered 
to have sarcopenia. CT scans closest to the date of listing, but within 90 days from the 
listing date, were used for analyses.
Figure 1. Cross-sectional skeletal muscle mass measurement.Example of a measurement of 
skeletal muscle mass on CT. The cross-sectional skeletal muscle area (129.74 cm²) is depicted 
of a 60-year-old female with a body mass index of 22.1 kg/m². With a body height of 1.74 
meters this resulted in a skeletal muscle index of 42.9 cm²/m². Consequently, this patient was 
considered not to have sarcopenia.
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Cost analyses
All hospital costs (i.e. both clinical and outpatient department costs) that were made 
during the period that patients were listed for liver transplantation (i.e. from the date of 
listing to the endpoint, excluding hospitalization for liver transplantation) were included, 
as previously described. Costs for medication were not included. In patients who 
underwent liver transplantation, total hospital costs during index admission (including 
the day of liver transplantation) for the liver transplantation and during readmission(s) 
within 30 days after discharge from the index admission were also collected. In these 
transplanted patients, the grand total was calculated by adding the total hospital costs 
during waiting list placement and total hospital costs during hospital admission for liver 
transplantation.
Costs were extracted from the hospital’s electronic accounting system. Total costs 
were calculated by the sum of all unit cost prices. Financial data was limited to hospital 
expenditure and did not include costs made outside our center. Adjustment for inflation 
was performed by indexing all cost prices to the year 2015 according to data of the 
Dutch Healthcare Authority. All financial data are reported in Euros (€).
Statistical analyses
Categorical data are reported as counts with percentages. Continuous data are 
reported as median with interquartile range (IQR) or mean with standard deviation (SD), 
depending on their distribution. The Chi-square test was used to compare categorical 
data, whereas the Mann-Whitney-U test was used to compare hospital costs between 
patients with and without sarcopenia. A multivariable linear regression analysis was 
performed to investigate the association of an incremental skeletal muscle index with 
total hospital costs after correction for possible confounding and clinically relevant 
factors. Sex was added to the model to adjust for differences in skeletal muscle mass per 
gender. Sex-specific skeletal muscle mass quartiles were compared using the Kruskal-
Wallis test. Subgroup analyses were performed for the presence of HCC. Two-sided 
p-values <0.05 were considered statistically significant. All analyses were performed 
using SPSS for Windows (IBM Corp., Armonk, NY, USA), version 22.
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RESULTS
Patients
In total, 362 patients with cirrhosis were listed for liver transplantation, of whom 224 
(61.9%) patients were eligible for the study (figure 2). Baseline characteristics are shown 
in table 1. Of these patients, 149 (66.5%) were male and 75 (33.5%) had concomitant 
HCC. Baseline characteristics and total hospital costs did not significantly differ between 
the included and excluded patients (data not shown). Baseline characteristics and 
outcome (i.e. total costs) did not significantly differ between in- and excluded patients.
In total, 165 (73.7%) patients eventually underwent liver transplantation. The remaining 
patients were removed from the waiting list due to infections (12.9%), rapid clinical 
deterioration with decompensated cirrhosis (2.7%), progression of HCC beyond the 
Milan criteria (8.5%), diagnosis of other malignancies (1.3%) or cardiopulmonary 
decompensation (0.9%).
Hospital costs
The median total hospital costs across the entire study cohort were €7,761 (IQR 1,630-
23,954), corresponding to €44 (IQR 12-164) per day on the waiting list. The median 
total hospital costs were significantly lower in patients who eventually underwent liver 
transplantation compared with patients who were removed from the waiting list (i.e. 
due to mortality, clinical deterioration, progression of HCC beyond the Milan criteria, 
or other malignancies).Furthermore, costs were significantly higher in patients without 
HCC compared with patients with HCC (table 2).
Skeletal muscle mass and total hospital costs during the waiting list period
The median time between CT and waiting list placement was 30 (IQR 17-51) days. The 
median skeletal muscle index was 50.4 cm²/m² (IQR 44.1-55.0) for males and 41.8 cm²/
m² (IQR 37.9-46.5) for females (p<0.001).
Total hospital costs decreased per incremental increase in SMI sex-specific quartile 
(Figures 3a and 3b). The median total hospital costs in patients with sarcopenia were 
€11,294 (IQR 3,570-46,469) compared with €6,878 (IQR 1,305-20,683) in patients 
without sarcopenia (p=0.008, table 2). This corresponds to €68 (IQR 16-503) per day on 
the waiting list in patients with sarcopenia compared with €40 (IQR 10-108) in patients 
without sarcopenia (p=0.013).
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Multivariable linear regression analysis on costs during the waiting list 
period
Adjusted for age at the moment of listing, sex, MELD score at the moment of listing, 
complications before listing, presence of malignancy (i.e. HCC or cholangiocarcinoma), 
and total time on the waiting list, an incremental increase in SMI was significantly 
associated with a decrease in total hospital costs (€455 per incremental increase in SMI, 
95% CI 11-900, p=0.045), independent of the total time on the waiting list (table 3).
Subgroup analyses in patients with and without HCC
Because patients without HCC had significantly higher total hospital costs compared 
with patients with HCC and a significantly higher number of HCC was observed in 
patients without sarcopenia compared with patients with sarcopenia (39.6% versus 
14.5%, p<0.001), subgroup analyses in patients with and without HCC were performed. 
Significantly more males then females presented with HCC (77.6% versus 22.4%, 
p=0.012). The median MELD score was significantly lower in patients with HCC compared 
with patients without HCC (10 [IQR 8-12] versus 19 [IQR 16-22], p<0.001).
Patients without HCC and sarcopenia had significantly higher total costs compared with 
patients without HCC without sarcopenia (€19,586 [IQR 3,573-52,406] versus €7,644 
[IQR 1,462-28,074], p=0.023), whereas no difference was found between HCC patients 
with and without sarcopenia (€4,610 [IQR 1,792-10,243] versus €5,001 [IQR 1,112-
12,209], p=0.933). In a multivariable linear regression model in patients without HCC, 
an incremental increase in SMI was associated with decreased total hospital costs (€692 
per incremental increase in SMI, 95% CI 77-1,306, p=0.028), independently of total time 
on the waiting list (€29 per day, 95% CI 12-46, p=0.001) (Supplementary table 1).
Skeletal muscle mass and total hospital costs in transplanted patients
The median time on the waiting list for the 165 patients (73.7%) who eventually 
underwent liver transplantation was 176 (IQR 51-306) days. The median time between 
CT and liver transplantation was 213 (IQR 90-343) days. Waiting time did not significantly 
differ between patients with and without sarcopenia (168 [IQR 39-301] versus 205 [IQR 
52-311] days, p=0.597), although patients with sarcopenia had a significantly higher 
MELD score on the moment of waiting list placement (18 [IQR 13-21] versus 15 [IQR 10-
19], p=0.044), and fewer patients had HCC (18.2% versus 39.7%, p=0.010) compared with 
patients without sarcopenia. The cumulative post-transplant LOS did not significantly 
differ between patients with and without sarcopenia (26 (IQR 15-36] versus 20 [IQR 15-
32] days, p=0.124).
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Figure 3a. Total hospital costs by skeletal muscle mass in sex-specific quartiles. The total 
hospital costs significantly decreased per sex-specific skeletal muscle mass quartile from 
a median of €11,294 (IQR 3,570-46,469) in the first quartile, €9,066 (IQR 1,515-26,648) in the 
second quartile, €5,781 (IQR 910-19,928) in the third quartile, to €4,366 (IQR 1,550-17,490) in 
the fourth quartile (p=0.026).
Figure 3b.The total hospital costs presented in a box-plot.l
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Table 1. Baseline characteristics.
Sarcopenia
(n=55)
No sarcopenia
(n=169)
p-value
Sex (male) 37 (67.3) 112 (66.3) 0.891
Age (years) 56 (48-62) 56 (49-61) 0.954
BMI (kg/m²) 23.1 (21.6-25.1) 26.3 (23.6-29.4) <0.001
Primary etiology of cirrhosis
 Alcoholic
 Hepatitis B virus
 Hepatitis C virus
 PSC/PBC
 HCC
 Cholangiocarcinoma
 NASH
 Cryptogenic
 Auto-immune hepatitis
 Other
9 (16.4)
3 (5.5)
3 (5.5)
21 (38.2)
8 (14.5)
0 (0.0)
5 (9.1)
2 (3.6)
1 (1.8)
3 (5.5)
19 (11.2)
4 (2.4)
13 (7.7)
44 (26.0)
67 (39.6)
1 (0.6)
2 (1.2)
7 (4.1)
4 (2.4)
8 (4.7)
0.012
Blood type
 O
 A
 B
 AB
29 (52.7)
19 (34.5)
6 (10.9)
1 (1.8)
67 (39.6)
67 (39.6)
24 (14.2)
11 (6.5)
0.264
MELD score 18 (15-21) 15 (11-20) 0.012
Complications before waiting list placement
 Any
 Ascites
 Spontaneous bacterial peritonitis
 Hepatic encephalopathy
 Esophageal variceal bleeding
45 (81.8)
43 (78.2)
12 (21.8)
20 (36.4)
16 (29.1)
112 (66.3)
99 (58.6)
24 (14.2)
41 (24.3)
42 (24.9)
0.029
0.009
0.182
0.080
0.533
Median days on the waiting list 165 (32-374) 170 (51-304) 0.755
Abbreviations: BMI, Body Mass Index; PSC, Primary Sclerosing Cholangitis; PBC, Primary Biliary Cirrhosis; HCC, Hepatocellular 
Carcinoma; NASH, Non-alcoholic Steatohepatitis; MELD, Model for End-stage Liver Disease.
Table 2. Indications for hospitalization during the waiting list period (n=194).
n %
Decompensation of cirrhosis
 Clinical deterioration of liver function
 Ascites
 Hepatic encephalopathy (+ infection)
3
26
10 (5)
1.5
13.4
5.2 (2.6)
Infection
 SBP (with hepatic encephalopathy)
31
5 (1)
16.0
2.6 (0.5)
Scheduled intervention 47 24.2
Other 62 32.0
Unknown 4 2.1
Abbreviations: SBP, Spontaneous Bacterial Peritonitis
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The median total hospital costs during the admission for liver transplantation of the 
entire cohort were €77,074 (IQR 54,410-98,505). These did not significantly differ 
between patients with and without sarcopenia (€81,569 [IQR 59,233-108,190] versus 
€74,612 [IQR 52,899-93,632], p=0.202). The grand total was €86,412 (IQR 62,478-
113,791). This was significantly higher in patients with sarcopenia (€98,703 [IQR 75,909-
121,071]) compared with patients without sarcopenia (€81,173 [IQR 58,961-110,258]), 
p=0.030.
Hospitalization and hospital costs
In total, 52 (23.2%) patients were admitted to the hospital during the waiting list period 
minimal once, accounting for 194 hospital admissions. In these patients, the median 
number of hospitalizations was 2 (IQR 1-3) with a median stay of 6 (IQR 2-14) days. 
The most frequent indication for hospitalization was a scheduled intervention (n=47, 
24.2%), followed by infection (n=42, 21.6%) (table 4). Twenty-six (50.0%) patients were 
hospitalized because of decompensated disease at least once, with a median of 2 (IQR 
1-3) hospital admissions for decompensated disease. Patients who were admitted 
during the waiting list period had significantly higher hospital costs (€16,799 [IQR 9,046-
29,064] versus €4,396 [IQR 1,049-20,043], p<0.001). Although a precise estimation could 
not be made, this would mean that an average day in the hospital costs a total of €1,034. 
Number of admissions (p=0.640) and cumulative length of hospitalization (p=0.609), 
however, did not differ between patients with and without sarcopenia. A not statistically 
significant higher proportion of patients with sarcopenia was admitted because of 
liver decompensation (n=9, 64.3%) compared with patients without sarcopenia (n=17, 
44.7%), p=0.211. These patients also showed a higher number of hospital admissions for 
decompensated disease (3 [IQR 0-2] versus 1 [IQR 0-4], p=0.150).
In patients without sarcopenia, those who were admitted had significantly higher 
hospital costs compared with those not admitted (€17,529 [IQR 10,088-27,989] versus 
€3,503 [IQR 979-16,267], p<0.001). However, in patients with sarcopenia, those who 
were admitted had comparable hospital costs compared with those not admitted 
(€16,087 [IQR 7,878-53,319] versus €10,746 [IQR 2,227-45,602], p=0.324).
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Table 3. Multivariable linear regression analysis for the total hospital costs per patient during 
waiting list placement (n=224).
Euros per 
unit
Standard 
Error,
Euros
p-value
Skeletal muscle index (per cm²/m²) -455 226 0.045
Sex (female versus male) -3,146 3,890 0.420
Age at moment of listing (per year) 18 163 0.911
MELD score at moment of listing (per point) 507 380 0.184
Complications before listing (yes versus no) 2,134 4,036 0.598
Malignancy (HCC/Cholangiocarcinoma versus other indication) -4,305 4,741 0.365
Time on the waiting list (per day) 30 7 <0.001
Abbreviations: MELD, Model for End-stage Liver Disease; HCC, Hepatocellular Carcinoma
Table 4. Indications for hospitalization during the waiting list period (n=194).
n %
Decompensation of cirrhosis
 Clinical deterioration of liver function
 Ascites
 Hepatic encephalopathy (+ infection)
3
26
10 (5)
1.5
13.4
5.2 (2.6)
Infection
 SBP (with hepatic encephalopathy)
31
5 (1)
16.0
2.6 (0.5)
Scheduled intervention 47 24.2
Other 62 32.0
Unknown 4 2.1
Abbreviations: SBP, Spontaneous Bacterial Peritonitis
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DISCUSSION
To the best of our knowledge, this is the first study to describe that health care costs 
in patients with cirrhosis and sarcopenia listed for liver transplantation are higher, and 
in our case involve almost €4,500 more, than patients without sarcopenia. In patients 
who eventually underwent liver transplantation, the difference in total costs (i.e. the 
sum of the hospital costs during waiting list placement and during the admission for 
transplantation) was even higher, over €17,000.
Frailty has previously been investigated in cirrhosis patients by Dunn et al. and Sinclair 
et al., and their conclusion is in line with our findings on sarcopenia. Frailty, a measure 
for contractile function and balance, was found to be an independent risk factor for 
cirrhosis complications needing hospitalization 11, 27 and increased hospital costs 11. 
The waiting list period offers a window of opportunity to improve functional status 
and skeletal muscle mass. Suggested regimens in patients with cirrhosis may consist 
of the use of proteins with low ammoniagenic potential, leucine enriched amino 
acid supplementation, long-term ammonia lowering strategies and a combination of 
resistance and endurance exercise to increase muscle mass and function 28. Reversing or 
halting skeletal muscle wasting may lead to decreased costs on the waiting list.
We found significantly lower hospital costs in patients with HCC compared with patients 
without HCC. The significantly lower MELD score in patients with HCC compared with 
patients without HCC may explain this difference. After all, the lower median MELD score 
indicates less severity of the liver disease in patients with HCC. In addition to cancer 29 
and age 30, liver disease itself is an important cause of skeletal muscle depletion 28. Not 
only alterations in food intake, hypermetabolism, amino acid profiles, endotoxemia, 
accelerated starvation and decreased mobility lead to liver disease induced skeletal 
muscle depletion, but recent findings also indicate hyper ammonia as a mediator in the 
liver-muscle axis 28.
Although the association between sarcopenia and hospital expenditure is strong, we 
do not believe this to be a causal relationship. Instead, we believe that cirrhotic frail 
patients or those with sarcopenia are at increased risk for morbidity and mortality due 
to clinical and subclinical sequelae 12 and have increased (re)admission rates 8, 9, 11 which 
eventually lead to increased hospital costs 11. Although we did not find differences 
in hospital admissions in general between patients with and without sarcopenia, we 
found a not statistically significant difference in the proportion of hospital admissions 
due to liver decompensation in favor of patients without sarcopenia. The low number of 
patients may have led to a type II error.
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The significantly lower prevalence of sarcopenia among patients with HCC seems to 
be in contrast with previous studies describing a high prevalence of sarcopenia among 
patients with HCC 29, 31. However, our study cohort consisted of patients within the Milan 
criteria only 23 and consequently the tumor load was limited. Furthermore, this difference 
may also be explained by the use of different cut-off values instead of continuous 
SMI in those studies 14. Many previous studies of liver transplant patients used cut-off 
values based on body mass index (BMI) or body surface area (BSA). In our opinion this 
is a suboptimal measurement, as both measures are calculated using body weight in 
patients with ascites 32-35. In a large series of Japanese patients with HCC (n=1,257), using 
cut-off values to predict mortality using optimal stratification in their patient cohort, a 
prevalence of low skeletal muscle mass of only 11.1% was found 31.
A statistically non-significant difference of €6,957 in hospital costs during the admission 
for liver transplantation, and a statistically significant difference of €17,530 in the 
grand total, favoring patients without sarcopenia was found. Since this was not the 
primary objective of the study, skeletal muscle mass was not measured on the CT 
closest to transplantation. Consequently, the median time interval between CT and 
liver transplantation was 208 days and the subgroup was relatively small (n=166). As 
patients may lose significant amounts of skeletal muscle mass during the waiting list 
period 13, these results should be interpreted with caution and should be validated in 
a future study with a smaller interval between CT and transplantation. The waiting list 
period may be used to halt or reverse skeletal muscle wasting. Currently, promising 
results have been shown in animal studies and multiple human phase II trials are being 
performed 36, 37.
There are no widely accepted cut-off values to classify patients as having sarcopenia yet. 
The most commonly used cut-off values are those of Martin and colleagues, established 
in a cohort of cancer patients 26. Recently, cut-off values for patients with end-stage 
liver disease have been proposed in a North-American population, which have not been 
validated yet 38. Due to differences between the American en European population, we 
chose to use our own cut-off values to exemplify cost differences between patients with 
low and high skeletal muscle mass. However, the independent association between 
skeletal muscle mass and hospital expenditure was shown using the skeletal muscle 
index (cm²/m²) as a continuous measure.
Although sarcopenia is a subject of interest in patients with liver disease, we are the 
first to show the actual costs involved alongside this comorbidity. However, there are 
some limitations in this study that need to be addressed. Firstly, we were, not able to 
include healthcare costs made outside the hospital. However, the median hospital costs 
van_Vugt-layout.indd   311 22/11/2017   12:43
312
Chapter 13
during the waiting list period (€ 7,761) were comparable with a previous German study 
(€ 6,294) 39. Furthermore, we may have missed some costs and these results should, 
therefore, be considered as estimates. Although the current results may consequently 
be an underestimation of the real costs, one may expect that sarcopenia is associated 
with increased resource utilization after hospital discharge. We therefore believe that 
the difference between patients with and without sarcopenia might be underestimated 
rather than overestimated. Secondly, selection bias may have occurred due to the 
retrospective design of the study. However, all consecutive patients listed for liver 
transplantation were identified. Although a substantial part of patients listed for liver 
transplantation was excluded, significant differences were not found between baseline 
characteristics and outcome. Consequently, selection bias seems highly unlikeable. 
Thirdly, we only measured skeletal muscle mass and did not assess muscle function. 
Lastly, we were not able to monitor skeletal muscle wasting over time because 
consecutive CT examinations were not routinely performed.
In conclusion, sarcopenia is independently associated with higher hospital costs 
during waiting list placement of liver transplant candidates, as well as with higher total 
hospital costs (i.e. during waiting list placement and the admission for transplantation) 
in patients undergoing liver transplantation. Optimizing patients’ skeletal muscle mass 
may therefore lead to a decrease in hospital expenditure. The differences in costs justify 
the efforts and the use of resources to explore therapies and treatments to reduce or 
stop skeletal muscle wasting in patients with end-stage liver disease. Furthermore, 
it underlines that low skeletal muscle mass may be used as a parameter for case-mix 
comparisons and corrections.
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SUPPLEMENTARY MATERIAL
Supplementary table 1. Multivariable linear regression analysis for the total hospital costs per 
patient in a subgroup of patients without hepatocellular carcinoma (n=148).
B,
Euros
Standard Error,
Euros
p-value
Skeletal muscle index (cm²/m²) -692 211 0.028
Sex (female) -1,183 4,890 0.809
Age at moment of listing (years) -109 207 0.597
MELD score at moment of listing 81 459 0.860
Complications before listing (yes) 3,403 6,054 0.575
Time on the waiting list (days) 29 8 0.001
Abbreviations: MELD, Model for End-stage Liver Disease; HCC, Hepatocellular Carcinoma
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Rationale and Study Design of a Randomized Controlled 
Trial to Reduce Fatigue and Increase Quality of Life with 
a Rehabilitation Program in Patients with Cancer of the 
Liver, Pancreas or Biliary Tract Undergoing Surgery
J.L.A. van Vugt, C.C.D. van der Rijt, H.J. Stam, J.J. van Busschbach, R.W.F. de Bruin,
H.A. Schepers-Uittenbogaard, J. Molinger, O.R.C. Busch, B.A. Bonsing, T.M. van Gulik,
E.W. Steyerberg, C.H.J. van Eijck, B. Groot Koerkamp, J.N.M. IJzermans
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ABSTRACT
Background: Currently, there is no standardized postoperative guidance and support 
program for patients who undergo surgery for cancer of the hepatopancreatobiliary 
(HPB) tract. Nevertheless, the incidence of fatigue complaints is high in these patients. 
Previous trials have shown beneficial effects of rehabilitation programs in patients 
with a relatively good prognosis and a high likelihood of reaching a functional status 
after treatment that is comparable with pre-disease levels compared with HPB cancer 
patients, who have a poor prognosis.
Objective: We initiate a randomized controlled trial to investigate the effect of a 
multidimensional rehabilitation program in HPB cancer patients aimed to reduce 
fatigue complaints and increase quality of life (QoL) after surgery.
Design: In this randomized controlled trial, patients aged ≥18 years with pancreatic, 
biliary tract, or liver cancer undergoing surgery will be included. Patients will be 
randomly assigned to an intervention arm (rehabilitation program) or control arm 
(standard care) in an 1:1 ratio.
Setting: This study will be conducted in three tertiary referral centers in the Netherlands. 
The intervention will take place in a local setting.
Intervention: Patients in the intervention arm will be offered a rehabilitation 
program consisting of physical exercise therapy, solution-focused therapy and dietary 
consultation.
Outcome: The primary outcome is fatigue, assessed using the Multimodal Fatigue 
Inventory (MFI). Secondary outcomes are QoL, body composition, muscle strength, 
physical fitness, and overall survival. Finally, cost-effectiveness of the intervention will 
be assessed.
Discussion: This randomized controlled trial will assess the efficacy of a rehabilitation 
program to reduce fatigue complaints in a highly complicated patient population with 
a relatively poor prognosis.
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INTRODUCTION
Cancer treatment has improved considerably in recent years. One-year overall survival 
rates of breast and colon cancer patients are as high as 97% and 80%, respectively 1, 2. 
For hepatopancreatobiliary (HPB) cancers, surgical resection is often considered the 
only curative treatment which is only feasible in up to 25% of patients. One-year overall 
survival rates of primary hepatic and pancreatic cancer patients in the Netherlands 
remain as low as 39% and 24% respectively 2. Besides tumor characteristics, factors such 
as frailty limit survival in cancer patients 3. Frailty is a state of increased vulnerability of an 
individual towards stressors, leading to an increased risk of developing adverse health 
outcomes 3. A hallmark sign is fatigue, the most frequently reported symptom in cancer 
patients during and after treatment 3. In gastrointestinal cancer patients, almost 30% of 
patients experience severe fatigue 4, 5. Low physical activity is independently associated 
with severe fatigue before cancer treatment 4. During cancer treatment, fatigue rates in 
patient populations vary between 25-99% 6. After successful cancer treatment, 19-38% 
of disease-free cancer survivors remain fatigued, underlining its persistent character 4, 6. 
In our own daily practice, we experience that fatigue in the first months is reported very 
frequently, particularly after major HPB cancer surgery. Although the exact pathogenesis 
of fatigue remains unknown, disturbances in physiology, biochemistry and psychology 
are considered to contribute to this multifactorial symptom 7. Another key determinant 
of fatigue may be attributed to age- and disease-related muscle depletion (i.e. 
sarcopenia) 8. Its prevalence is common in HPB cancer patients, exceeding rates of 50% 
in our population 9, 10. These patients experience muscle weakness that leads to physical 
impairment, increased fatigue and decreased quality of life 5. Furthermore, such frail 
patients are more prone to a reduced therapy effect, complications and increased 
chemotherapy toxicity 11.
The cancer itself, as well as the sequelae after surgery or chemo(radiation)therapy, 
may lead to physical and psychosocial impairment 12. As patients experience increased 
disease related fatigue, fear/anxiety, depression, muscle mass and strength loss, and 
subsequently a lower exercise tolerance, they are at great risk of spiraling down a 
vicious circle which progressively enhances these symptoms and further impairs their 
quality of life and self-management capacity 13, 14. Although this series of events is well 
recognized as a potential course after major HPB surgery, monitoring of patients’ well-
being after treatment frequently remains a neglected, unstandardized aspect of care. If 
fatigue complaints and weakness are recognized, it is still unknown how to offer these 
patients the best supportive care.
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Background and rationale
Since multiple dimensions (physical, emotional and cognitive) seem to be involved in 
fatigue, a multidimensional approach should be opted for 15. In patients who have been 
treated for cancer, psychotherapy was shown to significantly reduce fatigue 6. Particularly 
interventions with a more general approach, aiming at psychological distress, mood and 
physical symptoms, are effective in reducing fatigue 16 Furthermore, physical exercise has 
been demonstrated to reduce fatigue in cancer patients 17, 18 and cancer survivors 19, 20. 
The authors of a recent Cochrane review performed a meta-analysis compromising 
56 studies (4,068 participants with various cancers) that showed that physical exercise 
therapy can be regarded as beneficial for patients with cancer-related fatigue during 
the post-cancer therapy, particularly in patients with solid tumors 17.
Previously, van Weert et al. 21 compared the effect of combined physical training and 
cognitive-behavioral therapy with physical training only and no intervention on cancer-
related fatigue in cancer survivors (63.2% breast cancer, 19.7% hematological cancer, 
7.9% gynecological cancer, and 9.2% other cancer). Physical training combined with 
cognitive-behavioral therapy and physical training alone had significant beneficial 
effects on fatigue compared with no intervention. Physical training was as effective 
as physical training with cognitive-behavioral therapy. The study population included 
colorectal and breast cancer patients with relatively good prognosis. Furthermore, the 
physical exercise therapy program in this study included some elements of coping with 
fatigue, goal setting and exercise-relaxation balance activities, which may have reduced 
the effect of the cognitive-behavioral therapy. Solution focused therapy has also been 
proven effective in various patient populations. A great advantage of solution focused 
therapy is that a fewer number of sessions is needed to be effective compared with 
cognitive-behavioral therapy 22, 23. This translates into lower costs and could possibly 
lead to greater patient adherence.
These previous studies have been conducted in cancer patients with a relatively good 
prognosis, such as breast and colorectal cancer 19-21, 24-30. These populations generally 
reach a functional status after treatment that is comparable with pre-disease levels 
and patients may return to regular societal participation. Therefore, the results in 
these patient populations may not apply to patients undergoing surgical resection of 
malignancies with a more dismal outcome and high morbidity even mortality in the 
first years after surgery, such as HPB cancer patients. In addition, HPB cancer patients 
experience a greatly impaired quality of life according to data from the European 
Organisation for Research and Treatment of Cancer (EORTC) 31. The mean global health 
status or quality of life in HPB cancer patients (all stages) on the EORTC Quality of Life 
van_Vugt-layout.indd   322 22/11/2017   12:43
323
Study protocol rehabilitation after HPB cancer surgery
14
Questionaire-C30 is 56 points on a scale of 0-100, which is amongst the lowest scores for 
cancer patients. For example, breast cancer patients, colorectal cancer patients and the 
general population score 62, 61, and 71.2, respectively 31. Researchers in- 32, 33 and outside 
34, 35 of our research group have demonstrated that quality of life is greatly impaired in 
HPB cancer patients, including candidates for surgery. In particular in patients who are 
severely diseased and consequently with worsened survival, the quality of life is lowest 35. 
Aim
Although pre- and perioperative care (i.e. the introduction of the ERAS program) have 
greatly been improved during recent years, no standardized postoperative guidance 
and support, except a protocol follow-up consultation at the surgical outpatient 
department, is offered for HPB cancer patients who undergo major surgical resection. 
Therefore, we initiate a randomized controlled trial (RCT) to investigate the effect of 
rehabilitation in HPB cancer patients, known for a high incidence of fatigue complaints. 
The aim of our study is to assess the efficacy of a patient-tailored, supervised 12-
week rehabilitation program consisting of physical therapy and solution focused 
psychotherapy in a well-defined population of surgically treated HPB cancer patients 
with relatively poor prognosis.
Population
All consecutive patients undergoing surgery for HPB malignancies (i.e. bile duct cancer, 
pancreatic cancer, hepatic cancer) in Erasmus MC University Medical Center (Rotterdam, 
the Netherlands), Academic Medical Center (Amsterdam, the Netherlands) and Leiden 
University Medical Center (Leiden, the Netherlands) will be considered for eligibility 
for study participation. Particularly these patients may benefit from the described 
intervention. After all, they have a dismal prognosis, but are considered fit enough to 
undergo surgery as this is the only treatment option with curative intent.
Inclusion criteria
In order to be eligible to participate in this study, a subject must meet all of the following 
criteria:
• Undergoing curative intent surgery for HPB malignancies;
• Clinically suspect or histologically confirmed liver, bile duct or pancreatic carcinoma;
• Life expectancy of at least 6 months;
• Mild to severe fatigue after hospital discharge, according to the MFI;
• Able to read and understand the Dutch language;
• Written informed consent.
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Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from 
participation in this study:
• Treatment with adjuvant chemo(radiation)therapy
• Bone metastases or other high risk of fractures;
• Not able to perform basic activities of daily living (ECOG ≥3);
• Decompensated heart disease, uncontrolled hypertension (systolic blood pressure 
> 200 mmHg or diastolic blood pressure > 110 mmHg), heart failure (NYHA Class II 
or greater) or chronic obstructive pulmonary disease causing fatigue;
• Living in nursing homes;
• Cognitive impairment;
• BMI <15 kg2/m2, >5% weight loss per month or other health problems that would 
not allow physical exercise training;
• Anxiety or depression requiring psychiatric consultation;
• Cancer treatment in the previous 5 years (except basal skin cancer);
• Participation in other studies containing elements of physical exercise or 
psychological therapy.
STUDY OUTCOMES
The main outcome is general fatigue. Symptoms of fatigue are assessed using the 
Multidimensional Fatigue Inventory (MFI) 15. This 20-item questionnaire includes 
the following five scales: general fatigue, physical fatigue, reduced activity, reduced 
motivation, and mental fatigue. Each question can be scored with 1 to 5 points, with 
sub scores for the five dimensions ranging from 4 to 20. Higher scores indicate increased 
fatigue. Fatigue will be assessed preoperatively, postoperatively (before the rehabilitation 
program), directly after the rehabilitation program, and 6 and 12 months after surgery. 
Besides quality of life, other secondary outcome measures are: body composition (i.e. 
skeletal muscle mass and density, visceral and subcutaneous adipose tissue mass), 
muscle strength, frailty, anxiety and depression, and physical fitness. Measurements 
will be repeated at 6 and 12 months after surgery to explore long-term effects. We 
hypothesize that offering a combined physical exercise and psychotherapy program 
halts the vicious circle with down spiraling character. We assume that the combined 
treatment as proposed here is the best method to approach a multidimensional and 
multifactorial symptom such as fatigue, which will work synergistically and show the 
greatest result. Nevertheless, the individual effects of physical exercise therapy and 
psychotherapy remain unknown. Therefore, we also measure body composition and 
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muscle function and –strength to investigate if there are any differences in fatigue and 
quality of life between patients with lowmuscle mass, who are wasting muscle mass, 
or (re)gaining muscle mass. These data could be used to further guide future studies. 
Moreover, the effect on overall survival will be assessed. Finally, a cost-effectiveness 
analysis will be performed.
Quality of life
The (health-related) quality of life will be assessed using the EORTC-Quality of Life-C30 
questionnaire (version 3) and Short Form 36. Both Dutch versions of these questionnaires 
have been validated 36, 37.
Cardiopulmonary fitness
One of the most relevant characteristics of physical fitness is cardiopulmonary fitness. 
The golden standard to measure cardiopulmonary fitness is a cardiopulmonary 
exercise test (CPET) 38, 39. With a CPET, the entire cardiopulmonary system is tested. 
The oxygen use, carbon dioxide production, breathing patterns are measured and an 
electrocardiography is performed during a bike test. The CPETs will be performed at 
baseline to tailor a physical exercise program for each patient.
Body composition measurements
All patients will undergo computed tomography (CT) examinations preoperatively 
(within 4 weeks before surgery), at baseline (start rehabilitation program) and after 6 and 
12 months hereafter. All examinations, except those after 6 months, are part of standard 
care. The cross-sectional skeletal muscle area (cm²) will be measured on the level of 
the third lumbar vertebra (L3). This area will be adjusted for patients’ height, resulting 
in the L3 muscle index (cm²/m²). This measure is strongly correlated with total body 
skeletal muscle mass and is known for its high reliability and great reproducibility 10, 40. 
Additionally, the amount of visceral adipose tissue will be measured 41.
Muscle strength
Muscle strength is a predictor for survival in patients of average and higher age. 
Furthermore, muscle strength of the upper extremities is an important characteristic of 
functional decline in elderly 42. Muscle weakness results in decreased self-management 
and a higher rate of dependency. The strength of the quadriceps muscle will be 
measured using a handheld dynamometer. The peak force during contraction will be 
measured for 5 consecutive seconds 42. A JAMAR® hand dynamometer will be used to 
measure muscle strength of the upper extremities, according to a previously described 
method 43; sitting on a chair with the shoulders adducted and neutrally rotated, the arm 
van_Vugt-layout.indd   325 22/11/2017   12:43
326
Chapter 14
in vertical (next to the body) position and the wrist in neutral position, the subject is 
instructed to squeeze the grip with maximum strength. Decreased strength is defined 
as <85% of the population-based value, according to Webb and colleagues 44. These 
sex- and age specific cut-off values are routinely being used in physiotherapist practices 
in the Netherlands.
General physical performance
The performance status of patients during daily activities will be investigated using the 
Karnofsky performance scale. This is a scale ranging from 0 (dead) until 100 (normal 
general performance without complaints). An in- or decrease of 10 points will be used 
to detect significant differences. Furthermore, the timed sit-up-and-go test 45 as well as 
the six-minute walk test 46 will be performed.
Frailty and anxiety and depression assessment
Frailty will be assessed using the Groningen Frailty Indicator (GFI) 47. The GFI has been 
developed as a simple screening instrument for frailty. It screens on physical, cognitive, 
social, and emotional items. The maximum score is 15 points. Patients scoring 5 or more 
points are considered frail. Anxiety and depression mood will be measured using the 
Hospital Anxiety and Depression Scale (HADS), consisting of the anxiety (HADS-A) and 
depression (HADS-D) subscales. Both subscales have a score ranging from 0 to 21 with 
higher scores indicating more anxiety and depression 48.
Body height and weight
Body height and weight will be measured on the described time points and body mass 
index (BMI) will be calculated.
Overall survival
The possible effect of the intervention on overall survival will be assessed on various 
time points (1 and 3-year) after the intervention. Survival status will be subtracted from 
the municipal registration system or the electronic patient file.
Randomisation, blinding and treatment allocation
Patients will be included on the preoperative surgical outpatient department and with 
hospital discharge patients will randomly be assigned to the treatment (rehabilitation 
program) or control (standard care) group in a 1:1 ratio. Randomization will be 
conducted by an independent researcher using a computer-generated randomization 
procedure with variable block length. Neither patients nor therapists will be blinded for 
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the treatment group. Stratification for gender and age will be conducted. All therapists 
will be blinded for the Multidimensional Fatigue Inventory (MFI) score that will be 
obtained before the start of the rehabilitation program.
Study procedures
The intervention arm will be offered close to the patients’ home. Patients in the control 
arm are offered standard medical care according to the local protocols.
Physical exercise therapy
The physical exercise therapy program will start four weeks after hospital discharge for 
a duration of 12 weeks. The intervention group is offered a supervised and personalized 
exercise program that is aimed at both cardiorespiratory fitness (aerobic training) and 
muscle strength (resistance training) 49, which is also considered feasible in patients 
receiving chemotherapy 30. The program is developed in a close collaboration between 
physiotherapists, exercise physiologists, revalidation specialists, and medical and 
surgical oncologists. For each patient, an intake or baseline exercise measurement (i.e. 
CPET and muscle function tests) will be performed. Subsequently, the program will be 
specified to each patient’s personal preferences and physical fitness. Hereafter, patients 
will train for a period of one hour twice a week under the supervision of a physical 
therapist. Patients are offered the following program: muscle strength exercises for 30 
minutes per training session, starting with 12 repetitions at 70% of the one repetition 
maximum (1RM) and end with two series at 80% 1RM. One training exists of a minimum 
of six exercises: 1. Vertical row (longissimus, biceps brachii, rhomboideus); 2. Leg press 
(quadriceps, glutei, gastrocnemicus); 3. Bench press (pectoralis major, triceps); 4. Pull 
over (pectoralis, triceps brachii, deltoideus, trapezius); 5. Abdominal crunch (rectus 
abdominis); 6. Lunge (quadriceps, glutei, hamstrings). The aerobic training will be 
performed for the following 30 minutes. This program may be adjusted according to  
the individual patient’s preferences and abilities. We aim to increase or decrease the 
intensity of the training according to the Borg scale of perceived exertion, resulting in 
an exercise intensity with a Borg scale of around 14. The total workload will be 50-80% of 
the maximal workload. The heart rate should be between 60-90% of the maximum heart 
rate, which can be estimated as 220 minus age and is assessed during the baseline CPET 30. 
Patients will be informed about and motivated to perform daily exercise according to 
the Dutch Consensus on Healthy Exercise 50.
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Solution focused (psycho)therapy
Solution focused therapy has empirically been validated and shown successful in 
patients with chronic diseases 51. It has improved symptoms of fatigue in patient 
populations with somatic diseases, such as patients with inflammatory bowel disease, 
by our research group 22, 23. It was considered more feasible with fewer drop outs than 
problem solved therapy 23. Contrary to other forms of psychotherapy, solution focused 
therapy is goal-oriented, future-focused and focuses on solutions to patients’ problems 
rather than on their problems. This approach assumes that everyone has some 
knowledge of what would make their life better, as well as some necessary coping skills. 
It is a short-term psychological intervention during which patients will be offered various 
interventions to channel their attention towards constructing solutions, including: 
goal setting, compliments, miracle questions, scaling questions, coping questions, and 
exception questions. The solution focused therapy will be offered in six sessions of one 
hour during twelve weeks and will be focused on fatigue management.
Dietary consultation
A specialized dietician offers patients in the intervention arm postoperative dietary 
consultation with nutritional assessment. The individual energy and protein need is 
assessed using the Harris-Benedict method. Using this method, the basic metabolism 
will be calculated with the number of calories needed adjusted for the rate of activity.  If 
needed, additional consultations can be scheduled. Patients in the control arm receive 
standard dietary care; only in the postoperative phase during hospital admission, 
whereas the intervention arm will be followed after discharge.
Withdrawal and replacement of individual subjects
Subjects can leave the study at any time for any reason if they wish to do so without 
any consequences. The investigator can decide to withdraw a subject from the study for 
urgent medical reasons. Withdrawn subjects will not be replaced. Overall- and disease 
free survival will be assessed.
Premature termination of the study
Although we have currently no reason to believe that the intervention is too intensive 
for the patients to be included, the study will prematurely be terminated when the 
intervention seems to be unfeasible.
If the drop out of included patients exceeds the estimated dropout rate and inclusion of 
patients within the given study period will not be possible, the study will prematurely 
be terminated.
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STATISTICAL ANALYSIS
Statistical analyses will be performed using SPSS statistical software. Two-sided p-values 
<0.05 will be considered significant. Adjusted analysis with prognostic baseline 
characteristics (e.g., gender, age, disease stage, radicality of resection) will be performed. 
This results in increased statistical power, corrects for baseline differences (based on 
chance) and provides better individualized treatment effect estimates 52. Analyses of 
variance (ANOVA) and longitudinal data analyses will be used to compare fatigue and 
quality of life scores between the two groups, as well as measures of skeletal muscle 
mass and function, depression and anxiety, frailty, and functional capacity. Furthermore, 
differences in outcome between baseline and the sequential measurements will be 
performed. Clinically important changes will be estimated as effect sizes using Cohen’s 
guidelines. An effect size of 0.2 will be considered as small, 0.5 as medium, and 0.8 as 
large.
Sample size
General fatigue (assessed with the Multidimensional Fatigue Inventory (MFI)) is the 
primary outcome. To detect a medium difference in MFI-General fatigue (Cohen’s d = 
0.50) with a power of 0.80 and alpha of 0.05 (two-sided), both groups should include 
64 patients. With an expected 20% drop out rate 24, a total of 154 patients are needed. 
Approximately 120 HCC, 150 pancreatic cancer and 30 bile duct cancer patients undergo 
surgery in the three participating centers annually. Consequently, patient inclusion 
should be finished within something more than one year considering an inclusion 
rate of 50%. Follow-up will be conducted until death to explore a possible association 
between the interventional and survival benefit.
Cost-effectiveness analysis
A cost-utility analysis will be performed to identify the most cost-effective treatment 
(i.e. standard care or rehabilitation program), according to the Dutch guidelines. Both 
societal and healthcare provider perspectives will be addressed. The time horizon will 
be 12 months from surgery. The quality of life and costs will be assessed for each study 
arm. QALYs (based on the EQ-5D-5L) will be the outcome measure for quality of life and 
costs per QALY for the effectiveness analysis. If no differences in QALYs between the 
treatment arms are found, a cost-effectiveness analysis will be performed from both 
societal and healthcare provider perspectives, based on the QLQ-C30. The incremental 
cost-effectiveness ratios (ICERs), defined as differences in costs of the rehabilitation arm 
versus the standard care arm divided by the average change in QALYs or HRQoL, of the 
arms will be calculated. Sensitivity analyses will be performed to test the sensitivity of 
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various costs per unit of resource. No discounting for costs and effects will be used, 
due to the relatively short time horizon of 12 months. Direct and indirect costs will be 
accounted for in the cost analysis and estimated by multiplying resource utilization 
with the cost per unit of resource following the micro-costing method which is based 
on comprehensive ‘bottom-up’ analyses and included costs of employment, material 
and equipment.  In other words, direct costs of each treatment arm will be accounted 
for. Hospital databases will be used to collect costs. Direct non-medical costs (e.g., 
travel costs of patients) will be determined using ZIP (postal) codes. The SF-HLW and 
friction cost approach will be used to take the indirect non-medical costs into account. 
Sensitivity analyses will be performed for uncertain and variable input variables to 
perform robust calculations.
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Summary
SUMMARY AND GENERAL DISCUSSION
In this thesis, we investigated the use of computed tomography (CT) to measure skeletal 
muscle mass and explored the impact and consequences of low skeletal muscle mass 
in surgical populations. Skeletal muscle mass may be an objective measure, reflecting a 
patient’s physiological status and reserves accurately. This may particularly be relevant 
in an era of an increasingly aging population in which cancer is the leading cause of 
death and liver transplantation is hampered by a shortage of donors. We investigated 
the long and short-term effects of low skeletal muscle mass in surgical patients, which 
are described in this thesis.
In part I of this thesis we investigated the accuracy of techniques to measure skeletal 
muscle mass and density on CT. Over the last years, numerous studies have used CT 
to quantify skeletal muscle mass, for example in medical 1-5 and surgical oncology 6, 
vascular surgery 7, and transplantation surgery 8, 9 patients. Furthermore, multiple studies 
measured visceral and/or subcutaneous adipose tissue on CT 10-13. However, different 
software programs have been used to perform these body composition analyses, such 
as FatSeg 13, OsiriX 14, ImageJ 3, and SliceOmatic 2. To adequately interpret and compare 
the study results using these different programs, we investigated their comparability in 
chapter 2. We showed excellent inter-software agreement between these four software 
packages for skeletal muscle, subcutaneous adipose tissue and visceral adipose tissue 
measurements. Although we found small but statistically significant differences within 
and between observers in skeletal muscle mass measurements, these differences were 
found not clinically relevant. Cohen’s κ was excellent for the classification of patients 
with or without sarcopenia. Differences within and between observers were greatest 
for visceral adipose tissue measurements. After all, the distribution of the intra-
abdominal organs (e.g. bowel) can greatly differ between slices. Although previous 
studies frequently described single slice visceral adipose tissue measurements 10, 13, 15, 
these measurements may not be clinically applicable and should be reserved for clinical 
research of patient cohorts rather than individual patients.
Although many research groups consider CT the gold standard for body composition 
measurements 1, 16, there currently is no standardized method or protocol to perform 
these measurements. One of the unknown aspects, for example, was the effect of 
contrast-enhancement of CT examinations. Therefore, we investigated the effect of 
contrast-enhancement (i.e. unenhanced, portal-venous, and arterial phase) on skeletal 
muscle mass and density measurements on CT in chapter 3. We found statistically 
significant differences in skeletal muscle mass between contrast-enhancement phases. 
However, these differences were very small and likely not clinically relevant. Significant 
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differences in skeletal muscle density were found between the unenhanced and both 
contrast-enhanced phases, but not between the portal-venous and arterial phase. 
Similar results were recently described by Van der Werf et al. 17. Based on these results, 
we recommend using the portal-venous phase, which is routinely performed in cancer 
and liver transplant patients, to measure skeletal muscle mass and density. Studies 
using the same contrast-enhancement phase to measure skeletal muscle mass will lead 
to higher comparability and uniformity of results. International consensus on using the 
portal venous phase should be advocated.
Despite a great number of studies in which only the psoas muscle was measured 6, 7, 9, we 
chose to measure the cross-section skeletal muscle area at the level of the third lumbar 
vertebra (L3), including the rectus abdominis, obliquus internus abdominis, obliquus 
externus abdominis, transversus abdominis, psoas major, quadratus lumborum and the 
erector spinae muscles. We support the concept presented by  Baracos, who described 
the psoas muscle as a proxy for sarcopenia as a ‘flawed premise’ 18. The psoas muscle 
alone is not representative for total body skeletal muscle mass for varying reasons: it 
only includes a low proportion of the total (<10%), comes with higher measurement 
errors, has a weak correlation with the total lumbar muscle area, and is subject to a 
high likelihood of isolated atrophy (e.g. due to osteoarthritis of the hip) 18. In a group 
of ovarian cancer patients, Rutten et al. described a weak correlation between the 
cross-sectional skeletal muscle area and the bilateral psoas area, both measured using 
software and calculated using the psoas width and length 19. Consequently, expert 
groups advise not to measure one muscle as a sentinel for total skeletal muscle mass 18. 
Although psoas measurements could be somewhat less time consuming than cross-
sectional skeletal muscle area measurements, the latter method takes a few minutes 
only 20. Furthermore, automated software is currently being developed 20, 21, which may 
facilitate the clinical applicability.
There is still much debate regarding adequate cut-off points for the skeletal muscle 
index to define sarcopenia. Prado et al. used cut-off values based on risk stratification2. 
These have been used commonly by others, yet some studies use different cut-off 
values, such as the sex-specific median or lowest quartile for skeletal muscle mass 13, 22, 23. 
No international consensus has been reached yet and there is insufficient knowledge 
on skeletal muscle mass in healthy persons.
In chapter 4 we measured skeletal muscle mass and density on CT in over 1,000 living 
kidney donors, who may be considered as healthy subjects. We found that skeletal 
muscle mass and density were significantly associated with sex, age, and body mass 
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index (BMI). We developed a nomogram and online calculator to estimate a patient’s 
healthy skeletal muscle mass and density, adjusted for these parameters. The nomogram 
requires external validation.
The consequences of low skeletal muscle mass and density for surgical oncology 
patients are described in part II of this thesis. In chapter 5 we performed a systematic 
review on the impact of sarcopenia on outcome after surgery for gastrointestinal and 
hepatopancreatobiliary cancer surgery. In total, 13 studies with a total of 2,884 patients 
were included. Overall, we found that sarcopenia was independently associated with 
reduced overall survival in seven out of ten studies. An association between sarcopenia, 
postoperative complications, and mortality was observed in patients undergoing partial 
colectomy or hepatectomy for colorectal cancer in particular. A great variety in methods 
and definitions of sarcopenia precluded performing meta-analyses, underscoring the 
need for more uniformity.
In chapter 6 we investigated the association of functional compromise with 
postoperative complications and mortality in a cohort of 310 patients undergoing 
colorectal cancer surgery. Functional compromise was defined as the sarcopenia 
measured on CT, frailty, and nutritional depletion, both measured using questionnaires. 
Mortality was significantly higher in patients with sarcopenia compared with patients 
without sarcopenia (8.8% versus 0.7%, p=0.001; OR 15.5, 95% confidence interval 
[CI] 2.00-120). Sarcopenia was not predictive for anastomotic leakage or sepsis. The 
combination of sarcopenia, frailty, and nutritional depletion, however, was strongly 
predictive for sepsis (OR 25.1, 95% CI 5.11-123, p=0.001), with a sensitivity of 46% and 
specificity of 97%. An association between low skeletal muscle mass and infectious 
complications has been described before in multiple studies 24-26. An explanation of the 
higher occurrence of infections in patients with low skeletal muscle mass may be an 
increased systemic inflammatory state 27-29.
In the next two chapters we validated these findings in colorectal cancer patients 
in two cohorts of patients. First, in chapter 7, we found an independent association 
between an incremental increase in skeletal muscle mass (L3 index, cm2/m2) protecting 
against the occurrence of severe complications (i.e. Clavien Dindo grade ≥3a) in 
patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal 
chemotherapy (HIPEC) for colorectal cancer that has been metastasized to the 
peritoneum (OR 0.93, 95% CI 0.87-0.99, p=0.018). Second, in chapter 8 we described the 
association between skeletal muscle mass and density and both short-term and long-
term outcome in patients undergoing surgery for stage I-III colorectal cancer for which 
we used a prospective, multicenter cohort of 816 patients. As for the studies described 
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in chapter 6 and chapter 7, we found a significantly higher rate of severe complications 
in patients with low skeletal muscle mass or density. Low skeletal muscle density was 
independently associated with the occurrence of severe postoperative complications 
(OR 1.89, 95% CI 1.11-3.23, p=0.020). Furthermore, we found a higher mortality rate in 
patients with low skeletal muscle density (3.4% versus 1.0%, p=0.038) and low skeletal 
muscle mass (3.6% versus 1.7%, p=0.091). In univariable analysis, both low skeletal 
muscle density and mass were associated with impaired overall survival. The fact that 
low skeletal muscle mass and density are associated with short-term, but not long-term, 
outcome suggests an increased vulnerability of colorectal cancer patients towards 
stressors, such as surgery (i.e. frailty) 30. Once patients have survived the postoperative 
period, the effects of low skeletal muscle mass and density disappear. Other risk factors, 
such as age, tumor stage, and comorbidity, become more important for the clinical 
course of a given patient. We hypothesize that patients with stage I-III colorectal cancer 
surviving the perioperative period, generally reach a functional status that is close to 
pre-disease levels 31. However, patients undergoing chemotherapy and elderly are at 
increased risk for functional status decline after cancer treatment 32.
Previous studies described sarcopenia as an independent prognostic factor in patients 
with perihilar cholangiocarcinoma (PHC) following hepatectomy 22 and as a risk factor 
for postoperative complications 22, 33. Unfortunately, only a minority of patients presents 
with resectable disease. We aimed to investigate the association between low skeletal 
muscle mass and density in all patients with PHC, regardless of subsequent treatment, 
in chapter 9. Although we did not find an association between low skeletal muscle mass 
and overall survival, patients with low skeletal muscle density showed a significantly 
shorter overall survival compared with patients without low skeletal muscle density: 
7.0 versus 12.1 months (p=0.004). This effect was time-dependent; an independent 
association was found within the first six months after presentation (HR 1.78, 95% CI 
1.03-3.07, p=0.04), but not after six months (HR 0.68, 95% CI 0.44-1.07, p=0.093) after 
adjustment for age, tumor size, and suspicion of distant metastases. In conclusion, low 
skeletal muscle density identified patients with PHC most prone for early death.
Remarkably, we found a long-term effect of sarcopenia in patients with PHC, but not in 
patients with colorectal carcinoma, in which we found independent short-term effects 
(i.e. increased postoperative complication and mortality rate) and only long-term 
effects in univariable analysis. One could hypothesize that once patients have survived 
the postoperative period, the effects of low skeletal muscle mass and density diminish. 
Other risk factors, such as age and comorbidity that are also strongly correlated with 
skeletal muscle mass and density, become more important for the clinical course of a 
given patient. We hypothesize that most cancer populations, such as stage I-III colorectal 
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cancer patients, generally reach a functional status after treatment that is close to 
pre-disease levels 34. In contrast, other cancer populations including sicker patients 
with an unfavorable prognosis and more dismal outcome, such as pancreatic or liver 
cancer patients, have an increased risk of spiraling down a vicious circle progressively 
enhancing physical impairment. Furthermore, tumor location, tumor biology, and 
tumor metabolism may determine the proportion of skeletal muscle wasting rather 
than tumor stage. Finally, our studies are limited by the fact that skeletal muscle mass 
was measured on one time point only, whereas skeletal muscle wasting is a process over 
time. Some studies showed that the loss of skeletal muscle mass during this period was 
more predictive of outcome than single measurements 15, 35, 36. Moreover, anti-cancer 
surgery may also halt further skeletal muscle wasting.
A recent study found that advanced age, female gender, higher ASA classification, and 
an altered systemic inflammatory response were significantly associated with loss of 
skeletal muscle mass over time after colorectal surgery 37. However, its prognostic value 
was not described and consequently remains unknown. Postoperative skeletal muscle 
depletion after resection for hepatocellular carcinoma did indeed identify patients with 
recurrence 38. Future studies among patients with other tumors should therefore also 
elaborate on the question whether anticancer treatment may halt muscle wasting, and 
if postoperative skeletal muscle mass loss, which could be measured on sequential CT 
examinations, may predict mortality or could be used as a biomarker to identify disease 
recurrence in an early phase. We believe that the majority of patients with colorectal 
cancer undergoing surgery almost fully recover. Nonetheless, particularly elderly show 
a permanent loss in physical capacity after colorectal cancer surgery 34. Early physical 
activity after surgery, however, seems important to maintain physical status 39.
In part III of this thesis we investigated the consequences of sarcopenia in patients listed 
for or undergoing liver transplantation. First, we performed a systematic review and 
meta-analysis, which is described in chapter 10. We included 19 studies with a total of 
3,803 patients. After pooling the data, a non-significant association between sarcopenia 
and waiting list mortality (HR 1.75, 95% CI, 0.99-3.00, p=0.05) and an independent 
association between sarcopenia and post-transplant survival (HR 1.84, 95% CI 1.11-
3.05, p=0.02) was found, independent of Model for End-stage Liver Disease (MELD) 
score. Although the MELD score is a very strong predictor for waiting list mortality, we 
successfully validated the association between sarcopenia and waiting list mortality in 
all consecutive patients with cirrhosis listed for transplantation between 2007 and 2014 
in the Netherlands in chapter 11. In the 585 included patients, we found a significantly 
shorter waiting list survival in patients with sarcopenia, particularly in patients with a 
low MELD score. A final model developed using competing risk analysis, included MELD, 
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sarcopenia, hepatic encephalopathy before listing, and age. However, incorporating 
sarcopenia in the MELD score to enhance prioritizing liver transplant candidates and 
allocating donor organs has limited added value. The discrepancy between our results 
and the results of previous studies may be explained by the fact that we used competing 
risk analysis rather than Cox regression analysis, which  indeed resulted in a significantly 
shorter waiting list survival in our patients with sarcopenia. Furthermore, it may be 
attributed to the fact that prioritization and allocation of donor organs and transplant 
candidates as well as waiting list mortality are all strongly related to the MELD score. 
This may have led to a self-fulfilling prophecy.
All patients included in chapters 10 and 11 with hepatocellular carcinoma (HCC) 
underwent liver transplantation within the Milan criteria 40. These criteria state that 
patients are selected for liver transplantation when there is a single lesion smaller than 
five centimeters, or when there are up to three lesions smaller than three centimeters, 
without any vascular invasion. Patients meeting the Milan criteria have a 5-year survival 
rate of at least 70% and recurrence incidence of only 10% 41, 42. However, in recent years 
it has been argued that the Milan criteria are too restrictive. Although most patients 
with HCC beyond the Milan criteria may experience disease recurrence after liver 
transplantation leading to decreased 5-year survival rates (53.6% versus 73.3%) 42, 
selected patients may still benefit and reach a 5-year survival that is comparable with 
recipients fulfilling the Milan criteria. The latest proposal to select eligible patients is 
known as the up-to-seven rule: the sum of the number of nodule(s) and the maximum 
diameter of the nodule(s) must not exceed the value of seven which resulted in a 5-year 
overall survival of 70% inpatients transplanted beyond the Milan criteria 42. Future 
studies may investigate the addition of skeletal muscle mass as a biomarker to improve 
identification of patients with HCC who may or may not benefit from transplantation.
The socio-economic consequences of low skeletal muscle mass are described in part IV 
of this thesis. Following a study from the United States that described significantly higher 
hospital costs in patients with sarcopenia after cancer surgery 43, we found significantly 
higher hospital expenditure in patients with sarcopenia undergoing abdominal cancer 
surgery in a Western-European healthcare system (chapter 12). Independently of age, 
sex, BMI, ASA classification, and the extent of surgery, total hospital costs in patients 
with sarcopenia were almost €5,000 higher compared with patients without sarcopenia 
(p=0.004). Low skeletal muscle mass, as a measure of patient frailty, may thus be used as 
a parameter for case-mix corrections to compare treatment outcomes between centers.
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In chapter 13 we found similar results for patients with cirrhosis listed for liver 
transplantation: the median total hospital costs for patients with sarcopenia were 
€11,294 (IQR 3,570-46,469) compared with €6,878 (IQR 1,305-20,683) in patients 
without sarcopenia (p=0.008). In multivariable regression analysis, an incremental 
increase in skeletal muscle index (SMI) was significantly associated with a decrease 
in total costs (€458 per incremental SMI, 95%CI 14-902, p=0.043), independent of the 
total time on the waiting list. Results are in line with previous reports on hospital costs 
and an underestimation rather than an overestimation. Based on these two studies, we 
conclude that sarcopenia is independently associated with increased health-related 
costs for patients undergoing cancer surgery and patients on the waiting list for liver 
transplantation. These results justify the use of resources to find ways to optimize 
skeletal muscle mass, which may lead to a decrease in hospital expenditure, in addition 
to greater health benefit for the patient in an era of incremental healthcare costs and 
an increasingly aging population. Future prospective studies regarding skeletal muscle 
mass should consider including total costs as outcome measure.
van_Vugt-layout.indd   347 22/11/2017   12:43
348
Chapter 15
FUTURE PERSPECTIVES
Future studies are needed to search for strategies to treat skeletal muscle wasting, which 
should be multimodal. A combination of physical exercise and nutritional support with 
or without therapeutic to treat low skeletal muscle mass and to halt or reverse skeletal 
muscle wasting should be opted for. In patients undergoing surgery, future research 
should reveal whether this should preferably be performed pre- and/or postoperatively. 
Modernizing waiting list targets may be needed to enable preoperative rehabilitation, 
and consequently longer waiting lists, may be beneficial 44. After all. it may lead to 
decreased postoperative morbidity and increased survival, as well as increased quality 
of life 45, 46 and decreased fatigue complaints 47. Recently, serum levels of myostatin, a 
cytokine involved in the regulation of muscle protein synthesis, was identified to be 
correlated with skeletal muscle mass and overall survival in patients with liver cirrhosis 48. 
Although these results have not been validated yet, myostatin seems a highly interesting 
and potential biomarker for further research. Myostatin not only seems a promising 
biomarker for skeletal muscle loss and survival prediction, but also is a potential target 
to develop therapies to halt or reverse skeletal muscle wasting. The study by Zhou et 
al., showing that myostatin antagonism successfully reduces skeletal muscle depletion 
in a mouse model, is a key publication within the field of experimental skeletal muscle 
wasting research 49. Currently, some phase II studies are being conducted to halt or 
reverse skeletal muscle wasting as part of the cancer cachexia syndrome 50.
In chapter 14 we propose a study aimed to assess the efficacy of a patient-
tailored, supervised 12-week rehabilitation program consisting of physical therapy, 
solution focused psychotherapy, and dietary optimization in surgically treated 
hepatopancreatobiliary cancer patients. The primary outcome will be fatigue following 
the intervention program, which is considered a clinically relevant and invalidating 
complaint in this population. Quality of life, which is greatly hampered in these patients 51-54, 
will be assessed. In addition, skeletal muscle mass and strength, physical fitness, 
overall survival, and cost-effectiveness are the other secondary outcome measures. 
Measurements will be repeated at six and twelve months after surgery to explore long 
term effects. Furthermore, the association between skeletal muscle mass and the other 
outcome measures will be investigated.
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NEDERLANDSE SAMENVATTING
Met name in een periode van toenemende vergrijzing, waarin kanker een van de 
belangrijkste doodsoorzaken is en het tekort aan donororganen toeneemt, zou 
skeletspiermassa gemeten op computed tomography (CT) van toegevoegde waarde 
kunnen zijn om de fysiologische reserves van een patiënt op een objectieve manier 
in te schatten. Daarom onderzochten wij de lange- en korte termijn effecten van lage 
skeletspiermassa in chirurgische patiënten, welke beschreven staan in deze dissertatie.
In deel I van dit proefschrift onderzochten we de accuratesse van verschillende 
methoden voor het meten van skeletspiermassa en - dichtheid op CT afbeeldingen. De 
afgelopen jaren zijn er vele studies uitgevoerd waarbij spiermassa gemeten is op CT in 
verschillende populaties, zoals medisch- of chirurgisch oncologische, vaatchirurgische 
en transplantatie patiënten. Daarnaast werd tevens vaak vetmassa gemeten op CT 
afbeeldingen. Hiervoor werden echter verschillende soorten software gebruikt, zoals 
FatSeg, OsiriX, ImageJ en SliceOmatic. Om studieresultaten te kunnen vergelijken, 
hebben we deze verschillende software in hoofdstuk 2 met elkaar vergeleken. Uit 
de resultaten bleek dat de metingen verricht met verschillende soorten software en 
uitgevoerd door verschillende onderzoekers uitstekend overeen kwamen.
Hoewel CT als de gouden standaard beschouwd wordt voor het meten van 
lichaamssamenstelling (dat wil zeggen: spiermassa en vetmassa), bestaat er momenteel 
geen gestandaardiseerde methode om deze metingen te verrichten. De invloed van 
intraveneus contrast, bijvoorbeeld, was onbekend. Daarom hebben we in hoofdstuk 
3 de invloed van intraveneus contrast op de gemeten hoeveelheid spiermassa en 
de dichtheid van de spiermassa onderzocht. De resultaten toonden dat intraveneus 
contrast geen invloed heeft op de gemeten hoeveelheid spiermassa, maar wel op de 
gemeten dichtheid. Welke contrast-fase gebruikt wordt, maakt echter niet uit. Daarom 
pleiten wij voor het gebruik van de (porto)veneuze contrastfase, aangezien deze bij 
kanker- en levertransplantatie patiënten het meest voorhanden is.
Omdat er tot op heden veel discussie bestaat over gebruikte afkapwaarden om patiënten 
in te delen in groepen met hoge- dan wel lage spiermassa en er weinig bekend is over op 
CT gemeten spiermassa in gezonde personen, hebben we in hoofdstuk 4 spiermassa 
en spierdichtheid gemeten in ruim 1.000 levende nier donoren. Levende nierdonoren 
dienen niet als patiënt beschouwd te worden, maar als ‘gezonde vrijwilliger’. De 
hoeveelheid spiermassa en de spierdichtheid waren sterk afhankelijk van geslacht, 
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leeftijd en body mass index (BMI). Op basis van de gevonden resultaten hebben we een 
nomogram ontwikkeld, waarmee de geschatte gezonde spiermassa- en dichtheid van 
een patiënt berekend kunnen worden.
De impact van lage skeletspiermassa en –dichtheid voor chirurgisch-oncologische 
patiënten wordt beschreven in deel II van dit proefschrift.  In hoofdstuk 5 hebben we 
een systematische review verricht waarbij we de impact van lage skeletspiermassa op 
postoperatieve uitkomsten in gastro-intestinale en hepatopancreatobiliaire chirurgie 
beschrijven op basis van de huidige literatuur. Er werden in totaal 13 studies met 
2.884 patiënten geïncludeerd. Met name in patiënten die chirurgie ondergingen van 
colorectale kanker werd een associatie gevonden tussen lage spiermassa en korte termijn 
postoperatieve uitkomsten. We vonden een grote variatie in gebruikte methoden voor 
het meten van skeletspiermassa en het definiëren van lage skeletspiermassa, waardoor 
we niet in staat waren een meta-analyse van de resultaten te verrichten.
In hoofdstuk 6 beschrijven we de associatie tussen verminderde weerbaarheid 
(gedefinieerd als lage skeletspiermassa, kwetsbaarheid (‘frailty’) en ondervoeding) en 
uitkomsten na chirurgie vanwege colorectaal carcinoom. Mortaliteit was significant 
hoger in patiënten met lage skeletspiermassa vergeleken met patiënten met een 
hoge skeletspiermassa. Hoewel lage skeletspiermassa niet geassocieerd was met 
postoperatieve naadlekkage en sepsis, was de combinatie van lage skeletspiermassa, 
kwetsbaarheid en ondervoeding sterk voorspellend voor het optreden van 
postoperatieve sepsis.
In de twee daarop volgende hoofdstukken hebben we de resultaten in colorectaal 
carcinoom patiënten gevalideerd. Allereerst vonden we in hoofdstuk 7 een 
significante associatie tussen de hoeveelheid skeletspiermassa en het optreden van 
ernstige postoperatieve complicaties na cytoreductieve chirurgie in combinatie met 
hyperthermische intraperitioneale chemotherapie (HIPEC). Vervolgens vonden we in 
hoofdstuk 8 in een groot, multicentrisch cohort van stadium I-III colorectaal carcinoom 
patiënten een significante associatie tussen lage skeletspiermassa en postoperatieve 
complicaties. Een associatie met lange termijn ziektevrije-, kanker specifieke- of 
algemene overleving vonden we niet. In hoofdstuk 9 vonden we een significant 
kortere algemene overleving in patiënten met perihilair cholangiocarcinoom met een 
lage skeletspierdichtheid vergeleken met patiënten met een hoge skeletspierdichtheid, 
ongeacht het soort therapie dat de patiënten onderging. Een effect van skeletspiermassa 
op overleving werd niet gevonden.
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In deel III onderzochten we het effect van lage skeletspiermassa in levertransplantatie 
patiënten. In hoofdstuk 10 beschrijven we de resultaten van een systematisch 
review en meta-analyse waarin 19 studies met een totaal van 3.803 patiënten werden 
geïncludeerd. De meta-analyse van de gepoolde data resulteerde in een niet-
significante associatie tussen lage skeletspiermassa en mortaliteit op de wachtlijst 
voor levertransplantatie en een significante associatie tussen lage skeletspiermassa 
en overleving na levertransplantatie. Dit laatste effect was onafhankelijk van de MELD-
score. Zoals bij de chirurgisch-oncologische studies, vonden we ook hier een grote 
diversiteit aan methodiek. Bovendien was een groot deel van de studies verricht in 
overlappende studiepopulaties. Daarom onderzochten we in een cohort van alle 
patiënten die in Nederland tussen 2007 en 2014 op de wachtlijst geplaatst werden 
voor levertransplantatie vanwege levercirrose, zoals beschreven in hoofdstuk 11, de 
associatie tussen lage skeletspiermassa en wachtlijst mortaliteit middels een competing 
risk analyse. We vonden een significant lagere wachtlijst overleving in patiënten met een 
lage skeletspiermassa. Lage skeletspiermassa had echter geen toegevoegde waarde op 
de MELD-score voor het voorspellen van wachtlijst mortaliteit.
De socio-economische consequenties van lage skeletspiermassa worden beschreven 
in deel IV van deze dissertatie. In hoofdstuk 12 beschrijven we een studie naar de 
associatie tussen preoperatieve spiermassa en perioperatieve ziekenhuiskosten in 
patiënten die chirurgie ondergaan vanwege gastro-intestinale maligniteiten. Uit de 
resultaten bleek dat de ziekenhuiskosten bijna €5.000 hoger waren in patiënten met 
een lage skeletspiermassa vergeleken met patiënten met een hoge skeletspiermassa, 
waarbij gecorrigeerd werd voor leeftijd, geslacht, BMI, ASA classificatie en de grootte 
van de ingreep. Vergelijkbare resultaten werden gevonden in de studie beschreven in 
hoofdstuk 13, waarin we hebben onderzocht wat het effect is van lage skeletspiermassa 
op de ziekenhuiskosten ten tijde van wachtlijst plaatsing voor levertransplantatie. Een 
toenemende skeletspiermassa was onafhankelijk geassocieerd met een afname in 
totale ziekenhuiskosten (€458 per toegenomen cm²/m² van de skeletal muscle index). 
Dit effect was onafhankelijk van bijvoorbeeld de totale periode dat een patiënt op de 
wachtlijst geplaatst stond.
In hoofdstuk 14 wordt het protocol van een gerandomiseerde studie beschreven waarin 
we het effect van een rehabilitatieprogramma - bestaande uit fysiotherapie, psychosociale 
therapie en voedingsadviezen – zullen onderzoeken op vermoeidheidsklachten bij 
patiënten die chirurgie ondergaan vanwege hepatopancreatobiliaire maligniteiten. 
Ernstige vermoeidheid komt veel voor bij deze groep patiënten en heeft invaliderende 
gevolgen die leiden tot een verminderde kwaliteit van leven. Daarom zal ook het effect 
op kwaliteit van leven onderzocht worden, evenals het effect op spiermassa, spierkracht 
van_Vugt-layout.indd   357 22/11/2017   12:43
358
Chapter 15
en de fysieke conditie. Ook het effect op overleving en de kosteneffectiviteit van het 
programma zullen bepaald worden. Indien dit programma succesvol blijkt, zullen wij 
streven naar implementatie hiervan in de reguliere zorg.
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